
<html lang="en"     class="pb-page"  data-request-id="3c3a57f7-5f3d-42cc-8c7f-383de6d30753"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;article:article:10.1021/acs.jmedchem.6b01821;wgroup:string:ACHS website Group;issue:issue:10.1021/jmcmar.2017.60.issue-4;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="dc.Title" content="Discovery of a Phosphoinositide 3-Kinase (PI3K) β/δ Inhibitor for the Treatment of Phosphatase and Tensin Homolog (PTEN) Deficient Tumors: Building PI3Kβ Potency in a PI3Kδ-Selective Template by Targeting Nonconserved Asp856" /></meta><meta name="dc.Creator" content="Stephane  Perreault" /></meta><meta name="dc.Creator" content="Jayaraman  Chandrasekhar" /></meta><meta name="dc.Creator" content="Zhi-Hua  Cui" /></meta><meta name="dc.Creator" content="Jerry  Evarts" /></meta><meta name="dc.Creator" content="Jia  Hao" /></meta><meta name="dc.Creator" content="Joshua A.  Kaplan" /></meta><meta name="dc.Creator" content="Adam  Kashishian" /></meta><meta name="dc.Creator" content="Kathleen S.  Keegan" /></meta><meta name="dc.Creator" content="Thomas  Kenney" /></meta><meta name="dc.Creator" content="David  Koditek" /></meta><meta name="dc.Creator" content="Latesh  Lad" /></meta><meta name="dc.Creator" content="Eve-Irene  Lepist" /></meta><meta name="dc.Creator" content="Mary E.  McGrath" /></meta><meta name="dc.Creator" content="Leena  Patel" /></meta><meta name="dc.Creator" content="Bart  Phillips" /></meta><meta name="dc.Creator" content="Joseph  Therrien" /></meta><meta name="dc.Creator" content="Jennifer  Treiberg" /></meta><meta name="dc.Creator" content="Anella  Yahiaoui" /></meta><meta name="dc.Creator" content="Gary  Phillips" /></meta><meta name="dc.Description" content="Phosphoinositide 3-kinase (PI3K) β signaling is required to sustain cancer cell growth in which the tumor suppressor phosphatase and tensin homolog (PTEN) has been deactivated. This manuscript desc..." /></meta><meta name="Description" content="Phosphoinositide 3-kinase (PI3K) β signaling is required to sustain cancer cell growth in which the tumor suppressor phosphatase and tensin homolog (PTEN) has been deactivated. This manuscript desc..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="February 7, 2017" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.6b01821" /></meta><meta name="dc.Language" content="EN" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2017 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.6b01821" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.6b01821" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.6b01821" /></link>
        
    
    

<title>Discovery of a Phosphoinositide 3-Kinase (PI3K) β/δ Inhibitor for the Treatment of Phosphatase and Tensin Homolog (PTEN) Deficient Tumors: Building PI3Kβ Potency in a PI3Kδ-Selective Template by Targeting Nonconserved Asp856 | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.6b01821" /></meta><meta property="og:title" content="Discovery of a Phosphoinositide 3-Kinase (PI3K) β/δ Inhibitor for the Treatment of Phosphatase and Tensin Homolog (PTEN) Deficient Tumors: Building PI3Kβ Potency in a PI3Kδ-Selective Template by Targeting Nonconserved Asp856" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-4/acs.jmedchem.6b01821/20170216/images/large/jm-2016-01821e_0014.jpeg" /></meta><meta property="og:description" content="Phosphoinositide 3-kinase (PI3K) β signaling is required to sustain cancer cell growth in which the tumor suppressor phosphatase and tensin homolog (PTEN) has been deactivated. This manuscript describes the discovery, optimization, and in vivo evaluation of a novel series of PI3Kβ/δ inhibitors in which PI3Kβ potency was built in a PI3Kδ-selective template. This work led to the discovery of a highly selective PI3Kβ/δ inhibitor displaying excellent pharmacokinetic profile and efficacy in a human PTEN-deficient LNCaP prostate carcinoma xenograft tumor model." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.6b01821"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.6b01821">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.6b01821&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.6b01821&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.6b01821&amp;href=/doi/10.1021/acs.jmedchem.6b01821" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2017</span><span class="cit-fg-volume">, 60</span><span class="cit-fg-issue">, 4</span><span class="cit-fg-pageRange">, 1555-1567</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/60/4" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.6b01801" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.6b01849" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Discovery of a Phosphoinositide 3-Kinase (PI3K) β/δ Inhibitor for the Treatment of Phosphatase and Tensin Homolog (PTEN) Deficient Tumors: Building PI3Kβ Potency in a PI3Kδ-Selective Template by Targeting Nonconserved Asp856</span></h1><ul class="loa non-jats-loa"><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Stephane++Perreault">Stephane Perreault</a></span><span class="author-xref-symbol "><sup>*</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span><span class="loa-info-orcid"><a href="http://orcid.org/0000-0001-8732-5243" title="Orcid link"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img></a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jayaraman++Chandrasekhar">Jayaraman Chandrasekhar</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Zhi-Hua++Cui">Zhi-Hua Cui</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jerry++Evarts">Jerry Evarts</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span><span class="author-xref-symbol "><sup>§</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jia++Hao">Jia Hao</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Joshua+A.++Kaplan">Joshua A. Kaplan</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Adam++Kashishian">Adam Kashishian</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Kathleen+S.++Keegan">Kathleen S. Keegan</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Thomas++Kenney">Thomas Kenney</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=David++Koditek">David Koditek</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Latesh++Lad">Latesh Lad</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Eve-Irene++Lepist">Eve-Irene Lepist</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Mary+E.++McGrath">Mary E. McGrath</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Leena++Patel">Leena Patel</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Bart++Phillips">Bart Phillips</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Joseph++Therrien">Joseph Therrien</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jennifer++Treiberg">Jennifer Treiberg</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Anella++Yahiaoui">Anella Yahiaoui</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Gary++Phillips">Gary Phillips</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator"></span></ul><div class="affiliations"><div class="view-affs"><span class="title">View Author Information</span><i class="caret-icon icon-angle-down"></i></div><div class="all-aff-infos hlFld-Affiliation"><div class="aff-info" id="aff1"><span class="aff-symbol">†</span> <span class="aff-text">Gilead Sciences, Inc., 199 E. Blaine Street, Seattle, Washington 98102, United States</span></div><div class="aff-info" id="aff2"><span class="aff-symbol">‡</span> <span class="aff-text">Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, California 94404, United States</span></div><div class="corresp-info"><strong>*</strong>E-mail: <a href="/cdn-cgi/l/email-protection#5d2e29382d353c3338732d382f2f383c2831291d3a3431383c39733e3230"><span class="__cf_email__" data-cfemail="0c7f78697c646d6269227c697e7e696d7960784c6b6560696d68226f6361">[email protected]</span></a>. Phone: (206) 832-2029.</div></div></div><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.6b01821&amp;href=/doi/10.1021%2Facs.jmedchem.6b01821" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2017</span></span><span class="cit-volume">, 60</span><span class="cit-issue">, 4</span><span class="cit-pageRange">, 1555–1567</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">January 20, 2017</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>14 December 2016</li><li><span class="item_label"><b>Published</b> online</span>7 February 2017</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 23 February 2017</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.6b01821" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.6b01821</a></div><div class="article_header-article-copyright"><strong>Copyright © 2017 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D1555%26pageCount%3D13%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DStephane%2BPerreault%252C%2BJayaraman%2BChandrasekhar%252C%2BZhi-Hua%2BCui%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D60%26issueNum%3D4%26contentID%3Dacs.jmedchem.6b01821%26title%3DDiscovery%2Bof%2Ba%2BPhosphoinositide%2B3-Kinase%2B%2528PI3K%2529%2B%25CE%25B2%252F%25CE%25B4%2BInhibitor%2Bfor%2Bthe%2BTreatment%2Bof%2BPhosphatase%2Band%2BTensin%2BHomolog%2B%2528PTEN%2529%2BDeficient%2BTumors%253A%2BBuilding%2BPI3K%25CE%25B2%2BPotency%2Bin%2Ba%2BPI3K%25CE%25B4-Selective%2BTemplate%2Bby%2BTargeting%2BNonconserved%2BAsp856%26numPages%3D13%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D1567%26publicationDate%3DFebruary%2B2017">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.6b01821"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">2000</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">23</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.6b01821" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Discovery of a Phosphoinositide 3-Kinase (PI3K) β/δ Inhibitor for the Treatment of Phosphatase and Tensin Homolog (PTEN) Deficient Tumors: Building PI3Kβ Potency in a PI3Kδ-Selective Template by Targeting Nonconserved Asp856&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Stephane&quot;,&quot;last_name&quot;:&quot;Perreault&quot;},{&quot;first_name&quot;:&quot;Jayaraman&quot;,&quot;last_name&quot;:&quot;Chandrasekhar&quot;},{&quot;first_name&quot;:&quot;Zhi-Hua&quot;,&quot;last_name&quot;:&quot;Cui&quot;},{&quot;first_name&quot;:&quot;Jerry&quot;,&quot;last_name&quot;:&quot;Evarts&quot;},{&quot;first_name&quot;:&quot;Jia&quot;,&quot;last_name&quot;:&quot;Hao&quot;},{&quot;first_name&quot;:&quot;Joshua&quot;,&quot;last_name&quot;:&quot;A. Kaplan&quot;},{&quot;first_name&quot;:&quot;Adam&quot;,&quot;last_name&quot;:&quot;Kashishian&quot;},{&quot;first_name&quot;:&quot;Kathleen&quot;,&quot;last_name&quot;:&quot;S. Keegan&quot;},{&quot;first_name&quot;:&quot;Thomas&quot;,&quot;last_name&quot;:&quot;Kenney&quot;},{&quot;first_name&quot;:&quot;David&quot;,&quot;last_name&quot;:&quot;Koditek&quot;},{&quot;first_name&quot;:&quot;Latesh&quot;,&quot;last_name&quot;:&quot;Lad&quot;},{&quot;first_name&quot;:&quot;Eve-Irene&quot;,&quot;last_name&quot;:&quot;Lepist&quot;},{&quot;first_name&quot;:&quot;Mary&quot;,&quot;last_name&quot;:&quot;E. McGrath&quot;},{&quot;first_name&quot;:&quot;Leena&quot;,&quot;last_name&quot;:&quot;Patel&quot;},{&quot;first_name&quot;:&quot;Bart&quot;,&quot;last_name&quot;:&quot;Phillips&quot;},{&quot;first_name&quot;:&quot;Joseph&quot;,&quot;last_name&quot;:&quot;Therrien&quot;},{&quot;first_name&quot;:&quot;Jennifer&quot;,&quot;last_name&quot;:&quot;Treiberg&quot;},{&quot;first_name&quot;:&quot;Anella&quot;,&quot;last_name&quot;:&quot;Yahiaoui&quot;},{&quot;first_name&quot;:&quot;Gary&quot;,&quot;last_name&quot;:&quot;Phillips&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2017&quot;,&quot;month&quot;:&quot;02&quot;,&quot;day&quot;:&quot;07&quot;,&quot;issue&quot;:&quot;4&quot;,&quot;volume&quot;:&quot;60&quot;,&quot;pages&quot;:&quot;1555-1567&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.6b01821&quot;},&quot;abstract&quot;:&quot;Phosphoinositide 3-kinase (PI3K) β signaling is required to sustain cancer cell growth in which the tumor suppressor phosphatase and tensin homolog (PTEN) has been deactivated. This manuscript describes the discovery, optimization, and in vivo evaluation of a novel series of PI3Kβ/δ inhibitors in which PI3Kβ potency was built in a PI3Kδ-selective template. This work led to the discovery of a highly selective PI3Kβ/δ inhibitor displaying excellent pharmacokinetic profile and efficacy in a human PTEN-deficient LNCaP prostate carcinoma xenograft tumor model.&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.6b01821&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.6b01821" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.6b01821&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.6b01821" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.6b01821&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.6b01821" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.6b01821&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.6b01821&amp;href=/doi/10.1021/acs.jmedchem.6b01821" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.6b01821" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.6b01821" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (3 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.6b01821&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.6b01821%26sid%3Dliteratum%253Aachs%26pmid%3D28106991%26genre%3Darticle%26aulast%3DPerreault%26date%3D2017%26atitle%3DDiscovery%2Bof%2Ba%2BPhosphoinositide%2B3-Kinase%2B%2528PI3K%2529%2B%25CE%25B2%252F%25CE%25B4%2BInhibitor%2Bfor%2Bthe%2BTreatment%2Bof%2BPhosphatase%2Band%2BTensin%2BHomolog%2B%2528PTEN%2529%2BDeficient%2BTumors%253A%2BBuilding%2BPI3K%25CE%25B2%2BPotency%2Bin%2Ba%2BPI3K%25CE%25B4-Selective%2BTemplate%2Bby%2BTargeting%2BNonconserved%2BAsp856%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D60%26issue%3D4%26spage%3D1555%26epage%3D1567%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (5)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=292464" title="Rodent models">Rodent models</a>,</li><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a>,</li><li><a href="/action/doSearch?ConceptID=291711" title="Selectivity">Selectivity</a>,</li><li><a href="/action/doSearch?ConceptID=292504" title="Permeability">Permeability</a>,</li><li><a href="/action/doSearch?ConceptID=292153" title="Tumors">Tumors</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/60/4" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-4/jmcmar.2017.60.issue-4/20170223/jmcmar.2017.60.issue-4.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="f_tgr1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-4/acs.jmedchem.6b01821/20170216/images/medium/jm-2016-01821e_0014.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-4/acs.jmedchem.6b01821/20170216/images/large/jm-2016-01821e_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01821&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Phosphoinositide 3-kinase (PI3K) β signaling is required to sustain cancer cell growth in which the tumor suppressor phosphatase and tensin homolog (PTEN) has been deactivated. This manuscript describes the discovery, optimization, and in vivo evaluation of a novel series of PI3Kβ/δ inhibitors in which PI3Kβ potency was built in a PI3Kδ-selective template. This work led to the discovery of a highly selective PI3Kβ/δ inhibitor displaying excellent pharmacokinetic profile and efficacy in a human PTEN-deficient LNCaP prostate carcinoma xenograft tumor model.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i1">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_85462" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_85462" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The phosphoinositide 3-kinase (PI3K) pathway plays a role in a wide range of key cellular functions such as cell growth, proliferation, and survival.<a onclick="showRef(event, 'ref1 ref2 ref3 ref4'); return false;" href="javascript:void(0);" class="ref ref1 ref2 ref3 ref4">(1-4)</a> Aberrant activation of the PI3K/AKT pathway has been observed with high frequency in human malignancies, suggesting a significant role in tumorigenesis, cancer progression, and treatment resistance.<a onclick="showRef(event, 'ref5 ref6'); return false;" href="javascript:void(0);" class="ref ref5 ref6">(5, 6)</a> Class I PI3Ks are heterodimers bearing regulatory and catalytic subunits, which are further subdivided into class IA and class IB.<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> Class IA comprises three isoforms of the catalytic subunit, p110α, p110β, and p110δ, while p110γ is the only isoform in class IB. PI3Kα and -β are ubiquitously expressed in all tissues, while PI3Kδ and -γ are confined to leukocytes.</div><div class="NLM_p">Class I PI3Ks catalyze the phosphorylation of phosphatidylinositol 4,5-bisphosphate (PIP2) to produce the second messenger phosphatidylinositol 3,4,5-trisphosphate (PIP3).<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> Pan inhibitors of the class I PI3Ks, along with molecules that inhibit additional downstream targets, such as mTOR, have provided evidence that attenuating signaling through this node can yield clinical benefit in oncology.<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> However, the utility of pan inhibitors has been limited by side effects, such as hyperglycemia, resulting in dose reductions that erode efficacy. Most recent efforts are devoted to target the relevant oncogenic PI3K isoform with isoform-selective inhibitors in order to circumvent off-target toxicities and to provide a larger therapeutic window.<a onclick="showRef(event, 'ref10 ref11 ref12 ref13 ref14 ref15 ref16'); return false;" href="javascript:void(0);" class="ref ref10 ref11 ref12 ref13 ref14 ref15 ref16">(10-16)</a></div><div class="NLM_p">In many solid tumors associated with aberrant signaling of the PI3Kβ isoform, the increased signaling through the PI3K pathway is not induced via activating mutations in PI3Kβ but rather by deactivation of the tumor suppressor phosphatase and tensin homolog (PTEN).<a onclick="showRef(event, 'ref17 ref18'); return false;" href="javascript:void(0);" class="ref ref17 ref18">(17, 18)</a> The protein encoded by this gene is a phosphatidylinositol 3,4,5-trisphosphate 3-phosphatase which functions as a negative regulator of the lipid kinase activity. Preclinical studies have shown that down-regulation of PI3Kβ in PTEN-deficient cancer cells results in pathway inactivation and subsequent inhibition of growth in both cell-based and in vivo settings.<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> This discovery provided strong rationale for the development of PI3Kβ-selective inhibitors. GSK-2636771<a onclick="showRef(event, 'ref10 ref19'); return false;" href="javascript:void(0);" class="ref ref10 ref19">(10, 19)</a> and AZD8186<a onclick="showRef(event, 'ref10 ref20'); return false;" href="javascript:void(0);" class="ref ref10 ref20">(10, 20)</a> are β-weighted β/δ inhibitors currently under clinical evaluation for the treatment of castration-resistant prostate cancer (<a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>).<a onclick="showRef(event, 'ref21 ref22 ref23 ref24 ref25 ref26 ref27'); return false;" href="javascript:void(0);" class="ref ref21 ref22 ref23 ref24 ref25 ref26 ref27">(21-27)</a></div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-4/acs.jmedchem.6b01821/20170216/images/medium/jm-2016-01821e_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-4/acs.jmedchem.6b01821/20170216/images/large/jm-2016-01821e_0001.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. PI3Kβ inhibitors in clinical trials.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-4/acs.jmedchem.6b01821/20170216/images/large/jm-2016-01821e_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01821&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">In this manuscript, we describe our efforts toward identifying potent, selective, and metabolically stable PI3Kβ inhibitors suitable for the treatment of PTEN-deficient tumors. Our goals were threefold: potent inhibition of PI3Kβ in PTEN-deficient PC3 prostate cancer cells (inhibition of pAKT with EC<sub>50</sub> < 20 nM), isoform selectivity of greater than 100-fold over PI3Kα and PI3Kγ in order to allow EC<sub>90</sub> coverage of PI3Kβ at trough concentrations without compromising isoform selectivity, and in vitro human predicted clearance of 0.2 L h<sup>–1</sup> kg<sup>–1</sup> or below to allow for a twice-daily dosing regimen.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_51051" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_51051" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">In an effort to develop isoform-selective PI3K inhibitors, we envisaged building PI3Kβ potency from our previously disclosed PI3Kδ-selective template, exemplified by idelalisib (<b>1</b>).<a onclick="showRef(event, 'ref28 ref29'); return false;" href="javascript:void(0);" class="ref ref28 ref29">(28, 29)</a> As revealed by its X-ray crystal structure in the PI3Kδ isoform, the quinazolinone of idelalisib occupies a specificity pocket between Met752 and Trp760, a closed pocket in the apo structure of the enzyme (<a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a>a).<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> This binding mode may imbue propeller shaped inhibitors such as idelalisib with improved selectivity over other lipid kinases that show reduced conformational flexibility in this region.<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> This orthogonal arrangement orients the phenyl group to sit on the hydrophobic region II (H2). While many residues in the ATP pocket are conserved among all four class I PI3K isoforms, sequence alignment of the residues in the hydrophobic region II shows several variations, such as Asp856, which is unique to PI3Kβ (<a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a>b).<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> Accordingly, we reasoned that a well-placed hydrogen bond donor could engage in an interaction with Asp856 resulting in an improvement in PI3Kβ potency.<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> Proof of concept was achieved through the introduction of a 4-hydroxy group on the phenyl ring of idelalisib (<a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>, <b>1</b> vs <b>2</b>). This modification leads to a 1000-fold improvement in PI3Kβ potency. With our knowledge that the primary site of metabolism of idelalisib is the purine moiety,<a onclick="showRef(event, 'ref34 ref35'); return false;" href="javascript:void(0);" class="ref ref34 ref35">(34, 35)</a> we also evaluated our hypothesis in a second analogous series bearing a 4-amino-5-cyanopyrimidine hinge binder and a similar increase in PI3Kβ potency was observed (<b>3</b> vs <b>4</b>). From these results, we began a medicinal chemistry effort toward the identification of potent and selective PI3Kβ/δ inhibitors.</div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-4/acs.jmedchem.6b01821/20170216/images/medium/jm-2016-01821e_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-4/acs.jmedchem.6b01821/20170216/images/large/jm-2016-01821e_0002.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. (a) 2.4 Å X-ray crystal structure of idelalisib (<b>1</b>) bound in the PI3Kδ ATP binding site (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4XE0">4XE0</a>; coordinates available).<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> Asp832 and Asn836 (highlighted in yellow) differ among the PI3K isoforms. For clarity, all other residues have been removed. Blue dashed lines show hydrogen bond contacts between the inhibitor and the protein. (b) Different residues in the hydrophobic region II among class I PI3Ks. Asn836 of PI3Kδ corresponds to Asp856 of PI3Kβ.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-4/acs.jmedchem.6b01821/20170216/images/large/jm-2016-01821e_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01821&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Building PI3Kβ Potency in a PI3Kδ-Selective Template</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-4/acs.jmedchem.6b01821/20170216/images/medium/jm-2016-01821e_0008.gif" alt="" id="fx1" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup>Table a</sup><p class="last">The activity against each class I PI3K was evaluated in in vitro kinase assays containing 2<i>K</i><sub>m</sub> steady state concentrations of ATP (average of ≥2 determinations).</p></div><div class="footnote" id="t1fn2"><sup>Table b</sup><p class="last">Numbers in parentheses represent fold selectivity over PI3Kβ (PI3Kα or PI3Kγ IC<sub>50</sub> divided by PI3Kβ IC<sub>50</sub>).</p></div></div><div></div></div><div class="NLM_p">Phenol-containing compounds are prone to pharmacokinetic (fast glucuronidation as prelude to excretion) and/or toxicological limitations (formation of quinones as chemically reactive metabolites). To eliminate the phenol but retain the proposed hydrogen bond interaction between the inhibitor and Asp856, a variety of moieties were prepared and tested, including, but not limited to, heterocycles, such as indoles, indazoles, benzotriazoles, pyrazoles, and acylated or sulfonylated (hetero)aryl amines such as carbamates and ureas.<a onclick="showRef(event, 'ref36 ref37 ref38 ref39'); return false;" href="javascript:void(0);" class="ref ref36 ref37 ref38 ref39">(36-39)</a> Our studies indicated that pyrazoles <b>5</b> (pyrazol-3-yl) and <b>6</b> (pyrazol-4-yl) appeared to be attractive starting points (<a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>). Further profiling of compounds <b>5</b> and <b>6</b> revealed very high predicted clearance in human hepatocytes (>0.95 L h<sup>–1</sup> kg<sup>–1</sup>). This observation is consistent with our previously disclosed PI3Kδ-selective series: the 4-amino-5-cyanopyrimidine hinge binder is a substrate for aldehyde oxidase-mediated metabolism leading to C2-oxidation on the pyrimidine.<a onclick="showRef(event, 'ref13 ref40'); return false;" href="javascript:void(0);" class="ref ref13 ref40">(13, 40)</a> Despite the lower selectivity for the PI3Kα isoform, we first decided to investigate the pyrazol-3-yl series due to the favorable PI3Kβ potency of <b>5</b>.</div><div class="NLM_p">Alternative substitutions around the pyrimidine hinge binder were explored in an effort to mitigate the high predicted clearance of <b>5</b> (<a class="ref internalNav" href="#tbl2" aria-label="Table 2">Table 2</a>). As discovered previously, introduction of a primary C2-amine is well tolerated and prevents oxidation of the pyrimidine (<b>7</b>).<a onclick="showRef(event, 'ref12 ref13'); return false;" href="javascript:void(0);" class="ref ref12 ref13">(12, 13)</a> The low predicted hepatic clearance was attractive but dampened by the concomitant increase in PI3Kα and PI3Kγ potency. It is likely that the increased potency in all isoforms is the result of a third hydrogen bond involving the 2-amino moiety of the pyrimidine hinge binder. Additionally, compound <b>7</b>, as well as closely related cyclopropyl analog <b>8</b>, displays very low forward permeability as determined by a Caco-2 cell monolayer assay.</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Optimization of the 2-Aminopyrimidine Hinge Binder</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-4/acs.jmedchem.6b01821/20170216/images/medium/jm-2016-01821e_0009.gif" alt="" id="fx3" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-4/acs.jmedchem.6b01821/20170216/images/medium/jm-2016-01821e_0010.gif" alt="" id="fx4" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup>Table a</sup><p class="last">The activity against each class I PI3K was evaluated in in vitro kinase assays containing 2<i>K</i><sub>m</sub> steady state concentrations of ATP (average of ≥2 determinations).</p></div><div class="footnote" id="t2fn2"><sup>Table b</sup><p class="last">Numbers in parentheses represent fold selectivity over PI3Kβ (PI3Kα or PI3Kγ IC<sub>50</sub> divided by PI3Kβ IC<sub>50</sub>).</p></div><div class="footnote" id="t2fn3"><sup>Table c</sup><p class="last">Determined from human hepatocytes.</p></div><div class="footnote" id="t2fn4"><sup>Table d</sup><p class="last">10<sup>6</sup> cm/s. ND = value not determined.</p></div></div><div></div></div><div class="NLM_p">Our first approach to improving the permeability of this series consisted of reducing the total polar surface area (tPSA) and increasing the lipophilicity as measured by cLogP. Substitution of the nitrile group at the C5-position of the pyrimidine by a hydrogen atom (<b>9</b>) contributes to a reduction in tPSA (170 Å<sup>2</sup> to 146 Å<sup>2</sup>). Unfortunately, this modification results in a substantial loss in potency. Replacement of the nitrile group by a chlorine atom (<b>10</b>) is well tolerated in terms of PI3Kβ potency. This change is also accompanied by a desirable increase in forward permeability, presumably the result of a higher cLogP and lower tPSA (146 Å<sup>2</sup>). A more lipophilic cyclopropyl group at R<sup>1</sup> (<b>11</b>) leads to an even greater improvement in permeability. Moreover, compounds <b>10</b> and <b>11</b> afford better selectivity over the PI3Kα and PI3Kγ isoforms relative to the nitrile analogs <b>7</b> and <b>8</b>. The predicted clearances of <b>10</b> and <b>11</b> are higher but remain in an acceptable range for further consideration. Metabolite identification studies on compound <b>11</b>, after incubation with human hepatocytes, reveal the formation of an oxidative metabolite (M + 16) of the pyrimidine moiety. This metabolic pathway is not observed in compounds with the electron withdrawing nitrile group at the C5-position of the pyrimidine (<b>7</b> and <b>8)</b>.</div><div class="NLM_p">As a second approach to improve the permeability, we envisaged reducing the number of hydrogen bond donors. Replacement of the primary amine at R<sup>3</sup> by a methyl group (<b>12</b>) or a chlorine atom (<b>13</b>) results in an increase in forward permeability at the expense of higher predicted clearances. The loss in metabolic stability can be rescued by introducing a difluoromethyl group at R<sup>3</sup> (<b>14</b>). This modification is also accompanied by a substantial improvement in forward permeability. The trifluoromethyl analog <b>15</b> exhibits low PI3Kβ potency. We believe this is the result of an inevitable electrostatic repulsion between the third fluorine and the carbonyl group of Glu846 in PI3Kβ (vide infra).</div><div class="NLM_p">These results prompted us to further investigate different quinazolinone and R<sup>1</sup> substitutions in the 2,6-diamino-5-chloropyrimidine and the 2-amino-5-cyano-4-(difluoromethyl)pyrimidine hinge binder series. While exploring alternative substitutions on the quinazolinone ring, we found that minor modifications have substantial impact on potency and selectivity (<a class="ref internalNav" href="#tbl3" aria-label="Table 3">Table 3</a>). Substituents such as 5-fluoro (<b>16a</b>,<b>b</b>), 6-fluoro (<b>17a</b>,<b>b</b>), and 8-fluoro (<b>18a</b>,<b>b</b>) all result in a loss of PI3Kβ potency. Interestingly, the 6,8-difluoroquinazolinone motif found in <b>19a</b>,<b>b</b> results in a 2-fold increase in PI3Kβ potency relative to the monofluorinated analogs <b>17a</b>,<b>b</b> and <b>18a</b>,<b>b</b>. Potency and isoform selectivity can be further improved by replacing the 8-fluoro with an 8-chloro (<b>20a</b>,<b>b</b>). Combining the 8-chloro-6-fluoroquinazolinone with various R<sup>1</sup> moieties (<b>21a</b>,<b>b</b> and <b>22a</b>,<b>b</b>) results in a loss of potency. Nonetheless, the biochemical profile of compound <b>21b</b> remains promising based on potency and isoform selectivity.</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. SAR results for quinazolinone ring and R<sup>1</sup> modifications</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-4/acs.jmedchem.6b01821/20170216/images/medium/jm-2016-01821e_0011.gif" alt="" id="fx5" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup>Table a</sup><p class="last">The activity against each class I PI3K was evaluated in in vitro kinase assays containing 2<i>K</i><sub>m</sub> steady state concentrations of ATP (average of ≥2 determinations).</p></div><div class="footnote" id="t3fn2"><sup>Table b</sup><p class="last">Numbers in parentheses represent fold selectivity over PI3Kβ (PI3Kα or PI3Kγ IC<sub>50</sub> divided by PI3Kβ IC<sub>50</sub>).</p></div></div><div></div></div><div class="NLM_p">The improvement in PI3Kβ potency observed with the introduction of the C2-amine on the pyrimidine hinge binder (<b>5</b> vs <b>7</b>) led us to further explore the pyrazol-4-yl series exemplified by compound <b>6</b> (<a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>). However, in a head-to-head comparison between the pyrazol-3-yl series (<b>23</b>) and the corresponding pyrazol-4-yl series (<b>24</b>) (SAR pair analysis of compounds in which the only variable is the connectivity point on the pyrazole, <a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a>a), we observed that the pyrazol-4-yl leads to inferior PI3Kβ potency in most cases (<a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a>b). In terms of selectivity, it appears that the combination of the pyrazol-3-yl with the 2,6-diamino-5-chloropyrimidine (green circles) leads to greater PI3Kα selectivity (<a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a>c). In a third analysis, we observed that the pyrazol-3-yl analog generally leads to greater PI3Kγ selectivity when compared to the corresponding pyrazol-4-yl compound (<a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a>d). This last trend was independent of the hinge binder and led us to abandon the pyrazol-4-yl series.</div><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-4/acs.jmedchem.6b01821/20170216/images/medium/jm-2016-01821e_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-4/acs.jmedchem.6b01821/20170216/images/large/jm-2016-01821e_0003.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. SAR pair analysis illustrating that the pyrazol-3-yl series (<b>23</b>) is superior to the pyrazol-4-yl series (<b>24</b>) in terms of PI3Kβ potency and PI3Kγ selectivity. Each colored shape represents a pair of compounds <b>23</b> and <b>24</b> with identical substituents X<sub>n</sub>, R<sup>1</sup>, R<sup>2</sup>, and R<sup>3</sup>, the only variable being the connectivity point on the pyrazole (pyrazol-3-yl vs pyrazol-4-yl). The value on the <i>x</i>-axis corresponds to the pyrazol-4-yl compound <b>24</b> and the value on the <i>y</i>-axis is for the corresponding pyrazol-3-yl compound <b>23</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-4/acs.jmedchem.6b01821/20170216/images/large/jm-2016-01821e_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01821&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The binding mode of this series of inhibitors has not been characterized crystallographically in PI3Kβ.<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a> However, it can be modeled in a PI3Kβ homology model (coordinates have been included in <a class="ref internalNav" href="#notes-1" aria-label="Supporting Information">Supporting Information</a>) based on the crystal structure of PI3Kδ cocrystallized with recently disclosed (<i>S</i>)-2,4-diamino-6-((5-chloro-8-fluoro-4-oxo-3-(pyridin-3-yl)-3,4-dihydroquinazolin-2-yl)(cyclopropyl)methylamino)pyrimidine-5-carbonitrile (GS-9901, PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5T8I">5T8I</a>).<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> Compounds such as <b>11</b> and <b>14</b> are likely to bind to the ATP binding site of the kinase domain of PI3Kβ (<a class="ref internalNav" href="#fig4" aria-label="Figure 4">Figure 4</a>). Similar to other propeller shaped PI3K inhibitors, the quinazolinone occupies an induced specificity pocket between Met773 and Trp781 of PI3Kβ. Additionally, molecular modeling indicates that the hydrogen bond donor in the pyrazole ring can form an energetically favorable interaction with Asp856. The 2,6-diamino-5-chloropyrimidine of <b>11</b> is expected to serve as a three-point hinge binder (<a class="ref internalNav" href="#fig4" aria-label="Figure 4">Figure 4</a>a). On the other hand, the 2-amino-5-cyano-4-(difluoromethyl)pyrimidine moiety of compound <b>14</b> is likely to bind to the hinge with two hydrogen bonds (<a class="ref internalNav" href="#fig4" aria-label="Figure 4">Figure 4</a>b). Modeling also suggests a weakly attractive interaction between the hydrogen of the 4-difluoromethyl group and the carbonyl of Glu846. Previously discussed compound <b>15</b>, bearing a 4-trifluoromethyl group on the pyrimidine, most likely suffers from a repulsive interaction with the same Glu846 carbonyl.</div><figure id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-4/acs.jmedchem.6b01821/20170216/images/medium/jm-2016-01821e_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-4/acs.jmedchem.6b01821/20170216/images/large/jm-2016-01821e_0004.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Docked poses of compounds <b>11</b> (a) and <b>14</b> (b) in the homology model of PI3Kβ. In both cases, the pyrazole-NH is predicted to hydrogen-bond to Asp856. For clarity, all other residues have been removed. Blue dashed lines show predicted hydrogen bond contacts between the inhibitor and the protein. The PI3Kβ homology model used was built from the crystal structure PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5T8I">5T8I</a> (coordinates have been included in <a class="ref internalNav" href="#notes-1" aria-label="Supporting Information">Supporting Information</a>).<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-4/acs.jmedchem.6b01821/20170216/images/large/jm-2016-01821e_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01821&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">To shed some light on this possible interaction between the pyrazole moiety and Asp856, we synthesized the corresponding isoxazole <b>25</b> (<a class="ref internalNav" href="#tbl4" aria-label="Table 4">Table 4</a>). The ring lacks the hydrogen bond donor and leads to a 250-fold drop in PI3Kβ potency while PI3Kδ remains equipotent. This result supports the prediction of an interaction between the hydrogen bond donating pyrazole and Asp856 in this series of PI3Kβ/δ inhibitors.</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. Pyrazol-3-yl vs Isoxazol-3-yl</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-4/acs.jmedchem.6b01821/20170216/images/medium/jm-2016-01821e_0012.gif" alt="" id="fx7" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t4fn1"><div class="footnote" id="t4fn1"><sup>Table a</sup><p class="last">The activity against each class I PI3K was evaluated in in vitro kinase assays containing 2<i>K</i><sub>m</sub> steady state concentrations of ATP (average of ≥2 determinations).</p></div></div><div></div></div><div class="NLM_p">Compounds meeting potency and selectivity criteria were then evaluated for tumor cell activity by measuring inhibition of AKT phosphorylation in the PTEN-deficient PC3 prostate cancer cell line (<a class="ref internalNav" href="#tbl5" aria-label="Table 5">Table 5</a>). Correlation between biochemical and cellular potency is more consistent for compounds with the 2,6-diamino-5-chloropyrimidine hinge binder (<b>10</b>, <b>11</b>, and <b>20a</b>), while larger shifts were observed with the 2-amino-5-cyano-4-(difluoromethyl)pyrimidine (<b>14</b>, <b>20b</b>, and <b>21b</b>). This observation, combined with higher predicted human clearances for compounds <b>20b</b> and <b>21b</b>, led us to focus on analogs with the 2,6-diamino-5-chloropyrimidine hinge binder (<b>10</b>, <b>11</b>, and <b>20a</b>).</div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. Activity against AKT Phosphorylation in PC3 Cells and Predicted Human Hepatic Clearance</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center">PI3Kβ IC<sub>50</sub> (nM)<a class="ref internalNav" href="#t5fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center">PC3 EC<sub>50</sub> (nM)<a class="ref internalNav" href="#t5fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center">CL<sub>pr</sub> (L h<sup>–1</sup> kg<sup>–1</sup>)<a class="ref internalNav" href="#t5fn2" aria-label="b">b</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>10</b></td><td class="colsep0 rowsep0" align="left">2.1</td><td class="colsep0 rowsep0" align="left">4.2</td><td class="colsep0 rowsep0" align="left">0.22</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>11</b></td><td class="colsep0 rowsep0" align="left">7.9</td><td class="colsep0 rowsep0" align="left">7.6</td><td class="colsep0 rowsep0" align="left">0.20</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>20a</b></td><td class="colsep0 rowsep0" align="left">7.8</td><td class="colsep0 rowsep0" align="left">20</td><td class="colsep0 rowsep0" align="left">0.17</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>14</b></td><td class="colsep0 rowsep0" align="left">9.3</td><td class="colsep0 rowsep0" align="left">45</td><td class="colsep0 rowsep0" align="left">0.16</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>20b</b></td><td class="colsep0 rowsep0" align="left">2.6</td><td class="colsep0 rowsep0" align="left">15</td><td class="colsep0 rowsep0" align="left">0.29</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>21b</b></td><td class="colsep0 rowsep0" align="left">4.5</td><td class="colsep0 rowsep0" align="left">42</td><td class="colsep0 rowsep0" align="left">0.34</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t5fn1"><div class="footnote" id="t5fn1"><sup>a</sup><p class="last">Average of ≥2 determinations.</p></div><div class="footnote" id="t5fn2"><sup>b</sup><p class="last">Determined from human hepatocytes.</p></div></div></div><div class="NLM_p">We next evaluated the pharmacokinetic profiles of the most promising compounds <b>10</b>, <b>11</b>, and <b>20a</b>. Despite moderate oral bioavailability, the in vivo rat pharmacokinetic profile of <b>10</b> was promising, exhibiting good correlation between in vitro and in vivo clearances (<a class="ref internalNav" href="#tbl6" aria-label="Table 6">Table 6</a>). Introduction of a more lipophilic cyclopropyl at R<sup>1</sup> (<b>11</b>) enhances the forward permeability leading to an overall improvement in oral bioavailability. Compound <b>20a</b>, bearing an 8-chloro-6-fluoroquinazolinone, leads to an oral bioavailability of 66% in rat. We attribute this result to lower observed clearance and improved forward permeability as measured by a Caco-2 cell monolayer assay.</div><div class="NLM_table-wrap" id="tbl6"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 6. Summary of Pharmacokinetic Profiles in Rat</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-4/acs.jmedchem.6b01821/20170216/images/medium/jm-2016-01821e_0013.gif" alt="" id="GRAPHIC-d117e1167-autogenerated" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t6fn1"><div class="footnote" id="t6fn1"><sup>Table a</sup><p class="last">Average of ≥2 determinations.</p></div><div class="footnote" id="t6fn2"><sup>Table b</sup><p class="last">10<sup>6</sup> cm/s.</p></div><div class="footnote" id="t6fn3"><sup>Table c</sup><p class="last">Predicted clearance in hepatocytes.</p></div><div class="footnote" id="t6fn4"><sup>Table d</sup><p class="last">Intravenous dose of 1 mg/kg.</p></div><div class="footnote" id="t6fn5"><sup>Table e</sup><p class="last">Volume of distribution at steady state.</p></div><div class="footnote" id="t6fn6"><sup>Table f</sup><p class="last">Oral dose of 5 mg/kg.</p></div><div class="footnote" id="t6fn7"><sup>Table g</sup><p class="last">Number of animals per dosing route = 3. ND = value not determined. h = human. r = rat.</p></div></div><div></div></div><div class="NLM_p">Inspired by the rat pharmacokinetic profiles of <b>11</b> and <b>20a</b>, we envisaged combining the positive features of these two analogs in one compound along with the metabolically stable 2,6-diamino-5-cyanopyrimidine hinge binder exemplified in compounds <b>7</b> and <b>8</b>. The resulting compound (<b>26</b>) yields a promising amalgamation of both bio- and physicochemical properties including a significant improvement in forward permeability in comparison to <b>7</b> and <b>8</b>. Encouraged by the low predicted clearance and the improved permeability, we progressed compound <b>26</b> to in vivo pharmacokinetic evaluation. In addition to poor correlation between predicted and observed clearances, oral dosing of <b>26</b> at 5 mg/kg in rat suffers from a disappointing bioavailability of 12%. Among these four compounds, <b>20a</b> is the most attractive based on its combination of potency and selectivity, lower predicted and observed clearances, and bioavailability.</div><div class="NLM_p">A summary of the pharmacokinetic parameters in additional preclinical species after intravenous and oral administration of <b>20a</b> is presented in <a class="ref internalNav" href="#tbl7" aria-label="Table 7">Table 7</a>. The in vivo data indicate that <b>20a</b> has low to intermediate total clearance (CL) in comparison to hepatic blood flow in all species evaluated. Volumes of distribution (<i>V</i><sub>ss</sub>) are higher than total body water in all species with the exception of rat in which higher plasma protein binding (PPB) is observed. The apparent elimination half-life (<i>t</i><sub>1/2</sub>) and mean residence time (MRT) are 2–3 h in rat, 4–5 h in dog and rhesus monkey, and 5–6 h in cynomolgus monkey. More than half of the administered dose is orally bioavailable in rat, dog, and cynomolgus monkey. The high oral bioavailability is consistent with low observed clearance.</div><div class="NLM_table-wrap" id="tbl7"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 7. Summary of Pharmacokinetic Parameters for <b>20a</b> in Preclinical Species</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">parameter</th><th class="colsep0 rowsep0" align="center">Sprague-Dawley rat</th><th class="colsep0 rowsep0" align="center">beagle dog</th><th class="colsep0 rowsep0" align="center">cynomolgus monkey</th><th class="colsep0 rowsep0" align="center">rhesus monkey</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">PPB (% free)<a class="ref internalNav" href="#t7fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="left">0.85</td><td class="colsep0 rowsep0" align="left">1.96</td><td class="colsep0 rowsep0" align="left">3.05</td><td class="colsep0 rowsep0" align="left">3.33</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><sup>3</sup>H CL<sub>pr</sub> (L h<sup>–1</sup> kg<sup>–1</sup>)<a class="ref internalNav" href="#t7fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">0.89</td><td class="colsep0 rowsep0" align="left">0.67</td><td class="colsep0 rowsep0" align="left">0.25</td><td class="colsep0 rowsep0" align="left">0.58</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CL (L h<sup>–1</sup> kg<sup>–1</sup>)<a class="ref internalNav" href="#t7fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="left">0.26 ± 0.02</td><td class="colsep0 rowsep0" align="left">0.25 ± 0.11</td><td class="colsep0 rowsep0" align="left">0.24 ± 0.07</td><td class="colsep0 rowsep0" align="left">0.41 ± 0.03</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">V<sub>ss</sub> (L/kg)<a class="ref internalNav" href="#t7fn4" aria-label="d">d</a></td><td class="colsep0 rowsep0" align="left">0.52 ± 0.03</td><td class="colsep0 rowsep0" align="left">1.14 ± 0.36</td><td class="colsep0 rowsep0" align="left">1.50 ± 0.34</td><td class="colsep0 rowsep0" align="left">1.88 ± 0.17</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">terminal <i>t</i><sub>1/2</sub> (h)<a class="ref internalNav" href="#t7fn5" aria-label="e">e</a></td><td class="colsep0 rowsep0" align="left">2.69 ± 0.27</td><td class="colsep0 rowsep0" align="left">3.91 ± 0.23</td><td class="colsep0 rowsep0" align="left">4.96 ± 0.46</td><td class="colsep0 rowsep0" align="left">3.61 ± 0.21</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">MRT (h)<a class="ref internalNav" href="#t7fn6" aria-label="f">f</a></td><td class="colsep0 rowsep0" align="left">1.97 ± 0.20</td><td class="colsep0 rowsep0" align="left">4.77 ± 0.56</td><td class="colsep0 rowsep0" align="left">6.28 ± 0.59</td><td class="colsep0 rowsep0" align="left">4.54 ± 0.19</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>F</i> (%)<a class="ref internalNav" href="#t7fn7" aria-label="g">g</a></td><td class="colsep0 rowsep0" align="left">66.4 ± 17.5</td><td class="colsep0 rowsep0" align="left">90.4 ± 21.7</td><td class="colsep0 rowsep0" align="left">68.6 ± 10.5</td><td class="colsep0 rowsep0" align="left">ND</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t7fn1"><div class="footnote" id="t7fn1"><sup>a</sup><p class="last">Plasma protein binding.</p></div><div class="footnote" id="t7fn2"><sup>b</sup><p class="last">Predicted clearance in hepatocytes using <sup>3</sup>H compound.</p></div><div class="footnote" id="t7fn3"><sup>c</sup><p class="last">Intravenous dose of 1 mg/kg.</p></div><div class="footnote" id="t7fn4"><sup>d</sup><p class="last">Volume of distribution at steady state.</p></div><div class="footnote" id="t7fn5"><sup>e</sup><p class="last">Half-life iv.</p></div><div class="footnote" id="t7fn6"><sup>f</sup><p class="last">Mean residence time iv.</p></div><div class="footnote" id="t7fn7"><sup>g</sup><p class="last">Oral doses of <b>20a</b> (5 mg/kg) were formulated in 5% ethanol, 50% PEG 300, and 45% water. ND = value not determined. Mean ± SD, <i>n</i> = 3.</p></div></div></div><div class="NLM_p">Further characterization of <b>20a</b> revealed that it does not inhibit major human CYP450 enzymes (IC<sub>50</sub> > 25 uM) or hERG (IC<sub>50</sub> > 25 μM) in binding assays. Compound <b>20a</b> does not significantly interact with any protein kinases using the KINOMEscan (DiscoveRx) platform at a compound concentration of 10 μM, validating that <b>20a</b> is a potent and selective inhibitor of PI3Kβ/δ (see <a href="/doi/suppl/10.1021/acs.jmedchem.6b01821/suppl_file/jm6b01821_si_001.pdf" class="ext-link">Supporting Information</a>).</div><div class="NLM_p">As previously discussed, in PTEN-deficient tumors, the counterbalance to constitutive PI3Kβ activity is absent, leading to increased signaling through the PI3K/AKT pathway. The phosphorylation state of AKT has been extensively used as a downstream measure of PI3K activity.<a onclick="showRef(event, 'ref12 ref13 ref14 ref15 ref16 ref17 ref18 ref19 ref20 ref21 ref22 ref23 ref24 ref25 ref26 ref27'); return false;" href="javascript:void(0);" class="ref ref12 ref13 ref14 ref15 ref16 ref17 ref18 ref19 ref20 ref21 ref22 ref23 ref24 ref25 ref26 ref27">(12-27)</a> Downstream signaling effects of <b>20a</b> inhibition have been characterized in a subset of PTEN-deficient tumor cell lines that show dependence on PI3Kβ for viability: the prostate carcinomas PC3 and LNCaP, and the breast adenocarcinomas MDA-MB-415 and ZR-75-1 (<a class="ref internalNav" href="#tbl8" aria-label="Table 8">Table 8</a>). We also included the kidney carcinoma A498 cell line which has a PI3Kβ activating mutation. Compound <b>20a</b> inhibits the phosphorylation of AKT1 Ser473 in these PI3Kβ-dependent cell lines with EC<sub>50</sub> values ranging from 3.4 nM to 7.3 nM. Cell viability was also found to be potently inhibited by <b>20a</b> with GI<sub>50</sub> ranging from 2 to 120 nM.</div><div class="NLM_table-wrap" id="tbl8"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 8. Activity of <b>20a</b> against AKT1 Ser473 Phosphorylation in PI3Kβ-Dependent Tumor Cell Lines</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">cell line</th><th class="colsep0 rowsep0" align="center" char=".">EC<sub>50</sub> (nM)<a class="ref internalNav" href="#t8fn3" aria-label="c">c</a></th><th class="colsep0 rowsep0" align="center" char=".">GI<sub>50</sub> (nM)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">PC3<a class="ref internalNav" href="#t8fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="char" char=".">5.4</td><td class="colsep0 rowsep0" align="char" char=".">120</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">LNCaP<a class="ref internalNav" href="#t8fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="char" char=".">7.3</td><td class="colsep0 rowsep0" align="char" char=".">38</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">MDA-MB-415<a class="ref internalNav" href="#t8fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="char" char=".">5.7</td><td class="colsep0 rowsep0" align="char" char=".">12</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">ZR-75-1<a class="ref internalNav" href="#t8fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="char" char=".">3.4</td><td class="colsep0 rowsep0" align="char" char=".">2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">A498<a class="ref internalNav" href="#t8fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="char" char=".">5.6</td><td class="colsep0 rowsep0" align="char" char=".">80</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t8fn1"><div class="footnote" id="t8fn1"><sup>a</sup><p class="last">PTEN-deficient.</p></div><div class="footnote" id="t8fn2"><sup>b</sup><p class="last">PI3Kβ mutant.</p></div><div class="footnote" id="t8fn3"><sup>c</sup><p class="last">Data determined from the ratio of units of pAKT1 Ser473 per nanogram of total AKT1.</p></div></div></div><div class="NLM_p">The activity of <b>20a</b> was assessed in a human PTEN-deficient, androgen-responsive LNCaP xenograft tumor model. As shown previously, AKT Ser473 phosphorylation and cell viability of LNCaP tumor cells are potently inhibited by PI3Kβ inhibitor <b>20a</b> (EC<sub>50</sub> = 7.3 nM and GI<sub>50</sub> = 38 nM). Mice engrafted with LNCaP tumor cells were treated with <b>20a</b> at 15 mg/kg, 7.5 mg/kg, and 3 mg/kg twice a day for 13 consecutive days following the establishment of the tumor (<a class="ref internalNav" href="#fig5" aria-label="Figure 5">Figure 5</a>). Tumor burden expressed as volume (mm<sup>3</sup>) was measured twice a week throughout the experiment. After the final dose, treatment with <b>20a</b> resulted in tumor growth inhibition of 73%, 65%, and 42% in the 15 mg/kg, 7.5 mg/kg, and 3 mg/kg dose groups, respectively (<i>p</i> < 0.0001). There was no statistical difference between the tumor growth inhibition at 7.5 mg/kg and 15 mg/kg, suggesting a maximal efficacious dose of 7.5 mg/kg in this experiment.</div><figure id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-4/acs.jmedchem.6b01821/20170216/images/medium/jm-2016-01821e_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-4/acs.jmedchem.6b01821/20170216/images/large/jm-2016-01821e_0005.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Activity of <b>20a</b> in a human PTEN-deficient, androgen-responsive LNCaP xenograft tumor model in mice. <b>20a</b> was dosed twice a day for 13 consecutive days following the establishment of the tumor.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-4/acs.jmedchem.6b01821/20170216/images/large/jm-2016-01821e_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01821&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Inhibition of pAKT1 Ser473 was assessed in the LNCaP xenograft model at study completion. After the final dose, each treatment group was divided into subgroups of three mice. Plasma and tumors were harvested at 2, 8, or 12 h postdose. Plasma levels of <b>20a</b> were determined, and tumors were lysed and assayed for the presence of pAKT1 and total AKT1 at each time point (<a class="ref internalNav" href="#fig6" aria-label="Figure 6">Figure 6</a>). Maximum inhibition of AKT1 phosphorylation (64%) was observed at 8 h in the 7.5 mg/kg and 2 h in the 15 mg/kg treatment groups. Target coverage in the tumor was compared to the protein adjusted EC<sub>90</sub> (highest dotted line in <a class="ref internalNav" href="#fig6" aria-label="Figure 6">Figure 6</a>). At the 12 h time point, coverage over protein adjusted EC<sub>90</sub> was shown to be 7× and 17× for the 3 mg/kg and 7.5 mg/kg doses, respectively.</div><figure id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-4/acs.jmedchem.6b01821/20170216/images/medium/jm-2016-01821e_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-4/acs.jmedchem.6b01821/20170216/images/large/jm-2016-01821e_0006.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. AKT1 phosphorylation levels in LNCaP xenograft tumors treated with <b>20a</b> with corresponding mice plasma levels. Data are presented as the ratio of units of pAKT1 Ser473 per nanogram of total AKT1. The lower and higher dashed lines represent protein adjusted EC<sub>50</sub> and EC<sub>90</sub>, respectively.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-4/acs.jmedchem.6b01821/20170216/images/large/jm-2016-01821e_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01821&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i11">Chemistry</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_58046" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_58046" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Analogs <b>1</b>–<b>26</b> were synthesized following the previously described general synthetic route shown in <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>.<a onclick="showRef(event, 'ref12 ref13'); return false;" href="javascript:void(0);" class="ref ref12 ref13">(12, 13)</a> The quinazolinone core <b>31</b> is constructed via a one-pot, two-step dehydrative cyclization.<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> Oxazinone intermediate <b>29</b> is prepared by treatment of an anthranilic acid <b>27</b> with a protected amino acid <b>28</b> in the presence of diphenyl phosphite in pyridine. Subsequent addition of aniline (<b>30a</b>), 4-((<i>tert</i>-butyldimethylsilyl)oxy)aniline (<b>30b</b>), 3-amino-1<i>H</i>-pyrazole (<b>30c</b>), 4-amino-1<i>H</i>-pyrazole (<b>30d</b>), or 3-aminoisoxazole (<b>30e</b>) to the reaction mixture results in the formation of the quinazolinone <b>31</b>. Removal of the <i>tert</i>-butoxycarbonyl group of <b>31</b> (as well as the <i>tert</i>-butyldimethylsilyl group in the cases of <b>31c</b> and <b>31d</b>) with trifluoroacetic acid affords the primary amine <b>32</b> which is reacted with a substituted halopyrimidine <b>33</b> for the incorporation of the hinge binder to afford the final PI3Kβ/δ inhibitors (<b>1</b>–<b>26</b>).</div><figure id="sch1" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-4/acs.jmedchem.6b01821/20170216/images/medium/jm-2016-01821e_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-4/acs.jmedchem.6b01821/20170216/images/large/jm-2016-01821e_0007.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. General Synthetic Sequence<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-4/acs.jmedchem.6b01821/20170216/images/large/jm-2016-01821e_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01821&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (i) pyridine, diphenyl phosphite, 40 °C, 2 h; (ii) 50 °C, 3–20 h, 50–100%; (iii) CF<sub>3</sub>CO<sub>2</sub>H, CH<sub>2</sub>Cl<sub>2</sub>, rt, 0.5–4 h, quant; (iv) <i>i</i>-Pr<sub>2</sub>NEt, isopropanol, 80–130 °C, microwave or thermal, 80–130 °C, 1–24 h, 30–90%. Boc = <i>tert</i>-butoxycarbonyl. TBS = <i>tert</i>-butyldimethylsilyl.</p></p></figure></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i13">Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_32508" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_32508" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">In summary, we have discovered and optimized a series of potent and highly selective PI3Kβ/δ inhibitors. This was achieved by building PI3Kβ potency in a PI3Kδ-selective template by introducing a pyrazole moiety which presumably engages an interaction with Asp856. The pyrimidine hinge binder was optimized to yield adequate metabolic stability and forward permeability. Modification of the quinazolinone substituents led to improved isoform selectivity, culminating in <b>20a</b>, a potent and selective inhibitor of PI3Kβ/δ with good pharmacokinetic properties. Moreover, <b>20a</b> demonstrated efficacy in a human PTEN-deficient LNCaP prostate carcinoma xenograft tumor model. Additional studies will be presented in future publications.</div></div><div id="sec5" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i14">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_11517" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_11517" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec5_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i15" class="anchor-spacer"></div><h3 class="article-section__title" id="_i15"> General Procedures</h3><div class="NLM_p last">All commercial reagents and anhydrous solvents were used as provided without further purification. Microwave reactions were completed using a benchtop CEM microwave reactor. Flash chromatography was performed using an ISCO Combiflash or a Biotage Isolera purification system with Silicycle prepacked silica gel cartridges. Final compounds were purified by prep HPLC on a Gilson 271 system, with a Phenomenex Kinetex C18 column (250 mm × 30 mm, 100 Å, 5 μm) and a gradient elution of acetonitrile/water with 5–95% for 20 min at a flow rate of 35 mL/min. For all samples, 0.1% TFA was added to both eluents. All <sup>1</sup>H NMR spectra were recorded on a Varian 400-MR 400 MHz spectrometer. Proton chemical shifts are reported in parts per million from an internal standard or residual solvent. The purity of the tested compounds was assessed by an Agilent LCMS. A Silicycle Siliachrom SB C18 column (4.6 mm × 50 mm, 3 μm) was used with a gradient elution of acetonitrile in water, 0–95% for 7 min at a flow rate of 0.9 mL/min with detection at 256 nm. Alternatively, a Chromolith column (50 mm × 2 mm) was used with a gradient elution of acetonitrile in water, 0–95% for 3 min at a flow rate of 1.9 mL/min with detection at 256 nm wavelength. For all samples 0.1% TFA was added to both eluents. All final compounds were determined to be at least 95% pure by LC analysis.</div></div><div id="sec5_1_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i16" class="anchor-spacer"></div><h3 class="article-section__title" id="_i16"> (<i>S</i>)-2-(1-((9<i>H</i>-Purin-6-yl)amino)propyl)-5-fluoro-3-(4-hydroxyphenyl)quinazolin-4(3<i>H</i>)-one (<b>2</b>)</h3><div class="NLM_p last">2-Propanol (3 mL) was added to (<i>S</i>)-2-(1-aminopropyl)-5-fluoro-3-(4-hydroxyphenyl)quinazolin-4(3<i>H</i>)-one 2,2,2-trifluoroacetic acid salt (<b>32b</b>) (0.25 mmol), and the solution was transferred to a sealed tube containing 6-chloro-9-(tetrahydro-2<i>H</i>-pyran-2-yl)-9<i>H</i>-purine (<b>33a</b>) (60 mg, 0.25 mmol). Diisopropylethylamine (0.25 mL, 1.5 mmol) was added, and the reaction mixture was heated to 100 °C for 16 h. The reaction was cooled to room temperature and concentrated. Dichloromethane (2.5 mL) and trifluoroacetic acid (0.39 mL, 5.0 mmol) were added. The solution was stirred at room temperature for 3 h and concentrated in vacuuo. A DMSO solution of the crude mixture was then purified by HPLC, eluting with 5–95% water/acetonitrile (0.1% v/v trifluoroacetic acid). The appropriate fractions were pooled and lyophilized to afford (<i>S</i>)-2-(1-((9<i>H</i>-purin-6-yl)amino)propyl)-5-fluoro-3-(4-hydroxyphenyl)quinazolin-4(3<i>H</i>)-one 2,2,2-trifluoroacetic acid salt (<b>2</b>) as a white solid (51 mg). <sup>1</sup>H NMR (400 MHz, DMSO) δ 12.97 (s, 1H), 9.84 (s, 1H), 8.29–8.11 (m, 2H), 7.85–7.70 (m, 2H) 7.42 (d, <i>J</i> = 8.4 Hz, 2H), 7.35–7.40 (m, 2H), 6.95–6.80 (m, 2H), 4.74 (br s, 1H), 1.89 (br s, 2H), 0.76 (t, <i>J</i> = 7.2 Hz). ES/MS <i>m</i>/<i>z</i> = 432.3 (M + H)<sup>+</sup>.</div></div><div id="sec5_2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i17" class="anchor-spacer"></div><h3 class="article-section__title" id="_i17"> General Procedure A. (<i>S</i>)-4-Amino-6-((1-(5-chloro-4-oxo-3-phenyl-3,4-dihydroquinazolin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile (<b>3</b>)</h3><div class="NLM_p last">2-Propanol (3 mL) was added to (<i>S</i>)-2-(1-aminoethyl)-5-chloro-3-phenylquinazolin-4(3<i>H</i>)-one 2,2,2-trifluoroacetic acid salt (<b>32c</b>) (0.25 mmol), and the solution was transferred to a sealed tube containing 4-amino-6-chloropyrimidine-5-carbonitrile (<b>33b</b>) (39 mg, 0.25 mmol). Diisopropylethylamine (0.25 mL, 1.5 mmol) was added, and the reaction mixture was heated to 80 °C for 16 h. The reaction was cooled to room temperature and concentrated. A DMSO solution of the crude mixture was then purified by HPLC, eluting with 5–95% water/acetonitrile (0.1% v/v trifluoroacetic acid). The appropriate fractions were pooled and lyophilized to afford (<i>S</i>)-4-amino-6-((1-(5-chloro-4-oxo-3-phenyl-3,4-dihydroquinazolin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile (<b>3</b>) as a white solid (53 mg). <sup>1</sup>H NMR (400 MHz, DMSO) δ 7.85 (s, 1H), 7.80–7.40 (m, 8H), 7.25 (br, 2H), 4.75 (m, 1H), 1.33 (d, 3H). ES/MS <i>m</i>/<i>z</i> = 418.1 (M + H)<sup>+</sup>.</div></div><div id="sec5_2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i18" class="anchor-spacer"></div><h3 class="article-section__title" id="_i18"> (<i>S</i>)-4-Amino-6-((1-(5-chloro-3-(4-hydroxyphenyl)-4-oxo-3,4-dihydroquinazolin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile (<b>4</b>)</h3><div class="NLM_p last">Prepared according to general procedure A using <b>32d</b>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.79 (s, 1H), 7.95 (s, 1H), 7.76 (t, <i>J</i> = 8.0 Hz, 1H), 7.61 (dd, <i>J</i> = 8.2, 1.2 Hz, 1H), 7.56 (dd, <i>J</i> = 7.7, 1.2 Hz, 1H), 7.50 (d, <i>J</i> = 6.6 Hz, 1H), 7.28 (ddt, <i>J</i> = 7.0, 4.5, 2.6 Hz, 3H), 6.90–6.80 (m, 2H), 4.79 (p, <i>J</i> = 6.6 Hz, 1H), 1.35 (d, <i>J</i> = 6.7 Hz, 3H). ES/MS <i>m</i>/<i>z</i> = 434.1 (M + H)<sup>+</sup>.</div></div><div id="sec5_2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i19" class="anchor-spacer"></div><h3 class="article-section__title" id="_i19"> (<i>S</i>)-4-Amino-6-((1-(5-chloro-4-oxo-3-(1<i>H</i>-pyrazol-3-yl)-3,4-dihydroquinazolin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile (<b>5</b>)</h3><div class="NLM_p last">Prepared according to general procedure A using <b>32e</b>. <sup>1</sup>H NMR (400 MHz, DMSO) δ 13.14 (br s, 1H), 7.93 (s, 1H), 7.87 (d, <i>J</i> = 2 Hz, 1H), 7.75 (t, <i>J</i> = 8 Hz, 1H), 7.58 (dd, <i>J</i> = 8, 1 Hz), 7.54 (dd, <i>J</i> = 8, 1 Hz, 1H), 7.43 (d, <i>J</i> = 7 Hz, 1H), 7.26 (s, 2H), 6.40 (d, <i>J</i> = 2 Hz, 1H), 4.82 (p, <i>J</i> = 7 Hz, 1H), 1.36 (d, <i>J</i> = 7 Hz, 3H). ES/MS <i>m</i>/<i>z</i> = 408.1 (M + H)<sup>+</sup>.</div></div><div id="sec5_2_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i20" class="anchor-spacer"></div><h3 class="article-section__title" id="_i20"> (<i>S</i>)-4-Amino-6-((1-(5-chloro-4-oxo-3-(1<i>H</i>-pyrazol-4-yl)-3,4-dihydroquinazolin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile (<b>6</b>)</h3><div class="NLM_p last">Prepared according to general procedure A using <b>32f</b>. <sup>1</sup>H NMR (400 MHz, DMSO) δ 8.04 (s, 1H), 7.84 (s, 2H), 7.75 (d, <i>J</i> = 8 Hz, 2H), 7.60 (dd, <i>J</i> = 8.4, 1.2 Hz, 1H), 7.57 (dd, <i>J</i> = 6.4, 1.2 Hz, 1H), 7.45 (bs, 2H), 4.94 (m, 1H), 1.38 (d, <i>J</i> = 6.8 Hz, 3H). ES/MS <i>m</i>/<i>z</i> = 408.1 (M + H)<sup>+</sup>.</div></div><div id="sec5_3_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i21" class="anchor-spacer"></div><h3 class="article-section__title" id="_i21"> General Procedure B. (<i>S</i>)-2,4-Diamino-6-((1-(5-chloro-4-oxo-3-(1<i>H</i>-pyrazol-3-yl)-3,4-dihydroquinazolin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile (<b>7</b>)</h3><div class="NLM_p last">2-Propanol (3 mL) was added to (<i>S</i>)-2-(1-aminoethyl)-5-chloro-3-(1<i>H</i>-pyrazol-3-yl)quinazolin-4(3<i>H</i>)-one 2,2,2-trifluoroacetic acid salt (<b>32e</b>) (0.25 mmol), and the resulting solution was transferred to a microwave vial containing 2,4-diamino-6-chloropyrimidine-5-carbonitrile (<b>33c</b>) (42 mg, 0.25 mmol). Diisopropylethylamine (0.25 mL, 1.5 mmol) was added and the reaction mixture was heated to 130 °C for 14 h in the microwave. The reaction was cooled to room temperature and concentrated. A DMSO solution of the crude mixture was then purified by HPLC, eluting with 5–95% water/acetonitrile (0.1% v/v trifluoroacetic acid). The appropriate fractions were pooled and lyophilized to afford (<i>S</i>)-2,4-diamino-6-((1-(5-chloro-4-oxo-3-(1<i>H</i>-pyrazol-3-yl)-3,4-dihydroquinazolin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile 2,2,2-trifluoroacetic acid salt (<b>7</b>) as a white solid (60 mg). <sup>1</sup>H NMR (400 MHz, DMSO) δ 13.20 (br s, 1H), 7.91 (d, <i>J</i> = 2.4 Hz, 1H), 7.84–7.77 (m, 1H), 7.65–7.59 (m, 2H), 6.55–6.52 (m, 1H), 4.85–4.75 (m, 1H), 1.41 (d, <i>J</i> = 6.7 Hz, 3H). ES/MS <i>m</i>/<i>z</i> = 423.1 (M + H)<sup>+</sup>.</div></div><div id="sec5_3_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i22" class="anchor-spacer"></div><h3 class="article-section__title" id="_i22"> (<i>S</i>)-2,4-Diamino-6-(((5-chloro-4-oxo-3-(1<i>H</i>-pyrazol-3-yl)-3,4-dihydroquinazolin-2-yl)(cyclopropyl)methyl)amino)pyrimidine-5-carbonitrile (<b>8</b>)</h3><div class="NLM_p last">Prepared according to general procedure B using <b>32g</b>. <sup>1</sup>H NMR (400 MHz, DMSO) δ 13.15 (br s, 1H), 7.90–7.74 (m, 2H), 7.69–7.61 (m, 2H), 6.38 (d, <i>J</i> = 2.3 Hz, 1H), 4.72 (t, <i>J</i> = 7.6 Hz, 1H), 1.47–1.37 (m, 1H), 0.53–0.36 (m, 3H), 0.24–0.14 (m, 1H). ES/MS <i>m</i>/<i>z</i> = 449.1 (M + H)<sup>+</sup>.</div></div><div id="sec5_3_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i23" class="anchor-spacer"></div><h3 class="article-section__title" id="_i23"> (<i>S</i>)-5-Chloro-2-(1-((2,6-diaminopyrimidin-4-yl)amino)ethyl)-3-(1<i>H</i>-pyrazol-3-yl)quinazolin-4(3<i>H</i>)-one (<b>9</b>)</h3><div class="NLM_p last">Prepared according to general procedure B using <b>32e</b> and 6-chloropyrimidine-2,4-diamine (<b>33d</b>). <sup>1</sup>H NMR (400 MHz, DMSO) δ 13.17 (s, 1H), 10.89 (s, 1H), 8.22 (d, <i>J</i> = 6.6 Hz, 1H), 7.89 (s, 1H), 7.78–7.70 (m, 1H), 7.60–7.52 (m, 2H), 7.11 (s, 1H), 7.02 (s, 1H), 6.66 (d, <i>J</i> = 2.4 Hz, 1H), 5.17 (s, 1H), 4.57–4.47 (m, 1H), 1.34 (d, <i>J</i> = 6.9 Hz, 3H). ES/MS <i>m</i>/<i>z</i> = 398.1 (M + H)<sup>+</sup>.</div></div><div id="sec5_4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i24" class="anchor-spacer"></div><h3 class="article-section__title" id="_i24"> General Procedure C. (<i>S</i>)-5-Chloro-2-(1-((2,6-diamino-5-chloropyrimidin-4-yl)amino)ethyl)-3-(1<i>H</i>-pyrazol-3-yl)quinazolin-4(3<i>H</i>)-one (<b>10</b>)</h3><div class="NLM_p last">2-Propanol (3 mL) was added to (<i>S</i>)-2-(1-aminoethyl)-5-chloro-3-(1<i>H</i>-pyrazol-3-yl)quinazolin-4(3<i>H</i>)-one 2,2,2-trifluoroacetic acid salt (<b>32e</b>) (0.25 mmol), and the solution was transferred to a microwave vial containing 5-chloro-6-fluoropyrimidine-2,4-diamine (<b>33e</b>) (41 mg, 0.25 mmol). Diisopropylethylamine (0.25 mL, 1.5 mmol) was added, and the reaction mixture was heated to 130 °C for 14 h in the microwave. The reaction was cooled to room temperature and concentrated. A DMSO solution of the crude mixture was then purified by HPLC, eluting with 5–95% water/acetonitrile (0.1% v/v trifluoroacetic acid). The appropriate fractions were pooled and lyophilized to afford (<i>S</i>)-5-chloro-2-(1-((2,6-diamino-5-chloropyrimidin-4-yl)amino)ethyl)-3-(1<i>H</i>-pyrazol-3-yl)quinazolin-4(3<i>H</i>)-one (<b>10</b>) as a white solid (55 mg). <sup>1</sup>H NMR (400 MHz, DMSO) δ 13.22 (br s, 1H), 7.91 (d, <i>J</i> = 2.4 Hz, 1H), 7.81 (t, <i>J</i> = 8.0 Hz, 1H), 7.71 (d, <i>J</i> = 6.8 Hz, 1H), 7.66 (dd, <i>J</i> = 8.2, 1.2 Hz, 1H), 7.62 (dd, <i>J</i> = 7.8, 1.2 Hz, 1H), 7.52 (br s, 2H), 7.38 (br s, 2H), 6.54 (d, <i>J</i> = 2.4 Hz, 1H), 4.79 (p, <i>J</i> = 6.7 Hz, 1H), 1.43 (d, <i>J</i> = 6.8 Hz, 3H). ES/MS 432.1 (M + H)<sup>+</sup>.</div></div><div id="sec5_4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i25" class="anchor-spacer"></div><h3 class="article-section__title" id="_i25"> (<i>S</i>)-5-Chloro-2-(cyclopropyl((2,6-diamino-5-chloropyrimidin-4-yl)amino)methyl)-3-(1<i>H</i>-pyrazol-3-yl)quinazolin-4(3<i>H</i>)-one (<b>11</b>)</h3><div class="NLM_p last">Prepared according to general procedure C using <b>32g</b>. <sup>1</sup>H NMR (400 MHz, DMSO) δ 13.17 (br s, 1H), 7.86 (d, <i>J</i> = 2.3 Hz, 1H), 7.82 (t, <i>J</i> = 8.0 Hz, 1H), 7.70 (dd, <i>J</i> = 8.2, 1.2 Hz, 1H), 7.63 (dd, <i>J</i> = 7.8, 1.2 Hz, 1H), 7.49 (br s, 3H), 7.35 (br s, 2H), 6.38 (d, <i>J</i> = 2.3 Hz, 1H), 4.71 (t, <i>J</i> = 7.7 Hz, 1H), 1.42–1.32 (m, 1H), 0.53–0.37 (m, 3H), 0.22–0.13 (m, 1H). ES/MS <i>m</i>/<i>z</i> = 458.1 (M + H)<sup>+</sup>.</div></div><div id="sec5_4_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i26" class="anchor-spacer"></div><h3 class="article-section__title" id="_i26"> (<i>S</i>)-2-Amino-4-(((5-chloro-4-oxo-3-(1<i>H</i>-pyrazol-3-yl)-3,4-dihydroquinazolin-2-yl)(cyclopropyl)methyl)amino)-6-methylpyrimidine-5-carbonitrile (<b>12</b>)</h3><div class="NLM_p last">2-Propanol (3 mL) was added to (<i>S</i>)-2-(amino(cyclopropyl)methyl)-5-chloro-3-(1<i>H</i>-pyrazol-3-yl)quinazolin-4(3<i>H</i>)-one 2,2,2-trifluoroacetic acid salt (<b>32g</b>) (0.25 mmol), and the resulting solution was transferred to a microwave vial containing 2-amino-4-chloro-6-methylpyrimidine-5-carbonitrile (<b>33f</b>) (41 mg, 0.25 mmol). Diisopropylethylamine (0.25 mL, 1.5 mmol) was added, and the reaction mixture was heated to 90 °C for 16 h in the microwave. The reaction was cooled to room temperature and concentrated. A DMSO solution of the crude mixture was then purified by HPLC, eluting with 5–95% water/acetonitrile (0.1% v/v trifluoroacetic acid). The appropriate fractions were pooled and lyophilized to afford (<i>S</i>)-2-amino-4-(((5-chloro-4-oxo-3-(1<i>H</i>-pyrazol-3-yl)-3,4-dihydroquinazolin-2-yl)(cyclopropyl)methyl)amino)-6-methylpyrimidine-5-carbonitrile 2,2,2-trifluoroacetic acid salt (<b>12</b>) as a white solid (44 mg). <sup>1</sup>H NMR (400 MHz, DMSO) δ 13.11 (br s, 1H), 7.87–7.79 (m, 2H), 7.67 (dd, <i>J</i> = 8.2, 1.2 Hz, 1H), 7.62 (dd, <i>J</i> = 7.8, 1.2 Hz, 1H), 6.38 (d, <i>J</i> = 2.3 Hz, 1H), 4.73 (t, <i>J</i> = 7.6 Hz, 1H), 2.30 (s, 3H), 1.47–1.37 (m, 1H), 0.53–0.37 (m, 3H), 0.24–0.15 (m, 1H). ES/MS <i>m</i>/<i>z</i> = 448.1 (M + H)<sup>+</sup>.</div></div><div id="sec5_4_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i27" class="anchor-spacer"></div><h3 class="article-section__title" id="_i27"> (<i>S</i>)-2-Amino-4-chloro-6-(((5-chloro-4-oxo-3-(1<i>H</i>-pyrazol-3-yl)-3,4-dihydroquinazolin-2-yl)(cyclopropyl)methyl)amino)pyrimidine-5-carbonitrile (<b>13</b>)</h3><div class="NLM_p last">2-Propanol (3 mL) was added to (<i>S</i>)-2-(amino(cyclopropyl)methyl)-5-chloro-3-(1<i>H</i>-pyrazol-3-yl)quinazolin-4(3<i>H</i>)-one 2,2,2-trifluoroacetic acid salt (<b>32g</b>) (0.25 mmol), and the solution was transferred to a sealed tube containing 2-amino-4,6-dichloropyrimidine-5-carbonitrile (<b>33g</b>) (47 mg, 0.25 mmol). Diisopropylethylamine (0.25 mL, 1.5 mmol) was added, and the reaction mixture was heated to 130 °C for 16 h. The reaction was cooled to room temperature and concentrated. A DMSO solution of the crude mixture was then purified by HPLC, eluting with 5–95% water/acetonitrile (0.1% v/v trifluoroacetic acid). The appropriate fractions were pooled and lyophilized to afford (<i>S</i>)-2-amino-4-chloro-6-(((5-chloro-4-oxo-3-(1<i>H</i>-pyrazol-3-yl)-3,4-dihydroquinazolin-2-yl)(cyclopropyl)methyl)amino)pyrimidine-5-carbonitrile 2,2,2-trifluoroacetic acid salt (<b>13</b>) as a white solid (65 mg). <sup>1</sup>H NMR (400 MHz, DMSO) δ 13.08 (br s, 1H), 7.85–7.78 (m, 2H), 7.67 (dd, <i>J</i> = 8.2, 1.2 Hz, 1H), 7.62 (dd, <i>J</i> = 7.8, 1.2 Hz, 1H), 7.57 (d, <i>J</i> = 7.4 Hz, 1H), 7.29 (br s, 1H), 6.35 (d, <i>J</i> = 2.4 Hz, 1H), 4.71 (t, <i>J</i> = 7.7 Hz, 1H), 1.48–1.39 (m, 1H), 0.54–0.38 (m, 3H), 0.22–0.13 (m, 1H). ES/MS <i>m</i>/<i>z</i> = 468.1 (M + H)<sup>+</sup>.</div></div><div id="sec5_5_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i28" class="anchor-spacer"></div><h3 class="article-section__title" id="_i28"> General Procedure D. (<i>S</i>)-2-Amino-4-(((5-chloro-4-oxo-3-(1<i>H</i>-pyrazol-3-yl)-3,4-dihydroquinazolin-2-yl)(cyclopropyl)methyl)amino)-6-(difluoromethyl)pyrimidine-5-carbonitrile (<b>14</b>)</h3><div class="NLM_p last">2-Propanol (3 mL) was added to (<i>S</i>)-2-(amino(cyclopropyl)methyl)-5-chloro-3-(1<i>H</i>-pyrazol-3-yl)quinazolin-4(3<i>H</i>)-one 2,2,2-trifluoroacetic acid salt (<b>32g</b>) (0.25 mmol), and the solution was transferred to a sealed tube containing 2-amino-4-chloro-6-(difluoromethyl)pyrimidine-5-carbonitrile (<b>33h</b>) (51 mg, 0.25 mmol). Diisopropylethylamine (0.25 mL, 1.5 mmol) was added, and the reaction mixture was heated to 80 °C for 2 h. The reaction was cooled to room temperature and concentrated. A DMSO solution of the crude mixture was then purified by HPLC, eluting with 5–95% water/acetonitrile (0.1% v/v trifluoroacetic acid). The appropriate fractions were pooled and lyophilized to afford (<i>S</i>)-2-amino-4-(((5-chloro-4-oxo-3-(1<i>H</i>-pyrazol-3-yl)-3,4-dihydroquinazolin-2-yl)(cyclopropyl)methyl)amino)-6-(difluoromethyl)pyrimidine-5-carbonitrile 2,2,2-trifluoroacetic acid salt (<b>14</b>) as a white solid (59 mg). <sup>1</sup>H NMR (400 MHz, DMSO) δ 13.10 (br s, 1H), 7.82–7.75 (m, 2H), 7.63 (dd, <i>J</i> = 8.2, 1.2 Hz, 1H), 7.59 (dd, <i>J</i> = 7.8, 1.2 Hz, 1H), 7.54 (br s, 1H), 7.42 (d, <i>J</i> = 7.4 Hz, 1H), 7.22 (br s, 1H), 6.63 (t, <i>J</i> = 53.6 Hz, 1H), 6.34 (d, <i>J</i> = 2.4 Hz, 1H), 4.74 (t, <i>J</i> = 7.5 Hz, 1H), 1.43–1.32 (m, 1H), 0.48–0.34 (m, 3H), 0.19–0.11 (m, 1H). ES/MS <i>m</i>/<i>z</i> = 484.1 (M + H)<sup>+</sup>.</div></div><div id="sec5_5_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i29" class="anchor-spacer"></div><h3 class="article-section__title" id="_i29"> (<i>S</i>)-2-Amino-4-((1-(5-chloro-4-oxo-3-(1<i>H</i>-pyrazol-3-yl)-3,4-dihydroquinazolin-2-yl)ethyl)amino)-6-(trifluoromethyl)pyrimidine-5-carbonitrile (<b>15</b>)</h3><div class="NLM_p last">2-Propanol (3 mL) was added to (<i>S</i>)-2-(1-aminoethyl)-5-chloro-3-(1<i>H</i>-pyrazol-3-yl)quinazolin-4(3<i>H</i>)-one 2,2,2-trifluoroacetic acid salt (<b>32e</b>) (0.25 mmol), and the resulting solution was transferred to a sealed tube containing 2-amino-4-chloro-6-(trifluoromethyl)pyrimidine-5-carbonitrile (<b>33i</b>) (56 mg, 0.25 mmol). Diisopropylethylamine (0.25 mL, 1.5 mmol) was added, and the reaction mixture was heated to 80 °C for 1 h. The reaction was cooled to room temperature and concentrated. A DMSO solution of the crude mixture was then purified by HPLC, eluting with 5%–95% water/acetonitrile (0.1%v/v trifluoroacetic acid). The appropriate fractions were pooled and lyophilized to afford (<i>S</i>)-2-amino-4-((1-(5-chloro-4-oxo-3-(1<i>H</i>-pyrazol-3-yl)-3,4-dihydroquinazolin-2-yl)ethyl)amino)-6-(trifluoromethyl)pyrimidine-5-carbonitrile 2,2,2-trifluoroacetic acid salt (<b>15</b>) as a white solid (57 mg). <sup>1</sup>H NMR (400 MHz, DMSO) δ 13.17 (s, 1H), 7.99 (d, <i>J</i> = 6.5 Hz, 1H), 7.87 (d, <i>J</i> = 2.4 Hz, 1H), 7.84–7.78 (m, 2H), 7.66–7.59 (m, 2H), 7.48 (br s, 1H), 6.53 (d, <i>J</i> = 2.4 Hz, 1H), 4.86 (p, <i>J</i> = 6.7 Hz, 1H), 1.45 (d, <i>J</i> = 6.7 Hz, 3H). ES/MS <i>m</i>/<i>z</i> = 476.1 (M + H)<sup>+</sup>.</div></div><div id="sec5_5_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i30" class="anchor-spacer"></div><h3 class="article-section__title" id="_i30"> (<i>S</i>)-2-(1-((2,6-Diamino-5-chloropyrimidin-4-yl)amino)ethyl)-5-fluoro-3-(1<i>H</i>-pyrazol-3-yl)quinazolin-4(3<i>H</i>)-one (<b>16a</b>)</h3><div class="NLM_p last">Prepared according to general procedure C using <b>32h</b>. <sup>1</sup>H NMR (400 MHz, DMSO) δ 13.21 (br s, 1H), 7.90 (d, <i>J</i> = 2.3 Hz, 1H), 7.89–7.82 (m, 1H), 7.71 (d, <i>J</i> = 6.7 Hz, 1H), 7.56–7.48 (m, 2H), 7.43–7.28 (m, 4H), 6.53 (d, <i>J</i> = 2.4 Hz, 1H), 4.79 (p, <i>J</i> = 6.7 Hz, 1H), 1.43 (d, <i>J</i> = 6.8 Hz, 3H). ES/MS 416.1 (M + H)<sup>+</sup>.</div></div><div id="sec5_5_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i31" class="anchor-spacer"></div><h3 class="article-section__title" id="_i31"> (<i>S</i>)-2-Amino-4-(difluoromethyl)-6-((1-(5-fluoro-4-oxo-3-(1<i>H</i>-pyrazol-3-yl)-3,4-dihydroquinazolin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile (<b>16b</b>)</h3><div class="NLM_p last">Prepared according to general procedure D using <b>32h</b>. <sup>1</sup>H NMR (400 MHz, DMSO) δ 13.18 (br s, 1H), 7.90–7.82 (m, 2H), 7.80 (d, <i>J</i> = 6.4 Hz, 1H), 7.58 (br s, 1H), 7.52–7.47 (m, 1H), 7.34 (ddd, <i>J</i> = 11.0, 8.2, 1.0 Hz, 1H), 7.23 (br s, 1H), 6.67 (t, <i>J</i> = 53.6 Hz, 1H), 6.55 (d, <i>J</i> = 2.4 Hz, 1H), 4.80 (p, <i>J</i> = 6.6 Hz, 1H), 1.44 (d, <i>J</i> = 6.7 Hz, 3H). ES/MS 442.0 (M + H)<sup>+</sup>.</div></div><div id="sec5_5_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i32" class="anchor-spacer"></div><h3 class="article-section__title" id="_i32"> (<i>S</i>)-2-(1-((2,6-Diamino-5-chloropyrimidin-4-yl)amino)ethyl)-6-fluoro-3-(1<i>H</i>-pyrazol-3-yl)quinazolin-4(3<i>H</i>)-one (<b>17a</b>)</h3><div class="NLM_p last">Prepared according to general procedure C using <b>32i</b>. <sup>1</sup>H NMR (400 MHz, DMSO) δ 13.21 (s, 1H), 7.92 (dd, <i>J</i> = 2.4, 1.7 Hz, 1H), 7.85–7.63 (m, 2H), 6.57 (t, <i>J</i> = 2.2 Hz, 1H), 6.25 (d, <i>J</i> = 7.4 Hz, 1H), 5.96 (s, 2H), 5.50 (s, 2H), 4.62 (p, <i>J</i> = 6.8 Hz, 1H), 1.34 (d, <i>J</i> = 6.7 Hz, 3H). ES/MS 416.1 (M + H)<sup>+</sup>.</div></div><div id="sec5_5_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i33" class="anchor-spacer"></div><h3 class="article-section__title" id="_i33"> (<i>S</i>)-2-Amino-4-(difluoromethyl)-6-((1-(6-fluoro-4-oxo-3-(1<i>H</i>-pyrazol-3-yl)-3,4-dihydroquinazolin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile (<b>17b</b>)</h3><div class="NLM_p last">Prepared according to general procedure D using <b>32i</b>. <sup>1</sup>H NMR (400 MHz, DMSO) δ 13.19 (br s, 1H), 7.87 (d, <i>J</i> = 2.4 Hz, 1H), 7.85–7.74 (m, 4H), 7.57 (br s, 1H), 7.23 (br s, 1H), 6.67 (t, <i>J</i> = 53.6 Hz, 1H), 6.55 (d, <i>J</i> = 2.4 Hz, 1H), 4.87 (p, <i>J</i> = 6.6 Hz, 1H), 1.45 (d, <i>J</i> = 6.7 Hz, 3H). ES/MS 442.1 (M + H)<sup>+</sup>.</div></div><div id="sec5_5_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i34" class="anchor-spacer"></div><h3 class="article-section__title" id="_i34"> (<i>S</i>)-2-(1-((2,6-Diamino-5-chloropyrimidin-4-yl)amino)ethyl)-8-fluoro-3-(1<i>H</i>-pyrazol-3-yl)quinazolin-4(3<i>H</i>)-one (<b>18a</b>)</h3><div class="NLM_p last">Prepared according to general procedure C using <b>32j</b>. <sup>1</sup>H NMR (400 MHz, DMSO) δ 13.24 (br s, 1H), 7.98–7.94 (m, 1H), 7.91 (d, <i>J</i> = 2.4 Hz, 1H), 7.78 (ddd, <i>J</i> = 10.5, 8.1, 1.4 Hz, 1H), 7.72 (d, <i>J</i> = 6.7 Hz, 1H), 7.58 (td, <i>J</i> = 8.1, 4.7 Hz, 1H), 7.48 (br s, 2H), 7.33 (br s, 2H), 6.54 (d, <i>J</i> = 2.3 Hz, 1H), 4.85 (p, <i>J</i> = 6.6 Hz, 1H), 1.45 (d, <i>J</i> = 6.7 Hz, 3H). ES/MS 416.1 (M + H)<sup>+</sup>.</div></div><div id="sec5_5_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i35" class="anchor-spacer"></div><h3 class="article-section__title" id="_i35"> (<i>S</i>)-2-Amino-4-(difluoromethyl)-6-((1-(8-fluoro-4-oxo-3-(1<i>H</i>-pyrazol-3-yl)-3,4-dihydroquinazolin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile (<b>18b</b>)</h3><div class="NLM_p last">Prepared according to general procedure D using <b>32j</b>. <sup>1</sup>H NMR (400 MHz, DMSO) δ 13.19 (br s, 1H), 7.97–7.93 (m, 1H), 7.87 (d, <i>J</i> = 2.4 Hz, 1H), 7.83 (d, <i>J</i> = 6.5 Hz, 1H), 7.77 (ddd, <i>J</i> = 10.5, 8.0, 1.4 Hz, 1H), 7.60–7.53 (m, 2H), 7.24 (br s, 1H), 6.67 (t, <i>J</i> = 53.5 Hz, 1H), 6.54 (d, <i>J</i> = 2.4 Hz, 1H), 4.88 (p, <i>J</i> = 6.7 Hz, 1H), 1.46 (d, <i>J</i> = 6.7 Hz, 3H). ES/MS 442.1 (M + H)<sup>+</sup>.</div></div><div id="sec5_5_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i36" class="anchor-spacer"></div><h3 class="article-section__title" id="_i36"> (<i>S</i>)-2-(1-((2,6-Diamino-5-chloropyrimidin-4-yl)amino)ethyl)-6,8-difluoro-3-(1<i>H</i>-pyrazol-3-yl)quinazolin-4(3<i>H</i>)-one (<b>19a</b>)</h3><div class="NLM_p last">Prepared according to general procedure C using <b>32k</b>. <sup>1</sup>H NMR (400 MHz, DMSO) δ 13.22 (br s, 1H), 7.95–7.85 (m, 1H), 7.87 (d, <i>J</i> = 2.3 Hz, 1H), 7.74–7.69 (m, 1H), 7.67 (ddd, <i>J</i> = 8.3, 3.0, 1.3 Hz, 1H), 7.50 (br s, 2H), 7.36 (br s, 2H), 6.49 (d, <i>J</i> = 2.4 Hz, 1H), 4.83 (p, <i>J</i> = 6.7 Hz, 1H), 1.41 (d, <i>J</i> = 6.7 Hz, 3H). ES/MS 434.1 (M + H)<sup>+</sup>.</div></div><div id="sec5_5_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i37" class="anchor-spacer"></div><h3 class="article-section__title" id="_i37"> (<i>S</i>)-2-Amino-4-((1-(6,8-difluoro-4-oxo-3-(1<i>H</i>-pyrazol-3-yl)-3,4-dihydroquinazolin-2-yl)ethyl)amino)-6-(difluoromethyl)pyrimidine-5-carbonitrile (<b>19b</b>)</h3><div class="NLM_p last">Prepared according to general procedure D using <b>32k</b>. <sup>1</sup>H NMR (400 MHz, DMSO) δ 13.21 (br s, 1H), 7.92 (ddd, <i>J</i> = 10.3, 8.9, 2.9 Hz, 1H), 7.87 (d, <i>J</i> = 2.4 Hz, 1H), 7.82 (d, <i>J</i> = 6.5 Hz, 1H), 7.70 (ddd, <i>J</i> = 8.2, 2.9, 1.2 Hz, 1H), 7.57 (br s, 1H), 7.23 (br s, 1H), 6.67 (t, <i>J</i> = 53.5 Hz, 1H), 6.54 (d, <i>J</i> = 2.4 Hz, 1H), 4.88 (p, <i>J</i> = 6.7 Hz, 1H), 1.45 (d, <i>J</i> = 6.7 Hz, 3H). ES/MS 460.1 (M + H)<sup>+</sup>.</div></div><div id="sec5_5_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i38" class="anchor-spacer"></div><h3 class="article-section__title" id="_i38"> (<i>S</i>)-8-Chloro-2-(1-((2,6-diamino-5-chloropyrimidin-4-yl)amino)ethyl)-6-fluoro-3-(1<i>H</i>-pyrazol-3-yl)quinazolin-4(3<i>H</i>)-one (<b>20a</b>)</h3><div class="NLM_p last">Prepared according to general procedure C using <b>32l</b>. <sup>1</sup>H NMR (400 MHz, DMSO) δ 13.26 (s, 1H), 8.10 (dd, <i>J</i> = 8.5, 2.9 Hz, 1H), 7.94 (dd, <i>J</i> = 2.4, 1.6 Hz, 1H), 7.78 (dd, <i>J</i> = 8.2, 2.9 Hz, 1H), 6.53 (t, <i>J</i> = 2.2 Hz, 1H), 6.39 (d, <i>J</i> = 7.5 Hz, 1H), 5.97 (s, 2H), 5.55 (s, 2H), 4.71 (dd, <i>J</i> = 7.4, 6.6 Hz, 1H), 1.33 (d, <i>J</i> = 6.6 Hz, 3H). ES/MS 450.1 (M + H)<sup>+</sup>.</div></div><div id="sec5_5_12" class="NLM_sec NLM_sec_level_2"><div id="ac_i39" class="anchor-spacer"></div><h3 class="article-section__title" id="_i39"> (<i>S</i>)-2-Amino-4-((1-(8-chloro-6-fluoro-4-oxo-3-(1<i>H</i>-pyrazol-3-yl)-3,4-dihydroquinazolin-2-yl)ethyl)amino)-6-(difluoromethyl)pyrimidine-5-carbonitrile (<b>20b</b>)</h3><div class="NLM_p last">Prepared according to general procedure D using <b>32l</b>. <sup>1</sup>H NMR (400 MHz, DMSO) δ 13.19 (s, 1H), 8.11 (dd, <i>J</i> = 8.5, 2.9 Hz, 1H), 7.86 (d, <i>J</i> = 2.4 Hz, 1H), 7.80 (dd, <i>J</i> = 8.2, 2.9 Hz, 1H), 7.72 (d, <i>J</i> = 6.6 Hz, 1H), 7.54 (br s, 1H), 7.30 (br s, 1H), 6.64 (t, <i>J</i> = 53.6 Hz, 1H), 6.46 (d, <i>J</i> = 2.4 Hz, 1H), 4.94 (p, <i>J</i> = 6.6 Hz, 1H), 1.42 (d, <i>J</i> = 6.6 Hz, 3H). ES/MS 476.1 (M + H)<sup>+</sup>.</div></div><div id="sec5_5_13" class="NLM_sec NLM_sec_level_2"><div id="ac_i40" class="anchor-spacer"></div><h3 class="article-section__title" id="_i40"> (<i>S</i>)-8-Chloro-2-(cyclopropyl((2,6-diamino-5-chloropyrimidin-4-yl)amino)methyl)-6-fluoro-3-(1<i>H</i>-pyrazol-3-yl)quinazolin-4(3<i>H</i>)-one (<b>21a</b>)</h3><div class="NLM_p last">Prepared according to general procedure C using <b>32m</b>. <sup>1</sup>H NMR (400 MHz, DMSO) δ 13.32 (d, <i>J</i> = 2.5 Hz, 1H), 8.14 (ddd, <i>J</i> = 8.6, 3.0, 1.7 Hz, 1H), 7.98 (t, <i>J</i> = 2.1 Hz, 1H), 7.82 (ddd, <i>J</i> = 8.2, 3.0, 1.7 Hz, 1H), 6.52 (q, <i>J</i> = 2.0 Hz, 1H), 6.24–5.89 (m, 3H), 5.61 (s, 2H), 4.92 (ddd, <i>J</i> = 7.9, 5.6, 1.8 Hz, 1H), 1.25 (qd, <i>J</i> = 7.3, 6.6, 3.8 Hz, 1H), 0.43–0.10 (m, 4H). ES/MS 476.1 (M + H)<sup>+</sup>.</div></div><div id="sec5_5_14" class="NLM_sec NLM_sec_level_2"><div id="ac_i41" class="anchor-spacer"></div><h3 class="article-section__title" id="_i41"> (<i>S</i>)-2-Amino-4-(((8-chloro-6-fluoro-4-oxo-3-(1<i>H</i>-pyrazol-3-yl)-3,4-dihydroquinazolin-2-yl)(cyclopropyl)methyl)amino)-6-(difluoromethyl)pyrimidine-5-carbonitrile (<b>21b</b>)</h3><div class="NLM_p last">Prepared according to general procedure D using <b>32m</b>. <sup>1</sup>H NMR (400 MHz, DMSO) δ 13.15 (s, 1H), 8.13 (dd, <i>J</i> = 8.5, 2.9 Hz, 1H), 7.84–7.78 (m, 2H), 7.55 (br s, 1H), 7.37 (d, <i>J</i> = 7.5 Hz, 1H), 7.29 (br s, 1H), 6.64 (t, <i>J</i> = 53.6 Hz, 1H), 6.35 (d, <i>J</i> = 2.4 Hz, 1H), 4.95 (t, <i>J</i> = 7.2 Hz, 1H), 1.48–1.34 (m, 1H), 0.48–0.33 (m, 3H), 0.19–0.10 (m, 1H). ES/MS 502.1 (M + H)<sup>+</sup>.</div></div><div id="sec5_5_15" class="NLM_sec NLM_sec_level_2"><div id="ac_i42" class="anchor-spacer"></div><h3 class="article-section__title" id="_i42"> (<i>S</i>)-8-Chloro-2-(1-((2,6-diamino-5-chloropyrimidin-4-yl)amino)propyl)-6-fluoro-3-(1<i>H</i>-pyrazol-3-yl)quinazolin-4(3<i>H</i>)-one (<b>22a</b>)</h3><div class="NLM_p last">Prepared according to general procedure C using <b>32n</b>. <sup>1</sup>H NMR (400 MHz, DMSO) δ 13.31 (d, <i>J</i> = 25.8 Hz, 1H), 8.18 (ddd, <i>J</i> = 12.4, 8.5, 2.9 Hz, 1H), 8.02–7.77 (m, 2H), 7.59 (d, <i>J</i> = 30.8 Hz, 2H), 7.41 (s, 2H), 6.54 (dd, <i>J</i> = 24.8, 2.4 Hz, 1H), 4.86 (td, <i>J</i> = 7.1, 4.6 Hz, 1H), 2.18–1.65 (m, 2H), 0.78 (dt, <i>J</i> = 14.4, 7.3 Hz, 3H). ES/MS 464.1 (M + H)<sup>+</sup>.</div></div><div id="sec5_5_16" class="NLM_sec NLM_sec_level_2"><div id="ac_i43" class="anchor-spacer"></div><h3 class="article-section__title" id="_i43"> (<i>S</i>)-2-Amino-4-((1-(8-chloro-6-fluoro-4-oxo-3-(1<i>H</i>-pyrazol-3-yl)-3,4-dihydroquinazolin-2-yl)propyl)amino)-6-(difluoromethyl)pyrimidine-5-carbonitrile (<b>22b</b>)</h3><div class="NLM_p last">Prepared according to general procedure D using <b>32n</b>. <sup>1</sup>H NMR (400 MHz, DMSO) δ 13.24 (br s, 1H), 8.14 (dd, <i>J</i> = 8.5, 2.9 Hz, 1H), 7.89 (d, <i>J</i> = 2.4 Hz, 1H), 7.83 (dd, <i>J</i> = 8.2, 2.9 Hz, 1H), 7.62 (d, <i>J</i> = 7.1 Hz, 1H), 7.58 (br s, 1H), 7.23 (br s, 1H), 6.68 (t, <i>J</i> = 53.5 Hz, 1H), 6.52 (d, <i>J</i> = 2.4 Hz, 1H), 4.94–4.88 (m, 1H), 2.12–1.99 (m, 1H), 1.78 (dq, <i>J</i> = 14.1, 7.1 Hz, 1H), 0.79 (t, <i>J</i> = 7.3 Hz, 3H). ES/MS 490.1 (M + H)<sup>+</sup>.</div></div><div id="sec5_5_17" class="NLM_sec NLM_sec_level_2"><div id="ac_i44" class="anchor-spacer"></div><h3 class="article-section__title" id="_i44"> (<i>S</i>)-5-Chloro-2-(1-((2,6-diamino-5-chloropyrimidin-4-yl)amino)ethyl)-3-(isoxazol-3-yl)quinazolin-4(3<i>H</i>)-one (<b>25</b>)</h3><div class="NLM_p last">Prepared according to general procedure C using <b>32o</b>. <sup>1</sup>H NMR (400 MHz, DMSO) δ 9.10 (d, <i>J</i> = 1.7 Hz, 1H), 7.82 (t, <i>J</i> = 8.0 Hz, 1H), 7.73–7.56 (m, 2H), 7.55–6.98 (m, 5H), 6.88 (d, <i>J</i> = 1.8 Hz, 1H), 4.96–4.78 (m, 1H), 1.43 (d, <i>J</i> = 6.7 Hz, 3H). ES/MS 433.1 (M + H)<sup>+</sup>.</div></div><div id="sec5_5_18" class="NLM_sec NLM_sec_level_2"><div id="ac_i45" class="anchor-spacer"></div><h3 class="article-section__title" id="_i45"> (<i>S</i>)-2,4-Diamino-6-(((8-chloro-6-fluoro-4-oxo-3-(1<i>H</i>-pyrazol-3-yl)-3,4-dihydroquinazolin-2-yl)(cyclopropyl)methyl)amino)pyrimidine-5-carbonitrile (<b>26</b>)</h3><div class="NLM_p last">Prepared according to general procedure B using <b>32l</b>. <sup>1</sup>H NMR (400 MHz, DMSO) δ 13.38–13.15 (m, 1H), 8.14 (dd, <i>J</i> = 8.5, 2.9 Hz, 1H), 7.94 (dd, <i>J</i> = 2.4, 1.6 Hz, 1H), 7.82 (dd, <i>J</i> = 8.1, 2.9 Hz, 1H), 6.65 (s, 2H), 6.52–6.42 (m, 2H), 6.36 (s, 2H), 4.96 (dd, <i>J</i> = 7.7, 6.2 Hz, 1H), 1.43–1.26 (m, 1H), 0.50–0.29 (m, 3H), 0.18 (tt, <i>J</i> = 8.5, 3.3 Hz, 1H). ES/MS <i>m</i>/<i>z</i> = 467.1 (M + H)<sup>+</sup>.</div></div><div id="sec5_6_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i46" class="anchor-spacer"></div><h3 class="article-section__title" id="_i46"> General Procedure E. <i>tert</i>-Butyl (<i>S</i>)-(1-(5-Chloro-4-oxo-3-(1<i>H</i>-pyrazol-3-yl)-3,4-dihydroquinazolin-2-yl)ethyl)carbamate (<b>31e</b>)</h3><div class="NLM_p last">Diphenyl phosphite (1.6 mL, 8.2 mmol) was added to a solution of 2-amino-6-chlorobenzoic acid (<b>27b</b>) (400 mg, 2.3 mmol) and <i>N</i>-(<i>tert</i>-butoxycarbonyl)-<span class="smallcaps smallerCapital">l</span>-alanine (<b>28b</b>) (568 mg, 3.0 mmol) in pyridine (2 mL). The reaction mixture was stirred at 40 °C for 2 h. 3-Amino-1<i>H</i>-pyrazole (<b>30c</b>) (232 mg, 2.8 mmol) was then added to the mixture, which was then stirred at 50 °C for 16 h. The reaction mixture was cooled to room temperature. This mixture was diluted with EtOAc (50 mL), washed with saturated aqueous NaHCO<sub>3</sub> (1 × 50 mL), brine (50 mL), and dried over magnesium sulfate. The organic layer was filtered and concentrated in vacuo to afford material which was purified by column chromatography on SiO<sub>2</sub>, eluting with EtOAc in hexanes (10–70%) to afford the title compound <i>tert</i>-butyl (<i>S</i>)-(1-(5-chloro-4-oxo-3-(1<i>H</i>-pyrazol-3-yl)-3,4-dihydroquinazolin-2-yl)ethyl)carbamate (<b>31e</b>) (789 mg, 88%). ES/MS <i>m</i>/<i>z</i> = 390.1 (M + H)<sup>+</sup>.</div></div><div id="sec5_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i47" class="anchor-spacer"></div><h3 class="article-section__title" id="_i47"> Intermediates <b>31a</b>–<b>o</b> Made Using General Procedure E</h3><div class="NLM_p last"><i>tert</i>-Butyl (<i>S</i>)-(1-(5-fluoro-4-oxo-3-phenyl-3,4-dihydroquinazolin-2-yl)propyl)carbamate (<b>31a</b>); <i>tert</i>-butyl (<i>S</i>)-(1-(3-(4-((<i>tert</i>-butyldimethylsilyl)oxy)phenyl)-5-fluoro-4-oxo-3,4-dihydroquinazolin-2-yl)propyl)carbamate (<b>31b</b>); <i>tert</i>-butyl (<i>S</i>)-(1-(5-chloro-4-oxo-3-phenyl-3,4-dihydroquinazolin-2-yl)ethyl)carbamate (<b>31c</b>); <i>tert</i>-butyl (<i>S</i>)-(1-(3-(4-((<i>tert</i>-butyldimethylsilyl)oxy)phenyl)-5-chloro-4-oxo-3,4-dihydroquinazolin-2-yl)ethyl)carbamate (<b>31d</b>); <i>tert</i>-butyl (<i>S</i>)-(1-(5-chloro-4-oxo-3-(1<i>H</i>-pyrazol-3-yl)-3,4-dihydroquinazolin-2-yl)ethyl)carbamate (<b>31e</b>); <i>tert</i>-butyl (<i>S</i>)-(1-(5-chloro-4-oxo-3-(1<i>H</i>-pyrazol-4-yl)-3,4-dihydroquinazolin-2-yl)ethyl)carbamate (<b>31f</b>); <i>tert</i>-butyl (<i>S</i>)-((5-chloro-4-oxo-3-(1<i>H</i>-pyrazol-3-yl)-3,4-dihydroquinazolin-2-yl)(cyclopropyl)methyl)carbamate (<b>31g</b>); <i>tert</i>-butyl (<i>S</i>)-(1-(5-fluoro-4-oxo-3-(<i>1H</i>-pyrazol-3-yl)-3,4-dihydroquinazolin-2-yl)ethyl)carbamate (<b>31h</b>); <i>tert</i>-butyl (<i>S</i>)-(1-(6-fluoro-4-oxo-3-(1<i>H</i>-pyrazol-3-yl)-3,4-dihydroquinazolin-2-yl)ethyl)carbamate (<b>31i</b>); <i>tert</i>-butyl (<i>S</i>)-(1-(8-fluoro-4-oxo-3-(1<i>H</i>-pyrazol-3-yl)-3,4-dihydroquinazolin-2-yl)ethyl)carbamate (<b>31j</b>); <i>tert</i>-butyl (<i>S</i>)-(1-(6,8-difluoro-4-oxo-3-(1<i>H</i>-pyrazol-3-yl)-3,4-dihydroquinazolin-2-yl)ethyl)carbamate (<b>31k</b>); <i>tert</i>-butyl (<i>S</i>)-(1-(8-chloro-6-fluoro-4-oxo-3-(1<i>H</i>-pyrazol-3-yl)-3,4-dihydroquinazolin-2-yl)ethyl)carbamate (<b>31l</b>); <i>tert</i>-butyl (<i>S</i>)-((8-chloro-6-fluoro-4-oxo-3-(1<i>H</i>-pyrazol-3-yl)-3,4-dihydroquinazolin-2-yl)(cyclopropyl)methyl)carbamate (<b>31m</b>); <i>tert</i>-butyl (<i>S</i>)-(1-(8-chloro-6-fluoro-4-oxo-3-(1<i>H</i>-pyrazol-3-yl)-3,4-dihydroquinazolin-2-yl)propyl)carbamate (<b>31n</b>); <i>tert</i>-butyl (<i>S</i>)-(1-(5-chloro-3-(isoxazol-3-yl)-4-oxo-3,4-dihydroquinazolin-2-yl)ethyl)carbamate (<b>31o</b>).</div></div><div id="sec5_8_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i48" class="anchor-spacer"></div><h3 class="article-section__title" id="_i48"> General Procedure F. (<i>S</i>)-2-(1-Aminoethyl)-5-chloro-3-(1<i>H</i>-pyrazol-3-yl)quinazolin-4(3<i>H</i>)-one (<b>32e</b>)</h3><div class="NLM_p last">Trifluoroacetic acid (0.39 mL, 5.0 mmol) was added to a suspension of <i>tert</i>-butyl (<i>S</i>)-(1-(5-chloro-4-oxo-3-(1<i>H</i>-pyrazol-3-yl)-3,4-dihydroquinazolin-2-yl)ethyl)carbamate (<b>31e</b>) (100 mg, 0.25 mmol) in dichloromethane (2.5 mL). The solution was stirred at room temperature for 3 h and concentrated in vacuuo to afford (<i>S</i>)-2-(1-aminoethyl)-5-chloro-3-(1<i>H</i>-pyrazol-3-yl)quinazolin-4(3<i>H</i>)-one 2,2,2-trifluoroacetic acid salt (<b>32e</b>) as a gum which was used without any further purification. ES/MS <i>m</i>/<i>z</i> = 290.1 (M + H)<sup>+</sup>.</div></div><div id="sec5_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i49" class="anchor-spacer"></div><h3 class="article-section__title" id="_i49"> Intermediates <b>32a</b>–<b>o</b> Made Using General Procedure F</h3><div class="NLM_p last">(<i>S</i>)-2-(1-Aminopropyl)-5-fluoro-3-phenylquinazolin-4(3<i>H</i>)-one (<b>32a</b>); (<i>S</i>)-2-(1-aminopropyl)-5-fluoro-3-(4-hydroxyphenyl)quinazolin-4(3<i>H</i>)-one (<b>32b</b>); (<i>S</i>)-2-(1-aminoethyl)-5-chloro-3-phenylquinazolin-4(3<i>H</i>)-one (<b>32c</b>); (<i>S</i>)-2-(1-aminoethyl)-5-chloro-3-(4-hydroxyphenyl)quinazolin-4(3<i>H</i>)-one (<b>32d</b>); (<i>S</i>)-2-(1-aminoethyl)-5-chloro-3-(1<i>H</i>-pyrazol-3-yl)quinazolin-4(3<i>H</i>)-one (<b>32e</b>); (<i>S</i>)-2-(1-aminoethyl)-5-chloro-3-(1<i>H</i>-pyrazol-4-yl)quinazolin-4(3<i>H</i>)-one (<b>32f</b>); (<i>S</i>)-2-(amino(cyclopropyl)methyl)-5-chloro-3-(1<i>H</i>-pyrazol-3-yl)quinazolin-4(3<i>H</i>)-one (<b>32g</b>); (<i>S</i>)-2-(1-aminoethyl)-5-fluoro-3-(1<i>H</i>-pyrazol-3-yl)quinazolin-4(3<i>H</i>)-one (<b>32h</b>); (<i>S</i>)-2-(1-aminoethyl)-6-fluoro-3-(1<i>H</i>-pyrazol-3-yl)quinazolin-4(3<i>H</i>)-one (<b>32i</b>); (<i>S</i>)-2-(1-aminoethyl)-8-fluoro-3-(1<i>H</i>-pyrazol-3-yl)quinazolin-4(3<i>H</i>)-one (<b>32j</b>); (<i>S</i>)-2-(1-aminoethyl)-6,8-difluoro-3-(1<i>H</i>-pyrazol-3-yl)quinazolin-4(3<i>H</i>)-one (<b>32k</b>); (<i>S</i>)-2-(1-aminoethyl)-8-chloro-6-fluoro-3-(1<i>H</i>-pyrazol-3-yl)quinazolin-4(3<i>H</i>)-one (<b>32l</b>); (<i>S</i>)-2-(amino(cyclopropyl)methyl)-8-chloro-6-fluoro-3-(1<i>H</i>-pyrazol-3-yl)quinazolin-4(3<i>H</i>)-one (<b>32m</b>); (<i>S</i>)-2-(1-aminopropyl)-8-chloro-6-fluoro-3-(1<i>H</i>-pyrazol-3-yl)quinazolin-4(3<i>H</i>)-one (<b>32n</b>); (S)-2-(1-aminoethyl)-5-chloro-3-(isoxazol-3-yl)quinazolin-4(3<i>H</i>)-one (<b>32o</b>).</div></div><div id="sec5_9_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i50" class="anchor-spacer"></div><h3 class="article-section__title" id="_i50"> 2,4-Diamino-6-chloropyrimidine-5-carbonitrile (<b>33c</b>)</h3><div class="NLM_p last">Ammonium hydroxide (20 mL) was added to a solution of 2,4,6-trichloropyrimidine-5-carbonitrile (5.0 g, 24 mmol) in dioxane (20 mL) at room temperature. The solution was warmed to 50 °C and stirred for 3 h. The reaction mixture was cooled to 10 °C, and water (50 mL) was added. The resulting solid was filtered, washed with water, and dried under high vacuum to afford the title compound as a white solid (4.5 g). <sup>13</sup>C NMR (100 MHz, DMSO) δ 164.8, 162.6, 161.9, 115.8, 77.6. ES/MS <i>m</i>/<i>z</i> = 169.9 (M + H)<sup>+</sup>.</div></div><div id="sec5_9_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i51" class="anchor-spacer"></div><h3 class="article-section__title" id="_i51"> 5-Chloro-6-fluoropyrimidine-2,4-diamine (<b>33e</b>)</h3><div class="NLM_p last">To 2,4,6-trifluoropyrimidine (10 g, 75 mmol) in acetonitrile (100 mL) cooled to 0 °C was added conc NH<sub>4</sub>OH (50 mL) in three portions. The reaction mixture was stirred at 40 °C for 12 h, after which time the reaction mixture was cooled to room temperature and concentrated in vacuuo. The resulting solid was dissolved in MeOH/EtOH (250 mL, 1:1) and cooled to 0 °C. <i>N</i>-Chlorosuccinimide (13 g, 97 mmol) was added portionwise to the solution. The reaction mixture was stirred at 50 °C for 12 h, after which time the cooled reaction mixture was concentrated to approximately 150 mL in vacuo. The resultant suspension was cooled to −10 °C, and the solid formed was collected by filtration and washed with water (100 mL), followed by 0.1 M NaOH (100 mL), and dried under high vacuum to afford the title compound as a white solid (8.7 g). ES/MS <i>m</i>/<i>z</i> = 163.1 (M + H)<sup>+</sup>.</div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i52"><a href="/doi/suppl/10.1021/acs.jmedchem.6b01821">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_47168" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_47168" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a href="/" class="ext-link">ACS Publications website</a> at DOI: <a href="/doi/abs/10.1021/acs.jmedchem.6b01821" class="ext-link">10.1021/acs.jmedchem.6b01821</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Details of all protocols for in vitro and in vivo experiments and kinase selectivity (<a href="/doi/suppl/10.1021/acs.jmedchem.6b01821/suppl_file/jm6b01821_si_001.pdf" class="ext-link">PDF</a>)</p></li><li><p class="inline">Structure coordinates (<a href="/doi/suppl/10.1021/acs.jmedchem.6b01821/suppl_file/jm6b01821_si_002.pdb" class="ext-link">PDB</a>)</p></li><li><p class="inline">Structure coordinates (<a href="/doi/suppl/10.1021/acs.jmedchem.6b01821/suppl_file/jm6b01821_si_003.pdb" class="ext-link">PDB</a>)</p></li><li><p class="inline">Structure coordinates (<a href="/doi/suppl/10.1021/acs.jmedchem.6b01821/suppl_file/jm6b01821_si_004.pdb" class="ext-link">PDB</a>)</p></li><li><p class="inline">Molecular formula strings and some data (<a href="/doi/suppl/10.1021/acs.jmedchem.6b01821/suppl_file/jm6b01821_si_005.csv" class="ext-link">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.6b01821/suppl_file/jm6b01821_si_001.pdf">jm6b01821_si_001.pdf (206.92 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.6b01821/suppl_file/jm6b01821_si_002.pdb">jm6b01821_si_002.pdb (540.22 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.6b01821/suppl_file/jm6b01821_si_003.pdb">jm6b01821_si_003.pdb (3.27 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.6b01821/suppl_file/jm6b01821_si_004.pdb">jm6b01821_si_004.pdb (3.57 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.6b01821/suppl_file/jm6b01821_si_005.csv">jm6b01821_si_005.csv (3.08 kb)</a></li></ul></div></div></div><span class="author-information-subsection-header">Accession Codes</span><p class="last">The PI3Kβ homology model used was built from the crystal structure of (<i>S</i>)-2,4-diamino-6-((5-chloro-8-fluoro-4-oxo-3-(pyridin-3-yl)-3,4-dihydroquinazolin-2-yl)(cyclopropyl)methylamino)pyrimidine-5-carbonitrile (GS-9901) bound to PI3Kδ (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5T8I">5T8I</a>; coordinates available in <a href="/doi/suppl/10.1021/acs.jmedchem.6b01821/suppl_file/jm6b01821_si_001.pdf" class="ext-link">Supporting Information</a>).<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a></p><div class="testing" data-doi="10.1021/acs.jmedchem.6b01821" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_72751" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_72751" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Stephane Perreault</span> - <span class="hlFld-Affiliation affiliation">Gilead Sciences,
Inc., 199 E. Blaine Street, Seattle, Washington 98102, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-8732-5243" title="Orcid link">http://orcid.org/0000-0001-8732-5243</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#b7c4c3d2c7dfd6d9d299c7d2c5c5d2d6c2dbc3f7d0dedbd2d6d399d4d8da"><span class="__cf_email__" data-cfemail="bfcccbdacfd7ded1da91cfdacdcddadecad3cbffd8d6d3dadedb91dcd0d2">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jayaraman Chandrasekhar</span> - <span class="hlFld-Affiliation affiliation">Gilead Sciences,
Inc., 199 E. Blaine Street, Seattle, Washington 98102, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Zhi-Hua Cui</span> - <span class="hlFld-Affiliation affiliation">Gilead Sciences,
Inc., 199 E. Blaine Street, Seattle, Washington 98102, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jerry Evarts</span> - <span class="hlFld-Affiliation affiliation">Gilead Sciences,
Inc., 199 E. Blaine Street, Seattle, Washington 98102, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jia Hao</span> - <span class="hlFld-Affiliation affiliation">Gilead
Sciences, Inc., 333 Lakeside
Drive, Foster City, California 94404, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Joshua A. Kaplan</span> - <span class="hlFld-Affiliation affiliation">Gilead
Sciences, Inc., 333 Lakeside
Drive, Foster City, California 94404, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Adam Kashishian</span> - <span class="hlFld-Affiliation affiliation">Gilead Sciences,
Inc., 199 E. Blaine Street, Seattle, Washington 98102, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Kathleen S. Keegan</span> - <span class="hlFld-Affiliation affiliation">Gilead Sciences,
Inc., 199 E. Blaine Street, Seattle, Washington 98102, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Thomas Kenney</span> - <span class="hlFld-Affiliation affiliation">Gilead Sciences,
Inc., 199 E. Blaine Street, Seattle, Washington 98102, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">David Koditek</span> - <span class="hlFld-Affiliation affiliation">Gilead
Sciences, Inc., 333 Lakeside
Drive, Foster City, California 94404, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Latesh Lad</span> - <span class="hlFld-Affiliation affiliation">Gilead
Sciences, Inc., 333 Lakeside
Drive, Foster City, California 94404, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Eve-Irene Lepist</span> - <span class="hlFld-Affiliation affiliation">Gilead
Sciences, Inc., 333 Lakeside
Drive, Foster City, California 94404, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Mary E. McGrath</span> - <span class="hlFld-Affiliation affiliation">Gilead
Sciences, Inc., 333 Lakeside
Drive, Foster City, California 94404, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Leena Patel</span> - <span class="hlFld-Affiliation affiliation">Gilead Sciences,
Inc., 199 E. Blaine Street, Seattle, Washington 98102, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Bart Phillips</span> - <span class="hlFld-Affiliation affiliation">Gilead
Sciences, Inc., 333 Lakeside
Drive, Foster City, California 94404, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Joseph Therrien</span> - <span class="hlFld-Affiliation affiliation">Gilead Sciences,
Inc., 199 E. Blaine Street, Seattle, Washington 98102, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jennifer Treiberg</span> - <span class="hlFld-Affiliation affiliation">Gilead Sciences,
Inc., 199 E. Blaine Street, Seattle, Washington 98102, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Anella Yahiaoui</span> - <span class="hlFld-Affiliation affiliation">Gilead Sciences,
Inc., 199 E. Blaine Street, Seattle, Washington 98102, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Gary Phillips</span> - <span class="hlFld-Affiliation affiliation">Gilead Sciences,
Inc., 199 E. Blaine Street, Seattle, Washington 98102, United States</span></div></li></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare the following competing financial interest(s): The authors are employees of Gilead Sciences except for J.E who was employed at Gilead Sciences during this research. All authors are shareholders of Gilead Sciences.<br /></br></div></li></ul></div><div id="" class="NLM_sec NLM_sec_level_1"><div id="ac_i55" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i55"> </h2><div class="NLM_p last"><table summary="" class="NLM_def-list" id="dl1"><div id="ac_i56" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i56"> Abreviations Used</h2><tr><td class="NLM_term">PI3K</td><td class="NLM_def"><p class="first last">phosphoinositide 3-kinase</p></td></tr><tr><td class="NLM_term">PTEN</td><td class="NLM_def"><p class="first last">phosphatase and tensin homolog</p></td></tr><tr><td class="NLM_term">mTOR</td><td class="NLM_def"><p class="first last">mechanistic target of rapamycin</p></td></tr><tr><td class="NLM_term">AKT</td><td class="NLM_def"><p class="first last">protein kinase B</p></td></tr><tr><td class="NLM_term">PIP2</td><td class="NLM_def"><p class="first last">phosphatidylinositol 4,5-bisphosphate</p></td></tr><tr><td class="NLM_term">PIP3</td><td class="NLM_def"><p class="first last">phosphatidylinositol 3,4,5-trisphosphate</p></td></tr><tr><td class="NLM_term">pAKT</td><td class="NLM_def"><p class="first last">phosphorylated protein kinase B</p></td></tr><tr><td class="NLM_term">tPSA</td><td class="NLM_def"><p class="first last">total polar surface area</p></td></tr><tr><td class="NLM_term">CL<sub>pr</sub></td><td class="NLM_def"><p class="first last">predicted clearance</p></td></tr></table></div></div><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i57">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_64700" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_64700" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 42 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group">Fruman, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rommel, C.</span><span> </span><span class="NLM_article-title">PI3K and cancer: lessons, challenges and opportunities</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">140</span><span class="NLM_x">–</span> <span class="NLM_lpage">156</span><span class="refDoi"> DOI: 10.1038/nrd4204</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01821&amp;key=10.1038%2Fnrd4204" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01821&amp;key=24481312" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01821&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs1SnsLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2014&pages=140-156&author=D.+A.+Frumanauthor=C.+Rommel&title=PI3K+and+cancer%3A+lessons%2C+challenges+and+opportunities&doi=10.1038%2Fnrd4204"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">PI3K and cancer: lessons, challenges and opportunities</span></div><div class="casAuthors">Fruman, David A.; Rommel, Christian</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">140-156</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The central role of phosphoinositide 3-kinase (PI3K) activation in tumor cell biol. has prompted a sizeable effort to target PI3K and/or downstream kinases such as AKT and mammalian target of rapamycin (mTOR) in cancer.  However, emerging clin. data show limited single-agent activity of inhibitors targeting PI3K, AKT or mTOR at tolerated doses.  One exception is the response to PI3Kδ inhibitors in chronic lymphocytic leukemia, where a combination of cell-intrinsic and -extrinsic activities drive efficacy.  Here, we review key challenges and opportunities for the clin. development of inhibitors targeting the PI3K-AKT-mTOR pathway.  Through a greater focus on patient selection, increased understanding of immune modulation and strategic application of rational combinations, it should be possible to realize the potential of this promising class of targeted anticancer agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqlD2rY54m9LbVg90H21EOLACvtfcHk0lh8LlOJvsOAvA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs1SnsLc%253D&md5=c4f6b4b9f9fcacd6ef55eb17d3a4f425</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1038%2Fnrd4204&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd4204%26sid%3Dliteratum%253Aachs%26aulast%3DFruman%26aufirst%3DD.%2BA.%26aulast%3DRommel%26aufirst%3DC.%26atitle%3DPI3K%2520and%2520cancer%253A%2520lessons%252C%2520challenges%2520and%2520opportunities%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2014%26volume%3D13%26spage%3D140%26epage%3D156%26doi%3D10.1038%2Fnrd4204" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group">Sadeghi, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gerber, D. E.</span><span> </span><span class="NLM_article-title">Targeting the PI3K pathway for cancer therapy</span> <span class="citation_source-journal">Future Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">1153</span><span class="NLM_x">–</span> <span class="NLM_lpage">1169</span><span class="refDoi"> DOI: 10.4155/fmc.12.56</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01821&amp;key=10.4155%2Ffmc.12.56" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01821&amp;key=22709255" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01821&amp;key=1%3ACAS%3A528%3ADC%252BC38Xoslalsbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2012&pages=1153-1169&author=N.+Sadeghiauthor=D.+E.+Gerber&title=Targeting+the+PI3K+pathway+for+cancer+therapy&doi=10.4155%2Ffmc.12.56"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting the PI3K pathway for cancer therapy</span></div><div class="casAuthors">Sadeghi, Navid; Gerber, David E.</div><div class="citationInfo"><span class="NLM_cas:title">Future Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1153-1169</span>CODEN:
                <span class="NLM_cas:coden">FMCUA7</span>;
        ISSN:<span class="NLM_cas:issn">1756-8919</span>.
    
            (<span class="NLM_cas:orgname">Future Science Ltd.</span>)
        </div><div class="casAbstract">A review.  The PI3K pathway plays an important role in key cellular functions such as cell growth, proliferation and survival.  Genetic and epigenetic alterations in different pathway components lead to aberrant pathway activation and have been obsd. in high frequencies in various tumor types.  Consequently, significant effort has been made to develop antineoplastic agents targeting different nodes in this pathway.  Addnl., PI3K pathway status may have predictive and prognostic implications, and may contribute to drug resistance in tumor cells.  This article provides an overview of our current knowledge of the PI3K pathway with an emphasis on its application in cancer treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqBOiXjDPa787Vg90H21EOLACvtfcHk0lh8LlOJvsOAvA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xoslalsbk%253D&md5=09fda93b8381b45fe1e8b8e1f99733e2</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.4155%2Ffmc.12.56&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4155%252Ffmc.12.56%26sid%3Dliteratum%253Aachs%26aulast%3DSadeghi%26aufirst%3DN.%26aulast%3DGerber%26aufirst%3DD.%2BE.%26atitle%3DTargeting%2520the%2520PI3K%2520pathway%2520for%2520cancer%2520therapy%26jtitle%3DFuture%2520Med.%2520Chem.%26date%3D2012%26volume%3D4%26spage%3D1153%26epage%3D1169%26doi%3D10.4155%2Ffmc.12.56" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group">Vanhaesebroeck, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stephens, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hawkins, P.</span><span> </span><span class="NLM_article-title">PI3K signaling: the path to discovery and understanding</span> <span class="citation_source-journal">Nat. Rev. Mol. Cell Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">195</span><span class="NLM_x">–</span> <span class="NLM_lpage">203</span><span class="refDoi"> DOI: 10.1038/nrm3290</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01821&amp;key=10.1038%2Fnrm3290" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01821&amp;key=22358332" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01821&amp;key=1%3ACAS%3A528%3ADC%252BC38Xis1eqt7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2012&pages=195-203&author=B.+Vanhaesebroeckauthor=L.+Stephensauthor=P.+Hawkins&title=PI3K+signaling%3A+the+path+to+discovery+and+understanding&doi=10.1038%2Fnrm3290"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">PI3K signalling: The path to discovery and understanding</span></div><div class="casAuthors">Vanhaesebroeck, Bart; Stephens, Len; Hawkins, Phillip</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Molecular Cell Biology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">195-203</span>CODEN:
                <span class="NLM_cas:coden">NRMCBP</span>;
        ISSN:<span class="NLM_cas:issn">1471-0072</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Over the past two decades, our understanding of phosphoinositide 3-kinases (PI3Ks) has progressed from the identification of an enzymic activity assocd. with growth factors, GPCRs and certain oncogene products to a disease target in cancer and inflammation, with PI3K inhibitors currently in clin. trials.  Elucidation of PI3K-dependent networks led to the discovery of the phosphoinositide-binding PH, PX and FYVE domains as conduits of intracellular lipid signalling, the detn. of the mol. function of the tumor suppressor PTEN and the identification of AKT and mTOR protein kinases as key regulators of cell growth.  Here we look back at the main discoveries that shaped the PI3K field.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq7WDc7Z5rhLLVg90H21EOLACvtfcHk0lifb7Z5q0RWvg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xis1eqt7s%253D&md5=ff960f9ebfb5b5f2d8fc214aba330eef</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1038%2Fnrm3290&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrm3290%26sid%3Dliteratum%253Aachs%26aulast%3DVanhaesebroeck%26aufirst%3DB.%26aulast%3DStephens%26aufirst%3DL.%26aulast%3DHawkins%26aufirst%3DP.%26atitle%3DPI3K%2520signaling%253A%2520the%2520path%2520to%2520discovery%2520and%2520understanding%26jtitle%3DNat.%2520Rev.%2520Mol.%2520Cell%2520Biol.%26date%3D2012%26volume%3D13%26spage%3D195%26epage%3D203%26doi%3D10.1038%2Fnrm3290" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group">Liu, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheng, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roberts, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, J. J.</span><span> </span><span class="NLM_article-title">Targeting the phosphoinositide 3-kinase pathway in cancer</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">627</span><span class="NLM_x">–</span> <span class="NLM_lpage">644</span><span class="refDoi"> DOI: 10.1038/nrd2926</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01821&amp;key=10.1038%2Fnrd2926" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01821&amp;key=19644473" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01821&amp;key=1%3ACAS%3A528%3ADC%252BD1MXpt1Wgtb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2009&pages=627-644&author=P.+Liuauthor=H.+Chengauthor=T.+M.+Robertsauthor=J.+J.+Zhao&title=Targeting+the+phosphoinositide+3-kinase+pathway+in+cancer&doi=10.1038%2Fnrd2926"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting the phosphoinositide 3-kinase pathway in cancer</span></div><div class="casAuthors">Liu, Pixu; Cheng, Hailing; Roberts, Thomas M.; Zhao, Jean J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">627-644</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The phosphoinositide 3-kinase (PI3K) pathway is a key signal transduction system that links oncogenes and multiple receptor classes to many essential cellular functions, and is perhaps the most commonly activated signalling pathway in human cancer.  This pathway therefore presents both an opportunity and a challenge for cancer therapy.  Even as inhibitors that target PI3K isoforms and other major nodes in the pathway, including AKT and mammalian target of rapamycin (mTOR), reach clin. trials, major issues remain.  Here, we highlight recent progress that has been made in our understanding of the PI3K pathway and discuss the potential of and challenges for the development of therapeutic agents that target this pathway in cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrUk9T-ZoNDtLVg90H21EOLACvtfcHk0lifb7Z5q0RWvg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXpt1Wgtb4%253D&md5=fdc94abd15178a9dbe7c56dafbfb7787</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1038%2Fnrd2926&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd2926%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DP.%26aulast%3DCheng%26aufirst%3DH.%26aulast%3DRoberts%26aufirst%3DT.%2BM.%26aulast%3DZhao%26aufirst%3DJ.%2BJ.%26atitle%3DTargeting%2520the%2520phosphoinositide%25203-kinase%2520pathway%2520in%2520cancer%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2009%26volume%3D8%26spage%3D627%26epage%3D644%26doi%3D10.1038%2Fnrd2926" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group">Yuan, T. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cantley, L. C.</span><span> </span><span class="NLM_article-title">PI3K pathway alterations in cancer: variations on a theme</span> <span class="citation_source-journal">Oncogene</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">27</span><span class="NLM_x">, </span> <span class="NLM_fpage">5497</span><span class="NLM_x">–</span> <span class="NLM_lpage">5510</span><span class="refDoi"> DOI: 10.1038/onc.2008.245</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01821&amp;key=10.1038%2Fonc.2008.245" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01821&amp;key=18794884" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01821&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtFWiurzI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2008&pages=5497-5510&author=T.+L.+Yuanauthor=L.+C.+Cantley&title=PI3K+pathway+alterations+in+cancer%3A+variations+on+a+theme&doi=10.1038%2Fonc.2008.245"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">PI3K pathway alterations in cancer: variations on a theme</span></div><div class="casAuthors">Yuan, T. L.; Cantley, L. C.</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">41</span>),
    <span class="NLM_cas:pages">5497-5510</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The high frequency of phosphoinositide 3-kinase (PI3K) pathway alterations in cancer has led to a surge in the development of PI3K inhibitors.  Many of these targeted therapies are currently in clin. trials and show great promise for the treatment of PI3K-addicted tumors.  These recent developments call for a re-evaluation of the oncogenic mechanisms behind PI3K pathway alterations.  This pathway is unique in that every major node is frequently mutated or amplified in a wide variety of solid tumors.  Receptor tyrosine kinases upstream of PI3K, the p110α catalytic subunit of PI3K, the downstream kinase, AKT, and the neg. regulator, PTEN, are all frequently altered in cancer.  In this review, we will examine the oncogenic properties of these genetic alterations to understand whether they are redundant or distinct and propose treatment strategies tailored for these genetic lesions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq-qvYXlFQJm7Vg90H21EOLACvtfcHk0lifb7Z5q0RWvg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtFWiurzI&md5=664ee1e69e409899531d737a58b46b36</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1038%2Fonc.2008.245&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fonc.2008.245%26sid%3Dliteratum%253Aachs%26aulast%3DYuan%26aufirst%3DT.%2BL.%26aulast%3DCantley%26aufirst%3DL.%2BC.%26atitle%3DPI3K%2520pathway%2520alterations%2520in%2520cancer%253A%2520variations%2520on%2520a%2520theme%26jtitle%3DOncogene%26date%3D2008%26volume%3D27%26spage%3D5497%26epage%3D5510%26doi%3D10.1038%2Fonc.2008.245" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group">Zhao, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vogt, P. K.</span><span> </span><span class="NLM_article-title">Class 1 PI3K in oncogenic cellular transformation</span> <span class="citation_source-journal">Oncogene</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">27</span><span class="NLM_x">, </span> <span class="NLM_fpage">5486</span><span class="NLM_x">–</span> <span class="NLM_lpage">5496</span><span class="refDoi"> DOI: 10.1038/onc.2008.244</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01821&amp;key=10.1038%2Fonc.2008.244" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2008&pages=5486-5496&author=L.+Zhaoauthor=P.+K.+Vogt&title=Class+1+PI3K+in+oncogenic+cellular+transformation&doi=10.1038%2Fonc.2008.244"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1038%2Fonc.2008.244&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fonc.2008.244%26sid%3Dliteratum%253Aachs%26aulast%3DZhao%26aufirst%3DL.%26aulast%3DVogt%26aufirst%3DP.%2BK.%26atitle%3DClass%25201%2520PI3K%2520in%2520oncogenic%2520cellular%2520transformation%26jtitle%3DOncogene%26date%3D2008%26volume%3D27%26spage%3D5486%26epage%3D5496%26doi%3D10.1038%2Fonc.2008.244" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group">Amzel, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, C.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mandelker, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lengauer, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gabelli, S. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vogelstein, B.</span><span> </span><span class="NLM_article-title">Structural comparisons of class I phosphoinositide 3-kinase</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">665</span><span class="NLM_x">–</span> <span class="NLM_lpage">669</span><span class="refDoi"> DOI: 10.1038/nrc2443</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01821&amp;key=10.1038%2Fnrc2443" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01821&amp;key=18633356" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01821&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtVWksLfJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2008&pages=665-669&author=L.+M.+Amzelauthor=C.-H.+Huangauthor=D.+Mandelkerauthor=C.+Lengauerauthor=S.+B.+Gabelliauthor=B.+Vogelstein&title=Structural+comparisons+of+class+I+phosphoinositide+3-kinase&doi=10.1038%2Fnrc2443"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Structural comparisons of class I phosphoinositide 3-kinases</span></div><div class="casAuthors">Amzel, L. Mario; Huang, Chuan-Hsiang; Mandelker, Diana; Lengauer, Christoph; Gabelli, Sandra B.; Vogelstein, Bert</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">665-669</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The recent detn. of the structure of the class I phosphoinositide 3-kinase PI3Kα has identified important structural differences between the class 1 PI3Ks.  How can this information be used to improve cancer therapy.  Class I phosphoinositide 3-kinases (PI3Ks) are lipid kinases that regulate cell growth.  One of these kinases, PI3Kα, is frequently mutated in diverse tumor types.  The recently detd. structure of PI3Kα reveals features that distinguish this enzyme from related lipid kinases.  In addn., wild-type PI3Kγ differs from PI3Kα by a substitution identical to a PI3Kα oncogenic mutant (His1047Arg) that might explain the differences in the enzymic activities of the normal and mutant PI3Kα.  Comparison of the PI3K structures also identified structural features that could potentially be exploited for the design of isoform-specific inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp-V2mKhromdrVg90H21EOLACvtfcHk0lg4XRrJSwbrqw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtVWksLfJ&md5=2f6c4b1db6f8c9eb6ab712f5a83f4e70</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1038%2Fnrc2443&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc2443%26sid%3Dliteratum%253Aachs%26aulast%3DAmzel%26aufirst%3DL.%2BM.%26aulast%3DHuang%26aufirst%3DC.-H.%26aulast%3DMandelker%26aufirst%3DD.%26aulast%3DLengauer%26aufirst%3DC.%26aulast%3DGabelli%26aufirst%3DS.%2BB.%26aulast%3DVogelstein%26aufirst%3DB.%26atitle%3DStructural%2520comparisons%2520of%2520class%2520I%2520phosphoinositide%25203-kinase%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2008%26volume%3D8%26spage%3D665%26epage%3D669%26doi%3D10.1038%2Fnrc2443" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group">Courtney, K. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Corcoran, R. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Engelman, J. A.</span><span> </span><span class="NLM_article-title">The PI3K pathway as drug target in human cancer</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">28</span><span class="NLM_x">, </span> <span class="NLM_fpage">1075</span><span class="NLM_x">–</span> <span class="NLM_lpage">1083</span><span class="refDoi"> DOI: 10.1200/JCO.2009.25.3641</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01821&amp;key=10.1200%2FJCO.2009.25.3641" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01821&amp;key=20085938" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01821&amp;key=1%3ACAS%3A528%3ADC%252BC3cXktF2lt7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2010&pages=1075-1083&author=K.+D.+Courtneyauthor=R.+B.+Corcoranauthor=J.+A.+Engelman&title=The+PI3K+pathway+as+drug+target+in+human+cancer&doi=10.1200%2FJCO.2009.25.3641"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">The PI3K pathway as drug target in human cancer</span></div><div class="casAuthors">Courtney, Kevin D.; Corcoran, Ryan B.; Engelman, Jeffrey A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1075-1083</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">A review.  The phosphatidylinositol 3-kinase (PI3K) signaling axis impacts on cancer cell growth, survival, motility, and metab.  This pathway is activated by several different mechanisms in cancers, including somatic mutation and amplification of genes encoding key components.  In addn., PI3K signaling may serve integral functions for noncancerous cells in the tumor microenvironment.  Consequently, therapeutics targeting the PI3K pathway are being developed at a rapid pace, and preclin. and early clin. studies are beginning to suggest specific strategies to effectively use them.  However, the central role of PI3K signaling in a large array of diverse biol. processes raises concerns about its use in therapeutics and increases the need to develop sophisticated strategies for its use.  In this review, we will discuss how PI3K signaling affects the growth and survival of tumor cells.  From this vantage, we will consider how inhibitors of the PI3K signaling cascade, either alone or in combination with other therapeutics, can most effectively be used for the treatment of cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrpPqtk2bVl0rVg90H21EOLACvtfcHk0lg4XRrJSwbrqw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXktF2lt7w%253D&md5=b88b394919647e2eb47e7735355fde2a</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1200%2FJCO.2009.25.3641&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2009.25.3641%26sid%3Dliteratum%253Aachs%26aulast%3DCourtney%26aufirst%3DK.%2BD.%26aulast%3DCorcoran%26aufirst%3DR.%2BB.%26aulast%3DEngelman%26aufirst%3DJ.%2BA.%26atitle%3DThe%2520PI3K%2520pathway%2520as%2520drug%2520target%2520in%2520human%2520cancer%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2010%26volume%3D28%26spage%3D1075%26epage%3D1083%26doi%3D10.1200%2FJCO.2009.25.3641" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group">Rodon, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dienstmann, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Serra, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tabernero, J.</span><span> </span><span class="NLM_article-title">Development of PI3K inhibitors: lessons learned from early clinical trials</span> <span class="citation_source-journal">Nat. Rev. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">143</span><span class="NLM_x">–</span> <span class="NLM_lpage">153</span><span class="refDoi"> DOI: 10.1038/nrclinonc.2013.10</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01821&amp;key=10.1038%2Fnrclinonc.2013.10" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01821&amp;key=23400000" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01821&amp;key=1%3ACAS%3A528%3ADC%252BC3sXjsFGgs7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2013&pages=143-153&author=J.+Rodonauthor=R.+Dienstmannauthor=V.+Serraauthor=J.+Tabernero&title=Development+of+PI3K+inhibitors%3A+lessons+learned+from+early+clinical+trials&doi=10.1038%2Fnrclinonc.2013.10"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Development of PI3K inhibitors: lessons learned from early clinical trials</span></div><div class="casAuthors">Rodon, Jordi; Dienstmann, Rodrigo; Serra, Violeta; Tabernero, Josep</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Clinical Oncology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">143-153</span>CODEN:
                <span class="NLM_cas:coden">NRCOAA</span>;
        ISSN:<span class="NLM_cas:issn">1759-4774</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The phosphatidylinositol 3-kinase (PI3K) pathway has an important role in cell metab., growth, migration, survival and angiogenesis.  Drug development aimed at targetable genetic aberrations in the PI3K/AKT/mTOR pathway has been fomented by observations that alterations in this pathway induce tumor formation and that inappropriate PI3K signalling is a frequent occurrence in human cancer.  Many of the agents developed have been evaluated in early stage clin. trials.  This Review focuses on early clin. and translational data related to inhibitors of the PI3K/AKT/mTOR pathway, as these data will likely guide the further clin. development of such agents.  We review data from those trials, delineating the safety profile of the agents-whether obsd. sequelae could be mechanism-based or off-target effects-and drug efficacy.  We describe predictive biomarkers explored in clin. trials and preclin. mechanisms of resistance.  We also discuss key unresolved translational questions related to the clin. development of inhibitors of the PI3K/AKT/mTOR pathway and propose designs for biomarker-driven trials to address those issues.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrGWCzGEBfFIbVg90H21EOLACvtfcHk0ljyFExmY1UWrg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXjsFGgs7w%253D&md5=cc6ef16605ed3f5f8619d6a1c7894d5c</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1038%2Fnrclinonc.2013.10&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrclinonc.2013.10%26sid%3Dliteratum%253Aachs%26aulast%3DRodon%26aufirst%3DJ.%26aulast%3DDienstmann%26aufirst%3DR.%26aulast%3DSerra%26aufirst%3DV.%26aulast%3DTabernero%26aufirst%3DJ.%26atitle%3DDevelopment%2520of%2520PI3K%2520inhibitors%253A%2520lessons%2520learned%2520from%2520early%2520clinical%2520trials%26jtitle%3DNat.%2520Rev.%2520Clin.%2520Oncol.%26date%3D2013%26volume%3D10%26spage%3D143%26epage%3D153%26doi%3D10.1038%2Fnrclinonc.2013.10" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group">Yap, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bjerke, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clarke, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Workman, P.</span><span> </span><span class="NLM_article-title">Drugging PI3K in cancer: refining targets and therapeutic strategies</span> <span class="citation_source-journal">Curr. Opin. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">98</span><span class="NLM_x">–</span> <span class="NLM_lpage">107</span><span class="refDoi"> DOI: 10.1016/j.coph.2015.05.016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01821&amp;key=10.1016%2Fj.coph.2015.05.016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01821&amp;key=26117819" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01821&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtVWrt7bJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2015&pages=98-107&author=T.+A.+Yapauthor=L.+Bjerkeauthor=P.+A.+Clarkeauthor=P.+Workman&title=Drugging+PI3K+in+cancer%3A+refining+targets+and+therapeutic+strategies&doi=10.1016%2Fj.coph.2015.05.016"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Drugging PI3K in cancer: refining targets and therapeutic strategies</span></div><div class="casAuthors">Yap, Timothy A.; Bjerke, Lynn; Clarke, Paul A.; Workman, Paul</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Pharmacology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">98-107</span>CODEN:
                <span class="NLM_cas:coden">COPUBK</span>;
        ISSN:<span class="NLM_cas:issn">1471-4892</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">The phosphatidylinositol-3 kinase (PI3K) pathway is one of the most frequently activated pathogenic signalling routes in human cancers, making it a rational and important target for innovative anticancer drug development and precision medicine.  The three main classes of PI3K inhibitors currently in clin. testing comprise dual pan-Class I PI3K/mTOR inhibitors, pan-Class I PI3K inhibitors lacking significant mTOR activity and isoform-selective PI3K inhibitors.  A major step forward in recent years is the progression of over 30 small mol. PI3K inhibitors into clin. trials and the first regulatory approval of the PI3Kδ inhibitor idelalisib for multiple B-cell malignancies.  This review article focuses on the progress made in the discovery and development of novel PI3K inhibitors, with an emphasis on antitumor activity and tolerability profiles for agents that have entered clin. trials.  We also discuss the key issues of drug resistance, patient selection approaches and rational targeted combinations.  Finally, we envision the future development and use of PI3K inhibitors for the treatment of patients with a range of malignancies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqDxyCAEREi_7Vg90H21EOLACvtfcHk0ljyFExmY1UWrg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtVWrt7bJ&md5=9a0238f97d8ecdc54e0c5b9b6ce4fc76</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1016%2Fj.coph.2015.05.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.coph.2015.05.016%26sid%3Dliteratum%253Aachs%26aulast%3DYap%26aufirst%3DT.%2BA.%26aulast%3DBjerke%26aufirst%3DL.%26aulast%3DClarke%26aufirst%3DP.%2BA.%26aulast%3DWorkman%26aufirst%3DP.%26atitle%3DDrugging%2520PI3K%2520in%2520cancer%253A%2520refining%2520targets%2520and%2520therapeutic%2520strategies%26jtitle%3DCurr.%2520Opin.%2520Pharmacol.%26date%3D2015%26volume%3D23%26spage%3D98%26epage%3D107%26doi%3D10.1016%2Fj.coph.2015.05.016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group">Cushing, T. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Metz, D. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whittington, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McGee, L. R.</span><span> </span><span class="NLM_article-title">PI3Kδ and PI3Kγ as target for autoimmune and inflammatory diseases</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">8559</span><span class="NLM_x">–</span> <span class="NLM_lpage">8581</span><span class="refDoi"> DOI: 10.1021/jm300847w</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm300847w" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=8559-8581&author=T.+D.+Cushingauthor=D.+P.+Metzauthor=D.+A.+Whittingtonauthor=L.+R.+McGee&title=PI3K%CE%B4+and+PI3K%CE%B3+as+target+for+autoimmune+and+inflammatory+diseases&doi=10.1021%2Fjm300847w"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1021%2Fjm300847w&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm300847w%26sid%3Dliteratum%253Aachs%26aulast%3DCushing%26aufirst%3DT.%2BD.%26aulast%3DMetz%26aufirst%3DD.%2BP.%26aulast%3DWhittington%26aufirst%3DD.%2BA.%26aulast%3DMcGee%26aufirst%3DL.%2BR.%26atitle%3DPI3K%25CE%25B4%2520and%2520PI3K%25CE%25B3%2520as%2520target%2520for%2520autoimmune%2520and%2520inflammatory%2520diseases%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D8559%26epage%3D8581%26doi%3D10.1021%2Fjm300847w" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group">Patel, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chandrasekhar, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Evarts, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Forseth, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haran, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ip, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kashishian, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koditek, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koppenol, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lad, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lepist, E.-I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McGrath, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perreault, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Puri, K. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Villasenor, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Somoza, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steiner, B. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Therrien, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Treiberg, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Phillips, G.</span><span> </span><span class="NLM_article-title">Discovery of orally efficacious phosphoinositide 3-kinase δ inhibitors with improved metabolic stability</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">59</span><span class="NLM_x">, </span> <span class="NLM_fpage">9228</span><span class="NLM_x">–</span> <span class="NLM_lpage">9242</span><span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b01169</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b01169" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01821&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsFGrs7rF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=9228-9242&author=L.+Patelauthor=J.+Chandrasekharauthor=J.+Evartsauthor=K.+Forsethauthor=A.+C.+Haranauthor=C.+Ipauthor=A.+Kashishianauthor=M.+Kimauthor=D.+Koditekauthor=S.+Koppenolauthor=L.+Ladauthor=E.-I.+Lepistauthor=M.+E.+McGrathauthor=S.+Perreaultauthor=K.+D.+Puriauthor=A.+G.+Villasenorauthor=J.+R.+Somozaauthor=B.+H.+Steinerauthor=J.+Therrienauthor=J.+Treibergauthor=G.+Phillips&title=Discovery+of+orally+efficacious+phosphoinositide+3-kinase+%CE%B4+inhibitors+with+improved+metabolic+stability&doi=10.1021%2Facs.jmedchem.6b01169"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Orally Efficacious Phosphoinositide 3-Kinase δ Inhibitors with Improved Metabolic Stability</span></div><div class="casAuthors">Patel, Leena; Chandrasekhar, Jayaraman; Evarts, Jerry; Forseth, Kristen; Haran, Aaron C.; Ip, Carmen; Kashishian, Adam; Kim, Musong; Koditek, David; Koppenol, Sandy; Lad, Latesh; Lepist, Eve-Irene; McGrath, Mary E.; Perreault, Stephane; Puri, Kamal D.; Villasenor, Armando G.; Somoza, John R.; Steiner, Bart H.; Therrien, Joseph; Treiberg, Jennifer; Phillips, Gary</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">9228-9242</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Aberrant signaling of phosphoinositide-3-kinase delta (PI3K-delta) has been implicated in numerous pathologies including hematol. malignancies and rheumatoid arthritis.  Described in this manuscript is the discovery, optimization and in vivo evaluation of a novel series of pyridine-contg. PI3K-delta inhibitors.  This work led to the discovery of I, a highly selective inhibitor of PI3K-delta which displays an excellent pharmacokinetic profile and is efficacious in a rodent model of rheumatoid arthritis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo1LgrP9YV8frVg90H21EOLACvtfcHk0lgBYsiFpdEscQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsFGrs7rF&md5=6d9dff0ec5270aab250fcb4800d8635a</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b01169&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b01169%26sid%3Dliteratum%253Aachs%26aulast%3DPatel%26aufirst%3DL.%26aulast%3DChandrasekhar%26aufirst%3DJ.%26aulast%3DEvarts%26aufirst%3DJ.%26aulast%3DForseth%26aufirst%3DK.%26aulast%3DHaran%26aufirst%3DA.%2BC.%26aulast%3DIp%26aufirst%3DC.%26aulast%3DKashishian%26aufirst%3DA.%26aulast%3DKim%26aufirst%3DM.%26aulast%3DKoditek%26aufirst%3DD.%26aulast%3DKoppenol%26aufirst%3DS.%26aulast%3DLad%26aufirst%3DL.%26aulast%3DLepist%26aufirst%3DE.-I.%26aulast%3DMcGrath%26aufirst%3DM.%2BE.%26aulast%3DPerreault%26aufirst%3DS.%26aulast%3DPuri%26aufirst%3DK.%2BD.%26aulast%3DVillasenor%26aufirst%3DA.%2BG.%26aulast%3DSomoza%26aufirst%3DJ.%2BR.%26aulast%3DSteiner%26aufirst%3DB.%2BH.%26aulast%3DTherrien%26aufirst%3DJ.%26aulast%3DTreiberg%26aufirst%3DJ.%26aulast%3DPhillips%26aufirst%3DG.%26atitle%3DDiscovery%2520of%2520orally%2520efficacious%2520phosphoinositide%25203-kinase%2520%25CE%25B4%2520inhibitors%2520with%2520improved%2520metabolic%2520stability%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D9228%26epage%3D9242%26doi%3D10.1021%2Facs.jmedchem.6b01169" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group">Patel, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chandrasekhar, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Evarts, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haran, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ip, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaplan, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koditek, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lad, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lepist, E.-I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McGrath, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Novikov, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perreault, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Puri, K. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Somoza, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steiner, B. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stevens, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Therrien, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Treiberg, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Villaseñor, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yeung, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Phillips, G.</span><span> </span><span class="NLM_article-title">2,4,6-Triaminopyrimidine as a novel hinge binder in a series of PI3Kδ selective inhibitors</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">59</span><span class="NLM_x">, </span> <span class="NLM_fpage">3532</span><span class="NLM_x">–</span> <span class="NLM_lpage">3548</span><span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b00213</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00213" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01821&amp;key=1%3ACAS%3A528%3ADC%252BC28Xkt1CgtL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=3532-3548&author=L.+Patelauthor=J.+Chandrasekharauthor=J.+Evartsauthor=A.+C.+Haranauthor=C.+Ipauthor=J.+A.+Kaplanauthor=M.+Kimauthor=D.+Koditekauthor=L.+Ladauthor=E.-I.+Lepistauthor=M.+E.+McGrathauthor=N.+Novikovauthor=S.+Perreaultauthor=K.+D.+Puriauthor=J.+R.+Somozaauthor=B.+H.+Steinerauthor=K.+L.+Stevensauthor=J.+Therrienauthor=J.+Treibergauthor=A.+G.+Villase%C3%B1orauthor=A.+Yeungauthor=G.+Phillips&title=2%2C4%2C6-Triaminopyrimidine+as+a+novel+hinge+binder+in+a+series+of+PI3K%CE%B4+selective+inhibitors&doi=10.1021%2Facs.jmedchem.6b00213"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">2,4,6-Triaminopyrimidine as a Novel Hinge Binder in a Series of PI3Kδ Selective Inhibitors</span></div><div class="casAuthors">Patel, Leena; Chandrasekhar, Jayaraman; Evarts, Jerry; Haran, Aaron C.; Ip, Carmen; Kaplan, Joshua A.; Kim, Musong; Koditek, David; Lad, Latesh; Lepist, Eve-Irene; McGrath, Mary E.; Novikov, Nikolai; Perreault, Stephane; Puri, Kamal D.; Somoza, John R.; Steiner, Bart H.; Stevens, Kirk L.; Therrien, Joseph; Treiberg, Jennifer; Villasenor, Armando G.; Yeung, Arthur; Phillips, Gary</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">3532-3548</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Inhibition of phosphoinositide 3-kinase δ (PI3Kδ) is an appealing target for several hematol. malignancies and inflammatory diseases.  Herein, we describe the discovery and optimization of a series of propeller shaped PI3Kδ inhibitors comprising a novel triaminopyrimidine hinge binder.  Combinations of electronic and structural strategies were employed to mitigate aldehyde oxidase mediated metab.  This medicinal chem. effort culminated in the identification of 52, a potent and highly selective inhibitor of PI3Kδ that demonstrates efficacy in a rat model of arthritis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpygPlHbWp_TLVg90H21EOLACvtfcHk0lgBYsiFpdEscQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xkt1CgtL4%253D&md5=9e01fff097eccd127a9b9284d725d7e1</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00213&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00213%26sid%3Dliteratum%253Aachs%26aulast%3DPatel%26aufirst%3DL.%26aulast%3DChandrasekhar%26aufirst%3DJ.%26aulast%3DEvarts%26aufirst%3DJ.%26aulast%3DHaran%26aufirst%3DA.%2BC.%26aulast%3DIp%26aufirst%3DC.%26aulast%3DKaplan%26aufirst%3DJ.%2BA.%26aulast%3DKim%26aufirst%3DM.%26aulast%3DKoditek%26aufirst%3DD.%26aulast%3DLad%26aufirst%3DL.%26aulast%3DLepist%26aufirst%3DE.-I.%26aulast%3DMcGrath%26aufirst%3DM.%2BE.%26aulast%3DNovikov%26aufirst%3DN.%26aulast%3DPerreault%26aufirst%3DS.%26aulast%3DPuri%26aufirst%3DK.%2BD.%26aulast%3DSomoza%26aufirst%3DJ.%2BR.%26aulast%3DSteiner%26aufirst%3DB.%2BH.%26aulast%3DStevens%26aufirst%3DK.%2BL.%26aulast%3DTherrien%26aufirst%3DJ.%26aulast%3DTreiberg%26aufirst%3DJ.%26aulast%3DVillase%25C3%25B1or%26aufirst%3DA.%2BG.%26aulast%3DYeung%26aufirst%3DA.%26aulast%3DPhillips%26aufirst%3DG.%26atitle%3D2%252C4%252C6-Triaminopyrimidine%2520as%2520a%2520novel%2520hinge%2520binder%2520in%2520a%2520series%2520of%2520PI3K%25CE%25B4%2520selective%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D3532%26epage%3D3548%26doi%3D10.1021%2Facs.jmedchem.6b00213" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group">Cushing, T. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hao, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shin, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Andrews, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cardozo, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duquette, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fisher, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gonzalez-Lopez de Turiso, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">He, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Henne, K. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu, Y.-L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hungate, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kelly, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lucas, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCarter, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McGee, L. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Medina, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">San Miguel, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mohn, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pattaropong, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pettus, L. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reichelt, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rzasa, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seganish, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tasker, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wahl, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wannberg, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whittington, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whoriskey, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zalameda, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Metz, D. P.</span><span> </span><span class="NLM_article-title">Discovery and in vivo evaluation of (S)-N-(1-(7-fluoro-2-(pyridin-2-yl) quinolin-3-yl)ethyl)-9H-purin-6-amine (AMG319) and related PI3Kδ inhibitors for inflammation and autoimmune disease</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">58</span><span class="NLM_x">, </span> <span class="NLM_fpage">480</span><span class="NLM_x">–</span> <span class="NLM_lpage">511</span><span class="refDoi"> DOI: 10.1021/jm501624r</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm501624r" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=480-511&author=T.+D.+Cushingauthor=X.+Haoauthor=Y.+Shinauthor=K.+Andrewsauthor=M.+Brownauthor=M.+Cardozoauthor=Y.+Chenauthor=J.+Duquetteauthor=B.+Fisherauthor=F.+Gonzalez-Lopez+de+Turisoauthor=X.+Heauthor=K.+R.+Henneauthor=Y.-L.+Huauthor=R.+Hungateauthor=M.+G.+Johnsonauthor=R.+C.+Kellyauthor=B.+Lucasauthor=J.+D.+McCarterauthor=L.+R.+McGeeauthor=J.+C.+Medinaauthor=T.+San+Miguelauthor=D.+Mohnauthor=V.+Pattaropongauthor=L.+H.+Pettusauthor=A.+Reicheltauthor=R.+M.+Rzasaauthor=J.+Seganishauthor=A.+S.+Taskerauthor=R.+C.+Wahlauthor=S.+Wannbergauthor=D.+A.+Whittingtonauthor=J.+Whoriskeyauthor=G.+Yuauthor=L.+Zalamedaauthor=D.+Zhangauthor=D.+P.+Metz&title=Discovery+and+in+vivo+evaluation+of+%28S%29-N-%281-%287-fluoro-2-%28pyridin-2-yl%29+quinolin-3-yl%29ethyl%29-9H-purin-6-amine+%28AMG319%29+and+related+PI3K%CE%B4+inhibitors+for+inflammation+and+autoimmune+disease&doi=10.1021%2Fjm501624r"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1021%2Fjm501624r&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm501624r%26sid%3Dliteratum%253Aachs%26aulast%3DCushing%26aufirst%3DT.%2BD.%26aulast%3DHao%26aufirst%3DX.%26aulast%3DShin%26aufirst%3DY.%26aulast%3DAndrews%26aufirst%3DK.%26aulast%3DBrown%26aufirst%3DM.%26aulast%3DCardozo%26aufirst%3DM.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DDuquette%26aufirst%3DJ.%26aulast%3DFisher%26aufirst%3DB.%26aulast%3DGonzalez-Lopez%2Bde%2BTuriso%26aufirst%3DF.%26aulast%3DHe%26aufirst%3DX.%26aulast%3DHenne%26aufirst%3DK.%2BR.%26aulast%3DHu%26aufirst%3DY.-L.%26aulast%3DHungate%26aufirst%3DR.%26aulast%3DJohnson%26aufirst%3DM.%2BG.%26aulast%3DKelly%26aufirst%3DR.%2BC.%26aulast%3DLucas%26aufirst%3DB.%26aulast%3DMcCarter%26aufirst%3DJ.%2BD.%26aulast%3DMcGee%26aufirst%3DL.%2BR.%26aulast%3DMedina%26aufirst%3DJ.%2BC.%26aulast%3DSan%2BMiguel%26aufirst%3DT.%26aulast%3DMohn%26aufirst%3DD.%26aulast%3DPattaropong%26aufirst%3DV.%26aulast%3DPettus%26aufirst%3DL.%2BH.%26aulast%3DReichelt%26aufirst%3DA.%26aulast%3DRzasa%26aufirst%3DR.%2BM.%26aulast%3DSeganish%26aufirst%3DJ.%26aulast%3DTasker%26aufirst%3DA.%2BS.%26aulast%3DWahl%26aufirst%3DR.%2BC.%26aulast%3DWannberg%26aufirst%3DS.%26aulast%3DWhittington%26aufirst%3DD.%2BA.%26aulast%3DWhoriskey%26aufirst%3DJ.%26aulast%3DYu%26aufirst%3DG.%26aulast%3DZalameda%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DD.%26aulast%3DMetz%26aufirst%3DD.%2BP.%26atitle%3DDiscovery%2520and%2520in%2520vivo%2520evaluation%2520of%2520%2528S%2529-N-%25281-%25287-fluoro-2-%2528pyridin-2-yl%2529%2520quinolin-3-yl%2529ethyl%2529-9H-purin-6-amine%2520%2528AMG319%2529%2520and%2520related%2520PI3K%25CE%25B4%2520inhibitors%2520for%2520inflammation%2520and%2520autoimmune%2520disease%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D480%26epage%3D511%26doi%3D10.1021%2Fjm501624r" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group">Furet, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guagnano, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fairhurst, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Imbach-Weese, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bruce, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knapp, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fritsch, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blasco, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blanz, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aichholz, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamon, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fabbro, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caravatti, G.</span><span> </span><span class="NLM_article-title">Discovery of NVP-BYL719 a potent and selective phosphatidylinositol-3 kinase alpha inhibitor selected for clinical evaluation</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">3741</span><span class="NLM_x">–</span> <span class="NLM_lpage">3748</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2013.05.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01821&amp;key=10.1016%2Fj.bmcl.2013.05.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01821&amp;key=23726034" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01821&amp;key=1%3ACAS%3A528%3ADC%252BC3sXosFaisrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2013&pages=3741-3748&author=P.+Furetauthor=V.+Guagnanoauthor=R.+A.+Fairhurstauthor=P.+Imbach-Weeseauthor=I.+Bruceauthor=M.+Knappauthor=C.+Fritschauthor=F.+Blascoauthor=J.+Blanzauthor=R.+Aichholzauthor=J.+Hamonauthor=D.+Fabbroauthor=G.+Caravatti&title=Discovery+of+NVP-BYL719+a+potent+and+selective+phosphatidylinositol-3+kinase+alpha+inhibitor+selected+for+clinical+evaluation&doi=10.1016%2Fj.bmcl.2013.05.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of NVP-BYL719 a potent and selective phosphatidylinositol-3 kinase alpha inhibitor selected for clinical evaluation</span></div><div class="casAuthors">Furet, Pascal; Guagnano, Vito; Fairhurst, Robin A.; Imbach-Weese, Patricia; Bruce, Ian; Knapp, Mark; Fritsch, Christine; Blasco, Francesca; Blanz, Joachim; Aichholz, Reiner; Hamon, Jacques; Fabbro, Doriano; Caravatti, Giorgio</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">3741-3748</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Phosphatidylinositol-3-kinase α (PI3Kα) is a therapeutic target of high interest in anticancer drug research.  On the basis of a binding model rationalizing the high selectivity and potency of a particular series of 2-aminothiazole compds. in inhibiting PI3Kα, a medicinal chem. program has led to the discovery of the clin. candidate NVP-BYL719 I.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGraN93Vwrfb4bVg90H21EOLACvtfcHk0li05Ko83wqOlg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXosFaisrY%253D&md5=a0d2d69e01e7a82a5fed04114105925e</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2013.05.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2013.05.007%26sid%3Dliteratum%253Aachs%26aulast%3DFuret%26aufirst%3DP.%26aulast%3DGuagnano%26aufirst%3DV.%26aulast%3DFairhurst%26aufirst%3DR.%2BA.%26aulast%3DImbach-Weese%26aufirst%3DP.%26aulast%3DBruce%26aufirst%3DI.%26aulast%3DKnapp%26aufirst%3DM.%26aulast%3DFritsch%26aufirst%3DC.%26aulast%3DBlasco%26aufirst%3DF.%26aulast%3DBlanz%26aufirst%3DJ.%26aulast%3DAichholz%26aufirst%3DR.%26aulast%3DHamon%26aufirst%3DJ.%26aulast%3DFabbro%26aufirst%3DD.%26aulast%3DCaravatti%26aufirst%3DG.%26atitle%3DDiscovery%2520of%2520NVP-BYL719%2520a%2520potent%2520and%2520selective%2520phosphatidylinositol-3%2520kinase%2520alpha%2520inhibitor%2520selected%2520for%2520clinical%2520evaluation%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2013%26volume%3D23%26spage%3D3741%26epage%3D3748%26doi%3D10.1016%2Fj.bmcl.2013.05.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group">Heffron, T. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wei, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olivero, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Staben, S. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsui, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Do, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dotson, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Folkes, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldsmith, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldsmith, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gunzner, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lesnick, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lewis, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mathieu, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nonomiya, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shuttleworth, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sutherlin, D. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wan, C. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wiesmann, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, B.-Y.</span><span> </span><span class="NLM_article-title">Rational design of phosphoinositide 3-kinase α inhibitors that exhibit selectivity over the phosphoinositide 3-kinase β isoform</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">7815</span><span class="NLM_x">–</span> <span class="NLM_lpage">7833</span><span class="refDoi"> DOI: 10.1021/jm2007084</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm2007084" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01821&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtlGktrvE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=7815-7833&author=T.+P.+Heffronauthor=B.+Weiauthor=A.+Oliveroauthor=S.+T.+Stabenauthor=V.+Tsuiauthor=S.+Doauthor=J.+Dotsonauthor=A.+J.+Folkesauthor=P.+Goldsmithauthor=R.+Goldsmithauthor=J.+Gunznerauthor=J.+Lesnickauthor=C.+Lewisauthor=S.+Mathieuauthor=J.+Nonomiyaauthor=S.+Shuttleworthauthor=D.+P.+Sutherlinauthor=C.+W.+Wanauthor=S.+Wangauthor=C.+Wiesmannauthor=B.-Y.+Zhu&title=Rational+design+of+phosphoinositide+3-kinase+%CE%B1+inhibitors+that+exhibit+selectivity+over+the+phosphoinositide+3-kinase+%CE%B2+isoform&doi=10.1021%2Fjm2007084"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Rational Design of Phosphoinositide 3-Kinase α Inhibitors That Exhibit Selectivity over the Phosphoinositide 3-Kinase β Isoform</span></div><div class="casAuthors">Heffron, Timothy P.; Wei, Bin Qing; Olivero, Alan; Staben, Steven T.; Tsui, Vickie; Do, Steven; Dotson, Jennafer; Folkes, Adrian J.; Goldsmith, Paul; Goldsmith, Richard; Gunzner, Janet; Lesnick, John; Lewis, Cristina; Mathieu, Simon; Nonomiya, Jim; Shuttleworth, Stephen; Sutherlin, Daniel P.; Wan, Nan Chi; Wang, Shumei; Wiesmann, Christian; Zhu, Bing-Yan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">7815-7833</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Of the four class I phosphoinositide 3-kinase (PI3K) isoforms, PI3Kα has justly received the most attention for its potential in cancer therapy.  Herein we report our successful approaches to achieve PI3Kα vs PI3Kβ selectivity for two chem. series.  In the thienopyrimidine series of inhibitors, we propose that select ligands achieve selectivity derived from a hydrogen bonding interaction with Arg770 of PI3Kα that is not attained with the corresponding Lys777 of PI3Kβ.  In the benzoxepin series of inhibitors, the selectivity obsd. can be rationalized by the difference in electrostatic potential between the two isoforms in a given region rather than any specific interaction.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGquHPawgTpp87Vg90H21EOLACvtfcHk0li05Ko83wqOlg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtlGktrvE&md5=4ebed9c985c52238eddc45c6183cf3de</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1021%2Fjm2007084&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm2007084%26sid%3Dliteratum%253Aachs%26aulast%3DHeffron%26aufirst%3DT.%2BP.%26aulast%3DWei%26aufirst%3DB.%26aulast%3DOlivero%26aufirst%3DA.%26aulast%3DStaben%26aufirst%3DS.%2BT.%26aulast%3DTsui%26aufirst%3DV.%26aulast%3DDo%26aufirst%3DS.%26aulast%3DDotson%26aufirst%3DJ.%26aulast%3DFolkes%26aufirst%3DA.%2BJ.%26aulast%3DGoldsmith%26aufirst%3DP.%26aulast%3DGoldsmith%26aufirst%3DR.%26aulast%3DGunzner%26aufirst%3DJ.%26aulast%3DLesnick%26aufirst%3DJ.%26aulast%3DLewis%26aufirst%3DC.%26aulast%3DMathieu%26aufirst%3DS.%26aulast%3DNonomiya%26aufirst%3DJ.%26aulast%3DShuttleworth%26aufirst%3DS.%26aulast%3DSutherlin%26aufirst%3DD.%2BP.%26aulast%3DWan%26aufirst%3DC.%2BW.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DWiesmann%26aufirst%3DC.%26aulast%3DZhu%26aufirst%3DB.-Y.%26atitle%3DRational%2520design%2520of%2520phosphoinositide%25203-kinase%2520%25CE%25B1%2520inhibitors%2520that%2520exhibit%2520selectivity%2520over%2520the%2520phosphoinositide%25203-kinase%2520%25CE%25B2%2520isoform%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D7815%26epage%3D7833%26doi%3D10.1021%2Fjm2007084" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group">Wee, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wiederschain, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maira, S.-M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loo, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">deBeaumont, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stegmeier, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yao, Y.-M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lengauer, C.</span><span> </span><span class="NLM_article-title">PTEN-deficient cancers depend on PIK3CB</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">105</span><span class="NLM_x">, </span> <span class="NLM_fpage">13057</span><span class="NLM_x">–</span> <span class="NLM_lpage">13062</span><span class="refDoi"> DOI: 10.1073/pnas.0802655105</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01821&amp;key=10.1073%2Fpnas.0802655105" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01821&amp;key=18755892" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01821&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtFSitbrO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=105&publication_year=2008&pages=13057-13062&author=S.+Weeauthor=D.+Wiederschainauthor=S.-M.+Mairaauthor=A.+Looauthor=C.+Millerauthor=R.+deBeaumontauthor=F.+Stegmeierauthor=Y.-M.+Yaoauthor=C.+Lengauer&title=PTEN-deficient+cancers+depend+on+PIK3CB&doi=10.1073%2Fpnas.0802655105"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">PTEN-deficient cancers depend on PIK3CB</span></div><div class="casAuthors">Wee, Susan; Wiederschain, Dmitri; Maira, Sauveur-Michel; Loo, Alice; Miller, Christine; de Beaumont, Rosalie; Stegmeier, Frank; Yao, Yung-Mae; Lengauer, Christoph</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">105</span>
        (<span class="NLM_cas:issue">35</span>),
    <span class="NLM_cas:pages">13057-13062</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Deregulation of the PI3K signaling pathway is obsd. in many human cancers and occurs most frequently through loss of PTEN phosphatase tumor suppressor function or through somatic activating mutations in the Class IA PI3K, PIK3CA.  Tumors harboring activated p110α, the protein product of PIK3CA, require p110α activity for growth and survival and hence are expected to be responsive to inhibitors of its lipid kinase activity.  Whether PTEN-deficient cancers similarly depend on p110α activity to sustain activation of the PI3K pathway has been unclear.  In this study, we used a single-vector lentiviral inducible shRNA system to selectively inactivate the three Class IA PI3Ks, PIK3CA, PIK3CB, and PIK3CD, to det. which PI3K isoforms are responsible for driving the abnormal proliferation of PTEN-deficient cancers.  Down-regulation of PIK3CA in colorectal cancer cells harboring mutations in PIK3CA inhibited downstream PI3K signaling and cell growth.  Surprisingly, PIK3CA depletion affected neither PI3K signaling nor cell growth in 3 PTEN-deficient cancer cell lines.  In contrast, down-regulation of the PIK3CB isoform, which encodes p110β, resulted in pathway inactivation and subsequent inhibition of growth in both cell-based and in vivo settings.  This essential function of PIK3CB in PTEN-deficient cancer cells required its lipid kinase activity.  Our findings demonstrate that although p110α activation is required to sustain the proliferation of established PIK3CA-mutant tumors, PTEN-deficient tumors are dependent instead on p110β signaling.  This unexpected finding demonstrates the need to tailor therapeutic approaches to the genetic basis of PI3K pathway activation to achieve optimal treatment response.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr5ybGsv3DVCrVg90H21EOLACvtfcHk0lhKY2u11lKI7g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtFSitbrO&md5=b7c690d3631ac6cbee9d7d7414dae1da</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0802655105&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0802655105%26sid%3Dliteratum%253Aachs%26aulast%3DWee%26aufirst%3DS.%26aulast%3DWiederschain%26aufirst%3DD.%26aulast%3DMaira%26aufirst%3DS.-M.%26aulast%3DLoo%26aufirst%3DA.%26aulast%3DMiller%26aufirst%3DC.%26aulast%3DdeBeaumont%26aufirst%3DR.%26aulast%3DStegmeier%26aufirst%3DF.%26aulast%3DYao%26aufirst%3DY.-M.%26aulast%3DLengauer%26aufirst%3DC.%26atitle%3DPTEN-deficient%2520cancers%2520depend%2520on%2520PIK3CB%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2008%26volume%3D105%26spage%3D13057%26epage%3D13062%26doi%3D10.1073%2Fpnas.0802655105" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group">Jia, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Signoretti, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loda, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roberts, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, J. J.</span><span> </span><span class="NLM_article-title">Essential roles of PI(3)K-p110β in cell growth, metabolism and tumorigenesis</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">454</span><span class="NLM_x">, </span> <span class="NLM_fpage">776</span><span class="NLM_x">–</span> <span class="NLM_lpage">779</span><span class="refDoi"> DOI: 10.1038/nature07091</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01821&amp;key=10.1038%2Fnature07091" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01821&amp;key=18594509" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01821&amp;key=1%3ACAS%3A528%3ADC%252BD1cXps1Snu7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=454&publication_year=2008&pages=776-779&author=S.+Jiaauthor=Z.+Liuauthor=S.+Zhangauthor=P.+Liuauthor=L.+Zhangauthor=S.+H.+Leeauthor=L.+J.+Zhangauthor=S.+Signorettiauthor=M.+Lodaauthor=T.+M.+Robertsauthor=J.+J.+Zhao&title=Essential+roles+of+PI%283%29K-p110%CE%B2+in+cell+growth%2C+metabolism+and+tumorigenesis&doi=10.1038%2Fnature07091"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Essential roles of PI(3)K-p110β in cell growth, metabolism and tumorigenesis</span></div><div class="casAuthors">Jia, Shidong; Liu, Zhenning; Zhang, Sen; Liu, Pixu; Zhang, Lei; Lee, Sang Hyun; Zhang, Jing; Signoretti, Sabina; Loda, Massimo; Roberts, Thomas M.; Zhao, Jean J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">454</span>
        (<span class="NLM_cas:issue">7205</span>),
    <span class="NLM_cas:pages">776-779</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">On activation by receptors, the ubiquitously expressed class IA isoforms (p110α and p110β) of phosphatidylinositol-3-kinase (PI(3)K) generate lipid second messengers, which initiate multiple signal transduction cascades.  Recent studies have demonstrated specific functions for p110α in growth factor and insulin signaling.  To probe for distinct functions of p110β, we constructed conditional knockout mice.  Here we show that ablation of p110β in the livers of the resulting mice leads to impaired insulin sensitivity and glucose homeostasis, while having little effect on phosphorylation of Akt, suggesting the involvement of a kinase-independent role of p110β in insulin metabolic action.  Using established mouse embryonic fibroblasts, we found that removal of p110β also had little effect on Akt phosphorylation in response to stimulation by insulin and epidermal growth factor, but resulted in retarded cell proliferation.  Reconstitution of p110β-null cells with a wild-type or kinase-dead allele of p110β demonstrated that p110β possesses kinase-independent functions in regulating cell proliferation and trafficking.  However, the kinase activity of p110β was required for G-protein-coupled receptor signaling triggered by lysophosphatidic acid and had a function in oncogenic transformation.  Most strikingly, in an animal model of prostate tumor formation induced by Pten loss, ablation of p110β (also known as Pik3cb), but not that of p110α (also known as Pik3ca), impeded tumorigenesis with a concomitant diminution of Akt phosphorylation.  Taken together, our findings demonstrate both kinase-dependent and kinase-independent functions for p110β, and strongly indicate the kinase-dependent functions of p110β as a promising target in cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqm6EUnzNHwHrVg90H21EOLACvtfcHk0lhKY2u11lKI7g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXps1Snu7w%253D&md5=b32d9fcd1e8a0090da3ee8ae918a49db</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1038%2Fnature07091&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature07091%26sid%3Dliteratum%253Aachs%26aulast%3DJia%26aufirst%3DS.%26aulast%3DLiu%26aufirst%3DZ.%26aulast%3DZhang%26aufirst%3DS.%26aulast%3DLiu%26aufirst%3DP.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DLee%26aufirst%3DS.%2BH.%26aulast%3DZhang%26aufirst%3DL.%2BJ.%26aulast%3DSignoretti%26aufirst%3DS.%26aulast%3DLoda%26aufirst%3DM.%26aulast%3DRoberts%26aufirst%3DT.%2BM.%26aulast%3DZhao%26aufirst%3DJ.%2BJ.%26atitle%3DEssential%2520roles%2520of%2520PI%25283%2529K-p110%25CE%25B2%2520in%2520cell%2520growth%252C%2520metabolism%2520and%2520tumorigenesis%26jtitle%3DNature%26date%3D2008%26volume%3D454%26spage%3D776%26epage%3D779%26doi%3D10.1038%2Fnature07091" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group">Blackman, S. C.; Gainer, S. D.; Suttle, B. B.; Skordos, K. W.; Greshock, J. D.; Motwani, M.; Roadcap, L. T.; Hardwicke, M. A. A.; Wooster, R. F.</span><span> </span><span class="NLM_article-title">A phase I/IIa, first time in human, open-label dose escalation study of GSK2636771 in subjects with advanced solid tumors with PTEN deficiency</span>.  <span class="citation_source-book">Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research (AACR)</span>, Chicago, March 31–April 4,<span class="NLM_x"> </span><span class="NLM_year">2012</span><span class="NLM_x">; </span>Abstract 1752.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&author=S.+C.+Blackman&author=S.+D.+Gainer&author=B.+B.+Suttle&author=K.+W.+Skordos&author=J.+D.+Greshock&author=M.+Motwani&author=L.+T.+Roadcap&author=M.+A.+A.+Hardwicke&author=R.+F.+Wooster&title=Proceedings+of+the+103rd+Annual+Meeting+of+the+American+Association+for+Cancer+Research+%28AACR%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DBlackman%26aufirst%3DS.%2BC.%26atitle%3DA%2520phase%2520I%252FIIa%252C%2520first%2520time%2520in%2520human%252C%2520open-label%2520dose%2520escalation%2520study%2520of%2520GSK2636771%2520in%2520subjects%2520with%2520advanced%2520solid%2520tumors%2520with%2520PTEN%2520deficiency%26btitle%3DProceedings%2520of%2520the%2520103rd%2520Annual%2520Meeting%2520of%2520the%2520American%2520Association%2520for%2520Cancer%2520Research%2520%2528AACR%2529%26date%3D2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group">Barlaam, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cosulich, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Degorce, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fitzek, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Green, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hancox, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lambert-van der Brempt, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lohmann, J.-J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maudet, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morgentin, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pasquet, M.-J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Péru, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Plé, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saleh, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vautier, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walker, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ward, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Warin, N.</span><span> </span><span class="NLM_article-title">Discovery of (R)-8-(1-(3,5-difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4Hchromene-6-carboxamide (AZD8186): a potent and selective inhibitor of PI3Kβ and PI3Kδ for the treatment of PTEN-deficient cancers</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">58</span><span class="NLM_x">, </span> <span class="NLM_fpage">943</span><span class="NLM_x">–</span> <span class="NLM_lpage">962</span><span class="refDoi"> DOI: 10.1021/jm501629p</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm501629p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=943-962&author=B.+Barlaamauthor=S.+Cosulichauthor=S.+Degorceauthor=M.+Fitzekauthor=S.+Greenauthor=U.+Hancoxauthor=C.+Lambert-van+der+Bremptauthor=J.-J.+Lohmannauthor=M.+Maudetauthor=R.+Morgentinauthor=M.-J.+Pasquetauthor=A.+P%C3%A9ruauthor=P.+Pl%C3%A9author=T.+Salehauthor=M.+Vautierauthor=M.+Walkerauthor=L.+Wardauthor=N.+Warin&title=Discovery+of+%28R%29-8-%281-%283%2C5-difluorophenylamino%29ethyl%29-N%2CN-dimethyl-2-morpholino-4-oxo-4Hchromene-6-carboxamide+%28AZD8186%29%3A+a+potent+and+selective+inhibitor+of+PI3K%CE%B2+and+PI3K%CE%B4+for+the+treatment+of+PTEN-deficient+cancers&doi=10.1021%2Fjm501629p"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1021%2Fjm501629p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm501629p%26sid%3Dliteratum%253Aachs%26aulast%3DBarlaam%26aufirst%3DB.%26aulast%3DCosulich%26aufirst%3DS.%26aulast%3DDegorce%26aufirst%3DS.%26aulast%3DFitzek%26aufirst%3DM.%26aulast%3DGreen%26aufirst%3DS.%26aulast%3DHancox%26aufirst%3DU.%26aulast%3DLambert-van%2Bder%2BBrempt%26aufirst%3DC.%26aulast%3DLohmann%26aufirst%3DJ.-J.%26aulast%3DMaudet%26aufirst%3DM.%26aulast%3DMorgentin%26aufirst%3DR.%26aulast%3DPasquet%26aufirst%3DM.-J.%26aulast%3DP%25C3%25A9ru%26aufirst%3DA.%26aulast%3DPl%25C3%25A9%26aufirst%3DP.%26aulast%3DSaleh%26aufirst%3DT.%26aulast%3DVautier%26aufirst%3DM.%26aulast%3DWalker%26aufirst%3DM.%26aulast%3DWard%26aufirst%3DL.%26aulast%3DWarin%26aufirst%3DN.%26atitle%3DDiscovery%2520of%2520%2528R%2529-8-%25281-%25283%252C5-difluorophenylamino%2529ethyl%2529-N%252CN-dimethyl-2-morpholino-4-oxo-4Hchromene-6-carboxamide%2520%2528AZD8186%2529%253A%2520a%2520potent%2520and%2520selective%2520inhibitor%2520of%2520PI3K%25CE%25B2%2520and%2520PI3K%25CE%25B4%2520for%2520the%2520treatment%2520of%2520PTEN-deficient%2520cancers%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D943%26epage%3D962%26doi%3D10.1021%2Fjm501629p" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group">Cao, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cao, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luo, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhong, W.</span><span> </span><span class="NLM_article-title">Design, synthesis and biological evaluation of novel benzothiazole derivatives as selective PI3Kβ inhibitors</span> <span class="citation_source-journal">Molecules</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">876</span><span class="refDoi"> DOI: 10.3390/molecules21070876</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01821&amp;key=10.3390%2Fmolecules21070876" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2016&pages=876&author=S.+Caoauthor=R.+Caoauthor=X.+Liuauthor=X.+Luoauthor=W.+Zhong&title=Design%2C+synthesis+and+biological+evaluation+of+novel+benzothiazole+derivatives+as+selective+PI3K%CE%B2+inhibitors&doi=10.3390%2Fmolecules21070876"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.3390%2Fmolecules21070876&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fmolecules21070876%26sid%3Dliteratum%253Aachs%26aulast%3DCao%26aufirst%3DS.%26aulast%3DCao%26aufirst%3DR.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DLuo%26aufirst%3DX.%26aulast%3DZhong%26aufirst%3DW.%26atitle%3DDesign%252C%2520synthesis%2520and%2520biological%2520evaluation%2520of%2520novel%2520benzothiazole%2520derivatives%2520as%2520selective%2520PI3K%25CE%25B2%2520inhibitors%26jtitle%3DMolecules%26date%3D2016%26volume%3D21%26spage%3D876%26doi%3D10.3390%2Fmolecules21070876" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group">Zheng, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pinson, J.-A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mountford, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Orive, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schoenwaelder, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shackleford, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Powell, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nelson, E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamilton, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jackson, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jennings, I. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thompson, P. E.</span><span> </span><span class="NLM_article-title">Discovery and antiplatelet activity of a selective PI3Kβ inhibitor (MIPS-9922)</span> <span class="citation_source-journal">Eur. J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">122</span><span class="NLM_x">, </span> <span class="NLM_fpage">339</span><span class="NLM_x">–</span> <span class="NLM_lpage">351</span><span class="refDoi"> DOI: 10.1016/j.ejmech.2016.06.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01821&amp;key=10.1016%2Fj.ejmech.2016.06.010" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=122&publication_year=2016&pages=339-351&author=Z.+Zhengauthor=J.-A.+Pinsonauthor=S.+J.+Mountfordauthor=S.+Oriveauthor=M.+Schoenwaelderauthor=D.+Shacklefordauthor=A.+Powellauthor=E.+M.+Nelsonauthor=J.+R.+Hamiltonauthor=S.+P.+Jacksonauthor=I.+G.+Jenningsauthor=P.+E.+Thompson&title=Discovery+and+antiplatelet+activity+of+a+selective+PI3K%CE%B2+inhibitor+%28MIPS-9922%29&doi=10.1016%2Fj.ejmech.2016.06.010"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2016.06.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2016.06.010%26sid%3Dliteratum%253Aachs%26aulast%3DZheng%26aufirst%3DZ.%26aulast%3DPinson%26aufirst%3DJ.-A.%26aulast%3DMountford%26aufirst%3DS.%2BJ.%26aulast%3DOrive%26aufirst%3DS.%26aulast%3DSchoenwaelder%26aufirst%3DM.%26aulast%3DShackleford%26aufirst%3DD.%26aulast%3DPowell%26aufirst%3DA.%26aulast%3DNelson%26aufirst%3DE.%2BM.%26aulast%3DHamilton%26aufirst%3DJ.%2BR.%26aulast%3DJackson%26aufirst%3DS.%2BP.%26aulast%3DJennings%26aufirst%3DI.%2BG.%26aulast%3DThompson%26aufirst%3DP.%2BE.%26atitle%3DDiscovery%2520and%2520antiplatelet%2520activity%2520of%2520a%2520selective%2520PI3K%25CE%25B2%2520inhibitor%2520%2528MIPS-9922%2529%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2016%26volume%3D122%26spage%3D339%26epage%3D351%26doi%3D10.1016%2Fj.ejmech.2016.06.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group">Barlaam, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cosulich, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Degorce, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fitzek, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Green, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hancox, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lambert van der Brempt, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lohmann, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maudet, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morgentin, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Péru, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Plé, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saleh, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ward, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Warin, N.</span><span> </span><span class="NLM_article-title">Discovery of a series of 8-(2,3-dihydro-1,4-benzoxazin-4-ylmethyl)-2-morpholino-4-oxo-chromene-6-carboxamides as PI3Kβ/δ inhibitors for the treatment of PTEN-deficient tumours</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">2318</span><span class="NLM_x">–</span> <span class="NLM_lpage">2323</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2016.03.034</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01821&amp;key=10.1016%2Fj.bmcl.2016.03.034" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2016&pages=2318-2323&author=B.+Barlaamauthor=S.+Cosulichauthor=S.+Degorceauthor=M.+Fitzekauthor=S.+Greenauthor=U.+Hancoxauthor=C.+Lambert+van+der+Bremptauthor=J.+J.+Lohmannauthor=M.+Maudetauthor=R.+Morgentinauthor=A.+P%C3%A9ruauthor=P.+Pl%C3%A9author=T.+Salehauthor=L.+Wardauthor=N.+Warin&title=Discovery+of+a+series+of+8-%282%2C3-dihydro-1%2C4-benzoxazin-4-ylmethyl%29-2-morpholino-4-oxo-chromene-6-carboxamides+as+PI3K%CE%B2%2F%CE%B4+inhibitors+for+the+treatment+of+PTEN-deficient+tumours&doi=10.1016%2Fj.bmcl.2016.03.034"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2016.03.034&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2016.03.034%26sid%3Dliteratum%253Aachs%26aulast%3DBarlaam%26aufirst%3DB.%26aulast%3DCosulich%26aufirst%3DS.%26aulast%3DDegorce%26aufirst%3DS.%26aulast%3DFitzek%26aufirst%3DM.%26aulast%3DGreen%26aufirst%3DS.%26aulast%3DHancox%26aufirst%3DU.%26aulast%3DLambert%2Bvan%2Bder%2BBrempt%26aufirst%3DC.%26aulast%3DLohmann%26aufirst%3DJ.%2BJ.%26aulast%3DMaudet%26aufirst%3DM.%26aulast%3DMorgentin%26aufirst%3DR.%26aulast%3DP%25C3%25A9ru%26aufirst%3DA.%26aulast%3DPl%25C3%25A9%26aufirst%3DP.%26aulast%3DSaleh%26aufirst%3DT.%26aulast%3DWard%26aufirst%3DL.%26aulast%3DWarin%26aufirst%3DN.%26atitle%3DDiscovery%2520of%2520a%2520series%2520of%25208-%25282%252C3-dihydro-1%252C4-benzoxazin-4-ylmethyl%2529-2-morpholino-4-oxo-chromene-6-carboxamides%2520as%2520PI3K%25CE%25B2%252F%25CE%25B4%2520inhibitors%2520for%2520the%2520treatment%2520of%2520PTEN-deficient%2520tumours%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2016%26volume%3D26%26spage%3D2318%26epage%3D2323%26doi%3D10.1016%2Fj.bmcl.2016.03.034" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group">Certal, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Halley, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Virone-Oddos, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Delorme, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karlsson, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Charrier, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rak, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thompson, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Filoche-Rommé, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">El-Ahmad, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carry, J.-C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abecassis, P.-Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Amara, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vincent, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bonnevaux, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nicolas, J.-P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bertrand, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marquette, J.-P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Michot, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Benard, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Below, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vade, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chatreaux, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lebourg, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pilorge, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Angouillant-Boniface, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Louboutin, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lengauer, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schio, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mathieu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perrin, M.-A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lemaitre, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guerif, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perron, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Monget, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gruss-Leleu, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doerflinger, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guizani, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brollo, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Delbarre, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bertin, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richepin, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loyau, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garcia-Echeverria, C.</span><span> </span><span class="NLM_article-title">Discovery and optimization of pyrimidone indoline amide PI3Kβ inhibitors for the treatment of phosphatase and tensin homologue (PTEN)-deficient cancers</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">903</span><span class="NLM_x">–</span> <span class="NLM_lpage">920</span><span class="refDoi"> DOI: 10.1021/jm401642q</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm401642q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=903-920&author=V.+Certalauthor=F.+Halleyauthor=A.+Virone-Oddosauthor=C.+Delormeauthor=A.+Karlssonauthor=V.+Charrierauthor=A.+Rakauthor=F.+Thompsonauthor=B.+Filoche-Romm%C3%A9author=Y.+El-Ahmadauthor=J.-C.+Carryauthor=P.-Y.+Abecassisauthor=C.+Amaraauthor=L.+Vincentauthor=H.+Bonnevauxauthor=J.-P.+Nicolasauthor=T.+Bertrandauthor=J.-P.+Marquetteauthor=N.+Michotauthor=T.+Benardauthor=P.+Belowauthor=I.+Vadeauthor=F.+Chatreauxauthor=G.+Lebourgauthor=F.+Pilorgeauthor=O.+Angouillant-Bonifaceauthor=A.+Louboutinauthor=C.+Lengauerauthor=L.+Schioauthor=M.+Mathieuauthor=M.-A.+Perrinauthor=O.+Lemaitreauthor=S.+Guerifauthor=S.+Perronauthor=S.+Mongetauthor=F.+Gruss-Leleuauthor=G.+Doerflingerauthor=H.+Guizaniauthor=M.+Brolloauthor=L.+Delbarreauthor=L.+Bertinauthor=P.+Richepinauthor=V.+Loyauauthor=C.+Garcia-Echeverria&title=Discovery+and+optimization+of+pyrimidone+indoline+amide+PI3K%CE%B2+inhibitors+for+the+treatment+of+phosphatase+and+tensin+homologue+%28PTEN%29-deficient+cancers&doi=10.1021%2Fjm401642q"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1021%2Fjm401642q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm401642q%26sid%3Dliteratum%253Aachs%26aulast%3DCertal%26aufirst%3DV.%26aulast%3DHalley%26aufirst%3DF.%26aulast%3DVirone-Oddos%26aufirst%3DA.%26aulast%3DDelorme%26aufirst%3DC.%26aulast%3DKarlsson%26aufirst%3DA.%26aulast%3DCharrier%26aufirst%3DV.%26aulast%3DRak%26aufirst%3DA.%26aulast%3DThompson%26aufirst%3DF.%26aulast%3DFiloche-Romm%25C3%25A9%26aufirst%3DB.%26aulast%3DEl-Ahmad%26aufirst%3DY.%26aulast%3DCarry%26aufirst%3DJ.-C.%26aulast%3DAbecassis%26aufirst%3DP.-Y.%26aulast%3DAmara%26aufirst%3DC.%26aulast%3DVincent%26aufirst%3DL.%26aulast%3DBonnevaux%26aufirst%3DH.%26aulast%3DNicolas%26aufirst%3DJ.-P.%26aulast%3DBertrand%26aufirst%3DT.%26aulast%3DMarquette%26aufirst%3DJ.-P.%26aulast%3DMichot%26aufirst%3DN.%26aulast%3DBenard%26aufirst%3DT.%26aulast%3DBelow%26aufirst%3DP.%26aulast%3DVade%26aufirst%3DI.%26aulast%3DChatreaux%26aufirst%3DF.%26aulast%3DLebourg%26aufirst%3DG.%26aulast%3DPilorge%26aufirst%3DF.%26aulast%3DAngouillant-Boniface%26aufirst%3DO.%26aulast%3DLouboutin%26aufirst%3DA.%26aulast%3DLengauer%26aufirst%3DC.%26aulast%3DSchio%26aufirst%3DL.%26aulast%3DMathieu%26aufirst%3DM.%26aulast%3DPerrin%26aufirst%3DM.-A.%26aulast%3DLemaitre%26aufirst%3DO.%26aulast%3DGuerif%26aufirst%3DS.%26aulast%3DPerron%26aufirst%3DS.%26aulast%3DMonget%26aufirst%3DS.%26aulast%3DGruss-Leleu%26aufirst%3DF.%26aulast%3DDoerflinger%26aufirst%3DG.%26aulast%3DGuizani%26aufirst%3DH.%26aulast%3DBrollo%26aufirst%3DM.%26aulast%3DDelbarre%26aufirst%3DL.%26aulast%3DBertin%26aufirst%3DL.%26aulast%3DRichepin%26aufirst%3DP.%26aulast%3DLoyau%26aufirst%3DV.%26aulast%3DGarcia-Echeverria%26aufirst%3DC.%26atitle%3DDiscovery%2520and%2520optimization%2520of%2520pyrimidone%2520indoline%2520amide%2520PI3K%25CE%25B2%2520inhibitors%2520for%2520the%2520treatment%2520of%2520phosphatase%2520and%2520tensin%2520homologue%2520%2528PTEN%2529-deficient%2520cancers%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D903%26epage%3D920%26doi%3D10.1021%2Fjm401642q" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group">Lin, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schulz, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xie, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zeng, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luengo, J. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Squire, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tedesco, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Erhard, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mack, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raha, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Plant, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rominger, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ariazi, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sherk, C. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schaber, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McSurdy-Freed, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spengler, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davis, C. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hardwicke, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rivero, R. A.</span><span> </span><span class="NLM_article-title">Rational design, synthesis, and SAR of a novel thiazolopyrimidinone series of selective PI3K-beta inhibitors</span> <span class="citation_source-journal">ACS Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">524</span><span class="NLM_x">–</span> <span class="NLM_lpage">529</span><span class="refDoi"> DOI: 10.1021/ml300045b</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml300045b" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01821&amp;key=1%3ACAS%3A528%3ADC%252BC38XnsFOntr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2012&pages=524-529&author=H.+Linauthor=M.+J.+Schulzauthor=R.+Xieauthor=J.+Zengauthor=J.+I.+Luengoauthor=M.+D.+Squireauthor=R.+Tedescoauthor=J.+Quauthor=K.+Erhardauthor=J.+F.+Mackauthor=K.+Rahaauthor=R.+Plantauthor=C.+M.+Romingerauthor=J.+L.+Ariaziauthor=C.+S.+Sherkauthor=M.+D.+Schaberauthor=J.+McSurdy-Freedauthor=M.+D.+Spenglerauthor=C.+B.+Davisauthor=M.+A.+Hardwickeauthor=R.+A.+Rivero&title=Rational+design%2C+synthesis%2C+and+SAR+of+a+novel+thiazolopyrimidinone+series+of+selective+PI3K-beta+inhibitors&doi=10.1021%2Fml300045b"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Rational Design, Synthesis, and SAR of a Novel Thiazolopyrimidinone Series of Selective PI3K-beta Inhibitors</span></div><div class="casAuthors">Lin, Hong; Schulz, Mark J.; Xie, Ren; Zeng, Jin; Luengo, Juan I.; Squire, Michael D.; Tedesco, Rosanna; Qu, Junya; Erhard, Karl; Mack, James F.; Raha, Kaushik; Plant, Ramona; Rominger, Cynthia M.; Ariazi, Jennifer L.; Sherk, Christian S.; Schaber, Michael D.; McSurdy-Freed, Jeanelle; Spengler, Michael D.; Davis, Charles B.; Hardwicke, Mary Ann; Rivero, Ralph A.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">524-529</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A novel thiazolopyrimidinone series of PI3K-beta selective inhibitors has been identified.  This chemotype has provided an excellent tool compd., 18, that showed potent growth inhibition in the PTEN-deficient breast cancer cell line MDA-MB-468 under anchorage-independent conditions, and it also demonstrated pharmacodynamic effects and efficacy in a PTEN-deficient prostate cancer PC-3 xenograft mouse model.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqBdoBlyIkf9LVg90H21EOLACvtfcHk0ljAPoxl2yG3Ng"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XnsFOntr0%253D&md5=dfa2f5598b9b5d1e7a8bfb584fa50982</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1021%2Fml300045b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml300045b%26sid%3Dliteratum%253Aachs%26aulast%3DLin%26aufirst%3DH.%26aulast%3DSchulz%26aufirst%3DM.%2BJ.%26aulast%3DXie%26aufirst%3DR.%26aulast%3DZeng%26aufirst%3DJ.%26aulast%3DLuengo%26aufirst%3DJ.%2BI.%26aulast%3DSquire%26aufirst%3DM.%2BD.%26aulast%3DTedesco%26aufirst%3DR.%26aulast%3DQu%26aufirst%3DJ.%26aulast%3DErhard%26aufirst%3DK.%26aulast%3DMack%26aufirst%3DJ.%2BF.%26aulast%3DRaha%26aufirst%3DK.%26aulast%3DPlant%26aufirst%3DR.%26aulast%3DRominger%26aufirst%3DC.%2BM.%26aulast%3DAriazi%26aufirst%3DJ.%2BL.%26aulast%3DSherk%26aufirst%3DC.%2BS.%26aulast%3DSchaber%26aufirst%3DM.%2BD.%26aulast%3DMcSurdy-Freed%26aufirst%3DJ.%26aulast%3DSpengler%26aufirst%3DM.%2BD.%26aulast%3DDavis%26aufirst%3DC.%2BB.%26aulast%3DHardwicke%26aufirst%3DM.%2BA.%26aulast%3DRivero%26aufirst%3DR.%2BA.%26atitle%3DRational%2520design%252C%2520synthesis%252C%2520and%2520SAR%2520of%2520a%2520novel%2520thiazolopyrimidinone%2520series%2520of%2520selective%2520PI3K-beta%2520inhibitors%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D3%26spage%3D524%26epage%3D529%26doi%3D10.1021%2Fml300045b" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group">Pinson, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zheng, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chalmers, D. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jennings, I. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thompson, P. E.</span><span> </span><span class="NLM_article-title">L-Aminoacyl-triazine derivatives are isoform-selective PI3Kβ inhibitors that target nonconserved Asp862 of PI3Kβ</span> <span class="citation_source-journal">ACS Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">206</span><span class="NLM_x">–</span> <span class="NLM_lpage">210</span><span class="refDoi"> DOI: 10.1021/ml300336j</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml300336j" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2013&pages=206-210&author=J.+A.+Pinsonauthor=Z.+Zhengauthor=M.+S.+Millerauthor=D.+K.+Chalmersauthor=I.+G.+Jenningsauthor=P.+E.+Thompson&title=L-Aminoacyl-triazine+derivatives+are+isoform-selective+PI3K%CE%B2+inhibitors+that+target+nonconserved+Asp862+of+PI3K%CE%B2&doi=10.1021%2Fml300336j"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1021%2Fml300336j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml300336j%26sid%3Dliteratum%253Aachs%26aulast%3DPinson%26aufirst%3DJ.%2BA.%26aulast%3DZheng%26aufirst%3DZ.%26aulast%3DMiller%26aufirst%3DM.%2BS.%26aulast%3DChalmers%26aufirst%3DD.%2BK.%26aulast%3DJennings%26aufirst%3DI.%2BG.%26aulast%3DThompson%26aufirst%3DP.%2BE.%26atitle%3DL-Aminoacyl-triazine%2520derivatives%2520are%2520isoform-selective%2520PI3K%25CE%25B2%2520inhibitors%2520that%2520target%2520nonconserved%2520Asp862%2520of%2520PI3K%25CE%25B2%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2013%26volume%3D4%26spage%3D206%26epage%3D210%26doi%3D10.1021%2Fml300336j" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group">Gonzalez-Lopez de Turiso, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shin, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cardozo, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fong, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hao, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">He, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Henne, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu, Y.-L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kohn, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lohman, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McBride, H. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McGee, L. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Medina, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Metz, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miner, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mohn, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pattaropong, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seganish, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simard, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wannberg, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whittington, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cushing, T. D.</span><span> </span><span class="NLM_article-title">Discovery and in vivo evaluation of dual PI3Kβ/δ inhibitors</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">7667</span><span class="NLM_x">–</span> <span class="NLM_lpage">7685</span><span class="refDoi"> DOI: 10.1021/jm300679u</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm300679u" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01821&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtFKnsr3J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=7667-7685&author=F.+Gonzalez-Lopez+de+Turisoauthor=Y.+Shinauthor=M.+Brownauthor=M.+Cardozoauthor=Y.+Chenauthor=D.+Fongauthor=X.+Haoauthor=X.+Heauthor=K.+Henneauthor=Y.-L.+Huauthor=M.+G.+Johnsonauthor=T.+Kohnauthor=J.+Lohmanauthor=H.+J.+McBrideauthor=L.+R.+McGeeauthor=J.+C.+Medinaauthor=D.+Metzauthor=K.+Minerauthor=D.+Mohnauthor=V.+Pattaropongauthor=J.+Seganishauthor=J.+L.+Simardauthor=S.+Wannbergauthor=D.+A.+Whittingtonauthor=G.+Yuauthor=T.+D.+Cushing&title=Discovery+and+in+vivo+evaluation+of+dual+PI3K%CE%B2%2F%CE%B4+inhibitors&doi=10.1021%2Fjm300679u"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and in Vivo Evaluation of Dual PI3Kβ/δ Inhibitors</span></div><div class="casAuthors">Gonzalez-Lopez de Turiso, Felix; Shin, Youngsook; Brown, Matthew; Cardozo, Mario; Chen, Yi; Fong, David; Hao, Xiaolin; He, Xiao; Henne, Kirk; Hu, Yi-Ling; Johnson, Michael G.; Kohn, Todd; Lohman, Julia; McBride, Helen J.; McGee, Lawrence R.; Medina, Julio C.; Metz, Daniela; Miner, Kent; Mohn, Deanna; Pattaropong, Vatee; Seganish, Jennifer; Simard, Jillian L.; Wannberg, Sharon; Whittington, Douglas A.; Yu, Gang; Cushing, Timothy D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">7667-7685</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Structure-based rational design led to the synthesis of a novel series of potent PI3K inhibitors.  The optimized pyrrolopyridine analog I was a potent and selective PI3Kβ/δ dual inhibitor that displayed suitable physicochem. properties and pharmacokinetic profile for animal studies.  Analog I was found to be efficacious in animal models of inflammation including a keyhole limpet hemocyanin (KLH) study and a collagen-induced arthritis (CIA) disease model of rheumatoid arthritis.  These studies highlight the potential therapeutic value of inhibiting both the PI3Kβ and δ isoforms in the treatment of a no. of inflammatory diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpslq3QL1Tg7LVg90H21EOLACvtfcHk0lj5AXPVJCr0FQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtFKnsr3J&md5=fbf690a0e702faf17e16ef68db076635</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1021%2Fjm300679u&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm300679u%26sid%3Dliteratum%253Aachs%26aulast%3DGonzalez-Lopez%2Bde%2BTuriso%26aufirst%3DF.%26aulast%3DShin%26aufirst%3DY.%26aulast%3DBrown%26aufirst%3DM.%26aulast%3DCardozo%26aufirst%3DM.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DFong%26aufirst%3DD.%26aulast%3DHao%26aufirst%3DX.%26aulast%3DHe%26aufirst%3DX.%26aulast%3DHenne%26aufirst%3DK.%26aulast%3DHu%26aufirst%3DY.-L.%26aulast%3DJohnson%26aufirst%3DM.%2BG.%26aulast%3DKohn%26aufirst%3DT.%26aulast%3DLohman%26aufirst%3DJ.%26aulast%3DMcBride%26aufirst%3DH.%2BJ.%26aulast%3DMcGee%26aufirst%3DL.%2BR.%26aulast%3DMedina%26aufirst%3DJ.%2BC.%26aulast%3DMetz%26aufirst%3DD.%26aulast%3DMiner%26aufirst%3DK.%26aulast%3DMohn%26aufirst%3DD.%26aulast%3DPattaropong%26aufirst%3DV.%26aulast%3DSeganish%26aufirst%3DJ.%26aulast%3DSimard%26aufirst%3DJ.%2BL.%26aulast%3DWannberg%26aufirst%3DS.%26aulast%3DWhittington%26aufirst%3DD.%2BA.%26aulast%3DYu%26aufirst%3DG.%26aulast%3DCushing%26aufirst%3DT.%2BD.%26atitle%3DDiscovery%2520and%2520in%2520vivo%2520evaluation%2520of%2520dual%2520PI3K%25CE%25B2%252F%25CE%25B4%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D7667%26epage%3D7685%26doi%3D10.1021%2Fjm300679u" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group">Lannutti, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meadows, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herman, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kashishian, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steiner, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Byrd, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tyner, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loriaux, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deininger, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Druker, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Puri, K. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ulrich, R. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giese, N. A.</span><span> </span><span class="NLM_article-title">CAL-101, a p110delta selective phosphatidyl-inositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">117</span><span class="NLM_x">, </span> <span class="NLM_fpage">591</span><span class="NLM_x">–</span> <span class="NLM_lpage">594</span><span class="refDoi"> DOI: 10.1182/blood-2010-03-275305</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01821&amp;key=10.1182%2Fblood-2010-03-275305" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=117&publication_year=2011&pages=591-594&author=B.+J.+Lannuttiauthor=S.+A.+Meadowsauthor=S.+E.+Hermanauthor=A.+Kashishianauthor=B.+Steinerauthor=A.+J.+Johnsonauthor=J.+C.+Byrdauthor=J.+W.+Tynerauthor=M.+M.+Loriauxauthor=M.+Deiningerauthor=B.+J.+Drukerauthor=K.+D.+Puriauthor=R.+G.+Ulrichauthor=N.+A.+Giese&title=CAL-101%2C+a+p110delta+selective+phosphatidyl-inositol-3-kinase+inhibitor+for+the+treatment+of+B-cell+malignancies%2C+inhibits+PI3K+signaling+and+cellular+viability&doi=10.1182%2Fblood-2010-03-275305"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1182%2Fblood-2010-03-275305&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2010-03-275305%26sid%3Dliteratum%253Aachs%26aulast%3DLannutti%26aufirst%3DB.%2BJ.%26aulast%3DMeadows%26aufirst%3DS.%2BA.%26aulast%3DHerman%26aufirst%3DS.%2BE.%26aulast%3DKashishian%26aufirst%3DA.%26aulast%3DSteiner%26aufirst%3DB.%26aulast%3DJohnson%26aufirst%3DA.%2BJ.%26aulast%3DByrd%26aufirst%3DJ.%2BC.%26aulast%3DTyner%26aufirst%3DJ.%2BW.%26aulast%3DLoriaux%26aufirst%3DM.%2BM.%26aulast%3DDeininger%26aufirst%3DM.%26aulast%3DDruker%26aufirst%3DB.%2BJ.%26aulast%3DPuri%26aufirst%3DK.%2BD.%26aulast%3DUlrich%26aufirst%3DR.%2BG.%26aulast%3DGiese%26aufirst%3DN.%2BA.%26atitle%3DCAL-101%252C%2520a%2520p110delta%2520selective%2520phosphatidyl-inositol-3-kinase%2520inhibitor%2520for%2520the%2520treatment%2520of%2520B-cell%2520malignancies%252C%2520inhibits%2520PI3K%2520signaling%2520and%2520cellular%2520viability%26jtitle%3DBlood%26date%3D2011%26volume%3D117%26spage%3D591%26epage%3D594%26doi%3D10.1182%2Fblood-2010-03-275305" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group">Herman, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gordon, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wagner, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heerema, N. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flynn, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Andritsos, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Puri, K. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lannutti, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giese, N. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wei, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Byrd, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, A. J.</span><span> </span><span class="NLM_article-title">Phosphatidylinositol 3-kinase-δ inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">116</span><span class="NLM_x">, </span> <span class="NLM_fpage">2078</span><span class="NLM_x">–</span> <span class="NLM_lpage">2088</span><span class="refDoi"> DOI: 10.1182/blood-2010-02-271171</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01821&amp;key=10.1182%2Fblood-2010-02-271171" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=116&publication_year=2010&pages=2078-2088&author=S.+E.+Hermanauthor=A.+L.+Gordonauthor=A.+J.+Wagnerauthor=N.+A.+Heeremaauthor=W.+Zhaoauthor=J.+M.+Flynnauthor=J.+Jonesauthor=L.+Andritsosauthor=K.+D.+Puriauthor=B.+J.+Lannuttiauthor=N.+A.+Gieseauthor=X.+Zhangauthor=L.+Weiauthor=J.+C.+Byrdauthor=A.+J.+Johnson&title=Phosphatidylinositol+3-kinase-%CE%B4+inhibitor+CAL-101+shows+promising+preclinical+activity+in+chronic+lymphocytic+leukemia+by+antagonizing+intrinsic+and+extrinsic+cellular+survival+signals&doi=10.1182%2Fblood-2010-02-271171"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1182%2Fblood-2010-02-271171&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2010-02-271171%26sid%3Dliteratum%253Aachs%26aulast%3DHerman%26aufirst%3DS.%2BE.%26aulast%3DGordon%26aufirst%3DA.%2BL.%26aulast%3DWagner%26aufirst%3DA.%2BJ.%26aulast%3DHeerema%26aufirst%3DN.%2BA.%26aulast%3DZhao%26aufirst%3DW.%26aulast%3DFlynn%26aufirst%3DJ.%2BM.%26aulast%3DJones%26aufirst%3DJ.%26aulast%3DAndritsos%26aufirst%3DL.%26aulast%3DPuri%26aufirst%3DK.%2BD.%26aulast%3DLannutti%26aufirst%3DB.%2BJ.%26aulast%3DGiese%26aufirst%3DN.%2BA.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DWei%26aufirst%3DL.%26aulast%3DByrd%26aufirst%3DJ.%2BC.%26aulast%3DJohnson%26aufirst%3DA.%2BJ.%26atitle%3DPhosphatidylinositol%25203-kinase-%25CE%25B4%2520inhibitor%2520CAL-101%2520shows%2520promising%2520preclinical%2520activity%2520in%2520chronic%2520lymphocytic%2520leukemia%2520by%2520antagonizing%2520intrinsic%2520and%2520extrinsic%2520cellular%2520survival%2520signals%26jtitle%3DBlood%26date%3D2010%26volume%3D116%26spage%3D2078%26epage%3D2088%26doi%3D10.1182%2Fblood-2010-02-271171" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group">Somoza, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koditek, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Villasenor, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Novikov, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liclican, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xing, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lagpacan, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schultz, B. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Papalia, G. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Samuel, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lad, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McGrath, M. E.</span><span> </span><span class="NLM_article-title">Structural, biochemical, and biophysical characterization of idelalisib binding to phosphoinositide 3-kinase δ</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">290</span><span class="NLM_x">, </span> <span class="NLM_fpage">8439</span><span class="NLM_x">–</span> <span class="NLM_lpage">8446</span><span class="refDoi"> DOI: 10.1074/jbc.M114.634683</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01821&amp;key=10.1074%2Fjbc.M114.634683" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01821&amp;key=25631052" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01821&amp;key=1%3ACAS%3A528%3ADC%252BC2MXlsVSqtrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=290&publication_year=2015&pages=8439-8446&author=J.+R.+Somozaauthor=D.+Koditekauthor=A.+G.+Villasenorauthor=N.+Novikovauthor=M.+H.+Wongauthor=A.+Liclicanauthor=W.+Xingauthor=L.+Lagpacanauthor=R.+Wangauthor=B.+E.+Schultzauthor=G.+A.+Papaliaauthor=D.+Samuelauthor=L.+Ladauthor=M.+E.+McGrath&title=Structural%2C+biochemical%2C+and+biophysical+characterization+of+idelalisib+binding+to+phosphoinositide+3-kinase+%CE%B4&doi=10.1074%2Fjbc.M114.634683"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Structural, Biochemical, and Biophysical Characterization of Idelalisib Binding to Phosphoinositide 3-Kinase δ</span></div><div class="casAuthors">Somoza, John R.; Koditek, David; Villasenor, Armando G.; Novikov, Nikolai; Wong, Melanie H.; Liclican, Albert; Xing, Weimei; Lagpacan, Leanna; Wang, Ruth; Schultz, Brian E.; Papalia, Giuseppe A.; Samuel, Dharmaraj; Lad, Latesh; McGrath, Mary E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">290</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">8439-8446</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Idelalisib (also known as GS-1101, CAL-101, IC489666, and Zydelig) is a PI3Kδ inhibitor that has recently been approved for the treatment of several hematol. malignancies.  Given its use in human diseases, we needed a clear picture of how idelalisib binds to and inhibits PI3Kδ.  Our data show that idelalisib is a potent and selective inhibitor of the kinase activity of PI3Kδ.  A kinetic characterization clearly demonstrated ATP-competitive inhibition, and several addnl. biochem. and biophys. assays showed that the compd. binds reversibly and noncovalently to the kinase.  A crystal structure of idelalisib bound to the p110δ subunit of PI3Kδ furthers our understanding of the binding interactions that confer the potency and selectivity of idelalisib.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpnXZo8_qK79rVg90H21EOLACvtfcHk0liIedmSlgdzbQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXlsVSqtrs%253D&md5=2969b7407f4edc367249215bbbf22a0e</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M114.634683&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M114.634683%26sid%3Dliteratum%253Aachs%26aulast%3DSomoza%26aufirst%3DJ.%2BR.%26aulast%3DKoditek%26aufirst%3DD.%26aulast%3DVillasenor%26aufirst%3DA.%2BG.%26aulast%3DNovikov%26aufirst%3DN.%26aulast%3DWong%26aufirst%3DM.%2BH.%26aulast%3DLiclican%26aufirst%3DA.%26aulast%3DXing%26aufirst%3DW.%26aulast%3DLagpacan%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DR.%26aulast%3DSchultz%26aufirst%3DB.%2BE.%26aulast%3DPapalia%26aufirst%3DG.%2BA.%26aulast%3DSamuel%26aufirst%3DD.%26aulast%3DLad%26aufirst%3DL.%26aulast%3DMcGrath%26aufirst%3DM.%2BE.%26atitle%3DStructural%252C%2520biochemical%252C%2520and%2520biophysical%2520characterization%2520of%2520idelalisib%2520binding%2520to%2520phosphoinositide%25203-kinase%2520%25CE%25B4%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2015%26volume%3D290%26spage%3D8439%26epage%3D8446%26doi%3D10.1074%2Fjbc.M114.634683" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group">Berndt, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Le, D. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Houseman, B. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pacold, J. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gorrec, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hon, W.-C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rommel, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gaillard, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruckle, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schwarz, M. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shokat, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shaw, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, R. L.</span><span> </span><span class="NLM_article-title">The p110δ crystal structure uncovers mechanisms for selectivity and potency of novel PI3K inhibitors</span> <span class="citation_source-journal">Nat. Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">117</span><span class="NLM_x">–</span> <span class="NLM_lpage">124</span><span class="refDoi"> DOI: 10.1038/nchembio.293</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01821&amp;key=10.1038%2Fnchembio.293" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01821&amp;key=20081827" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01821&amp;key=1%3ACAS%3A528%3ADC%252BC3cXlvFGrsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2010&pages=117-124&author=A.+Berndtauthor=S.+Millerauthor=O.+Williamsauthor=D.+D.+Leauthor=B.+T.+Housemanauthor=J.+I.+Pacoldauthor=F.+Gorrecauthor=W.-C.+Honauthor=Y.+Liuauthor=C.+Rommelauthor=P.+Gaillardauthor=T.+Ruckleauthor=M.+K.+Schwarzauthor=K.+M.+Shokatauthor=J.+P.+Shawauthor=R.+L.+Williams&title=The+p110%CE%B4+crystal+structure+uncovers+mechanisms+for+selectivity+and+potency+of+novel+PI3K+inhibitors&doi=10.1038%2Fnchembio.293"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">The p110δ structure: mechanisms for selectivity and potency of new PI(3)K inhibitors</span></div><div class="casAuthors">Berndt, Alex; Miller, Simon; Williams, Olusegun; Le, Daniel D.; Houseman, Benjamin T.; Pacold, Joseph I.; Gorrec, Fabrice; Hon, Wai-Ching; Liu, Yi; Rommel, Christian; Gaillard, Pascale; Rueckle, Thomas; Schwarz, Matthias K.; Shokat, Kevan M.; Shaw, Jeffrey P.; Williams, Roger L.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">117-124</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Deregulation of the phosphoinositide-3-OH kinase (PI(3)K) pathway has been implicated in numerous pathologies including cancer, diabetes, thrombosis, rheumatoid arthritis, and asthma.  Recently, small-mol. and ATP-competitive PI(3)K inhibitors with a wide range of selectivities have entered clin. development.  To understand the mechanisms underlying the isoform selectivity of these inhibitors, we developed a new expression strategy that enabled us to det. to our knowledge the first crystal structure of the catalytic subunit of the class IA PI(3)K p110δ.  Structures of this enzyme in complex with a broad panel of isoform- and pan-selective class I PI(3)K inhibitors reveal that selectivity toward p110δ can be achieved by exploiting its conformational flexibility and the sequence diversity of active site residues that do not contact ATP.  We have used these observations to rationalize and synthesize highly selective inhibitors for p110δ with greatly improved potencies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqL8d01cEl_y7Vg90H21EOLACvtfcHk0liIedmSlgdzbQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXlvFGrsw%253D%253D&md5=8a0ce73ab8ca88ea9a48a2cb7fdb1975</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.293&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.293%26sid%3Dliteratum%253Aachs%26aulast%3DBerndt%26aufirst%3DA.%26aulast%3DMiller%26aufirst%3DS.%26aulast%3DWilliams%26aufirst%3DO.%26aulast%3DLe%26aufirst%3DD.%2BD.%26aulast%3DHouseman%26aufirst%3DB.%2BT.%26aulast%3DPacold%26aufirst%3DJ.%2BI.%26aulast%3DGorrec%26aufirst%3DF.%26aulast%3DHon%26aufirst%3DW.-C.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DRommel%26aufirst%3DC.%26aulast%3DGaillard%26aufirst%3DP.%26aulast%3DRuckle%26aufirst%3DT.%26aulast%3DSchwarz%26aufirst%3DM.%2BK.%26aulast%3DShokat%26aufirst%3DK.%2BM.%26aulast%3DShaw%26aufirst%3DJ.%2BP.%26aulast%3DWilliams%26aufirst%3DR.%2BL.%26atitle%3DThe%2520p110%25CE%25B4%2520crystal%2520structure%2520uncovers%2520mechanisms%2520for%2520selectivity%2520and%2520potency%2520of%2520novel%2520PI3K%2520inhibitors%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2010%26volume%3D6%26spage%3D117%26epage%3D124%26doi%3D10.1038%2Fnchembio.293" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="note"><p class="first last">For selected examples of isoform-selective PI3K inhibitors targeting nonconserved residues, see ref <a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">15</a> (Gln859 of PI3Kα), ref <a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">21</a> (Asp856 of PI3Kβ), ref <a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">22</a> (Asp862 of PI3Kβ), and ref <a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">26</a> (Asp862 of PI3Kβ).</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group">Chan, A. W. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laskowski, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Selwood, D. L.</span><span> </span><span class="NLM_article-title">Chemical fragments that hydrogen bond to Asp, Glu, Arg, and His side chains in protein binding sites</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">3086</span><span class="NLM_x">–</span> <span class="NLM_lpage">3094</span><span class="refDoi"> DOI: 10.1021/jm901696w</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm901696w" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01821&amp;key=1%3ACAS%3A528%3ADC%252BC3cXjt1enu7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=3086-3094&author=A.+W.+E.+Chanauthor=R.+A.+Laskowskiauthor=D.+L.+Selwood&title=Chemical+fragments+that+hydrogen+bond+to+Asp%2C+Glu%2C+Arg%2C+and+His+side+chains+in+protein+binding+sites&doi=10.1021%2Fjm901696w"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Chemical Fragments that Hydrogen Bond to Asp, Glu, Arg, and His Side Chains in Protein Binding Sites</span></div><div class="casAuthors">Chan, A. W. Edith; Laskowski, Roman A.; Selwood, David L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">3086-3094</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">We present an anal. of the chem. fragments from lead-like ligands in the Protein Data Bank (PDB) that form hydrogen bonds to the side chains of Asp, Glu, Arg, and His, which are the most common residues found in ligand binding sites.  A fragment is defined as the largest ring assembly contg. the atoms involved in hydrogen bonding.  In total, 462 fragments were found in 2038 ligands from over 8000 protein-ligand structures in the PDB.  The results show which fragments have a higher propensity for interaction with specific side chains.  Some fragments interact with Asp but not with Glu, and vice versa, despite these side chains sharing the same chem. moiety.  Arg side chains form hydrogen bonds almost exclusively with O-mediated ligands, and the fragments are the most diverse.  Hydrogen bond distances from the imidazole of His showed a wider range than the other three amino acids.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpNNuJszKkQobVg90H21EOLACvtfcHk0ljyPI_ARVanAg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXjt1enu7o%253D&md5=ae7c315b3974738b610bd82fff960d06</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1021%2Fjm901696w&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm901696w%26sid%3Dliteratum%253Aachs%26aulast%3DChan%26aufirst%3DA.%2BW.%2BE.%26aulast%3DLaskowski%26aufirst%3DR.%2BA.%26aulast%3DSelwood%26aufirst%3DD.%2BL.%26atitle%3DChemical%2520fragments%2520that%2520hydrogen%2520bond%2520to%2520Asp%252C%2520Glu%252C%2520Arg%252C%2520and%2520His%2520side%2520chains%2520in%2520protein%2520binding%2520sites%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D3086%26epage%3D3094%26doi%3D10.1021%2Fjm901696w" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group">Ramanathan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jin, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sharma, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kearney, B. P.</span><span> </span><span class="NLM_article-title">Clinical pharmacokinetic and pharmacodynamic profile of idelalisib</span> <span class="citation_source-journal">Clin. Pharmacokinet.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">33</span><span class="NLM_x">–</span> <span class="NLM_lpage">45</span><span class="refDoi"> DOI: 10.1007/s40262-015-0304-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01821&amp;key=10.1007%2Fs40262-015-0304-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01821&amp;key=26242379" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01821&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtlSit7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2016&pages=33-45&author=S.+Ramanathanauthor=F.+Jinauthor=S.+Sharmaauthor=B.+P.+Kearney&title=Clinical+pharmacokinetic+and+pharmacodynamic+profile+of+idelalisib&doi=10.1007%2Fs40262-015-0304-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Clinical Pharmacokinetic and Pharmacodynamic Profile of Idelalisib</span></div><div class="casAuthors">Ramanathan, Srinivasan; Jin, Feng; Sharma, Shringi; Kearney, Brian P.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Pharmacokinetics</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">33-45</span>CODEN:
                <span class="NLM_cas:coden">CPKNDH</span>;
        ISSN:<span class="NLM_cas:issn">0312-5963</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">Idelalisib is a potent and selective phosphatidylinositol 3-kinase-δ inhibitor, which is a first-in-class agent to be approved for the treatment of relapsed chronic lymphocytic leukemia, follicular B cell non-Hodgkin's lymphoma and small lymphocytic lymphoma.  In dose-ranging studies, idelalisib exposure increased in a less than dose-proportional manner, likely because of soly.-limited absorption.  The approved starting dose of 150 mg twice daily was supported by extensive exposure-response evaluations, with dose redn. to 100 mg twice daily being allowed for specific toxicities.  Idelalisib may be administered without regard to food on the basis of the absence of clin. relevant food effects, and was accordingly dosed in primary efficacy/safety studies.  Idelalisib is metabolized primarily via aldehyde oxidase (AO) and, to a lesser extent, via cytochrome P 450 (CYP) 3A.  Coadministration with the strong CYP3A inhibitor ketoconazole 400 mg once daily resulted in a ∼79 % increase in the idelalisib area under the plasma concn.-time curve (AUC).  Administration with the potent inducer rifampin resulted in a 75 % decrease in idelalisib exposure (AUC) and, as such, coadministration with strong inducers should be avoided.  GS-563117 is an inactive primary circulating metabolite of idelalisib formed mainly via AO.  Unlike idelalisib, GS-563117 is a mechanism-based inhibitor of CYP3A.  Accordingly, idelalisib 150 mg twice-daily dosing increases the midazolam AUC 5.4-fold.  Clin., idelalisib is not an inhibitor of the transporters P-glycoprotein, breast cancer resistance protein, org. anion-transporting polypeptide (OATP) 1B1 or OAPT1B3.  In a population pharmacokinetic model, no meaningful impact on idelalisib pharmacokinetics was noted for any of the covariates tested.  Idelalisib exposure was ∼60 % higher with moderate/severe hepatic impairment; no relevant changes were obsd. with severe renal impairment.  This article reviews a comprehensive pharmacol. program, including drug-drug interaction studies and mechanistic and special population studies, which has allowed a thorough understanding of idelalisib clin. pharmacokinetics and their impact on clin. safety and efficacy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGprSL8hV_Gha7Vg90H21EOLACvtfcHk0ljyPI_ARVanAg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtlSit7o%253D&md5=df1082fcbb0e1a9aa941769ade9fe962</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1007%2Fs40262-015-0304-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40262-015-0304-0%26sid%3Dliteratum%253Aachs%26aulast%3DRamanathan%26aufirst%3DS.%26aulast%3DJin%26aufirst%3DF.%26aulast%3DSharma%26aufirst%3DS.%26aulast%3DKearney%26aufirst%3DB.%2BP.%26atitle%3DClinical%2520pharmacokinetic%2520and%2520pharmacodynamic%2520profile%2520of%2520idelalisib%26jtitle%3DClin.%2520Pharmacokinet.%26date%3D2016%26volume%3D55%26spage%3D33%26epage%3D45%26doi%3D10.1007%2Fs40262-015-0304-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group">Jin, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robeson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moyer, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilbert, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murray, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ramanathan, S.</span><span> </span><span class="NLM_article-title">Clinical drug interaction profile of idelalisib in healthy subjects</span> <span class="citation_source-journal">J. Clin. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">909</span><span class="NLM_x">–</span> <span class="NLM_lpage">919</span><span class="refDoi"> DOI: 10.1002/jcph.495</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01821&amp;key=10.1002%2Fjcph.495" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01821&amp;key=25760671" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01821&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtFCru7%252FM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2015&pages=909-919&author=F.+Jinauthor=M.+Robesonauthor=H.+Zhouauthor=C.+Moyerauthor=S.+Wilbertauthor=B.+Murrayauthor=S.+Ramanathan&title=Clinical+drug+interaction+profile+of+idelalisib+in+healthy+subjects&doi=10.1002%2Fjcph.495"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Clinical drug interaction profile of idelalisib in healthy subjects</span></div><div class="casAuthors">Jin, Feng; Robeson, Michelle; Zhou, Huafeng; Moyer, Candra; Wilbert, Sibylle; Murray, Bernard; Ramanathan, Srini</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Pharmacology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">909-919</span>CODEN:
                <span class="NLM_cas:coden">JCPCBR</span>;
        ISSN:<span class="NLM_cas:issn">0091-2700</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Idelalisib, a potent phosphatidylinositol-3-kinase delta (PI3Kδ) inhibitor, is metabolized primarily by aldehyde oxidase to form GS-563117 and to a lesser extent by cytochrome P 450 (CYP) 3A and uridine 5'-diphospho-glucuronosyltransferase 1A4.  In vitro, idelalisib inhibits P-glycoprotein (P-gp) and org. anion transporting polypeptides 1B1 and 1B3, and GS-563117 is a time-dependent CYP3A inhibitor.  This study enrolled 24 healthy subjects and evaluated (1) the effect of idelalisib on the pharmacokinetics (PK) of digoxin, a P-gp probe substrate, rosuvastatin, a breast cancer resistance protein, and OATP1B1/OATP1B3 substrate, and midazolam, a CYP3A substrate; and (2) the effect of a strong inducer, rifampin, on idelalisib PK.  On treatment, the most common clin. adverse events (AEs) were headache and pyrexia.  Grade 3 transaminase increases were obsd. in 5 of 24 subjects and were reversible.  Two subjects had serious AEs after treatment completion (grade 3 pyrexia and/or drug-induced liver injury).  Idelalisib coadministration did not affect digoxin and rosuvastatin PK.  Coadministration with idelalisib increased plasma exposures of midazolam (138% and 437% for max. obsd. plasma concn. [Cmax] and area under the plasma concn.-time curve from time 0 extrapolated to infinity [AUCinf], resp.), consistent with the in vitro finding of CYP3A inhibition by GS-563117.  Rifampin caused a substantial decrease in idelalisib (58% and 75%, Cmax and AUCinf, resp.) and GS-563117 exposures, indicating an enhanced contribution of CYP3A to idelalisib metab. under a strongly induced state.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqnGy4bARtgkLVg90H21EOLACvtfcHk0lgreWsU7IiHcg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtFCru7%252FM&md5=b4e8bb97a51561cecda3ecd0c7a16372</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1002%2Fjcph.495&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjcph.495%26sid%3Dliteratum%253Aachs%26aulast%3DJin%26aufirst%3DF.%26aulast%3DRobeson%26aufirst%3DM.%26aulast%3DZhou%26aufirst%3DH.%26aulast%3DMoyer%26aufirst%3DC.%26aulast%3DWilbert%26aufirst%3DS.%26aulast%3DMurray%26aufirst%3DB.%26aulast%3DRamanathan%26aufirst%3DS.%26atitle%3DClinical%2520drug%2520interaction%2520profile%2520of%2520idelalisib%2520in%2520healthy%2520subjects%26jtitle%3DJ.%2520Clin.%2520Pharmacol.%26date%3D2015%26volume%3D55%26spage%3D909%26epage%3D919%26doi%3D10.1002%2Fjcph.495" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group">Meanwell, N.</span><span> </span><span class="NLM_article-title">Synopsis of some recent tactical application of bioisosteres in drug design</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">2529</span><span class="NLM_x">–</span> <span class="NLM_lpage">2591</span><span class="refDoi"> DOI: 10.1021/jm1013693</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm1013693" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01821&amp;key=1%3ACAS%3A528%3ADC%252BC3MXjsVCnu7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=2529-2591&author=N.+Meanwell&title=Synopsis+of+some+recent+tactical+application+of+bioisosteres+in+drug+design&doi=10.1021%2Fjm1013693"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Synopsis of Some Recent Tactical Application of Bioisosteres in Drug Design</span></div><div class="casAuthors">Meanwell, Nicholas A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2529-2591</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The established utility of bioisosteres is broad in nature, extending to improving potency, enhancing selectivity, altering phys. properties, reducing or redirecting metab., eliminating or modifying toxicophores, and acquiring novel intellectual property.  In this Perspective, some contemporary themes exploring the role of isosteres in drug design are sampled, with an emphasis placed on tactical applications designed to solve the kinds of problems that impinge on compd. optimization and the long-term success of drug candidates.  Interesting concepts that may have been poorly effective in the context examd. are captured, since the ideas may have merit in alternative circumstances.  A comprehensive cataloging of bioisosteres is beyond the scope of what will be provided, although a synopsis of relevant isosteres of a particular functionality is summarized in a succinct fashion in several sections.  Isosterism has also found productive application in the design and optimization of organocatalysts, and there are several examples in which functional mimicry established initially in a medicinal chem. setting has been adopted by this community.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrZ9z_aPcU4ubVg90H21EOLACvtfcHk0lgreWsU7IiHcg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXjsVCnu7o%253D&md5=0637ab60c379bef535f3f709b26f3582</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1021%2Fjm1013693&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm1013693%26sid%3Dliteratum%253Aachs%26aulast%3DMeanwell%26aufirst%3DN.%26atitle%3DSynopsis%2520of%2520some%2520recent%2520tactical%2520application%2520of%2520bioisosteres%2520in%2520drug%2520design%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D2529%26epage%3D2591%26doi%3D10.1021%2Fjm1013693" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group">Lin, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parikh, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lo, J.-L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, Y. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheng, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, R. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fisher, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wyvratt, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goulet, M. T.</span><span> </span><span class="NLM_article-title">Heterocyclic derivatives of 2-(3,5-dimethylphenyl)tryptamine as GnRH receptor antagonists</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">1077</span><span class="NLM_x">–</span> <span class="NLM_lpage">1080</span><span class="refDoi"> DOI: 10.1016/S0960-894X(01)00133-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01821&amp;key=10.1016%2FS0960-894X%2801%2900133-0" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2001&pages=1077-1080&author=P.+Linauthor=M.+Parikhauthor=J.-L.+Loauthor=Y.+T.+Yangauthor=K.+Chengauthor=R.+G.+Smithauthor=M.+H.+Fisherauthor=M.+J.+Wyvrattauthor=M.+T.+Goulet&title=Heterocyclic+derivatives+of+2-%283%2C5-dimethylphenyl%29tryptamine+as+GnRH+receptor+antagonists&doi=10.1016%2FS0960-894X%2801%2900133-0"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1016%2FS0960-894X%2801%2900133-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0960-894X%252801%252900133-0%26sid%3Dliteratum%253Aachs%26aulast%3DLin%26aufirst%3DP.%26aulast%3DParikh%26aufirst%3DM.%26aulast%3DLo%26aufirst%3DJ.-L.%26aulast%3DYang%26aufirst%3DY.%2BT.%26aulast%3DCheng%26aufirst%3DK.%26aulast%3DSmith%26aufirst%3DR.%2BG.%26aulast%3DFisher%26aufirst%3DM.%2BH.%26aulast%3DWyvratt%26aufirst%3DM.%2BJ.%26aulast%3DGoulet%26aufirst%3DM.%2BT.%26atitle%3DHeterocyclic%2520derivatives%2520of%25202-%25283%252C5-dimethylphenyl%2529tryptamine%2520as%2520GnRH%2520receptor%2520antagonists%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2001%26volume%3D11%26spage%3D1077%26epage%3D1080%26doi%3D10.1016%2FS0960-894X%2801%2900133-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group">Wright, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gregory, T. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kesten, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boxer, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Serpa, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meltzer, L. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wise, L. D.</span><span> </span><span class="NLM_article-title">Subtype-selective <i>N</i>-methyl-D-aspartate receptor antagonists: synthesis and biological evaluation of 1-(heteroarylalkynyl)-4-benzylpiperidines</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">43</span><span class="NLM_x">, </span> <span class="NLM_fpage">3408</span><span class="NLM_x">–</span> <span class="NLM_lpage">3419</span><span class="refDoi"> DOI: 10.1021/jm000023o</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm000023o" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01821&amp;key=1%3ACAS%3A528%3ADC%252BD3cXlslSrsr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2000&pages=3408-3419&author=J.+L.+Wrightauthor=T.+F.+Gregoryauthor=S.+R.+Kestenauthor=P.+A.+Boxerauthor=K.+A.+Serpaauthor=L.+T.+Meltzerauthor=L.+D.+Wise&title=Subtype-selective+N-methyl-D-aspartate+receptor+antagonists%3A+synthesis+and+biological+evaluation+of+1-%28heteroarylalkynyl%29-4-benzylpiperidines&doi=10.1021%2Fjm000023o"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Subtype-Selective N-Methyl-D-Aspartate Receptor Antagonists: Synthesis and Biological Evaluation of 1-(Heteroarylalkynyl)-4-benzylpiperidines</span></div><div class="casAuthors">Wright, Jon L.; Gregory, Tracy F.; Kesten, Suzanne R.; Boxer, Peter A.; Serpa, Kevin A.; Meltzer, Leonard T.; Wise, Lawrence D.; Espitia, Stephen A.; Konkoy, Christopher S.; Whittemore, Edward R.; Woodward, Richard M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">3408-3419</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">4-[4-(4-Benzylpiperidin-1-yl)but-1-ynyl]phenol and 4-[3-(4-benzylpiperidin-1-yl)prop-1-ynyl]phenol (I) are potent NR1A/2B receptor antagonists (IC50 values 0.17 and 0.10 μM, resp.).  Administered i.p., they both potentiated the activity of L-DOPA in the unilaterally 6-hydroxydopamine-lesioned (6-OHDA) rat, a model of Parkinson's disease.  However, I was not active orally, likely due to rapid first-pass metab. of the phenol moiety.  The phenol was replaced by several bicyclic heterocyclic systems contg. an NH group to function as a H-bond donor in the hope that these would be less likely to undergo rapid metab.  In general, indoles, indazoles, benzotriazoles, indolones, and isatins gave analogs with weaker NR1A/2B activity than the parent phenols, while benzimidazolones and benzimidazolinones gave equipotent or more potent analogs.  The preference for a para arrangement between the H-bond donor and the linking acetylene moiety was confirmed, and a propyne link was preferred over a butyne link.  Substitution on the benzyl group or a 4-hydroxyl group on the piperidine had little effect on NR1A/2B potency; however, 4-hydroxypiperidines demonstrated slightly improved selectivity for NR1A/2B receptors vs. α-1 adrenergic and dopamine D2 receptor affinity.  From this study, 5-[3-(4-benzylpiperidin-1-yl)prop-1-ynyl]-1,3-dihydrobenzimidazol-2-one (II) was identified as a very potent, selective NR1A/2B receptor antagonist (IC50 value 0.0053 μM).  After oral administration at 10 and 30 mg/kg, II potentiated the effects of L-DOPA in the 6-OHDA-lesioned rat and seemed to have improved oral bioavailability but lower brain penetration compared to I.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqcucGQrfk-zbVg90H21EOLACvtfcHk0lgreWsU7IiHcg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXlslSrsr4%253D&md5=d088cf30e4a342b2248481aaaa3f9cad</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1021%2Fjm000023o&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm000023o%26sid%3Dliteratum%253Aachs%26aulast%3DWright%26aufirst%3DJ.%2BL.%26aulast%3DGregory%26aufirst%3DT.%2BF.%26aulast%3DKesten%26aufirst%3DS.%2BR.%26aulast%3DBoxer%26aufirst%3DP.%2BA.%26aulast%3DSerpa%26aufirst%3DK.%2BA.%26aulast%3DMeltzer%26aufirst%3DL.%2BT.%26aulast%3DWise%26aufirst%3DL.%2BD.%26atitle%3DSubtype-selective%2520N-methyl-D-aspartate%2520receptor%2520antagonists%253A%2520synthesis%2520and%2520biological%2520evaluation%2520of%25201-%2528heteroarylalkynyl%2529-4-benzylpiperidines%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2000%26volume%3D43%26spage%3D3408%26epage%3D3419%26doi%3D10.1021%2Fjm000023o" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group">Mewshaw, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nelson, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shah, U. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shi, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mazandarani, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coupet, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marquis, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brennan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Andree, T. H.</span><span> </span><span class="NLM_article-title">New generation dopaminergic agents. 7. Heterocyclic bioisosteres that exploit the 3-OH-phenoxyethylamine D<sub>2</sub> template</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">2593</span><span class="NLM_x">–</span> <span class="NLM_lpage">2598</span><span class="refDoi"> DOI: 10.1016/S0960-894X(99)00434-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01821&amp;key=10.1016%2FS0960-894X%2899%2900434-5" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=1999&pages=2593-2598&author=R.+E.+Mewshawauthor=J.+A.+Nelsonauthor=U.+S.+Shahauthor=X.+Shiauthor=H.+Mazandaraniauthor=J.+Coupetauthor=K.+Marquisauthor=J.+Brennanauthor=T.+H.+Andree&title=New+generation+dopaminergic+agents.+7.+Heterocyclic+bioisosteres+that+exploit+the+3-OH-phenoxyethylamine+D2+template&doi=10.1016%2FS0960-894X%2899%2900434-5"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1016%2FS0960-894X%2899%2900434-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0960-894X%252899%252900434-5%26sid%3Dliteratum%253Aachs%26aulast%3DMewshaw%26aufirst%3DR.%2BE.%26aulast%3DNelson%26aufirst%3DJ.%2BA.%26aulast%3DShah%26aufirst%3DU.%2BS.%26aulast%3DShi%26aufirst%3DX.%26aulast%3DMazandarani%26aufirst%3DH.%26aulast%3DCoupet%26aufirst%3DJ.%26aulast%3DMarquis%26aufirst%3DK.%26aulast%3DBrennan%26aufirst%3DJ.%26aulast%3DAndree%26aufirst%3DT.%2BH.%26atitle%3DNew%2520generation%2520dopaminergic%2520agents.%25207.%2520Heterocyclic%2520bioisosteres%2520that%2520exploit%2520the%25203-OH-phenoxyethylamine%2520D2%2520template%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D1999%26volume%3D9%26spage%3D2593%26epage%3D2598%26doi%3D10.1016%2FS0960-894X%2899%2900434-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group">Pryde, D. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dalvie, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Obach, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tran, T.-D.</span><span> </span><span class="NLM_article-title">Aldehyde oxidase: an enzyme of emerging importance in drug discovery</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">8441</span><span class="NLM_x">–</span> <span class="NLM_lpage">8460</span><span class="refDoi"> DOI: 10.1021/jm100888d</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm100888d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01821&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtFygt73N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=8441-8460&author=D.+C.+Prydeauthor=D.+Dalvieauthor=Q.+Huauthor=P.+Jonesauthor=R.+S.+Obachauthor=T.-D.+Tran&title=Aldehyde+oxidase%3A+an+enzyme+of+emerging+importance+in+drug+discovery&doi=10.1021%2Fjm100888d"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Aldehyde Oxidase: An Enzyme of Emerging Importance in Drug Discovery</span></div><div class="casAuthors">Pryde, David C.; Dalvie, Deepak; Hu, Qiyue; Jones, Peter; Obach, R. Scott; Tran, Thien-Duc</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">8441-8460</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Aldehyde oxidase has for many years been recognized as a metabolizing enzyme contained within the cytosolic compartment of many tissues and in many species.  The first literature ref. to AO dates from the 1930s, but literature citations to this enzyme have been steadily growing ever since, esp. in the past decade.  It has been increasingly recognized in this past decade that AO, through its unique structure, distribution, and substrate recognition, has an important role to play in the metab. of drugs.  In this timely Perspective, we present the current knowledge of the enzyme's expression, its structure, and its distribution across species.  We offer an anal. of substrates recognized by AO and highlight clin. examples where metab. by this enzyme has had significant clin. impact or led to the termination of a drug development program.  Finally, through anal. of the structure of known substrates, we present data to suggest the significant impact AO could play on future drug discovery programs along with strategies that could be employed to mitigate this.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqALwFS70G6tLVg90H21EOLACvtfcHk0ljriByYZ2umAw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtFygt73N&md5=972eb9862a7dc7bff024b530ab40de7f</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1021%2Fjm100888d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm100888d%26sid%3Dliteratum%253Aachs%26aulast%3DPryde%26aufirst%3DD.%2BC.%26aulast%3DDalvie%26aufirst%3DD.%26aulast%3DHu%26aufirst%3DQ.%26aulast%3DJones%26aufirst%3DP.%26aulast%3DObach%26aufirst%3DR.%2BS.%26aulast%3DTran%26aufirst%3DT.-D.%26atitle%3DAldehyde%2520oxidase%253A%2520an%2520enzyme%2520of%2520emerging%2520importance%2520in%2520drug%2520discovery%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D8441%26epage%3D8460%26doi%3D10.1021%2Fjm100888d" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="note"><p class="first last">Crystal structure of mouse p110b (residues114–1064) with a bound ligand has been published (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4BFR">4BFR</a>).<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> Since the chemotype discussed in this manuscript is significantly different, we preferred to use a homology model based on the crystal structure of (<i>S</i>)-2,4-diamino-6-((5-chloro-8-fluoro-4-oxo-3-(pyridin-3-yl)-3,4-dihydroquinazolin-2-yl)(cyclopropyl)methylamino)pyrimidine-5-carbonitrile (GS-9901) bound to PI3Kδ (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5T8I">5T8I</a>)<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> for evaluating the binding mode.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group">Rabilloud, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sillion, B.</span><span> </span><span class="NLM_article-title">Synthesis of 4<i>H</i>-3,1-benzoxazin-4-ones and 4-(3<i>H</i>)quinazolinones from anthranilic acids and their derivatives by the use of triphenyl phosphite and pyridine</span> <span class="citation_source-journal">J. Heterocycl. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1980</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">1065</span><span class="NLM_x">–</span> <span class="NLM_lpage">1068</span><span class="refDoi"> DOI: 10.1002/jhet.5570170542</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01821&amp;key=10.1002%2Fjhet.5570170542" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=1980&pages=1065-1068&author=R.+Rabilloudauthor=B.+Sillion&title=Synthesis+of+4H-3%2C1-benzoxazin-4-ones+and+4-%283H%29quinazolinones+from+anthranilic+acids+and+their+derivatives+by+the+use+of+triphenyl+phosphite+and+pyridine&doi=10.1002%2Fjhet.5570170542"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1002%2Fjhet.5570170542&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjhet.5570170542%26sid%3Dliteratum%253Aachs%26aulast%3DRabilloud%26aufirst%3DR.%26aulast%3DSillion%26aufirst%3DB.%26atitle%3DSynthesis%2520of%25204H-3%252C1-benzoxazin-4-ones%2520and%25204-%25283H%2529quinazolinones%2520from%2520anthranilic%2520acids%2520and%2520their%2520derivatives%2520by%2520the%2520use%2520of%2520triphenyl%2520phosphite%2520and%2520pyridine%26jtitle%3DJ.%2520Heterocycl.%2520Chem.%26date%3D1980%26volume%3D17%26spage%3D1065%26epage%3D1068%26doi%3D10.1002%2Fjhet.5570170542" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':[],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':[],'ref42':['cit42']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 23 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Stephane Perreault, Fatima Arjmand, Jayaraman Chandrasekhar, Jia Hao, Kathleen S. Keegan, David Koditek, Eve-Irene Lepist, Clinton K. Matson, Mary E. McGrath, Leena Patel, Kassandra Sedillo, Joseph Therrien, Nicholas A. Till, Adrian Tomkinson, Jennifer Treiberg, Yelena Zherebina, <span class="NLM_string-name hlFld-ContribAuthor">Gary Phillips</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of an Atropisomeric PI3Kβ Selective Inhibitor through Optimization of the Hinge Binding Motif. </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2020,</strong> <em>11 </em>
                                    (6)
                                     , 1236-1243. <a href="https://doi.org/10.1021/acsmedchemlett.0c00095" title="DOI URL">https://doi.org/10.1021/acsmedchemlett.0c00095</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsmedchemlett.0c00095&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsmedchemlett.0c00095%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DDiscovery%252Bof%252Ban%252BAtropisomeric%252BPI3K%2525CE%2525B2%252BSelective%252BInhibitor%252Bthrough%252BOptimization%252Bof%252Bthe%252BHinge%252BBinding%252BMotif%26aulast%3DPerreault%26aufirst%3DStephane%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D22022020%26date%3D13042020%26date%3D15042020%26date%3D13042020%26volume%3D11%26issue%3D6%26spage%3D1236%26epage%3D1243" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Ashish Thakur, Gregory J. Tawa, Mark J. Henderson, Carina Danchik, Suiyang Liu, Pranav Shah, Amy Q. Wang, Garrett Dunn, Md Kabir, Elias C. Padilha, Xin Xu, Anton Simeonov, Surender Kharbanda, Richard Stone, <span class="NLM_string-name hlFld-ContribAuthor">Gurmit Grewal</span>. </span><span class="cited-content_cbyCitation_article-title">Design, Synthesis, and Biological Evaluation of Quinazolin-4-one-Based Hydroxamic Acids as Dual PI3K/HDAC Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (8)
                                     , 4256-4292. <a href="https://doi.org/10.1021/acs.jmedchem.0c00193" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c00193</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c00193&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c00193%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%25252C%252BSynthesis%25252C%252Band%252BBiological%252BEvaluation%252Bof%252BQuinazolin-4-one-Based%252BHydroxamic%252BAcids%252Bas%252BDual%252BPI3K%25252FHDAC%252BInhibitors%26aulast%3DThakur%26aufirst%3DAshish%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D03022020%26date%3D08042020%26date%3D26032020%26volume%3D63%26issue%3D8%26spage%3D4256%26epage%3D4292" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Gilles Ouvry, Laurence Clary, Loïc Tomas, Michèle Aurelly, Laetitia Bonnary, Emilie Borde, Claire Bouix-Peter, Laurent Chantalat, Claire Defoin-Platel, Sophie Deret, Mathieu Forissier, Craig S. Harris, Tatiana Isabet, Laurent Lamy, Anne-Pascale Luzy, Jonathan Pascau, Catherine Soulet, Alessandro Taddei, Nathalie Taquet, Etienne Thoreau, Emeric Varvier, Emmanuel Vial, <span class="NLM_string-name hlFld-ContribAuthor">Laurent F. Hennequin</span>. </span><span class="cited-content_cbyCitation_article-title">Impact of Minor Structural Modifications on Properties of a Series of mTOR Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2019,</strong> <em>10 </em>
                                    (11)
                                     , 1561-1567. <a href="https://doi.org/10.1021/acsmedchemlett.9b00401" title="DOI URL">https://doi.org/10.1021/acsmedchemlett.9b00401</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsmedchemlett.9b00401&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsmedchemlett.9b00401%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DImpact%252Bof%252BMinor%252BStructural%252BModifications%252Bon%252BProperties%252Bof%252Ba%252BSeries%252Bof%252BmTOR%252BInhibitors%26aulast%3DOuvry%26aufirst%3DGilles%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D30082019%26date%3D04102019%26date%3D08102019%26date%3D04102019%26volume%3D10%26issue%3D11%26spage%3D1561%26epage%3D1567" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Matthew W. D. Perry, Raolat Abdulai, Mickael Mogemark, Jens Petersen, Matthew J. Thomas, Barbara Valastro, <span class="NLM_string-name hlFld-ContribAuthor">Annika Westin Eriksson</span>. </span><span class="cited-content_cbyCitation_article-title">Evolution of PI3Kγ and δ Inhibitors for Inflammatory and Autoimmune Diseases. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>62 </em>
                                    (10)
                                     , 4783-4814. <a href="https://doi.org/10.1021/acs.jmedchem.8b01298" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b01298</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b01298&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.8b01298%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DEvolution%252Bof%252BPI3K%2525CE%2525B3%252Band%252B%2525CE%2525B4%252BInhibitors%252Bfor%252BInflammatory%252Band%252BAutoimmune%252BDiseases%26aulast%3DPerry%26aufirst%3DMatthew%2BW.%2BD.%26date%3D2019%26date%3D2018%26date%3D2018%26date%3D16082018%26date%3D24122018%26volume%3D62%26issue%3D10%26spage%3D4783%26epage%3D4814" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Aimie
E. Garces, <span class="NLM_string-name hlFld-ContribAuthor">Michael J. Stocks</span>. </span><span class="cited-content_cbyCitation_article-title">Class 1 PI3K Clinical Candidates and Recent Inhibitor Design Strategies: A Medicinal Chemistry Perspective. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>62 </em>
                                    (10)
                                     , 4815-4850. <a href="https://doi.org/10.1021/acs.jmedchem.8b01492" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b01492</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b01492&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.8b01492%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DClass%252B1%252BPI3K%252BClinical%252BCandidates%252Band%252BRecent%252BInhibitor%252BDesign%252BStrategies%25253A%252BA%252BMedicinal%252BChemistry%252BPerspective%26aulast%3DGarces%26aufirst%3DAimie%2BE.%26date%3D2019%26date%3D2018%26date%3D2018%26date%3D25092018%26date%3D24122018%26volume%3D62%26issue%3D10%26spage%3D4815%26epage%3D4850" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Jayaraman Chandrasekhar, Ryan Dick, Joshua Van Veldhuizen, David Koditek, Eve-Irene Lepist, Mary E. McGrath, Leena Patel, Gary Phillips, Kassandra Sedillo, John R. Somoza, Joseph Therrien, Nicholas A. Till, Jennifer Treiberg, Armando G. Villaseñor, Yelena Zherebina, <span class="NLM_string-name hlFld-ContribAuthor">Stephane Perreault</span>. </span><span class="cited-content_cbyCitation_article-title">Atropisomerism by Design: Discovery of a Selective and Stable Phosphoinositide 3-Kinase (PI3K) β Inhibitor. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>61 </em>
                                    (15)
                                     , 6858-6868. <a href="https://doi.org/10.1021/acs.jmedchem.8b00797" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b00797</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b00797&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.8b00797%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DAtropisomerism%252Bby%252BDesign%25253A%252BDiscovery%252Bof%252Ba%252BSelective%252Band%252BStable%252BPhosphoinositide%252B3-Kinase%252B%252528PI3K%252529%252B%2525CE%2525B2%252BInhibitor%26aulast%3DChandrasekhar%26aufirst%3DJayaraman%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D18052018%26date%3D30072018%26date%3D17072018%26volume%3D61%26issue%3D15%26spage%3D6858%26epage%3D6868" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Jin Liu, Yu-Ling Wang, Ji-Hong Zhang, Jian-Shan Yang, Han-Chuan Mou, Jun Lin, <span class="NLM_string-name hlFld-ContribAuthor">Sheng-Jiao Yan</span>. </span><span class="cited-content_cbyCitation_article-title">Phosphatase CDC25B Inhibitors Produced by Basic Alumina-Supported One-Pot Gram-Scale Synthesis of Fluorinated 2-Alkylthio-4-aminoquinazolines Using Microwave Irradiation. </span><span class="cited-content_cbyCitation_journal-name">ACS Omega</span><span> <strong>2018,</strong> <em>3 </em>
                                    (4)
                                     , 4534-4544. <a href="https://doi.org/10.1021/acsomega.8b00640" title="DOI URL">https://doi.org/10.1021/acsomega.8b00640</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsomega.8b00640&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsomega.8b00640%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Omega%26atitle%3DPhosphatase%252BCDC25B%252BInhibitors%252BProduced%252Bby%252BBasic%252BAlumina-Supported%252BOne-Pot%252BGram-Scale%252BSynthesis%252Bof%252BFluorinated%252B2-Alkylthio-4-aminoquinazolines%252BUsing%252BMicrowave%252BIrradiation%26aulast%3DLiu%26aufirst%3DJin%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D04042018%26date%3D17042018%26volume%3D3%26issue%3D4%26spage%3D4534%26epage%3D4544" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Heba S.A.  ElZahabi</span>, <span class="hlFld-ContribAuthor ">Mohamed S.  Nafie</span>, <span class="hlFld-ContribAuthor ">Dina  Osman</span>, <span class="hlFld-ContribAuthor ">Nehal H.  Elghazawy</span>, <span class="hlFld-ContribAuthor ">Dalia H.  Soliman</span>, <span class="hlFld-ContribAuthor ">Abdelghany Ali H.  EL-Helby</span>, <span class="hlFld-ContribAuthor ">Reem K.  Arafa</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis and evaluation of new quinazolin-4-one derivatives as apoptotic enhancers and autophagy inhibitors with potent antitumor activity. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>222 </em>, 113609. <a href="https://doi.org/10.1016/j.ejmech.2021.113609" title="DOI URL">https://doi.org/10.1016/j.ejmech.2021.113609</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2021.113609&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2021.113609%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%25252C%252Bsynthesis%252Band%252Bevaluation%252Bof%252Bnew%252Bquinazolin-4-one%252Bderivatives%252Bas%252Bapoptotic%252Benhancers%252Band%252Bautophagy%252Binhibitors%252Bwith%252Bpotent%252Bantitumor%252Bactivity%26aulast%3DElZahabi%26aufirst%3DHeba%2BS.A.%26date%3D2021%26volume%3D222%26spage%3D113609" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yeon Su  Kim</span>, <span class="hlFld-ContribAuthor ">Min Gyeong  Cheon</span>, <span class="hlFld-ContribAuthor ">Pulla Reddy  Boggu</span>, <span class="hlFld-ContribAuthor ">Su Youn  Koh</span>, <span class="hlFld-ContribAuthor ">Gi Min  Park</span>, <span class="hlFld-ContribAuthor ">Gahee  Kim</span>, <span class="hlFld-ContribAuthor ">Seo Hyun  Park</span>, <span class="hlFld-ContribAuthor ">Sung Lyea  Park</span>, <span class="hlFld-ContribAuthor ">Chi Woo  Lee</span>, <span class="hlFld-ContribAuthor ">Jong Woo  Kim</span>, <span class="hlFld-ContribAuthor ">Young Hoon  Jung</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis and biological evaluation of novel purinyl quinazolinone derivatives as PI3Kδ-specific inhibitors for the treatment of hematologic malignancies. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2021,</strong> <em>45 </em>, 116312. <a href="https://doi.org/10.1016/j.bmc.2021.116312" title="DOI URL">https://doi.org/10.1016/j.bmc.2021.116312</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2021.116312&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2021.116312%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3DSynthesis%252Band%252Bbiological%252Bevaluation%252Bof%252Bnovel%252Bpurinyl%252Bquinazolinone%252Bderivatives%252Bas%252BPI3K%2525CE%2525B4-specific%252Binhibitors%252Bfor%252Bthe%252Btreatment%252Bof%252Bhematologic%252Bmalignancies%26aulast%3DKim%26aufirst%3DYeon%2BSu%26date%3D2021%26volume%3D45%26spage%3D116312" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Bart  Vanhaesebroeck</span>, <span class="hlFld-ContribAuthor ">Matthew W. D.  Perry</span>, <span class="hlFld-ContribAuthor ">Jennifer R.  Brown</span>, <span class="hlFld-ContribAuthor ">Fabrice  André</span>, <span class="hlFld-ContribAuthor ">Klaus  Okkenhaug</span>. </span><span class="cited-content_cbyCitation_article-title">PI3K inhibitors are finally coming of age. </span><span class="cited-content_cbyCitation_journal-name">Nature Reviews Drug Discovery</span><span> <strong>2021,</strong> <em>170 </em><a href="https://doi.org/10.1038/s41573-021-00209-1" title="DOI URL">https://doi.org/10.1038/s41573-021-00209-1</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/s41573-021-00209-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fs41573-021-00209-1%26sid%3Dliteratum%253Aachs%26jtitle%3DNature%2520Reviews%2520Drug%2520Discovery%26atitle%3DPI3K%252Binhibitors%252Bare%252Bfinally%252Bcoming%252Bof%252Bage%26aulast%3DVanhaesebroeck%26aufirst%3DBart%26date%3D2021%26date%3D2021%26volume%3D170" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jingyu  Zhu</span>, <span class="hlFld-ContribAuthor ">Lei  Jia</span>, <span class="hlFld-ContribAuthor ">Yingmin  Jiang</span>, <span class="hlFld-ContribAuthor ">Qianqian  Yu</span>, <span class="hlFld-ContribAuthor ">Lei  Xu</span>, <span class="hlFld-ContribAuthor ">Yanfei  Cai</span>, <span class="hlFld-ContribAuthor ">Yun  Chen</span>, <span class="hlFld-ContribAuthor ">Huazhong  Li</span>, <span class="hlFld-ContribAuthor ">Huang  Gang</span>, <span class="hlFld-ContribAuthor ">Wenqing  Liang</span>, <span class="hlFld-ContribAuthor ">Jian  Jin</span>. </span><span class="cited-content_cbyCitation_article-title">Integrated molecular modeling techniques to reveal selective mechanisms of inhibitors to PI3Kδ with marketed Idelalisib. </span><span class="cited-content_cbyCitation_journal-name">Chemical Biology & Drug Design</span><span> <strong>2021,</strong> <em>97 </em>
                                    (6)
                                     , 1158-1169. <a href="https://doi.org/10.1111/cbdd.13838" title="DOI URL">https://doi.org/10.1111/cbdd.13838</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1111/cbdd.13838&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1111%2Fcbdd.13838%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520Biology%2520%2526%2520Drug%2520Design%26atitle%3DIntegrated%252Bmolecular%252Bmodeling%252Btechniques%252Bto%252Breveal%252Bselective%252Bmechanisms%252Bof%252Binhibitors%252Bto%252BPI3K%2525CE%2525B4%252Bwith%252Bmarketed%252BIdelalisib%26aulast%3DZhu%26aufirst%3DJingyu%26date%3D2021%26date%3D2021%26volume%3D97%26issue%3D6%26spage%3D1158%26epage%3D1169" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xiaoyu  Li</span>, <span class="hlFld-ContribAuthor ">Jennifer E.  Golden</span>. </span><span class="cited-content_cbyCitation_article-title">Construction of
              N
              ‐Boc‐2‐Alkylaminoquinazolin‐4(3
              H
              )‐Ones via a Three‐Component, One‐Pot Protocol Mediated by Copper(II) Chloride that Spares Enantiomeric Purity. </span><span class="cited-content_cbyCitation_journal-name">Advanced Synthesis & Catalysis</span><span> <strong>2021,</strong> <em>363 </em>
                                    (6)
                                     , 1638-1645. <a href="https://doi.org/10.1002/adsc.202001279" title="DOI URL">https://doi.org/10.1002/adsc.202001279</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/adsc.202001279&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fadsc.202001279%26sid%3Dliteratum%253Aachs%26jtitle%3DAdvanced%2520Synthesis%2520%2526%2520Catalysis%26atitle%3DConstruction%252Bof%252BN%252B%2525E2%252580%252590Boc%2525E2%252580%2525902%2525E2%252580%252590Alkylaminoquinazolin%2525E2%252580%2525904%2525283%252BH%252B%252529%2525E2%252580%252590Ones%252Bvia%252Ba%252BThree%2525E2%252580%252590Component%25252C%252BOne%2525E2%252580%252590Pot%252BProtocol%252BMediated%252Bby%252BCopper%252528II%252529%252BChloride%252Bthat%252BSpares%252BEnantiomeric%252BPurity%26aulast%3DLi%26aufirst%3DXiaoyu%26date%3D2021%26date%3D2021%26volume%3D363%26issue%3D6%26spage%3D1638%26epage%3D1645" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Fabiana  Plescia</span>, <span class="hlFld-ContribAuthor ">Benedetta  Maggio</span>, <span class="hlFld-ContribAuthor ">Giuseppe  Daidone</span>, <span class="hlFld-ContribAuthor ">Demetrio  Raffa</span>. </span><span class="cited-content_cbyCitation_article-title">4-(3H)-quinazolinones N-3 substituted with a five membered heterocycle: A promising scaffold towards bioactive molecules. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>213 </em>, 113070. <a href="https://doi.org/10.1016/j.ejmech.2020.113070" title="DOI URL">https://doi.org/10.1016/j.ejmech.2020.113070</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2020.113070&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2020.113070%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3D4-%2525283H%252529-quinazolinones%252BN-3%252Bsubstituted%252Bwith%252Ba%252Bfive%252Bmembered%252Bheterocycle%25253A%252BA%252Bpromising%252Bscaffold%252Btowards%252Bbioactive%252Bmolecules%26aulast%3DPlescia%26aufirst%3DFabiana%26date%3D2021%26volume%3D213%26spage%3D113070" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Stefan G.  Koenig</span>, <span class="hlFld-ContribAuthor ">Keena L.  Green</span>, <span class="hlFld-ContribAuthor ">Barbara  Müller</span>, <span class="hlFld-ContribAuthor ">C. Gregory  Sowell</span>, <span class="hlFld-ContribAuthor ">David  Askin</span>, <span class="hlFld-ContribAuthor ">Francis  Gosselin</span>. </span><span class="cited-content_cbyCitation_article-title">Development of a practical synthesis to PI3K α-selective inhibitor GDC-0326. </span><span class="cited-content_cbyCitation_journal-name">Tetrahedron</span><span> <strong>2021,</strong> <em>79 </em>, 131840. <a href="https://doi.org/10.1016/j.tet.2020.131840" title="DOI URL">https://doi.org/10.1016/j.tet.2020.131840</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.tet.2020.131840&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.tet.2020.131840%26sid%3Dliteratum%253Aachs%26jtitle%3DTetrahedron%26atitle%3DDevelopment%252Bof%252Ba%252Bpractical%252Bsynthesis%252Bto%252BPI3K%252B%2525CE%2525B1-selective%252Binhibitor%252BGDC-0326%26aulast%3DKoenig%26aufirst%3DStefan%2BG.%26date%3D2021%26volume%3D79%26spage%3D131840" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jianbo  Tian</span>, <span class="hlFld-ContribAuthor ">Ying  Zhu</span>, <span class="hlFld-ContribAuthor ">Meilin  Rao</span>, <span class="hlFld-ContribAuthor ">Yimin  Cai</span>, <span class="hlFld-ContribAuthor ">Zequn  Lu</span>, <span class="hlFld-ContribAuthor ">Danyi  Zou</span>, <span class="hlFld-ContribAuthor ">Xiating  Peng</span>, <span class="hlFld-ContribAuthor ">Pingting  Ying</span>, <span class="hlFld-ContribAuthor ">Ming  Zhang</span>, <span class="hlFld-ContribAuthor ">Siyuan  Niu</span>, <span class="hlFld-ContribAuthor ">Yue  Li</span>, <span class="hlFld-ContribAuthor ">Rong  Zhong</span>, <span class="hlFld-ContribAuthor ">Jiang  Chang</span>, <span class="hlFld-ContribAuthor ">Xiaoping  Miao</span>. </span><span class="cited-content_cbyCitation_article-title">N
              6
              -methyladenosine mRNA methylation of
              PIK3CB
              regulates AKT signalling to promote PTEN-deficient pancreatic cancer progression. </span><span class="cited-content_cbyCitation_journal-name">Gut</span><span> <strong>2020,</strong> <em>69 </em>
                                    (12)
                                     , 2180-2192. <a href="https://doi.org/10.1136/gutjnl-2019-320179" title="DOI URL">https://doi.org/10.1136/gutjnl-2019-320179</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1136/gutjnl-2019-320179&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1136%2Fgutjnl-2019-320179%26sid%3Dliteratum%253Aachs%26jtitle%3DGut%26atitle%3DN%252B6%252B-methyladenosine%252BmRNA%252Bmethylation%252Bof%252BPIK3CB%252Bregulates%252BAKT%252Bsignalling%252Bto%252Bpromote%252BPTEN-deficient%252Bpancreatic%252Bcancer%252Bprogression%26aulast%3DTian%26aufirst%3DJianbo%26date%3D2020%26date%3D2020%26volume%3D69%26issue%3D12%26spage%3D2180%26epage%3D2192" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jiajia  Sun</span>, <span class="hlFld-ContribAuthor ">Yifan  Feng</span>, <span class="hlFld-ContribAuthor ">Yuan  Huang</span>, <span class="hlFld-ContribAuthor ">San-Qi  Zhang</span>, <span class="hlFld-ContribAuthor ">Minhang  Xin</span>. </span><span class="cited-content_cbyCitation_article-title">Research advances on selective phosphatidylinositol 3 kinase δ (PI3Kδ) inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2020,</strong> <em>30 </em>
                                    (19)
                                     , 127457. <a href="https://doi.org/10.1016/j.bmcl.2020.127457" title="DOI URL">https://doi.org/10.1016/j.bmcl.2020.127457</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2020.127457&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2020.127457%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DResearch%252Badvances%252Bon%252Bselective%252Bphosphatidylinositol%252B3%252Bkinase%252B%2525CE%2525B4%252B%252528PI3K%2525CE%2525B4%252529%252Binhibitors%26aulast%3DSun%26aufirst%3DJiajia%26date%3D2020%26volume%3D30%26issue%3D19%26spage%3D127457" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jean-Marie  Nicolas</span>, <span class="hlFld-ContribAuthor ">Hugues  Chanteux</span>, <span class="hlFld-ContribAuthor ">Johan  Nicolaï</span>, <span class="hlFld-ContribAuthor ">Frédéric  Brouta</span>, <span class="hlFld-ContribAuthor ">Delphine  Viot</span>, <span class="hlFld-ContribAuthor ">Marie-Luce  Rosseels</span>, <span class="hlFld-ContribAuthor ">Eric  Gillent</span>, <span class="hlFld-ContribAuthor ">Pierre  Bonnaillie</span>, <span class="hlFld-ContribAuthor ">François-Xavier  Mathy</span>, <span class="hlFld-ContribAuthor ">Jeff  Long</span>, <span class="hlFld-ContribAuthor ">Eric  Helmer</span>. </span><span class="cited-content_cbyCitation_article-title">Role of P-glycoprotein in the brain disposition of seletalisib: Evaluation of the potential for drug-drug interactions. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Pharmaceutical Sciences</span><span> <strong>2020,</strong> <em>142 </em>, 105122. <a href="https://doi.org/10.1016/j.ejps.2019.105122" title="DOI URL">https://doi.org/10.1016/j.ejps.2019.105122</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejps.2019.105122&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejps.2019.105122%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Pharmaceutical%2520Sciences%26atitle%3DRole%252Bof%252BP-glycoprotein%252Bin%252Bthe%252Bbrain%252Bdisposition%252Bof%252Bseletalisib%25253A%252BEvaluation%252Bof%252Bthe%252Bpotential%252Bfor%252Bdrug-drug%252Binteractions%26aulast%3DNicolas%26aufirst%3DJean-Marie%26date%3D2020%26volume%3D142%26spage%3D105122" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xiaodong  Ma</span>, <span class="hlFld-ContribAuthor ">Jun  Wei</span>, <span class="hlFld-ContribAuthor ">Chang  Wang</span>, <span class="hlFld-ContribAuthor ">Dongyan  Gu</span>, <span class="hlFld-ContribAuthor ">Yongzhou  Hu</span>, <span class="hlFld-ContribAuthor ">Rong  Sheng</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis and biological evaluation of novel benzothiadiazine derivatives as potent PI3Kδ-selective inhibitors for treating B-cell-mediated malignancies. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>170 </em>, 112-125. <a href="https://doi.org/10.1016/j.ejmech.2019.03.005" title="DOI URL">https://doi.org/10.1016/j.ejmech.2019.03.005</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2019.03.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2019.03.005%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%25252C%252Bsynthesis%252Band%252Bbiological%252Bevaluation%252Bof%252Bnovel%252Bbenzothiadiazine%252Bderivatives%252Bas%252Bpotent%252BPI3K%2525CE%2525B4-selective%252Binhibitors%252Bfor%252Btreating%252BB-cell-mediated%252Bmalignancies%26aulast%3DMa%26aufirst%3DXiaodong%26date%3D2019%26volume%3D170%26spage%3D112%26epage%3D125" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ming  Lang</span>, <span class="hlFld-ContribAuthor ">Jian  Wang</span>. </span><span class="cited-content_cbyCitation_article-title">A carbene-catalyzed tandem isomerization/cyclisation strategy: an efficient assembly of benzoxazinones. </span><span class="cited-content_cbyCitation_journal-name">Organic Chemistry Frontiers</span><span> <strong>2019,</strong> <em>6 </em>
                                    (9)
                                     , 1367-1371. <a href="https://doi.org/10.1039/C9QO00094A" title="DOI URL">https://doi.org/10.1039/C9QO00094A</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C9QO00094A&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC9QO00094A%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Chemistry%2520Frontiers%26atitle%3DA%252Bcarbene-catalyzed%252Btandem%252Bisomerization%25252Fcyclisation%252Bstrategy%25253A%252Ban%252Befficient%252Bassembly%252Bof%252Bbenzoxazinones%26aulast%3DLang%26aufirst%3DMing%26date%3D2019%26date%3D2019%26volume%3D6%26issue%3D9%26spage%3D1367%26epage%3D1371" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Anne R  Bresnick</span>, <span class="hlFld-ContribAuthor ">Jonathan M  Backer</span>. </span><span class="cited-content_cbyCitation_article-title">PI3Kβ—A Versatile Transducer for GPCR, RTK, and Small GTPase Signaling. </span><span class="cited-content_cbyCitation_journal-name">Endocrinology</span><span> <strong>2019,</strong> <em>160 </em>
                                    (3)
                                     , 536-555. <a href="https://doi.org/10.1210/en.2018-00843" title="DOI URL">https://doi.org/10.1210/en.2018-00843</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1210/en.2018-00843&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1210%2Fen.2018-00843%26sid%3Dliteratum%253Aachs%26jtitle%3DEndocrinology%26atitle%3DPI3K%2525CE%2525B2%2525E2%252580%252594A%252BVersatile%252BTransducer%252Bfor%252BGPCR%25252C%252BRTK%25252C%252Band%252BSmall%252BGTPase%252BSignaling%26aulast%3DBresnick%26aufirst%3DAnne%2BR%26date%3D2019%26date%3D2019%26volume%3D160%26issue%3D3%26spage%3D536%26epage%3D555" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Michelle  Miller</span>, <span class="hlFld-ContribAuthor ">Philip  Thompson</span>, <span class="hlFld-ContribAuthor ">Sandra  Gabelli</span>. </span><span class="cited-content_cbyCitation_article-title">Structural Determinants of Isoform Selectivity in PI3K Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Biomolecules</span><span> <strong>2019,</strong> <em>9 </em>
                                    (3)
                                     , 82. <a href="https://doi.org/10.3390/biom9030082" title="DOI URL">https://doi.org/10.3390/biom9030082</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/biom9030082&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fbiom9030082%26sid%3Dliteratum%253Aachs%26jtitle%3DBiomolecules%26atitle%3DStructural%252BDeterminants%252Bof%252BIsoform%252BSelectivity%252Bin%252BPI3K%252BInhibitors%26aulast%3DMiller%26aufirst%3DMichelle%26date%3D2019%26date%3D2019%26volume%3D9%26issue%3D3%26spage%3D82" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">C.E.  Morais</span>, <span class="hlFld-ContribAuthor ">D.C.  Gurgel</span>, <span class="hlFld-ContribAuthor ">A.C.  Teixeira</span>, <span class="hlFld-ContribAuthor ">T.V. Arruda  Mattos</span>, <span class="hlFld-ContribAuthor ">A.V. Alves da  Silva</span>, <span class="hlFld-ContribAuthor ">F.  Tavora</span>. </span><span class="cited-content_cbyCitation_article-title">Prevalence of ERG expression and PTEN loss in a Brazilian prostate cancer cohort. </span><span class="cited-content_cbyCitation_journal-name">Brazilian Journal of Medical and Biological Research</span><span> <strong>2019,</strong> <em>52 </em>
                                    (12)
                                     <a href="https://doi.org/10.1590/1414-431x20198483" title="DOI URL">https://doi.org/10.1590/1414-431x20198483</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1590/1414-431x20198483&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1590%2F1414-431x20198483%26sid%3Dliteratum%253Aachs%26jtitle%3DBrazilian%2520Journal%2520of%2520Medical%2520and%2520Biological%2520Research%26atitle%3DPrevalence%252Bof%252BERG%252Bexpression%252Band%252BPTEN%252Bloss%252Bin%252Ba%252BBrazilian%252Bprostate%252Bcancer%252Bcohort%26aulast%3DMorais%26aufirst%3DC.E.%26date%3D2019%26date%3D2019%26volume%3D52%26issue%3D12" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Andreas S.  Kalogirou</span>, <span class="hlFld-ContribAuthor ">Maria  Manoli</span>, <span class="hlFld-ContribAuthor ">Panayiotis A.  Koutentis</span>. </span><span class="cited-content_cbyCitation_article-title">Two-step conversion of 3,4,4,5-tetrachloro-4 H -1,2,6-thiadiazine into 4,5,6-trichloropyrimidine-2-carbonitrile. </span><span class="cited-content_cbyCitation_journal-name">Tetrahedron Letters</span><span> <strong>2017,</strong> <em>58 </em>
                                    (26)
                                     , 2618-2621. <a href="https://doi.org/10.1016/j.tetlet.2017.05.082" title="DOI URL">https://doi.org/10.1016/j.tetlet.2017.05.082</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.tetlet.2017.05.082&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.tetlet.2017.05.082%26sid%3Dliteratum%253Aachs%26jtitle%3DTetrahedron%2520Letters%26atitle%3DTwo-step%252Bconversion%252Bof%252B3%25252C4%25252C4%25252C5-tetrachloro-4%252BH%252B-1%25252C2%25252C6-thiadiazine%252Binto%252B4%25252C5%25252C6-trichloropyrimidine-2-carbonitrile%26aulast%3DKalogirou%26aufirst%3DAndreas%2BS.%26date%3D2017%26volume%3D58%26issue%3D26%26spage%3D2618%26epage%3D2621" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="f_tgr1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-4/acs.jmedchem.6b01821/20170216/images/medium/jm-2016-01821e_0014.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-4/acs.jmedchem.6b01821/20170216/images/large/jm-2016-01821e_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01821&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-4/acs.jmedchem.6b01821/20170216/images/medium/jm-2016-01821e_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-4/acs.jmedchem.6b01821/20170216/images/large/jm-2016-01821e_0001.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. PI3Kβ inhibitors in clinical trials.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-4/acs.jmedchem.6b01821/20170216/images/large/jm-2016-01821e_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01821&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-4/acs.jmedchem.6b01821/20170216/images/medium/jm-2016-01821e_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-4/acs.jmedchem.6b01821/20170216/images/large/jm-2016-01821e_0002.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. (a) 2.4 Å X-ray crystal structure of idelalisib (<b>1</b>) bound in the PI3Kδ ATP binding site (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4XE0">4XE0</a>; coordinates available).<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> Asp832 and Asn836 (highlighted in yellow) differ among the PI3K isoforms. For clarity, all other residues have been removed. Blue dashed lines show hydrogen bond contacts between the inhibitor and the protein. (b) Different residues in the hydrophobic region II among class I PI3Ks. Asn836 of PI3Kδ corresponds to Asp856 of PI3Kβ.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-4/acs.jmedchem.6b01821/20170216/images/large/jm-2016-01821e_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01821&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-4/acs.jmedchem.6b01821/20170216/images/medium/jm-2016-01821e_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-4/acs.jmedchem.6b01821/20170216/images/large/jm-2016-01821e_0003.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. SAR pair analysis illustrating that the pyrazol-3-yl series (<b>23</b>) is superior to the pyrazol-4-yl series (<b>24</b>) in terms of PI3Kβ potency and PI3Kγ selectivity. Each colored shape represents a pair of compounds <b>23</b> and <b>24</b> with identical substituents X<sub>n</sub>, R<sup>1</sup>, R<sup>2</sup>, and R<sup>3</sup>, the only variable being the connectivity point on the pyrazole (pyrazol-3-yl vs pyrazol-4-yl). The value on the <i>x</i>-axis corresponds to the pyrazol-4-yl compound <b>24</b> and the value on the <i>y</i>-axis is for the corresponding pyrazol-3-yl compound <b>23</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-4/acs.jmedchem.6b01821/20170216/images/large/jm-2016-01821e_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01821&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-4/acs.jmedchem.6b01821/20170216/images/medium/jm-2016-01821e_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-4/acs.jmedchem.6b01821/20170216/images/large/jm-2016-01821e_0004.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Docked poses of compounds <b>11</b> (a) and <b>14</b> (b) in the homology model of PI3Kβ. In both cases, the pyrazole-NH is predicted to hydrogen-bond to Asp856. For clarity, all other residues have been removed. Blue dashed lines show predicted hydrogen bond contacts between the inhibitor and the protein. The PI3Kβ homology model used was built from the crystal structure PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5T8I">5T8I</a> (coordinates have been included in <a class="ref internalNav" href="#notes-1" aria-label="Supporting Information">Supporting Information</a>).<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-4/acs.jmedchem.6b01821/20170216/images/large/jm-2016-01821e_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01821&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-4/acs.jmedchem.6b01821/20170216/images/medium/jm-2016-01821e_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-4/acs.jmedchem.6b01821/20170216/images/large/jm-2016-01821e_0005.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Activity of <b>20a</b> in a human PTEN-deficient, androgen-responsive LNCaP xenograft tumor model in mice. <b>20a</b> was dosed twice a day for 13 consecutive days following the establishment of the tumor.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-4/acs.jmedchem.6b01821/20170216/images/large/jm-2016-01821e_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01821&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-4/acs.jmedchem.6b01821/20170216/images/medium/jm-2016-01821e_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-4/acs.jmedchem.6b01821/20170216/images/large/jm-2016-01821e_0006.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. AKT1 phosphorylation levels in LNCaP xenograft tumors treated with <b>20a</b> with corresponding mice plasma levels. Data are presented as the ratio of units of pAKT1 Ser473 per nanogram of total AKT1. The lower and higher dashed lines represent protein adjusted EC<sub>50</sub> and EC<sub>90</sub>, respectively.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-4/acs.jmedchem.6b01821/20170216/images/large/jm-2016-01821e_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01821&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-4/acs.jmedchem.6b01821/20170216/images/medium/jm-2016-01821e_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-4/acs.jmedchem.6b01821/20170216/images/large/jm-2016-01821e_0007.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. General Synthetic Sequence<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-4/acs.jmedchem.6b01821/20170216/images/large/jm-2016-01821e_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01821&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (i) pyridine, diphenyl phosphite, 40 °C, 2 h; (ii) 50 °C, 3–20 h, 50–100%; (iii) CF<sub>3</sub>CO<sub>2</sub>H, CH<sub>2</sub>Cl<sub>2</sub>, rt, 0.5–4 h, quant; (iv) <i>i</i>-Pr<sub>2</sub>NEt, isopropanol, 80–130 °C, microwave or thermal, 80–130 °C, 1–24 h, 30–90%. Boc = <i>tert</i>-butoxycarbonyl. TBS = <i>tert</i>-butyldimethylsilyl.</p></p></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i57">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_40082" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_40082" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 42 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group">Fruman, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rommel, C.</span><span> </span><span class="NLM_article-title">PI3K and cancer: lessons, challenges and opportunities</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">140</span><span class="NLM_x">–</span> <span class="NLM_lpage">156</span><span class="refDoi"> DOI: 10.1038/nrd4204</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01821&amp;key=10.1038%2Fnrd4204" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01821&amp;key=24481312" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01821&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs1SnsLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2014&pages=140-156&author=D.+A.+Frumanauthor=C.+Rommel&title=PI3K+and+cancer%3A+lessons%2C+challenges+and+opportunities&doi=10.1038%2Fnrd4204"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">PI3K and cancer: lessons, challenges and opportunities</span></div><div class="casAuthors">Fruman, David A.; Rommel, Christian</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">140-156</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The central role of phosphoinositide 3-kinase (PI3K) activation in tumor cell biol. has prompted a sizeable effort to target PI3K and/or downstream kinases such as AKT and mammalian target of rapamycin (mTOR) in cancer.  However, emerging clin. data show limited single-agent activity of inhibitors targeting PI3K, AKT or mTOR at tolerated doses.  One exception is the response to PI3Kδ inhibitors in chronic lymphocytic leukemia, where a combination of cell-intrinsic and -extrinsic activities drive efficacy.  Here, we review key challenges and opportunities for the clin. development of inhibitors targeting the PI3K-AKT-mTOR pathway.  Through a greater focus on patient selection, increased understanding of immune modulation and strategic application of rational combinations, it should be possible to realize the potential of this promising class of targeted anticancer agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqlD2rY54m9LbVg90H21EOLACvtfcHk0lgi2H5fPQFqog"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs1SnsLc%253D&md5=c4f6b4b9f9fcacd6ef55eb17d3a4f425</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1038%2Fnrd4204&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd4204%26sid%3Dliteratum%253Aachs%26aulast%3DFruman%26aufirst%3DD.%2BA.%26aulast%3DRommel%26aufirst%3DC.%26atitle%3DPI3K%2520and%2520cancer%253A%2520lessons%252C%2520challenges%2520and%2520opportunities%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2014%26volume%3D13%26spage%3D140%26epage%3D156%26doi%3D10.1038%2Fnrd4204" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group">Sadeghi, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gerber, D. E.</span><span> </span><span class="NLM_article-title">Targeting the PI3K pathway for cancer therapy</span> <span class="citation_source-journal">Future Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">1153</span><span class="NLM_x">–</span> <span class="NLM_lpage">1169</span><span class="refDoi"> DOI: 10.4155/fmc.12.56</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01821&amp;key=10.4155%2Ffmc.12.56" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01821&amp;key=22709255" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01821&amp;key=1%3ACAS%3A528%3ADC%252BC38Xoslalsbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2012&pages=1153-1169&author=N.+Sadeghiauthor=D.+E.+Gerber&title=Targeting+the+PI3K+pathway+for+cancer+therapy&doi=10.4155%2Ffmc.12.56"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting the PI3K pathway for cancer therapy</span></div><div class="casAuthors">Sadeghi, Navid; Gerber, David E.</div><div class="citationInfo"><span class="NLM_cas:title">Future Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1153-1169</span>CODEN:
                <span class="NLM_cas:coden">FMCUA7</span>;
        ISSN:<span class="NLM_cas:issn">1756-8919</span>.
    
            (<span class="NLM_cas:orgname">Future Science Ltd.</span>)
        </div><div class="casAbstract">A review.  The PI3K pathway plays an important role in key cellular functions such as cell growth, proliferation and survival.  Genetic and epigenetic alterations in different pathway components lead to aberrant pathway activation and have been obsd. in high frequencies in various tumor types.  Consequently, significant effort has been made to develop antineoplastic agents targeting different nodes in this pathway.  Addnl., PI3K pathway status may have predictive and prognostic implications, and may contribute to drug resistance in tumor cells.  This article provides an overview of our current knowledge of the PI3K pathway with an emphasis on its application in cancer treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqBOiXjDPa787Vg90H21EOLACvtfcHk0lgi2H5fPQFqog"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xoslalsbk%253D&md5=09fda93b8381b45fe1e8b8e1f99733e2</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.4155%2Ffmc.12.56&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4155%252Ffmc.12.56%26sid%3Dliteratum%253Aachs%26aulast%3DSadeghi%26aufirst%3DN.%26aulast%3DGerber%26aufirst%3DD.%2BE.%26atitle%3DTargeting%2520the%2520PI3K%2520pathway%2520for%2520cancer%2520therapy%26jtitle%3DFuture%2520Med.%2520Chem.%26date%3D2012%26volume%3D4%26spage%3D1153%26epage%3D1169%26doi%3D10.4155%2Ffmc.12.56" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group">Vanhaesebroeck, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stephens, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hawkins, P.</span><span> </span><span class="NLM_article-title">PI3K signaling: the path to discovery and understanding</span> <span class="citation_source-journal">Nat. Rev. Mol. Cell Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">195</span><span class="NLM_x">–</span> <span class="NLM_lpage">203</span><span class="refDoi"> DOI: 10.1038/nrm3290</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01821&amp;key=10.1038%2Fnrm3290" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01821&amp;key=22358332" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01821&amp;key=1%3ACAS%3A528%3ADC%252BC38Xis1eqt7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2012&pages=195-203&author=B.+Vanhaesebroeckauthor=L.+Stephensauthor=P.+Hawkins&title=PI3K+signaling%3A+the+path+to+discovery+and+understanding&doi=10.1038%2Fnrm3290"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">PI3K signalling: The path to discovery and understanding</span></div><div class="casAuthors">Vanhaesebroeck, Bart; Stephens, Len; Hawkins, Phillip</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Molecular Cell Biology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">195-203</span>CODEN:
                <span class="NLM_cas:coden">NRMCBP</span>;
        ISSN:<span class="NLM_cas:issn">1471-0072</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Over the past two decades, our understanding of phosphoinositide 3-kinases (PI3Ks) has progressed from the identification of an enzymic activity assocd. with growth factors, GPCRs and certain oncogene products to a disease target in cancer and inflammation, with PI3K inhibitors currently in clin. trials.  Elucidation of PI3K-dependent networks led to the discovery of the phosphoinositide-binding PH, PX and FYVE domains as conduits of intracellular lipid signalling, the detn. of the mol. function of the tumor suppressor PTEN and the identification of AKT and mTOR protein kinases as key regulators of cell growth.  Here we look back at the main discoveries that shaped the PI3K field.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq7WDc7Z5rhLLVg90H21EOLACvtfcHk0lhStwy_UjwmkA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xis1eqt7s%253D&md5=ff960f9ebfb5b5f2d8fc214aba330eef</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1038%2Fnrm3290&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrm3290%26sid%3Dliteratum%253Aachs%26aulast%3DVanhaesebroeck%26aufirst%3DB.%26aulast%3DStephens%26aufirst%3DL.%26aulast%3DHawkins%26aufirst%3DP.%26atitle%3DPI3K%2520signaling%253A%2520the%2520path%2520to%2520discovery%2520and%2520understanding%26jtitle%3DNat.%2520Rev.%2520Mol.%2520Cell%2520Biol.%26date%3D2012%26volume%3D13%26spage%3D195%26epage%3D203%26doi%3D10.1038%2Fnrm3290" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group">Liu, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheng, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roberts, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, J. J.</span><span> </span><span class="NLM_article-title">Targeting the phosphoinositide 3-kinase pathway in cancer</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">627</span><span class="NLM_x">–</span> <span class="NLM_lpage">644</span><span class="refDoi"> DOI: 10.1038/nrd2926</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01821&amp;key=10.1038%2Fnrd2926" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01821&amp;key=19644473" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01821&amp;key=1%3ACAS%3A528%3ADC%252BD1MXpt1Wgtb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2009&pages=627-644&author=P.+Liuauthor=H.+Chengauthor=T.+M.+Robertsauthor=J.+J.+Zhao&title=Targeting+the+phosphoinositide+3-kinase+pathway+in+cancer&doi=10.1038%2Fnrd2926"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting the phosphoinositide 3-kinase pathway in cancer</span></div><div class="casAuthors">Liu, Pixu; Cheng, Hailing; Roberts, Thomas M.; Zhao, Jean J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">627-644</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The phosphoinositide 3-kinase (PI3K) pathway is a key signal transduction system that links oncogenes and multiple receptor classes to many essential cellular functions, and is perhaps the most commonly activated signalling pathway in human cancer.  This pathway therefore presents both an opportunity and a challenge for cancer therapy.  Even as inhibitors that target PI3K isoforms and other major nodes in the pathway, including AKT and mammalian target of rapamycin (mTOR), reach clin. trials, major issues remain.  Here, we highlight recent progress that has been made in our understanding of the PI3K pathway and discuss the potential of and challenges for the development of therapeutic agents that target this pathway in cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrUk9T-ZoNDtLVg90H21EOLACvtfcHk0lhStwy_UjwmkA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXpt1Wgtb4%253D&md5=fdc94abd15178a9dbe7c56dafbfb7787</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1038%2Fnrd2926&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd2926%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DP.%26aulast%3DCheng%26aufirst%3DH.%26aulast%3DRoberts%26aufirst%3DT.%2BM.%26aulast%3DZhao%26aufirst%3DJ.%2BJ.%26atitle%3DTargeting%2520the%2520phosphoinositide%25203-kinase%2520pathway%2520in%2520cancer%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2009%26volume%3D8%26spage%3D627%26epage%3D644%26doi%3D10.1038%2Fnrd2926" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group">Yuan, T. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cantley, L. C.</span><span> </span><span class="NLM_article-title">PI3K pathway alterations in cancer: variations on a theme</span> <span class="citation_source-journal">Oncogene</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">27</span><span class="NLM_x">, </span> <span class="NLM_fpage">5497</span><span class="NLM_x">–</span> <span class="NLM_lpage">5510</span><span class="refDoi"> DOI: 10.1038/onc.2008.245</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01821&amp;key=10.1038%2Fonc.2008.245" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01821&amp;key=18794884" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01821&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtFWiurzI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2008&pages=5497-5510&author=T.+L.+Yuanauthor=L.+C.+Cantley&title=PI3K+pathway+alterations+in+cancer%3A+variations+on+a+theme&doi=10.1038%2Fonc.2008.245"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">PI3K pathway alterations in cancer: variations on a theme</span></div><div class="casAuthors">Yuan, T. L.; Cantley, L. C.</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">41</span>),
    <span class="NLM_cas:pages">5497-5510</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The high frequency of phosphoinositide 3-kinase (PI3K) pathway alterations in cancer has led to a surge in the development of PI3K inhibitors.  Many of these targeted therapies are currently in clin. trials and show great promise for the treatment of PI3K-addicted tumors.  These recent developments call for a re-evaluation of the oncogenic mechanisms behind PI3K pathway alterations.  This pathway is unique in that every major node is frequently mutated or amplified in a wide variety of solid tumors.  Receptor tyrosine kinases upstream of PI3K, the p110α catalytic subunit of PI3K, the downstream kinase, AKT, and the neg. regulator, PTEN, are all frequently altered in cancer.  In this review, we will examine the oncogenic properties of these genetic alterations to understand whether they are redundant or distinct and propose treatment strategies tailored for these genetic lesions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq-qvYXlFQJm7Vg90H21EOLACvtfcHk0lhStwy_UjwmkA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtFWiurzI&md5=664ee1e69e409899531d737a58b46b36</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1038%2Fonc.2008.245&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fonc.2008.245%26sid%3Dliteratum%253Aachs%26aulast%3DYuan%26aufirst%3DT.%2BL.%26aulast%3DCantley%26aufirst%3DL.%2BC.%26atitle%3DPI3K%2520pathway%2520alterations%2520in%2520cancer%253A%2520variations%2520on%2520a%2520theme%26jtitle%3DOncogene%26date%3D2008%26volume%3D27%26spage%3D5497%26epage%3D5510%26doi%3D10.1038%2Fonc.2008.245" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group">Zhao, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vogt, P. K.</span><span> </span><span class="NLM_article-title">Class 1 PI3K in oncogenic cellular transformation</span> <span class="citation_source-journal">Oncogene</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">27</span><span class="NLM_x">, </span> <span class="NLM_fpage">5486</span><span class="NLM_x">–</span> <span class="NLM_lpage">5496</span><span class="refDoi"> DOI: 10.1038/onc.2008.244</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01821&amp;key=10.1038%2Fonc.2008.244" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2008&pages=5486-5496&author=L.+Zhaoauthor=P.+K.+Vogt&title=Class+1+PI3K+in+oncogenic+cellular+transformation&doi=10.1038%2Fonc.2008.244"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1038%2Fonc.2008.244&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fonc.2008.244%26sid%3Dliteratum%253Aachs%26aulast%3DZhao%26aufirst%3DL.%26aulast%3DVogt%26aufirst%3DP.%2BK.%26atitle%3DClass%25201%2520PI3K%2520in%2520oncogenic%2520cellular%2520transformation%26jtitle%3DOncogene%26date%3D2008%26volume%3D27%26spage%3D5486%26epage%3D5496%26doi%3D10.1038%2Fonc.2008.244" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group">Amzel, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, C.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mandelker, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lengauer, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gabelli, S. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vogelstein, B.</span><span> </span><span class="NLM_article-title">Structural comparisons of class I phosphoinositide 3-kinase</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">665</span><span class="NLM_x">–</span> <span class="NLM_lpage">669</span><span class="refDoi"> DOI: 10.1038/nrc2443</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01821&amp;key=10.1038%2Fnrc2443" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01821&amp;key=18633356" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01821&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtVWksLfJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2008&pages=665-669&author=L.+M.+Amzelauthor=C.-H.+Huangauthor=D.+Mandelkerauthor=C.+Lengauerauthor=S.+B.+Gabelliauthor=B.+Vogelstein&title=Structural+comparisons+of+class+I+phosphoinositide+3-kinase&doi=10.1038%2Fnrc2443"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Structural comparisons of class I phosphoinositide 3-kinases</span></div><div class="casAuthors">Amzel, L. Mario; Huang, Chuan-Hsiang; Mandelker, Diana; Lengauer, Christoph; Gabelli, Sandra B.; Vogelstein, Bert</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">665-669</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The recent detn. of the structure of the class I phosphoinositide 3-kinase PI3Kα has identified important structural differences between the class 1 PI3Ks.  How can this information be used to improve cancer therapy.  Class I phosphoinositide 3-kinases (PI3Ks) are lipid kinases that regulate cell growth.  One of these kinases, PI3Kα, is frequently mutated in diverse tumor types.  The recently detd. structure of PI3Kα reveals features that distinguish this enzyme from related lipid kinases.  In addn., wild-type PI3Kγ differs from PI3Kα by a substitution identical to a PI3Kα oncogenic mutant (His1047Arg) that might explain the differences in the enzymic activities of the normal and mutant PI3Kα.  Comparison of the PI3K structures also identified structural features that could potentially be exploited for the design of isoform-specific inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp-V2mKhromdrVg90H21EOLACvtfcHk0ljcMWuqmhf6EA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtVWksLfJ&md5=2f6c4b1db6f8c9eb6ab712f5a83f4e70</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1038%2Fnrc2443&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc2443%26sid%3Dliteratum%253Aachs%26aulast%3DAmzel%26aufirst%3DL.%2BM.%26aulast%3DHuang%26aufirst%3DC.-H.%26aulast%3DMandelker%26aufirst%3DD.%26aulast%3DLengauer%26aufirst%3DC.%26aulast%3DGabelli%26aufirst%3DS.%2BB.%26aulast%3DVogelstein%26aufirst%3DB.%26atitle%3DStructural%2520comparisons%2520of%2520class%2520I%2520phosphoinositide%25203-kinase%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2008%26volume%3D8%26spage%3D665%26epage%3D669%26doi%3D10.1038%2Fnrc2443" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group">Courtney, K. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Corcoran, R. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Engelman, J. A.</span><span> </span><span class="NLM_article-title">The PI3K pathway as drug target in human cancer</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">28</span><span class="NLM_x">, </span> <span class="NLM_fpage">1075</span><span class="NLM_x">–</span> <span class="NLM_lpage">1083</span><span class="refDoi"> DOI: 10.1200/JCO.2009.25.3641</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01821&amp;key=10.1200%2FJCO.2009.25.3641" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01821&amp;key=20085938" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01821&amp;key=1%3ACAS%3A528%3ADC%252BC3cXktF2lt7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2010&pages=1075-1083&author=K.+D.+Courtneyauthor=R.+B.+Corcoranauthor=J.+A.+Engelman&title=The+PI3K+pathway+as+drug+target+in+human+cancer&doi=10.1200%2FJCO.2009.25.3641"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">The PI3K pathway as drug target in human cancer</span></div><div class="casAuthors">Courtney, Kevin D.; Corcoran, Ryan B.; Engelman, Jeffrey A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1075-1083</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">A review.  The phosphatidylinositol 3-kinase (PI3K) signaling axis impacts on cancer cell growth, survival, motility, and metab.  This pathway is activated by several different mechanisms in cancers, including somatic mutation and amplification of genes encoding key components.  In addn., PI3K signaling may serve integral functions for noncancerous cells in the tumor microenvironment.  Consequently, therapeutics targeting the PI3K pathway are being developed at a rapid pace, and preclin. and early clin. studies are beginning to suggest specific strategies to effectively use them.  However, the central role of PI3K signaling in a large array of diverse biol. processes raises concerns about its use in therapeutics and increases the need to develop sophisticated strategies for its use.  In this review, we will discuss how PI3K signaling affects the growth and survival of tumor cells.  From this vantage, we will consider how inhibitors of the PI3K signaling cascade, either alone or in combination with other therapeutics, can most effectively be used for the treatment of cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrpPqtk2bVl0rVg90H21EOLACvtfcHk0ljcMWuqmhf6EA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXktF2lt7w%253D&md5=b88b394919647e2eb47e7735355fde2a</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1200%2FJCO.2009.25.3641&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2009.25.3641%26sid%3Dliteratum%253Aachs%26aulast%3DCourtney%26aufirst%3DK.%2BD.%26aulast%3DCorcoran%26aufirst%3DR.%2BB.%26aulast%3DEngelman%26aufirst%3DJ.%2BA.%26atitle%3DThe%2520PI3K%2520pathway%2520as%2520drug%2520target%2520in%2520human%2520cancer%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2010%26volume%3D28%26spage%3D1075%26epage%3D1083%26doi%3D10.1200%2FJCO.2009.25.3641" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group">Rodon, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dienstmann, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Serra, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tabernero, J.</span><span> </span><span class="NLM_article-title">Development of PI3K inhibitors: lessons learned from early clinical trials</span> <span class="citation_source-journal">Nat. Rev. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">143</span><span class="NLM_x">–</span> <span class="NLM_lpage">153</span><span class="refDoi"> DOI: 10.1038/nrclinonc.2013.10</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01821&amp;key=10.1038%2Fnrclinonc.2013.10" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01821&amp;key=23400000" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01821&amp;key=1%3ACAS%3A528%3ADC%252BC3sXjsFGgs7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2013&pages=143-153&author=J.+Rodonauthor=R.+Dienstmannauthor=V.+Serraauthor=J.+Tabernero&title=Development+of+PI3K+inhibitors%3A+lessons+learned+from+early+clinical+trials&doi=10.1038%2Fnrclinonc.2013.10"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Development of PI3K inhibitors: lessons learned from early clinical trials</span></div><div class="casAuthors">Rodon, Jordi; Dienstmann, Rodrigo; Serra, Violeta; Tabernero, Josep</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Clinical Oncology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">143-153</span>CODEN:
                <span class="NLM_cas:coden">NRCOAA</span>;
        ISSN:<span class="NLM_cas:issn">1759-4774</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The phosphatidylinositol 3-kinase (PI3K) pathway has an important role in cell metab., growth, migration, survival and angiogenesis.  Drug development aimed at targetable genetic aberrations in the PI3K/AKT/mTOR pathway has been fomented by observations that alterations in this pathway induce tumor formation and that inappropriate PI3K signalling is a frequent occurrence in human cancer.  Many of the agents developed have been evaluated in early stage clin. trials.  This Review focuses on early clin. and translational data related to inhibitors of the PI3K/AKT/mTOR pathway, as these data will likely guide the further clin. development of such agents.  We review data from those trials, delineating the safety profile of the agents-whether obsd. sequelae could be mechanism-based or off-target effects-and drug efficacy.  We describe predictive biomarkers explored in clin. trials and preclin. mechanisms of resistance.  We also discuss key unresolved translational questions related to the clin. development of inhibitors of the PI3K/AKT/mTOR pathway and propose designs for biomarker-driven trials to address those issues.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrGWCzGEBfFIbVg90H21EOLACvtfcHk0ljcMWuqmhf6EA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXjsFGgs7w%253D&md5=cc6ef16605ed3f5f8619d6a1c7894d5c</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1038%2Fnrclinonc.2013.10&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrclinonc.2013.10%26sid%3Dliteratum%253Aachs%26aulast%3DRodon%26aufirst%3DJ.%26aulast%3DDienstmann%26aufirst%3DR.%26aulast%3DSerra%26aufirst%3DV.%26aulast%3DTabernero%26aufirst%3DJ.%26atitle%3DDevelopment%2520of%2520PI3K%2520inhibitors%253A%2520lessons%2520learned%2520from%2520early%2520clinical%2520trials%26jtitle%3DNat.%2520Rev.%2520Clin.%2520Oncol.%26date%3D2013%26volume%3D10%26spage%3D143%26epage%3D153%26doi%3D10.1038%2Fnrclinonc.2013.10" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group">Yap, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bjerke, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clarke, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Workman, P.</span><span> </span><span class="NLM_article-title">Drugging PI3K in cancer: refining targets and therapeutic strategies</span> <span class="citation_source-journal">Curr. Opin. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">98</span><span class="NLM_x">–</span> <span class="NLM_lpage">107</span><span class="refDoi"> DOI: 10.1016/j.coph.2015.05.016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01821&amp;key=10.1016%2Fj.coph.2015.05.016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01821&amp;key=26117819" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01821&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtVWrt7bJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2015&pages=98-107&author=T.+A.+Yapauthor=L.+Bjerkeauthor=P.+A.+Clarkeauthor=P.+Workman&title=Drugging+PI3K+in+cancer%3A+refining+targets+and+therapeutic+strategies&doi=10.1016%2Fj.coph.2015.05.016"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Drugging PI3K in cancer: refining targets and therapeutic strategies</span></div><div class="casAuthors">Yap, Timothy A.; Bjerke, Lynn; Clarke, Paul A.; Workman, Paul</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Pharmacology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">98-107</span>CODEN:
                <span class="NLM_cas:coden">COPUBK</span>;
        ISSN:<span class="NLM_cas:issn">1471-4892</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">The phosphatidylinositol-3 kinase (PI3K) pathway is one of the most frequently activated pathogenic signalling routes in human cancers, making it a rational and important target for innovative anticancer drug development and precision medicine.  The three main classes of PI3K inhibitors currently in clin. testing comprise dual pan-Class I PI3K/mTOR inhibitors, pan-Class I PI3K inhibitors lacking significant mTOR activity and isoform-selective PI3K inhibitors.  A major step forward in recent years is the progression of over 30 small mol. PI3K inhibitors into clin. trials and the first regulatory approval of the PI3Kδ inhibitor idelalisib for multiple B-cell malignancies.  This review article focuses on the progress made in the discovery and development of novel PI3K inhibitors, with an emphasis on antitumor activity and tolerability profiles for agents that have entered clin. trials.  We also discuss the key issues of drug resistance, patient selection approaches and rational targeted combinations.  Finally, we envision the future development and use of PI3K inhibitors for the treatment of patients with a range of malignancies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqDxyCAEREi_7Vg90H21EOLACvtfcHk0lhQep6JIYSNDQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtVWrt7bJ&md5=9a0238f97d8ecdc54e0c5b9b6ce4fc76</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1016%2Fj.coph.2015.05.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.coph.2015.05.016%26sid%3Dliteratum%253Aachs%26aulast%3DYap%26aufirst%3DT.%2BA.%26aulast%3DBjerke%26aufirst%3DL.%26aulast%3DClarke%26aufirst%3DP.%2BA.%26aulast%3DWorkman%26aufirst%3DP.%26atitle%3DDrugging%2520PI3K%2520in%2520cancer%253A%2520refining%2520targets%2520and%2520therapeutic%2520strategies%26jtitle%3DCurr.%2520Opin.%2520Pharmacol.%26date%3D2015%26volume%3D23%26spage%3D98%26epage%3D107%26doi%3D10.1016%2Fj.coph.2015.05.016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group">Cushing, T. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Metz, D. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whittington, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McGee, L. R.</span><span> </span><span class="NLM_article-title">PI3Kδ and PI3Kγ as target for autoimmune and inflammatory diseases</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">8559</span><span class="NLM_x">–</span> <span class="NLM_lpage">8581</span><span class="refDoi"> DOI: 10.1021/jm300847w</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm300847w" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=8559-8581&author=T.+D.+Cushingauthor=D.+P.+Metzauthor=D.+A.+Whittingtonauthor=L.+R.+McGee&title=PI3K%CE%B4+and+PI3K%CE%B3+as+target+for+autoimmune+and+inflammatory+diseases&doi=10.1021%2Fjm300847w"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1021%2Fjm300847w&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm300847w%26sid%3Dliteratum%253Aachs%26aulast%3DCushing%26aufirst%3DT.%2BD.%26aulast%3DMetz%26aufirst%3DD.%2BP.%26aulast%3DWhittington%26aufirst%3DD.%2BA.%26aulast%3DMcGee%26aufirst%3DL.%2BR.%26atitle%3DPI3K%25CE%25B4%2520and%2520PI3K%25CE%25B3%2520as%2520target%2520for%2520autoimmune%2520and%2520inflammatory%2520diseases%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D8559%26epage%3D8581%26doi%3D10.1021%2Fjm300847w" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group">Patel, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chandrasekhar, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Evarts, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Forseth, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haran, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ip, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kashishian, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koditek, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koppenol, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lad, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lepist, E.-I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McGrath, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perreault, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Puri, K. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Villasenor, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Somoza, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steiner, B. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Therrien, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Treiberg, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Phillips, G.</span><span> </span><span class="NLM_article-title">Discovery of orally efficacious phosphoinositide 3-kinase δ inhibitors with improved metabolic stability</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">59</span><span class="NLM_x">, </span> <span class="NLM_fpage">9228</span><span class="NLM_x">–</span> <span class="NLM_lpage">9242</span><span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b01169</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b01169" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01821&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsFGrs7rF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=9228-9242&author=L.+Patelauthor=J.+Chandrasekharauthor=J.+Evartsauthor=K.+Forsethauthor=A.+C.+Haranauthor=C.+Ipauthor=A.+Kashishianauthor=M.+Kimauthor=D.+Koditekauthor=S.+Koppenolauthor=L.+Ladauthor=E.-I.+Lepistauthor=M.+E.+McGrathauthor=S.+Perreaultauthor=K.+D.+Puriauthor=A.+G.+Villasenorauthor=J.+R.+Somozaauthor=B.+H.+Steinerauthor=J.+Therrienauthor=J.+Treibergauthor=G.+Phillips&title=Discovery+of+orally+efficacious+phosphoinositide+3-kinase+%CE%B4+inhibitors+with+improved+metabolic+stability&doi=10.1021%2Facs.jmedchem.6b01169"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Orally Efficacious Phosphoinositide 3-Kinase δ Inhibitors with Improved Metabolic Stability</span></div><div class="casAuthors">Patel, Leena; Chandrasekhar, Jayaraman; Evarts, Jerry; Forseth, Kristen; Haran, Aaron C.; Ip, Carmen; Kashishian, Adam; Kim, Musong; Koditek, David; Koppenol, Sandy; Lad, Latesh; Lepist, Eve-Irene; McGrath, Mary E.; Perreault, Stephane; Puri, Kamal D.; Villasenor, Armando G.; Somoza, John R.; Steiner, Bart H.; Therrien, Joseph; Treiberg, Jennifer; Phillips, Gary</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">9228-9242</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Aberrant signaling of phosphoinositide-3-kinase delta (PI3K-delta) has been implicated in numerous pathologies including hematol. malignancies and rheumatoid arthritis.  Described in this manuscript is the discovery, optimization and in vivo evaluation of a novel series of pyridine-contg. PI3K-delta inhibitors.  This work led to the discovery of I, a highly selective inhibitor of PI3K-delta which displays an excellent pharmacokinetic profile and is efficacious in a rodent model of rheumatoid arthritis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo1LgrP9YV8frVg90H21EOLACvtfcHk0lhQep6JIYSNDQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsFGrs7rF&md5=6d9dff0ec5270aab250fcb4800d8635a</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b01169&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b01169%26sid%3Dliteratum%253Aachs%26aulast%3DPatel%26aufirst%3DL.%26aulast%3DChandrasekhar%26aufirst%3DJ.%26aulast%3DEvarts%26aufirst%3DJ.%26aulast%3DForseth%26aufirst%3DK.%26aulast%3DHaran%26aufirst%3DA.%2BC.%26aulast%3DIp%26aufirst%3DC.%26aulast%3DKashishian%26aufirst%3DA.%26aulast%3DKim%26aufirst%3DM.%26aulast%3DKoditek%26aufirst%3DD.%26aulast%3DKoppenol%26aufirst%3DS.%26aulast%3DLad%26aufirst%3DL.%26aulast%3DLepist%26aufirst%3DE.-I.%26aulast%3DMcGrath%26aufirst%3DM.%2BE.%26aulast%3DPerreault%26aufirst%3DS.%26aulast%3DPuri%26aufirst%3DK.%2BD.%26aulast%3DVillasenor%26aufirst%3DA.%2BG.%26aulast%3DSomoza%26aufirst%3DJ.%2BR.%26aulast%3DSteiner%26aufirst%3DB.%2BH.%26aulast%3DTherrien%26aufirst%3DJ.%26aulast%3DTreiberg%26aufirst%3DJ.%26aulast%3DPhillips%26aufirst%3DG.%26atitle%3DDiscovery%2520of%2520orally%2520efficacious%2520phosphoinositide%25203-kinase%2520%25CE%25B4%2520inhibitors%2520with%2520improved%2520metabolic%2520stability%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D9228%26epage%3D9242%26doi%3D10.1021%2Facs.jmedchem.6b01169" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group">Patel, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chandrasekhar, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Evarts, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haran, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ip, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaplan, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koditek, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lad, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lepist, E.-I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McGrath, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Novikov, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perreault, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Puri, K. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Somoza, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steiner, B. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stevens, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Therrien, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Treiberg, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Villaseñor, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yeung, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Phillips, G.</span><span> </span><span class="NLM_article-title">2,4,6-Triaminopyrimidine as a novel hinge binder in a series of PI3Kδ selective inhibitors</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">59</span><span class="NLM_x">, </span> <span class="NLM_fpage">3532</span><span class="NLM_x">–</span> <span class="NLM_lpage">3548</span><span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b00213</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00213" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01821&amp;key=1%3ACAS%3A528%3ADC%252BC28Xkt1CgtL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=3532-3548&author=L.+Patelauthor=J.+Chandrasekharauthor=J.+Evartsauthor=A.+C.+Haranauthor=C.+Ipauthor=J.+A.+Kaplanauthor=M.+Kimauthor=D.+Koditekauthor=L.+Ladauthor=E.-I.+Lepistauthor=M.+E.+McGrathauthor=N.+Novikovauthor=S.+Perreaultauthor=K.+D.+Puriauthor=J.+R.+Somozaauthor=B.+H.+Steinerauthor=K.+L.+Stevensauthor=J.+Therrienauthor=J.+Treibergauthor=A.+G.+Villase%C3%B1orauthor=A.+Yeungauthor=G.+Phillips&title=2%2C4%2C6-Triaminopyrimidine+as+a+novel+hinge+binder+in+a+series+of+PI3K%CE%B4+selective+inhibitors&doi=10.1021%2Facs.jmedchem.6b00213"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">2,4,6-Triaminopyrimidine as a Novel Hinge Binder in a Series of PI3Kδ Selective Inhibitors</span></div><div class="casAuthors">Patel, Leena; Chandrasekhar, Jayaraman; Evarts, Jerry; Haran, Aaron C.; Ip, Carmen; Kaplan, Joshua A.; Kim, Musong; Koditek, David; Lad, Latesh; Lepist, Eve-Irene; McGrath, Mary E.; Novikov, Nikolai; Perreault, Stephane; Puri, Kamal D.; Somoza, John R.; Steiner, Bart H.; Stevens, Kirk L.; Therrien, Joseph; Treiberg, Jennifer; Villasenor, Armando G.; Yeung, Arthur; Phillips, Gary</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">3532-3548</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Inhibition of phosphoinositide 3-kinase δ (PI3Kδ) is an appealing target for several hematol. malignancies and inflammatory diseases.  Herein, we describe the discovery and optimization of a series of propeller shaped PI3Kδ inhibitors comprising a novel triaminopyrimidine hinge binder.  Combinations of electronic and structural strategies were employed to mitigate aldehyde oxidase mediated metab.  This medicinal chem. effort culminated in the identification of 52, a potent and highly selective inhibitor of PI3Kδ that demonstrates efficacy in a rat model of arthritis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpygPlHbWp_TLVg90H21EOLACvtfcHk0lgytvsg_dNEIw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xkt1CgtL4%253D&md5=9e01fff097eccd127a9b9284d725d7e1</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00213&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00213%26sid%3Dliteratum%253Aachs%26aulast%3DPatel%26aufirst%3DL.%26aulast%3DChandrasekhar%26aufirst%3DJ.%26aulast%3DEvarts%26aufirst%3DJ.%26aulast%3DHaran%26aufirst%3DA.%2BC.%26aulast%3DIp%26aufirst%3DC.%26aulast%3DKaplan%26aufirst%3DJ.%2BA.%26aulast%3DKim%26aufirst%3DM.%26aulast%3DKoditek%26aufirst%3DD.%26aulast%3DLad%26aufirst%3DL.%26aulast%3DLepist%26aufirst%3DE.-I.%26aulast%3DMcGrath%26aufirst%3DM.%2BE.%26aulast%3DNovikov%26aufirst%3DN.%26aulast%3DPerreault%26aufirst%3DS.%26aulast%3DPuri%26aufirst%3DK.%2BD.%26aulast%3DSomoza%26aufirst%3DJ.%2BR.%26aulast%3DSteiner%26aufirst%3DB.%2BH.%26aulast%3DStevens%26aufirst%3DK.%2BL.%26aulast%3DTherrien%26aufirst%3DJ.%26aulast%3DTreiberg%26aufirst%3DJ.%26aulast%3DVillase%25C3%25B1or%26aufirst%3DA.%2BG.%26aulast%3DYeung%26aufirst%3DA.%26aulast%3DPhillips%26aufirst%3DG.%26atitle%3D2%252C4%252C6-Triaminopyrimidine%2520as%2520a%2520novel%2520hinge%2520binder%2520in%2520a%2520series%2520of%2520PI3K%25CE%25B4%2520selective%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D3532%26epage%3D3548%26doi%3D10.1021%2Facs.jmedchem.6b00213" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group">Cushing, T. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hao, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shin, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Andrews, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cardozo, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duquette, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fisher, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gonzalez-Lopez de Turiso, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">He, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Henne, K. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu, Y.-L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hungate, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kelly, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lucas, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCarter, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McGee, L. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Medina, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">San Miguel, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mohn, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pattaropong, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pettus, L. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reichelt, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rzasa, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seganish, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tasker, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wahl, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wannberg, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whittington, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whoriskey, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zalameda, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Metz, D. P.</span><span> </span><span class="NLM_article-title">Discovery and in vivo evaluation of (S)-N-(1-(7-fluoro-2-(pyridin-2-yl) quinolin-3-yl)ethyl)-9H-purin-6-amine (AMG319) and related PI3Kδ inhibitors for inflammation and autoimmune disease</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">58</span><span class="NLM_x">, </span> <span class="NLM_fpage">480</span><span class="NLM_x">–</span> <span class="NLM_lpage">511</span><span class="refDoi"> DOI: 10.1021/jm501624r</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm501624r" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=480-511&author=T.+D.+Cushingauthor=X.+Haoauthor=Y.+Shinauthor=K.+Andrewsauthor=M.+Brownauthor=M.+Cardozoauthor=Y.+Chenauthor=J.+Duquetteauthor=B.+Fisherauthor=F.+Gonzalez-Lopez+de+Turisoauthor=X.+Heauthor=K.+R.+Henneauthor=Y.-L.+Huauthor=R.+Hungateauthor=M.+G.+Johnsonauthor=R.+C.+Kellyauthor=B.+Lucasauthor=J.+D.+McCarterauthor=L.+R.+McGeeauthor=J.+C.+Medinaauthor=T.+San+Miguelauthor=D.+Mohnauthor=V.+Pattaropongauthor=L.+H.+Pettusauthor=A.+Reicheltauthor=R.+M.+Rzasaauthor=J.+Seganishauthor=A.+S.+Taskerauthor=R.+C.+Wahlauthor=S.+Wannbergauthor=D.+A.+Whittingtonauthor=J.+Whoriskeyauthor=G.+Yuauthor=L.+Zalamedaauthor=D.+Zhangauthor=D.+P.+Metz&title=Discovery+and+in+vivo+evaluation+of+%28S%29-N-%281-%287-fluoro-2-%28pyridin-2-yl%29+quinolin-3-yl%29ethyl%29-9H-purin-6-amine+%28AMG319%29+and+related+PI3K%CE%B4+inhibitors+for+inflammation+and+autoimmune+disease&doi=10.1021%2Fjm501624r"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1021%2Fjm501624r&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm501624r%26sid%3Dliteratum%253Aachs%26aulast%3DCushing%26aufirst%3DT.%2BD.%26aulast%3DHao%26aufirst%3DX.%26aulast%3DShin%26aufirst%3DY.%26aulast%3DAndrews%26aufirst%3DK.%26aulast%3DBrown%26aufirst%3DM.%26aulast%3DCardozo%26aufirst%3DM.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DDuquette%26aufirst%3DJ.%26aulast%3DFisher%26aufirst%3DB.%26aulast%3DGonzalez-Lopez%2Bde%2BTuriso%26aufirst%3DF.%26aulast%3DHe%26aufirst%3DX.%26aulast%3DHenne%26aufirst%3DK.%2BR.%26aulast%3DHu%26aufirst%3DY.-L.%26aulast%3DHungate%26aufirst%3DR.%26aulast%3DJohnson%26aufirst%3DM.%2BG.%26aulast%3DKelly%26aufirst%3DR.%2BC.%26aulast%3DLucas%26aufirst%3DB.%26aulast%3DMcCarter%26aufirst%3DJ.%2BD.%26aulast%3DMcGee%26aufirst%3DL.%2BR.%26aulast%3DMedina%26aufirst%3DJ.%2BC.%26aulast%3DSan%2BMiguel%26aufirst%3DT.%26aulast%3DMohn%26aufirst%3DD.%26aulast%3DPattaropong%26aufirst%3DV.%26aulast%3DPettus%26aufirst%3DL.%2BH.%26aulast%3DReichelt%26aufirst%3DA.%26aulast%3DRzasa%26aufirst%3DR.%2BM.%26aulast%3DSeganish%26aufirst%3DJ.%26aulast%3DTasker%26aufirst%3DA.%2BS.%26aulast%3DWahl%26aufirst%3DR.%2BC.%26aulast%3DWannberg%26aufirst%3DS.%26aulast%3DWhittington%26aufirst%3DD.%2BA.%26aulast%3DWhoriskey%26aufirst%3DJ.%26aulast%3DYu%26aufirst%3DG.%26aulast%3DZalameda%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DD.%26aulast%3DMetz%26aufirst%3DD.%2BP.%26atitle%3DDiscovery%2520and%2520in%2520vivo%2520evaluation%2520of%2520%2528S%2529-N-%25281-%25287-fluoro-2-%2528pyridin-2-yl%2529%2520quinolin-3-yl%2529ethyl%2529-9H-purin-6-amine%2520%2528AMG319%2529%2520and%2520related%2520PI3K%25CE%25B4%2520inhibitors%2520for%2520inflammation%2520and%2520autoimmune%2520disease%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D480%26epage%3D511%26doi%3D10.1021%2Fjm501624r" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group">Furet, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guagnano, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fairhurst, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Imbach-Weese, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bruce, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knapp, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fritsch, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blasco, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blanz, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aichholz, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamon, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fabbro, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caravatti, G.</span><span> </span><span class="NLM_article-title">Discovery of NVP-BYL719 a potent and selective phosphatidylinositol-3 kinase alpha inhibitor selected for clinical evaluation</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">3741</span><span class="NLM_x">–</span> <span class="NLM_lpage">3748</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2013.05.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01821&amp;key=10.1016%2Fj.bmcl.2013.05.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01821&amp;key=23726034" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01821&amp;key=1%3ACAS%3A528%3ADC%252BC3sXosFaisrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2013&pages=3741-3748&author=P.+Furetauthor=V.+Guagnanoauthor=R.+A.+Fairhurstauthor=P.+Imbach-Weeseauthor=I.+Bruceauthor=M.+Knappauthor=C.+Fritschauthor=F.+Blascoauthor=J.+Blanzauthor=R.+Aichholzauthor=J.+Hamonauthor=D.+Fabbroauthor=G.+Caravatti&title=Discovery+of+NVP-BYL719+a+potent+and+selective+phosphatidylinositol-3+kinase+alpha+inhibitor+selected+for+clinical+evaluation&doi=10.1016%2Fj.bmcl.2013.05.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of NVP-BYL719 a potent and selective phosphatidylinositol-3 kinase alpha inhibitor selected for clinical evaluation</span></div><div class="casAuthors">Furet, Pascal; Guagnano, Vito; Fairhurst, Robin A.; Imbach-Weese, Patricia; Bruce, Ian; Knapp, Mark; Fritsch, Christine; Blasco, Francesca; Blanz, Joachim; Aichholz, Reiner; Hamon, Jacques; Fabbro, Doriano; Caravatti, Giorgio</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">3741-3748</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Phosphatidylinositol-3-kinase α (PI3Kα) is a therapeutic target of high interest in anticancer drug research.  On the basis of a binding model rationalizing the high selectivity and potency of a particular series of 2-aminothiazole compds. in inhibiting PI3Kα, a medicinal chem. program has led to the discovery of the clin. candidate NVP-BYL719 I.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGraN93Vwrfb4bVg90H21EOLACvtfcHk0liG79RGNN0Pfg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXosFaisrY%253D&md5=a0d2d69e01e7a82a5fed04114105925e</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2013.05.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2013.05.007%26sid%3Dliteratum%253Aachs%26aulast%3DFuret%26aufirst%3DP.%26aulast%3DGuagnano%26aufirst%3DV.%26aulast%3DFairhurst%26aufirst%3DR.%2BA.%26aulast%3DImbach-Weese%26aufirst%3DP.%26aulast%3DBruce%26aufirst%3DI.%26aulast%3DKnapp%26aufirst%3DM.%26aulast%3DFritsch%26aufirst%3DC.%26aulast%3DBlasco%26aufirst%3DF.%26aulast%3DBlanz%26aufirst%3DJ.%26aulast%3DAichholz%26aufirst%3DR.%26aulast%3DHamon%26aufirst%3DJ.%26aulast%3DFabbro%26aufirst%3DD.%26aulast%3DCaravatti%26aufirst%3DG.%26atitle%3DDiscovery%2520of%2520NVP-BYL719%2520a%2520potent%2520and%2520selective%2520phosphatidylinositol-3%2520kinase%2520alpha%2520inhibitor%2520selected%2520for%2520clinical%2520evaluation%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2013%26volume%3D23%26spage%3D3741%26epage%3D3748%26doi%3D10.1016%2Fj.bmcl.2013.05.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group">Heffron, T. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wei, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olivero, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Staben, S. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsui, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Do, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dotson, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Folkes, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldsmith, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldsmith, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gunzner, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lesnick, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lewis, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mathieu, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nonomiya, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shuttleworth, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sutherlin, D. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wan, C. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wiesmann, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, B.-Y.</span><span> </span><span class="NLM_article-title">Rational design of phosphoinositide 3-kinase α inhibitors that exhibit selectivity over the phosphoinositide 3-kinase β isoform</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">7815</span><span class="NLM_x">–</span> <span class="NLM_lpage">7833</span><span class="refDoi"> DOI: 10.1021/jm2007084</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm2007084" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01821&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtlGktrvE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=7815-7833&author=T.+P.+Heffronauthor=B.+Weiauthor=A.+Oliveroauthor=S.+T.+Stabenauthor=V.+Tsuiauthor=S.+Doauthor=J.+Dotsonauthor=A.+J.+Folkesauthor=P.+Goldsmithauthor=R.+Goldsmithauthor=J.+Gunznerauthor=J.+Lesnickauthor=C.+Lewisauthor=S.+Mathieuauthor=J.+Nonomiyaauthor=S.+Shuttleworthauthor=D.+P.+Sutherlinauthor=C.+W.+Wanauthor=S.+Wangauthor=C.+Wiesmannauthor=B.-Y.+Zhu&title=Rational+design+of+phosphoinositide+3-kinase+%CE%B1+inhibitors+that+exhibit+selectivity+over+the+phosphoinositide+3-kinase+%CE%B2+isoform&doi=10.1021%2Fjm2007084"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Rational Design of Phosphoinositide 3-Kinase α Inhibitors That Exhibit Selectivity over the Phosphoinositide 3-Kinase β Isoform</span></div><div class="casAuthors">Heffron, Timothy P.; Wei, Bin Qing; Olivero, Alan; Staben, Steven T.; Tsui, Vickie; Do, Steven; Dotson, Jennafer; Folkes, Adrian J.; Goldsmith, Paul; Goldsmith, Richard; Gunzner, Janet; Lesnick, John; Lewis, Cristina; Mathieu, Simon; Nonomiya, Jim; Shuttleworth, Stephen; Sutherlin, Daniel P.; Wan, Nan Chi; Wang, Shumei; Wiesmann, Christian; Zhu, Bing-Yan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">7815-7833</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Of the four class I phosphoinositide 3-kinase (PI3K) isoforms, PI3Kα has justly received the most attention for its potential in cancer therapy.  Herein we report our successful approaches to achieve PI3Kα vs PI3Kβ selectivity for two chem. series.  In the thienopyrimidine series of inhibitors, we propose that select ligands achieve selectivity derived from a hydrogen bonding interaction with Arg770 of PI3Kα that is not attained with the corresponding Lys777 of PI3Kβ.  In the benzoxepin series of inhibitors, the selectivity obsd. can be rationalized by the difference in electrostatic potential between the two isoforms in a given region rather than any specific interaction.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGquHPawgTpp87Vg90H21EOLACvtfcHk0lh9EC2SbcIFhg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtlGktrvE&md5=4ebed9c985c52238eddc45c6183cf3de</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1021%2Fjm2007084&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm2007084%26sid%3Dliteratum%253Aachs%26aulast%3DHeffron%26aufirst%3DT.%2BP.%26aulast%3DWei%26aufirst%3DB.%26aulast%3DOlivero%26aufirst%3DA.%26aulast%3DStaben%26aufirst%3DS.%2BT.%26aulast%3DTsui%26aufirst%3DV.%26aulast%3DDo%26aufirst%3DS.%26aulast%3DDotson%26aufirst%3DJ.%26aulast%3DFolkes%26aufirst%3DA.%2BJ.%26aulast%3DGoldsmith%26aufirst%3DP.%26aulast%3DGoldsmith%26aufirst%3DR.%26aulast%3DGunzner%26aufirst%3DJ.%26aulast%3DLesnick%26aufirst%3DJ.%26aulast%3DLewis%26aufirst%3DC.%26aulast%3DMathieu%26aufirst%3DS.%26aulast%3DNonomiya%26aufirst%3DJ.%26aulast%3DShuttleworth%26aufirst%3DS.%26aulast%3DSutherlin%26aufirst%3DD.%2BP.%26aulast%3DWan%26aufirst%3DC.%2BW.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DWiesmann%26aufirst%3DC.%26aulast%3DZhu%26aufirst%3DB.-Y.%26atitle%3DRational%2520design%2520of%2520phosphoinositide%25203-kinase%2520%25CE%25B1%2520inhibitors%2520that%2520exhibit%2520selectivity%2520over%2520the%2520phosphoinositide%25203-kinase%2520%25CE%25B2%2520isoform%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D7815%26epage%3D7833%26doi%3D10.1021%2Fjm2007084" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group">Wee, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wiederschain, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maira, S.-M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loo, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">deBeaumont, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stegmeier, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yao, Y.-M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lengauer, C.</span><span> </span><span class="NLM_article-title">PTEN-deficient cancers depend on PIK3CB</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">105</span><span class="NLM_x">, </span> <span class="NLM_fpage">13057</span><span class="NLM_x">–</span> <span class="NLM_lpage">13062</span><span class="refDoi"> DOI: 10.1073/pnas.0802655105</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01821&amp;key=10.1073%2Fpnas.0802655105" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01821&amp;key=18755892" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01821&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtFSitbrO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=105&publication_year=2008&pages=13057-13062&author=S.+Weeauthor=D.+Wiederschainauthor=S.-M.+Mairaauthor=A.+Looauthor=C.+Millerauthor=R.+deBeaumontauthor=F.+Stegmeierauthor=Y.-M.+Yaoauthor=C.+Lengauer&title=PTEN-deficient+cancers+depend+on+PIK3CB&doi=10.1073%2Fpnas.0802655105"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">PTEN-deficient cancers depend on PIK3CB</span></div><div class="casAuthors">Wee, Susan; Wiederschain, Dmitri; Maira, Sauveur-Michel; Loo, Alice; Miller, Christine; de Beaumont, Rosalie; Stegmeier, Frank; Yao, Yung-Mae; Lengauer, Christoph</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">105</span>
        (<span class="NLM_cas:issue">35</span>),
    <span class="NLM_cas:pages">13057-13062</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Deregulation of the PI3K signaling pathway is obsd. in many human cancers and occurs most frequently through loss of PTEN phosphatase tumor suppressor function or through somatic activating mutations in the Class IA PI3K, PIK3CA.  Tumors harboring activated p110α, the protein product of PIK3CA, require p110α activity for growth and survival and hence are expected to be responsive to inhibitors of its lipid kinase activity.  Whether PTEN-deficient cancers similarly depend on p110α activity to sustain activation of the PI3K pathway has been unclear.  In this study, we used a single-vector lentiviral inducible shRNA system to selectively inactivate the three Class IA PI3Ks, PIK3CA, PIK3CB, and PIK3CD, to det. which PI3K isoforms are responsible for driving the abnormal proliferation of PTEN-deficient cancers.  Down-regulation of PIK3CA in colorectal cancer cells harboring mutations in PIK3CA inhibited downstream PI3K signaling and cell growth.  Surprisingly, PIK3CA depletion affected neither PI3K signaling nor cell growth in 3 PTEN-deficient cancer cell lines.  In contrast, down-regulation of the PIK3CB isoform, which encodes p110β, resulted in pathway inactivation and subsequent inhibition of growth in both cell-based and in vivo settings.  This essential function of PIK3CB in PTEN-deficient cancer cells required its lipid kinase activity.  Our findings demonstrate that although p110α activation is required to sustain the proliferation of established PIK3CA-mutant tumors, PTEN-deficient tumors are dependent instead on p110β signaling.  This unexpected finding demonstrates the need to tailor therapeutic approaches to the genetic basis of PI3K pathway activation to achieve optimal treatment response.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr5ybGsv3DVCrVg90H21EOLACvtfcHk0lh9EC2SbcIFhg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtFSitbrO&md5=b7c690d3631ac6cbee9d7d7414dae1da</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0802655105&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0802655105%26sid%3Dliteratum%253Aachs%26aulast%3DWee%26aufirst%3DS.%26aulast%3DWiederschain%26aufirst%3DD.%26aulast%3DMaira%26aufirst%3DS.-M.%26aulast%3DLoo%26aufirst%3DA.%26aulast%3DMiller%26aufirst%3DC.%26aulast%3DdeBeaumont%26aufirst%3DR.%26aulast%3DStegmeier%26aufirst%3DF.%26aulast%3DYao%26aufirst%3DY.-M.%26aulast%3DLengauer%26aufirst%3DC.%26atitle%3DPTEN-deficient%2520cancers%2520depend%2520on%2520PIK3CB%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2008%26volume%3D105%26spage%3D13057%26epage%3D13062%26doi%3D10.1073%2Fpnas.0802655105" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group">Jia, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Signoretti, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loda, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roberts, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, J. J.</span><span> </span><span class="NLM_article-title">Essential roles of PI(3)K-p110β in cell growth, metabolism and tumorigenesis</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">454</span><span class="NLM_x">, </span> <span class="NLM_fpage">776</span><span class="NLM_x">–</span> <span class="NLM_lpage">779</span><span class="refDoi"> DOI: 10.1038/nature07091</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01821&amp;key=10.1038%2Fnature07091" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01821&amp;key=18594509" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01821&amp;key=1%3ACAS%3A528%3ADC%252BD1cXps1Snu7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=454&publication_year=2008&pages=776-779&author=S.+Jiaauthor=Z.+Liuauthor=S.+Zhangauthor=P.+Liuauthor=L.+Zhangauthor=S.+H.+Leeauthor=L.+J.+Zhangauthor=S.+Signorettiauthor=M.+Lodaauthor=T.+M.+Robertsauthor=J.+J.+Zhao&title=Essential+roles+of+PI%283%29K-p110%CE%B2+in+cell+growth%2C+metabolism+and+tumorigenesis&doi=10.1038%2Fnature07091"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Essential roles of PI(3)K-p110β in cell growth, metabolism and tumorigenesis</span></div><div class="casAuthors">Jia, Shidong; Liu, Zhenning; Zhang, Sen; Liu, Pixu; Zhang, Lei; Lee, Sang Hyun; Zhang, Jing; Signoretti, Sabina; Loda, Massimo; Roberts, Thomas M.; Zhao, Jean J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">454</span>
        (<span class="NLM_cas:issue">7205</span>),
    <span class="NLM_cas:pages">776-779</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">On activation by receptors, the ubiquitously expressed class IA isoforms (p110α and p110β) of phosphatidylinositol-3-kinase (PI(3)K) generate lipid second messengers, which initiate multiple signal transduction cascades.  Recent studies have demonstrated specific functions for p110α in growth factor and insulin signaling.  To probe for distinct functions of p110β, we constructed conditional knockout mice.  Here we show that ablation of p110β in the livers of the resulting mice leads to impaired insulin sensitivity and glucose homeostasis, while having little effect on phosphorylation of Akt, suggesting the involvement of a kinase-independent role of p110β in insulin metabolic action.  Using established mouse embryonic fibroblasts, we found that removal of p110β also had little effect on Akt phosphorylation in response to stimulation by insulin and epidermal growth factor, but resulted in retarded cell proliferation.  Reconstitution of p110β-null cells with a wild-type or kinase-dead allele of p110β demonstrated that p110β possesses kinase-independent functions in regulating cell proliferation and trafficking.  However, the kinase activity of p110β was required for G-protein-coupled receptor signaling triggered by lysophosphatidic acid and had a function in oncogenic transformation.  Most strikingly, in an animal model of prostate tumor formation induced by Pten loss, ablation of p110β (also known as Pik3cb), but not that of p110α (also known as Pik3ca), impeded tumorigenesis with a concomitant diminution of Akt phosphorylation.  Taken together, our findings demonstrate both kinase-dependent and kinase-independent functions for p110β, and strongly indicate the kinase-dependent functions of p110β as a promising target in cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqm6EUnzNHwHrVg90H21EOLACvtfcHk0lh9EC2SbcIFhg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXps1Snu7w%253D&md5=b32d9fcd1e8a0090da3ee8ae918a49db</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1038%2Fnature07091&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature07091%26sid%3Dliteratum%253Aachs%26aulast%3DJia%26aufirst%3DS.%26aulast%3DLiu%26aufirst%3DZ.%26aulast%3DZhang%26aufirst%3DS.%26aulast%3DLiu%26aufirst%3DP.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DLee%26aufirst%3DS.%2BH.%26aulast%3DZhang%26aufirst%3DL.%2BJ.%26aulast%3DSignoretti%26aufirst%3DS.%26aulast%3DLoda%26aufirst%3DM.%26aulast%3DRoberts%26aufirst%3DT.%2BM.%26aulast%3DZhao%26aufirst%3DJ.%2BJ.%26atitle%3DEssential%2520roles%2520of%2520PI%25283%2529K-p110%25CE%25B2%2520in%2520cell%2520growth%252C%2520metabolism%2520and%2520tumorigenesis%26jtitle%3DNature%26date%3D2008%26volume%3D454%26spage%3D776%26epage%3D779%26doi%3D10.1038%2Fnature07091" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group">Blackman, S. C.; Gainer, S. D.; Suttle, B. B.; Skordos, K. W.; Greshock, J. D.; Motwani, M.; Roadcap, L. T.; Hardwicke, M. A. A.; Wooster, R. F.</span><span> </span><span class="NLM_article-title">A phase I/IIa, first time in human, open-label dose escalation study of GSK2636771 in subjects with advanced solid tumors with PTEN deficiency</span>.  <span class="citation_source-book">Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research (AACR)</span>, Chicago, March 31–April 4,<span class="NLM_x"> </span><span class="NLM_year">2012</span><span class="NLM_x">; </span>Abstract 1752.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&author=S.+C.+Blackman&author=S.+D.+Gainer&author=B.+B.+Suttle&author=K.+W.+Skordos&author=J.+D.+Greshock&author=M.+Motwani&author=L.+T.+Roadcap&author=M.+A.+A.+Hardwicke&author=R.+F.+Wooster&title=Proceedings+of+the+103rd+Annual+Meeting+of+the+American+Association+for+Cancer+Research+%28AACR%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DBlackman%26aufirst%3DS.%2BC.%26atitle%3DA%2520phase%2520I%252FIIa%252C%2520first%2520time%2520in%2520human%252C%2520open-label%2520dose%2520escalation%2520study%2520of%2520GSK2636771%2520in%2520subjects%2520with%2520advanced%2520solid%2520tumors%2520with%2520PTEN%2520deficiency%26btitle%3DProceedings%2520of%2520the%2520103rd%2520Annual%2520Meeting%2520of%2520the%2520American%2520Association%2520for%2520Cancer%2520Research%2520%2528AACR%2529%26date%3D2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group">Barlaam, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cosulich, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Degorce, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fitzek, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Green, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hancox, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lambert-van der Brempt, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lohmann, J.-J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maudet, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morgentin, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pasquet, M.-J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Péru, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Plé, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saleh, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vautier, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walker, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ward, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Warin, N.</span><span> </span><span class="NLM_article-title">Discovery of (R)-8-(1-(3,5-difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4Hchromene-6-carboxamide (AZD8186): a potent and selective inhibitor of PI3Kβ and PI3Kδ for the treatment of PTEN-deficient cancers</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">58</span><span class="NLM_x">, </span> <span class="NLM_fpage">943</span><span class="NLM_x">–</span> <span class="NLM_lpage">962</span><span class="refDoi"> DOI: 10.1021/jm501629p</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm501629p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=943-962&author=B.+Barlaamauthor=S.+Cosulichauthor=S.+Degorceauthor=M.+Fitzekauthor=S.+Greenauthor=U.+Hancoxauthor=C.+Lambert-van+der+Bremptauthor=J.-J.+Lohmannauthor=M.+Maudetauthor=R.+Morgentinauthor=M.-J.+Pasquetauthor=A.+P%C3%A9ruauthor=P.+Pl%C3%A9author=T.+Salehauthor=M.+Vautierauthor=M.+Walkerauthor=L.+Wardauthor=N.+Warin&title=Discovery+of+%28R%29-8-%281-%283%2C5-difluorophenylamino%29ethyl%29-N%2CN-dimethyl-2-morpholino-4-oxo-4Hchromene-6-carboxamide+%28AZD8186%29%3A+a+potent+and+selective+inhibitor+of+PI3K%CE%B2+and+PI3K%CE%B4+for+the+treatment+of+PTEN-deficient+cancers&doi=10.1021%2Fjm501629p"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1021%2Fjm501629p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm501629p%26sid%3Dliteratum%253Aachs%26aulast%3DBarlaam%26aufirst%3DB.%26aulast%3DCosulich%26aufirst%3DS.%26aulast%3DDegorce%26aufirst%3DS.%26aulast%3DFitzek%26aufirst%3DM.%26aulast%3DGreen%26aufirst%3DS.%26aulast%3DHancox%26aufirst%3DU.%26aulast%3DLambert-van%2Bder%2BBrempt%26aufirst%3DC.%26aulast%3DLohmann%26aufirst%3DJ.-J.%26aulast%3DMaudet%26aufirst%3DM.%26aulast%3DMorgentin%26aufirst%3DR.%26aulast%3DPasquet%26aufirst%3DM.-J.%26aulast%3DP%25C3%25A9ru%26aufirst%3DA.%26aulast%3DPl%25C3%25A9%26aufirst%3DP.%26aulast%3DSaleh%26aufirst%3DT.%26aulast%3DVautier%26aufirst%3DM.%26aulast%3DWalker%26aufirst%3DM.%26aulast%3DWard%26aufirst%3DL.%26aulast%3DWarin%26aufirst%3DN.%26atitle%3DDiscovery%2520of%2520%2528R%2529-8-%25281-%25283%252C5-difluorophenylamino%2529ethyl%2529-N%252CN-dimethyl-2-morpholino-4-oxo-4Hchromene-6-carboxamide%2520%2528AZD8186%2529%253A%2520a%2520potent%2520and%2520selective%2520inhibitor%2520of%2520PI3K%25CE%25B2%2520and%2520PI3K%25CE%25B4%2520for%2520the%2520treatment%2520of%2520PTEN-deficient%2520cancers%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D943%26epage%3D962%26doi%3D10.1021%2Fjm501629p" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group">Cao, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cao, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luo, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhong, W.</span><span> </span><span class="NLM_article-title">Design, synthesis and biological evaluation of novel benzothiazole derivatives as selective PI3Kβ inhibitors</span> <span class="citation_source-journal">Molecules</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">876</span><span class="refDoi"> DOI: 10.3390/molecules21070876</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01821&amp;key=10.3390%2Fmolecules21070876" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2016&pages=876&author=S.+Caoauthor=R.+Caoauthor=X.+Liuauthor=X.+Luoauthor=W.+Zhong&title=Design%2C+synthesis+and+biological+evaluation+of+novel+benzothiazole+derivatives+as+selective+PI3K%CE%B2+inhibitors&doi=10.3390%2Fmolecules21070876"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.3390%2Fmolecules21070876&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fmolecules21070876%26sid%3Dliteratum%253Aachs%26aulast%3DCao%26aufirst%3DS.%26aulast%3DCao%26aufirst%3DR.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DLuo%26aufirst%3DX.%26aulast%3DZhong%26aufirst%3DW.%26atitle%3DDesign%252C%2520synthesis%2520and%2520biological%2520evaluation%2520of%2520novel%2520benzothiazole%2520derivatives%2520as%2520selective%2520PI3K%25CE%25B2%2520inhibitors%26jtitle%3DMolecules%26date%3D2016%26volume%3D21%26spage%3D876%26doi%3D10.3390%2Fmolecules21070876" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group">Zheng, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pinson, J.-A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mountford, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Orive, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schoenwaelder, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shackleford, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Powell, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nelson, E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamilton, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jackson, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jennings, I. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thompson, P. E.</span><span> </span><span class="NLM_article-title">Discovery and antiplatelet activity of a selective PI3Kβ inhibitor (MIPS-9922)</span> <span class="citation_source-journal">Eur. J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">122</span><span class="NLM_x">, </span> <span class="NLM_fpage">339</span><span class="NLM_x">–</span> <span class="NLM_lpage">351</span><span class="refDoi"> DOI: 10.1016/j.ejmech.2016.06.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01821&amp;key=10.1016%2Fj.ejmech.2016.06.010" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=122&publication_year=2016&pages=339-351&author=Z.+Zhengauthor=J.-A.+Pinsonauthor=S.+J.+Mountfordauthor=S.+Oriveauthor=M.+Schoenwaelderauthor=D.+Shacklefordauthor=A.+Powellauthor=E.+M.+Nelsonauthor=J.+R.+Hamiltonauthor=S.+P.+Jacksonauthor=I.+G.+Jenningsauthor=P.+E.+Thompson&title=Discovery+and+antiplatelet+activity+of+a+selective+PI3K%CE%B2+inhibitor+%28MIPS-9922%29&doi=10.1016%2Fj.ejmech.2016.06.010"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2016.06.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2016.06.010%26sid%3Dliteratum%253Aachs%26aulast%3DZheng%26aufirst%3DZ.%26aulast%3DPinson%26aufirst%3DJ.-A.%26aulast%3DMountford%26aufirst%3DS.%2BJ.%26aulast%3DOrive%26aufirst%3DS.%26aulast%3DSchoenwaelder%26aufirst%3DM.%26aulast%3DShackleford%26aufirst%3DD.%26aulast%3DPowell%26aufirst%3DA.%26aulast%3DNelson%26aufirst%3DE.%2BM.%26aulast%3DHamilton%26aufirst%3DJ.%2BR.%26aulast%3DJackson%26aufirst%3DS.%2BP.%26aulast%3DJennings%26aufirst%3DI.%2BG.%26aulast%3DThompson%26aufirst%3DP.%2BE.%26atitle%3DDiscovery%2520and%2520antiplatelet%2520activity%2520of%2520a%2520selective%2520PI3K%25CE%25B2%2520inhibitor%2520%2528MIPS-9922%2529%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2016%26volume%3D122%26spage%3D339%26epage%3D351%26doi%3D10.1016%2Fj.ejmech.2016.06.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group">Barlaam, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cosulich, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Degorce, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fitzek, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Green, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hancox, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lambert van der Brempt, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lohmann, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maudet, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morgentin, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Péru, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Plé, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saleh, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ward, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Warin, N.</span><span> </span><span class="NLM_article-title">Discovery of a series of 8-(2,3-dihydro-1,4-benzoxazin-4-ylmethyl)-2-morpholino-4-oxo-chromene-6-carboxamides as PI3Kβ/δ inhibitors for the treatment of PTEN-deficient tumours</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">2318</span><span class="NLM_x">–</span> <span class="NLM_lpage">2323</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2016.03.034</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01821&amp;key=10.1016%2Fj.bmcl.2016.03.034" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2016&pages=2318-2323&author=B.+Barlaamauthor=S.+Cosulichauthor=S.+Degorceauthor=M.+Fitzekauthor=S.+Greenauthor=U.+Hancoxauthor=C.+Lambert+van+der+Bremptauthor=J.+J.+Lohmannauthor=M.+Maudetauthor=R.+Morgentinauthor=A.+P%C3%A9ruauthor=P.+Pl%C3%A9author=T.+Salehauthor=L.+Wardauthor=N.+Warin&title=Discovery+of+a+series+of+8-%282%2C3-dihydro-1%2C4-benzoxazin-4-ylmethyl%29-2-morpholino-4-oxo-chromene-6-carboxamides+as+PI3K%CE%B2%2F%CE%B4+inhibitors+for+the+treatment+of+PTEN-deficient+tumours&doi=10.1016%2Fj.bmcl.2016.03.034"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2016.03.034&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2016.03.034%26sid%3Dliteratum%253Aachs%26aulast%3DBarlaam%26aufirst%3DB.%26aulast%3DCosulich%26aufirst%3DS.%26aulast%3DDegorce%26aufirst%3DS.%26aulast%3DFitzek%26aufirst%3DM.%26aulast%3DGreen%26aufirst%3DS.%26aulast%3DHancox%26aufirst%3DU.%26aulast%3DLambert%2Bvan%2Bder%2BBrempt%26aufirst%3DC.%26aulast%3DLohmann%26aufirst%3DJ.%2BJ.%26aulast%3DMaudet%26aufirst%3DM.%26aulast%3DMorgentin%26aufirst%3DR.%26aulast%3DP%25C3%25A9ru%26aufirst%3DA.%26aulast%3DPl%25C3%25A9%26aufirst%3DP.%26aulast%3DSaleh%26aufirst%3DT.%26aulast%3DWard%26aufirst%3DL.%26aulast%3DWarin%26aufirst%3DN.%26atitle%3DDiscovery%2520of%2520a%2520series%2520of%25208-%25282%252C3-dihydro-1%252C4-benzoxazin-4-ylmethyl%2529-2-morpholino-4-oxo-chromene-6-carboxamides%2520as%2520PI3K%25CE%25B2%252F%25CE%25B4%2520inhibitors%2520for%2520the%2520treatment%2520of%2520PTEN-deficient%2520tumours%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2016%26volume%3D26%26spage%3D2318%26epage%3D2323%26doi%3D10.1016%2Fj.bmcl.2016.03.034" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group">Certal, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Halley, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Virone-Oddos, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Delorme, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karlsson, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Charrier, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rak, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thompson, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Filoche-Rommé, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">El-Ahmad, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carry, J.-C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abecassis, P.-Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Amara, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vincent, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bonnevaux, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nicolas, J.-P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bertrand, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marquette, J.-P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Michot, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Benard, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Below, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vade, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chatreaux, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lebourg, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pilorge, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Angouillant-Boniface, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Louboutin, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lengauer, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schio, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mathieu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perrin, M.-A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lemaitre, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guerif, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perron, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Monget, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gruss-Leleu, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doerflinger, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guizani, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brollo, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Delbarre, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bertin, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richepin, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loyau, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garcia-Echeverria, C.</span><span> </span><span class="NLM_article-title">Discovery and optimization of pyrimidone indoline amide PI3Kβ inhibitors for the treatment of phosphatase and tensin homologue (PTEN)-deficient cancers</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">903</span><span class="NLM_x">–</span> <span class="NLM_lpage">920</span><span class="refDoi"> DOI: 10.1021/jm401642q</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm401642q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=903-920&author=V.+Certalauthor=F.+Halleyauthor=A.+Virone-Oddosauthor=C.+Delormeauthor=A.+Karlssonauthor=V.+Charrierauthor=A.+Rakauthor=F.+Thompsonauthor=B.+Filoche-Romm%C3%A9author=Y.+El-Ahmadauthor=J.-C.+Carryauthor=P.-Y.+Abecassisauthor=C.+Amaraauthor=L.+Vincentauthor=H.+Bonnevauxauthor=J.-P.+Nicolasauthor=T.+Bertrandauthor=J.-P.+Marquetteauthor=N.+Michotauthor=T.+Benardauthor=P.+Belowauthor=I.+Vadeauthor=F.+Chatreauxauthor=G.+Lebourgauthor=F.+Pilorgeauthor=O.+Angouillant-Bonifaceauthor=A.+Louboutinauthor=C.+Lengauerauthor=L.+Schioauthor=M.+Mathieuauthor=M.-A.+Perrinauthor=O.+Lemaitreauthor=S.+Guerifauthor=S.+Perronauthor=S.+Mongetauthor=F.+Gruss-Leleuauthor=G.+Doerflingerauthor=H.+Guizaniauthor=M.+Brolloauthor=L.+Delbarreauthor=L.+Bertinauthor=P.+Richepinauthor=V.+Loyauauthor=C.+Garcia-Echeverria&title=Discovery+and+optimization+of+pyrimidone+indoline+amide+PI3K%CE%B2+inhibitors+for+the+treatment+of+phosphatase+and+tensin+homologue+%28PTEN%29-deficient+cancers&doi=10.1021%2Fjm401642q"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1021%2Fjm401642q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm401642q%26sid%3Dliteratum%253Aachs%26aulast%3DCertal%26aufirst%3DV.%26aulast%3DHalley%26aufirst%3DF.%26aulast%3DVirone-Oddos%26aufirst%3DA.%26aulast%3DDelorme%26aufirst%3DC.%26aulast%3DKarlsson%26aufirst%3DA.%26aulast%3DCharrier%26aufirst%3DV.%26aulast%3DRak%26aufirst%3DA.%26aulast%3DThompson%26aufirst%3DF.%26aulast%3DFiloche-Romm%25C3%25A9%26aufirst%3DB.%26aulast%3DEl-Ahmad%26aufirst%3DY.%26aulast%3DCarry%26aufirst%3DJ.-C.%26aulast%3DAbecassis%26aufirst%3DP.-Y.%26aulast%3DAmara%26aufirst%3DC.%26aulast%3DVincent%26aufirst%3DL.%26aulast%3DBonnevaux%26aufirst%3DH.%26aulast%3DNicolas%26aufirst%3DJ.-P.%26aulast%3DBertrand%26aufirst%3DT.%26aulast%3DMarquette%26aufirst%3DJ.-P.%26aulast%3DMichot%26aufirst%3DN.%26aulast%3DBenard%26aufirst%3DT.%26aulast%3DBelow%26aufirst%3DP.%26aulast%3DVade%26aufirst%3DI.%26aulast%3DChatreaux%26aufirst%3DF.%26aulast%3DLebourg%26aufirst%3DG.%26aulast%3DPilorge%26aufirst%3DF.%26aulast%3DAngouillant-Boniface%26aufirst%3DO.%26aulast%3DLouboutin%26aufirst%3DA.%26aulast%3DLengauer%26aufirst%3DC.%26aulast%3DSchio%26aufirst%3DL.%26aulast%3DMathieu%26aufirst%3DM.%26aulast%3DPerrin%26aufirst%3DM.-A.%26aulast%3DLemaitre%26aufirst%3DO.%26aulast%3DGuerif%26aufirst%3DS.%26aulast%3DPerron%26aufirst%3DS.%26aulast%3DMonget%26aufirst%3DS.%26aulast%3DGruss-Leleu%26aufirst%3DF.%26aulast%3DDoerflinger%26aufirst%3DG.%26aulast%3DGuizani%26aufirst%3DH.%26aulast%3DBrollo%26aufirst%3DM.%26aulast%3DDelbarre%26aufirst%3DL.%26aulast%3DBertin%26aufirst%3DL.%26aulast%3DRichepin%26aufirst%3DP.%26aulast%3DLoyau%26aufirst%3DV.%26aulast%3DGarcia-Echeverria%26aufirst%3DC.%26atitle%3DDiscovery%2520and%2520optimization%2520of%2520pyrimidone%2520indoline%2520amide%2520PI3K%25CE%25B2%2520inhibitors%2520for%2520the%2520treatment%2520of%2520phosphatase%2520and%2520tensin%2520homologue%2520%2528PTEN%2529-deficient%2520cancers%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D903%26epage%3D920%26doi%3D10.1021%2Fjm401642q" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group">Lin, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schulz, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xie, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zeng, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luengo, J. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Squire, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tedesco, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Erhard, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mack, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raha, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Plant, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rominger, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ariazi, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sherk, C. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schaber, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McSurdy-Freed, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spengler, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davis, C. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hardwicke, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rivero, R. A.</span><span> </span><span class="NLM_article-title">Rational design, synthesis, and SAR of a novel thiazolopyrimidinone series of selective PI3K-beta inhibitors</span> <span class="citation_source-journal">ACS Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">524</span><span class="NLM_x">–</span> <span class="NLM_lpage">529</span><span class="refDoi"> DOI: 10.1021/ml300045b</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml300045b" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01821&amp;key=1%3ACAS%3A528%3ADC%252BC38XnsFOntr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2012&pages=524-529&author=H.+Linauthor=M.+J.+Schulzauthor=R.+Xieauthor=J.+Zengauthor=J.+I.+Luengoauthor=M.+D.+Squireauthor=R.+Tedescoauthor=J.+Quauthor=K.+Erhardauthor=J.+F.+Mackauthor=K.+Rahaauthor=R.+Plantauthor=C.+M.+Romingerauthor=J.+L.+Ariaziauthor=C.+S.+Sherkauthor=M.+D.+Schaberauthor=J.+McSurdy-Freedauthor=M.+D.+Spenglerauthor=C.+B.+Davisauthor=M.+A.+Hardwickeauthor=R.+A.+Rivero&title=Rational+design%2C+synthesis%2C+and+SAR+of+a+novel+thiazolopyrimidinone+series+of+selective+PI3K-beta+inhibitors&doi=10.1021%2Fml300045b"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Rational Design, Synthesis, and SAR of a Novel Thiazolopyrimidinone Series of Selective PI3K-beta Inhibitors</span></div><div class="casAuthors">Lin, Hong; Schulz, Mark J.; Xie, Ren; Zeng, Jin; Luengo, Juan I.; Squire, Michael D.; Tedesco, Rosanna; Qu, Junya; Erhard, Karl; Mack, James F.; Raha, Kaushik; Plant, Ramona; Rominger, Cynthia M.; Ariazi, Jennifer L.; Sherk, Christian S.; Schaber, Michael D.; McSurdy-Freed, Jeanelle; Spengler, Michael D.; Davis, Charles B.; Hardwicke, Mary Ann; Rivero, Ralph A.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">524-529</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A novel thiazolopyrimidinone series of PI3K-beta selective inhibitors has been identified.  This chemotype has provided an excellent tool compd., 18, that showed potent growth inhibition in the PTEN-deficient breast cancer cell line MDA-MB-468 under anchorage-independent conditions, and it also demonstrated pharmacodynamic effects and efficacy in a PTEN-deficient prostate cancer PC-3 xenograft mouse model.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqBdoBlyIkf9LVg90H21EOLACvtfcHk0lhXSLQDayqShA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XnsFOntr0%253D&md5=dfa2f5598b9b5d1e7a8bfb584fa50982</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1021%2Fml300045b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml300045b%26sid%3Dliteratum%253Aachs%26aulast%3DLin%26aufirst%3DH.%26aulast%3DSchulz%26aufirst%3DM.%2BJ.%26aulast%3DXie%26aufirst%3DR.%26aulast%3DZeng%26aufirst%3DJ.%26aulast%3DLuengo%26aufirst%3DJ.%2BI.%26aulast%3DSquire%26aufirst%3DM.%2BD.%26aulast%3DTedesco%26aufirst%3DR.%26aulast%3DQu%26aufirst%3DJ.%26aulast%3DErhard%26aufirst%3DK.%26aulast%3DMack%26aufirst%3DJ.%2BF.%26aulast%3DRaha%26aufirst%3DK.%26aulast%3DPlant%26aufirst%3DR.%26aulast%3DRominger%26aufirst%3DC.%2BM.%26aulast%3DAriazi%26aufirst%3DJ.%2BL.%26aulast%3DSherk%26aufirst%3DC.%2BS.%26aulast%3DSchaber%26aufirst%3DM.%2BD.%26aulast%3DMcSurdy-Freed%26aufirst%3DJ.%26aulast%3DSpengler%26aufirst%3DM.%2BD.%26aulast%3DDavis%26aufirst%3DC.%2BB.%26aulast%3DHardwicke%26aufirst%3DM.%2BA.%26aulast%3DRivero%26aufirst%3DR.%2BA.%26atitle%3DRational%2520design%252C%2520synthesis%252C%2520and%2520SAR%2520of%2520a%2520novel%2520thiazolopyrimidinone%2520series%2520of%2520selective%2520PI3K-beta%2520inhibitors%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D3%26spage%3D524%26epage%3D529%26doi%3D10.1021%2Fml300045b" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group">Pinson, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zheng, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chalmers, D. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jennings, I. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thompson, P. E.</span><span> </span><span class="NLM_article-title">L-Aminoacyl-triazine derivatives are isoform-selective PI3Kβ inhibitors that target nonconserved Asp862 of PI3Kβ</span> <span class="citation_source-journal">ACS Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">206</span><span class="NLM_x">–</span> <span class="NLM_lpage">210</span><span class="refDoi"> DOI: 10.1021/ml300336j</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml300336j" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2013&pages=206-210&author=J.+A.+Pinsonauthor=Z.+Zhengauthor=M.+S.+Millerauthor=D.+K.+Chalmersauthor=I.+G.+Jenningsauthor=P.+E.+Thompson&title=L-Aminoacyl-triazine+derivatives+are+isoform-selective+PI3K%CE%B2+inhibitors+that+target+nonconserved+Asp862+of+PI3K%CE%B2&doi=10.1021%2Fml300336j"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1021%2Fml300336j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml300336j%26sid%3Dliteratum%253Aachs%26aulast%3DPinson%26aufirst%3DJ.%2BA.%26aulast%3DZheng%26aufirst%3DZ.%26aulast%3DMiller%26aufirst%3DM.%2BS.%26aulast%3DChalmers%26aufirst%3DD.%2BK.%26aulast%3DJennings%26aufirst%3DI.%2BG.%26aulast%3DThompson%26aufirst%3DP.%2BE.%26atitle%3DL-Aminoacyl-triazine%2520derivatives%2520are%2520isoform-selective%2520PI3K%25CE%25B2%2520inhibitors%2520that%2520target%2520nonconserved%2520Asp862%2520of%2520PI3K%25CE%25B2%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2013%26volume%3D4%26spage%3D206%26epage%3D210%26doi%3D10.1021%2Fml300336j" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group">Gonzalez-Lopez de Turiso, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shin, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cardozo, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fong, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hao, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">He, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Henne, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu, Y.-L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kohn, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lohman, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McBride, H. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McGee, L. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Medina, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Metz, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miner, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mohn, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pattaropong, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seganish, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simard, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wannberg, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whittington, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cushing, T. D.</span><span> </span><span class="NLM_article-title">Discovery and in vivo evaluation of dual PI3Kβ/δ inhibitors</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">7667</span><span class="NLM_x">–</span> <span class="NLM_lpage">7685</span><span class="refDoi"> DOI: 10.1021/jm300679u</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm300679u" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01821&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtFKnsr3J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=7667-7685&author=F.+Gonzalez-Lopez+de+Turisoauthor=Y.+Shinauthor=M.+Brownauthor=M.+Cardozoauthor=Y.+Chenauthor=D.+Fongauthor=X.+Haoauthor=X.+Heauthor=K.+Henneauthor=Y.-L.+Huauthor=M.+G.+Johnsonauthor=T.+Kohnauthor=J.+Lohmanauthor=H.+J.+McBrideauthor=L.+R.+McGeeauthor=J.+C.+Medinaauthor=D.+Metzauthor=K.+Minerauthor=D.+Mohnauthor=V.+Pattaropongauthor=J.+Seganishauthor=J.+L.+Simardauthor=S.+Wannbergauthor=D.+A.+Whittingtonauthor=G.+Yuauthor=T.+D.+Cushing&title=Discovery+and+in+vivo+evaluation+of+dual+PI3K%CE%B2%2F%CE%B4+inhibitors&doi=10.1021%2Fjm300679u"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and in Vivo Evaluation of Dual PI3Kβ/δ Inhibitors</span></div><div class="casAuthors">Gonzalez-Lopez de Turiso, Felix; Shin, Youngsook; Brown, Matthew; Cardozo, Mario; Chen, Yi; Fong, David; Hao, Xiaolin; He, Xiao; Henne, Kirk; Hu, Yi-Ling; Johnson, Michael G.; Kohn, Todd; Lohman, Julia; McBride, Helen J.; McGee, Lawrence R.; Medina, Julio C.; Metz, Daniela; Miner, Kent; Mohn, Deanna; Pattaropong, Vatee; Seganish, Jennifer; Simard, Jillian L.; Wannberg, Sharon; Whittington, Douglas A.; Yu, Gang; Cushing, Timothy D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">7667-7685</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Structure-based rational design led to the synthesis of a novel series of potent PI3K inhibitors.  The optimized pyrrolopyridine analog I was a potent and selective PI3Kβ/δ dual inhibitor that displayed suitable physicochem. properties and pharmacokinetic profile for animal studies.  Analog I was found to be efficacious in animal models of inflammation including a keyhole limpet hemocyanin (KLH) study and a collagen-induced arthritis (CIA) disease model of rheumatoid arthritis.  These studies highlight the potential therapeutic value of inhibiting both the PI3Kβ and δ isoforms in the treatment of a no. of inflammatory diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpslq3QL1Tg7LVg90H21EOLACvtfcHk0ljbSLBX8UXnFQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtFKnsr3J&md5=fbf690a0e702faf17e16ef68db076635</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1021%2Fjm300679u&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm300679u%26sid%3Dliteratum%253Aachs%26aulast%3DGonzalez-Lopez%2Bde%2BTuriso%26aufirst%3DF.%26aulast%3DShin%26aufirst%3DY.%26aulast%3DBrown%26aufirst%3DM.%26aulast%3DCardozo%26aufirst%3DM.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DFong%26aufirst%3DD.%26aulast%3DHao%26aufirst%3DX.%26aulast%3DHe%26aufirst%3DX.%26aulast%3DHenne%26aufirst%3DK.%26aulast%3DHu%26aufirst%3DY.-L.%26aulast%3DJohnson%26aufirst%3DM.%2BG.%26aulast%3DKohn%26aufirst%3DT.%26aulast%3DLohman%26aufirst%3DJ.%26aulast%3DMcBride%26aufirst%3DH.%2BJ.%26aulast%3DMcGee%26aufirst%3DL.%2BR.%26aulast%3DMedina%26aufirst%3DJ.%2BC.%26aulast%3DMetz%26aufirst%3DD.%26aulast%3DMiner%26aufirst%3DK.%26aulast%3DMohn%26aufirst%3DD.%26aulast%3DPattaropong%26aufirst%3DV.%26aulast%3DSeganish%26aufirst%3DJ.%26aulast%3DSimard%26aufirst%3DJ.%2BL.%26aulast%3DWannberg%26aufirst%3DS.%26aulast%3DWhittington%26aufirst%3DD.%2BA.%26aulast%3DYu%26aufirst%3DG.%26aulast%3DCushing%26aufirst%3DT.%2BD.%26atitle%3DDiscovery%2520and%2520in%2520vivo%2520evaluation%2520of%2520dual%2520PI3K%25CE%25B2%252F%25CE%25B4%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D7667%26epage%3D7685%26doi%3D10.1021%2Fjm300679u" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group">Lannutti, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meadows, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herman, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kashishian, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steiner, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Byrd, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tyner, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loriaux, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deininger, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Druker, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Puri, K. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ulrich, R. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giese, N. A.</span><span> </span><span class="NLM_article-title">CAL-101, a p110delta selective phosphatidyl-inositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">117</span><span class="NLM_x">, </span> <span class="NLM_fpage">591</span><span class="NLM_x">–</span> <span class="NLM_lpage">594</span><span class="refDoi"> DOI: 10.1182/blood-2010-03-275305</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01821&amp;key=10.1182%2Fblood-2010-03-275305" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=117&publication_year=2011&pages=591-594&author=B.+J.+Lannuttiauthor=S.+A.+Meadowsauthor=S.+E.+Hermanauthor=A.+Kashishianauthor=B.+Steinerauthor=A.+J.+Johnsonauthor=J.+C.+Byrdauthor=J.+W.+Tynerauthor=M.+M.+Loriauxauthor=M.+Deiningerauthor=B.+J.+Drukerauthor=K.+D.+Puriauthor=R.+G.+Ulrichauthor=N.+A.+Giese&title=CAL-101%2C+a+p110delta+selective+phosphatidyl-inositol-3-kinase+inhibitor+for+the+treatment+of+B-cell+malignancies%2C+inhibits+PI3K+signaling+and+cellular+viability&doi=10.1182%2Fblood-2010-03-275305"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1182%2Fblood-2010-03-275305&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2010-03-275305%26sid%3Dliteratum%253Aachs%26aulast%3DLannutti%26aufirst%3DB.%2BJ.%26aulast%3DMeadows%26aufirst%3DS.%2BA.%26aulast%3DHerman%26aufirst%3DS.%2BE.%26aulast%3DKashishian%26aufirst%3DA.%26aulast%3DSteiner%26aufirst%3DB.%26aulast%3DJohnson%26aufirst%3DA.%2BJ.%26aulast%3DByrd%26aufirst%3DJ.%2BC.%26aulast%3DTyner%26aufirst%3DJ.%2BW.%26aulast%3DLoriaux%26aufirst%3DM.%2BM.%26aulast%3DDeininger%26aufirst%3DM.%26aulast%3DDruker%26aufirst%3DB.%2BJ.%26aulast%3DPuri%26aufirst%3DK.%2BD.%26aulast%3DUlrich%26aufirst%3DR.%2BG.%26aulast%3DGiese%26aufirst%3DN.%2BA.%26atitle%3DCAL-101%252C%2520a%2520p110delta%2520selective%2520phosphatidyl-inositol-3-kinase%2520inhibitor%2520for%2520the%2520treatment%2520of%2520B-cell%2520malignancies%252C%2520inhibits%2520PI3K%2520signaling%2520and%2520cellular%2520viability%26jtitle%3DBlood%26date%3D2011%26volume%3D117%26spage%3D591%26epage%3D594%26doi%3D10.1182%2Fblood-2010-03-275305" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group">Herman, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gordon, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wagner, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heerema, N. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flynn, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Andritsos, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Puri, K. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lannutti, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giese, N. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wei, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Byrd, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, A. J.</span><span> </span><span class="NLM_article-title">Phosphatidylinositol 3-kinase-δ inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">116</span><span class="NLM_x">, </span> <span class="NLM_fpage">2078</span><span class="NLM_x">–</span> <span class="NLM_lpage">2088</span><span class="refDoi"> DOI: 10.1182/blood-2010-02-271171</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01821&amp;key=10.1182%2Fblood-2010-02-271171" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=116&publication_year=2010&pages=2078-2088&author=S.+E.+Hermanauthor=A.+L.+Gordonauthor=A.+J.+Wagnerauthor=N.+A.+Heeremaauthor=W.+Zhaoauthor=J.+M.+Flynnauthor=J.+Jonesauthor=L.+Andritsosauthor=K.+D.+Puriauthor=B.+J.+Lannuttiauthor=N.+A.+Gieseauthor=X.+Zhangauthor=L.+Weiauthor=J.+C.+Byrdauthor=A.+J.+Johnson&title=Phosphatidylinositol+3-kinase-%CE%B4+inhibitor+CAL-101+shows+promising+preclinical+activity+in+chronic+lymphocytic+leukemia+by+antagonizing+intrinsic+and+extrinsic+cellular+survival+signals&doi=10.1182%2Fblood-2010-02-271171"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1182%2Fblood-2010-02-271171&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2010-02-271171%26sid%3Dliteratum%253Aachs%26aulast%3DHerman%26aufirst%3DS.%2BE.%26aulast%3DGordon%26aufirst%3DA.%2BL.%26aulast%3DWagner%26aufirst%3DA.%2BJ.%26aulast%3DHeerema%26aufirst%3DN.%2BA.%26aulast%3DZhao%26aufirst%3DW.%26aulast%3DFlynn%26aufirst%3DJ.%2BM.%26aulast%3DJones%26aufirst%3DJ.%26aulast%3DAndritsos%26aufirst%3DL.%26aulast%3DPuri%26aufirst%3DK.%2BD.%26aulast%3DLannutti%26aufirst%3DB.%2BJ.%26aulast%3DGiese%26aufirst%3DN.%2BA.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DWei%26aufirst%3DL.%26aulast%3DByrd%26aufirst%3DJ.%2BC.%26aulast%3DJohnson%26aufirst%3DA.%2BJ.%26atitle%3DPhosphatidylinositol%25203-kinase-%25CE%25B4%2520inhibitor%2520CAL-101%2520shows%2520promising%2520preclinical%2520activity%2520in%2520chronic%2520lymphocytic%2520leukemia%2520by%2520antagonizing%2520intrinsic%2520and%2520extrinsic%2520cellular%2520survival%2520signals%26jtitle%3DBlood%26date%3D2010%26volume%3D116%26spage%3D2078%26epage%3D2088%26doi%3D10.1182%2Fblood-2010-02-271171" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group">Somoza, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koditek, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Villasenor, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Novikov, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liclican, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xing, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lagpacan, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schultz, B. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Papalia, G. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Samuel, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lad, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McGrath, M. E.</span><span> </span><span class="NLM_article-title">Structural, biochemical, and biophysical characterization of idelalisib binding to phosphoinositide 3-kinase δ</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">290</span><span class="NLM_x">, </span> <span class="NLM_fpage">8439</span><span class="NLM_x">–</span> <span class="NLM_lpage">8446</span><span class="refDoi"> DOI: 10.1074/jbc.M114.634683</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01821&amp;key=10.1074%2Fjbc.M114.634683" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01821&amp;key=25631052" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01821&amp;key=1%3ACAS%3A528%3ADC%252BC2MXlsVSqtrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=290&publication_year=2015&pages=8439-8446&author=J.+R.+Somozaauthor=D.+Koditekauthor=A.+G.+Villasenorauthor=N.+Novikovauthor=M.+H.+Wongauthor=A.+Liclicanauthor=W.+Xingauthor=L.+Lagpacanauthor=R.+Wangauthor=B.+E.+Schultzauthor=G.+A.+Papaliaauthor=D.+Samuelauthor=L.+Ladauthor=M.+E.+McGrath&title=Structural%2C+biochemical%2C+and+biophysical+characterization+of+idelalisib+binding+to+phosphoinositide+3-kinase+%CE%B4&doi=10.1074%2Fjbc.M114.634683"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Structural, Biochemical, and Biophysical Characterization of Idelalisib Binding to Phosphoinositide 3-Kinase δ</span></div><div class="casAuthors">Somoza, John R.; Koditek, David; Villasenor, Armando G.; Novikov, Nikolai; Wong, Melanie H.; Liclican, Albert; Xing, Weimei; Lagpacan, Leanna; Wang, Ruth; Schultz, Brian E.; Papalia, Giuseppe A.; Samuel, Dharmaraj; Lad, Latesh; McGrath, Mary E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">290</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">8439-8446</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Idelalisib (also known as GS-1101, CAL-101, IC489666, and Zydelig) is a PI3Kδ inhibitor that has recently been approved for the treatment of several hematol. malignancies.  Given its use in human diseases, we needed a clear picture of how idelalisib binds to and inhibits PI3Kδ.  Our data show that idelalisib is a potent and selective inhibitor of the kinase activity of PI3Kδ.  A kinetic characterization clearly demonstrated ATP-competitive inhibition, and several addnl. biochem. and biophys. assays showed that the compd. binds reversibly and noncovalently to the kinase.  A crystal structure of idelalisib bound to the p110δ subunit of PI3Kδ furthers our understanding of the binding interactions that confer the potency and selectivity of idelalisib.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpnXZo8_qK79rVg90H21EOLACvtfcHk0ljU8aTeww1Xeg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXlsVSqtrs%253D&md5=2969b7407f4edc367249215bbbf22a0e</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M114.634683&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M114.634683%26sid%3Dliteratum%253Aachs%26aulast%3DSomoza%26aufirst%3DJ.%2BR.%26aulast%3DKoditek%26aufirst%3DD.%26aulast%3DVillasenor%26aufirst%3DA.%2BG.%26aulast%3DNovikov%26aufirst%3DN.%26aulast%3DWong%26aufirst%3DM.%2BH.%26aulast%3DLiclican%26aufirst%3DA.%26aulast%3DXing%26aufirst%3DW.%26aulast%3DLagpacan%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DR.%26aulast%3DSchultz%26aufirst%3DB.%2BE.%26aulast%3DPapalia%26aufirst%3DG.%2BA.%26aulast%3DSamuel%26aufirst%3DD.%26aulast%3DLad%26aufirst%3DL.%26aulast%3DMcGrath%26aufirst%3DM.%2BE.%26atitle%3DStructural%252C%2520biochemical%252C%2520and%2520biophysical%2520characterization%2520of%2520idelalisib%2520binding%2520to%2520phosphoinositide%25203-kinase%2520%25CE%25B4%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2015%26volume%3D290%26spage%3D8439%26epage%3D8446%26doi%3D10.1074%2Fjbc.M114.634683" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group">Berndt, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Le, D. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Houseman, B. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pacold, J. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gorrec, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hon, W.-C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rommel, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gaillard, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruckle, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schwarz, M. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shokat, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shaw, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, R. L.</span><span> </span><span class="NLM_article-title">The p110δ crystal structure uncovers mechanisms for selectivity and potency of novel PI3K inhibitors</span> <span class="citation_source-journal">Nat. Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">117</span><span class="NLM_x">–</span> <span class="NLM_lpage">124</span><span class="refDoi"> DOI: 10.1038/nchembio.293</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01821&amp;key=10.1038%2Fnchembio.293" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01821&amp;key=20081827" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01821&amp;key=1%3ACAS%3A528%3ADC%252BC3cXlvFGrsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2010&pages=117-124&author=A.+Berndtauthor=S.+Millerauthor=O.+Williamsauthor=D.+D.+Leauthor=B.+T.+Housemanauthor=J.+I.+Pacoldauthor=F.+Gorrecauthor=W.-C.+Honauthor=Y.+Liuauthor=C.+Rommelauthor=P.+Gaillardauthor=T.+Ruckleauthor=M.+K.+Schwarzauthor=K.+M.+Shokatauthor=J.+P.+Shawauthor=R.+L.+Williams&title=The+p110%CE%B4+crystal+structure+uncovers+mechanisms+for+selectivity+and+potency+of+novel+PI3K+inhibitors&doi=10.1038%2Fnchembio.293"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">The p110δ structure: mechanisms for selectivity and potency of new PI(3)K inhibitors</span></div><div class="casAuthors">Berndt, Alex; Miller, Simon; Williams, Olusegun; Le, Daniel D.; Houseman, Benjamin T.; Pacold, Joseph I.; Gorrec, Fabrice; Hon, Wai-Ching; Liu, Yi; Rommel, Christian; Gaillard, Pascale; Rueckle, Thomas; Schwarz, Matthias K.; Shokat, Kevan M.; Shaw, Jeffrey P.; Williams, Roger L.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">117-124</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Deregulation of the phosphoinositide-3-OH kinase (PI(3)K) pathway has been implicated in numerous pathologies including cancer, diabetes, thrombosis, rheumatoid arthritis, and asthma.  Recently, small-mol. and ATP-competitive PI(3)K inhibitors with a wide range of selectivities have entered clin. development.  To understand the mechanisms underlying the isoform selectivity of these inhibitors, we developed a new expression strategy that enabled us to det. to our knowledge the first crystal structure of the catalytic subunit of the class IA PI(3)K p110δ.  Structures of this enzyme in complex with a broad panel of isoform- and pan-selective class I PI(3)K inhibitors reveal that selectivity toward p110δ can be achieved by exploiting its conformational flexibility and the sequence diversity of active site residues that do not contact ATP.  We have used these observations to rationalize and synthesize highly selective inhibitors for p110δ with greatly improved potencies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqL8d01cEl_y7Vg90H21EOLACvtfcHk0lhtFQFm2KjnQA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXlvFGrsw%253D%253D&md5=8a0ce73ab8ca88ea9a48a2cb7fdb1975</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.293&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.293%26sid%3Dliteratum%253Aachs%26aulast%3DBerndt%26aufirst%3DA.%26aulast%3DMiller%26aufirst%3DS.%26aulast%3DWilliams%26aufirst%3DO.%26aulast%3DLe%26aufirst%3DD.%2BD.%26aulast%3DHouseman%26aufirst%3DB.%2BT.%26aulast%3DPacold%26aufirst%3DJ.%2BI.%26aulast%3DGorrec%26aufirst%3DF.%26aulast%3DHon%26aufirst%3DW.-C.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DRommel%26aufirst%3DC.%26aulast%3DGaillard%26aufirst%3DP.%26aulast%3DRuckle%26aufirst%3DT.%26aulast%3DSchwarz%26aufirst%3DM.%2BK.%26aulast%3DShokat%26aufirst%3DK.%2BM.%26aulast%3DShaw%26aufirst%3DJ.%2BP.%26aulast%3DWilliams%26aufirst%3DR.%2BL.%26atitle%3DThe%2520p110%25CE%25B4%2520crystal%2520structure%2520uncovers%2520mechanisms%2520for%2520selectivity%2520and%2520potency%2520of%2520novel%2520PI3K%2520inhibitors%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2010%26volume%3D6%26spage%3D117%26epage%3D124%26doi%3D10.1038%2Fnchembio.293" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="note"><p class="first last">For selected examples of isoform-selective PI3K inhibitors targeting nonconserved residues, see ref <a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">15</a> (Gln859 of PI3Kα), ref <a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">21</a> (Asp856 of PI3Kβ), ref <a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">22</a> (Asp862 of PI3Kβ), and ref <a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">26</a> (Asp862 of PI3Kβ).</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group">Chan, A. W. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laskowski, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Selwood, D. L.</span><span> </span><span class="NLM_article-title">Chemical fragments that hydrogen bond to Asp, Glu, Arg, and His side chains in protein binding sites</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">3086</span><span class="NLM_x">–</span> <span class="NLM_lpage">3094</span><span class="refDoi"> DOI: 10.1021/jm901696w</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm901696w" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01821&amp;key=1%3ACAS%3A528%3ADC%252BC3cXjt1enu7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=3086-3094&author=A.+W.+E.+Chanauthor=R.+A.+Laskowskiauthor=D.+L.+Selwood&title=Chemical+fragments+that+hydrogen+bond+to+Asp%2C+Glu%2C+Arg%2C+and+His+side+chains+in+protein+binding+sites&doi=10.1021%2Fjm901696w"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Chemical Fragments that Hydrogen Bond to Asp, Glu, Arg, and His Side Chains in Protein Binding Sites</span></div><div class="casAuthors">Chan, A. W. Edith; Laskowski, Roman A.; Selwood, David L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">3086-3094</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">We present an anal. of the chem. fragments from lead-like ligands in the Protein Data Bank (PDB) that form hydrogen bonds to the side chains of Asp, Glu, Arg, and His, which are the most common residues found in ligand binding sites.  A fragment is defined as the largest ring assembly contg. the atoms involved in hydrogen bonding.  In total, 462 fragments were found in 2038 ligands from over 8000 protein-ligand structures in the PDB.  The results show which fragments have a higher propensity for interaction with specific side chains.  Some fragments interact with Asp but not with Glu, and vice versa, despite these side chains sharing the same chem. moiety.  Arg side chains form hydrogen bonds almost exclusively with O-mediated ligands, and the fragments are the most diverse.  Hydrogen bond distances from the imidazole of His showed a wider range than the other three amino acids.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpNNuJszKkQobVg90H21EOLACvtfcHk0lhZ85vZwb9c1w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXjt1enu7o%253D&md5=ae7c315b3974738b610bd82fff960d06</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1021%2Fjm901696w&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm901696w%26sid%3Dliteratum%253Aachs%26aulast%3DChan%26aufirst%3DA.%2BW.%2BE.%26aulast%3DLaskowski%26aufirst%3DR.%2BA.%26aulast%3DSelwood%26aufirst%3DD.%2BL.%26atitle%3DChemical%2520fragments%2520that%2520hydrogen%2520bond%2520to%2520Asp%252C%2520Glu%252C%2520Arg%252C%2520and%2520His%2520side%2520chains%2520in%2520protein%2520binding%2520sites%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D3086%26epage%3D3094%26doi%3D10.1021%2Fjm901696w" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group">Ramanathan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jin, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sharma, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kearney, B. P.</span><span> </span><span class="NLM_article-title">Clinical pharmacokinetic and pharmacodynamic profile of idelalisib</span> <span class="citation_source-journal">Clin. Pharmacokinet.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">33</span><span class="NLM_x">–</span> <span class="NLM_lpage">45</span><span class="refDoi"> DOI: 10.1007/s40262-015-0304-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01821&amp;key=10.1007%2Fs40262-015-0304-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01821&amp;key=26242379" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01821&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtlSit7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2016&pages=33-45&author=S.+Ramanathanauthor=F.+Jinauthor=S.+Sharmaauthor=B.+P.+Kearney&title=Clinical+pharmacokinetic+and+pharmacodynamic+profile+of+idelalisib&doi=10.1007%2Fs40262-015-0304-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Clinical Pharmacokinetic and Pharmacodynamic Profile of Idelalisib</span></div><div class="casAuthors">Ramanathan, Srinivasan; Jin, Feng; Sharma, Shringi; Kearney, Brian P.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Pharmacokinetics</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">33-45</span>CODEN:
                <span class="NLM_cas:coden">CPKNDH</span>;
        ISSN:<span class="NLM_cas:issn">0312-5963</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">Idelalisib is a potent and selective phosphatidylinositol 3-kinase-δ inhibitor, which is a first-in-class agent to be approved for the treatment of relapsed chronic lymphocytic leukemia, follicular B cell non-Hodgkin's lymphoma and small lymphocytic lymphoma.  In dose-ranging studies, idelalisib exposure increased in a less than dose-proportional manner, likely because of soly.-limited absorption.  The approved starting dose of 150 mg twice daily was supported by extensive exposure-response evaluations, with dose redn. to 100 mg twice daily being allowed for specific toxicities.  Idelalisib may be administered without regard to food on the basis of the absence of clin. relevant food effects, and was accordingly dosed in primary efficacy/safety studies.  Idelalisib is metabolized primarily via aldehyde oxidase (AO) and, to a lesser extent, via cytochrome P 450 (CYP) 3A.  Coadministration with the strong CYP3A inhibitor ketoconazole 400 mg once daily resulted in a ∼79 % increase in the idelalisib area under the plasma concn.-time curve (AUC).  Administration with the potent inducer rifampin resulted in a 75 % decrease in idelalisib exposure (AUC) and, as such, coadministration with strong inducers should be avoided.  GS-563117 is an inactive primary circulating metabolite of idelalisib formed mainly via AO.  Unlike idelalisib, GS-563117 is a mechanism-based inhibitor of CYP3A.  Accordingly, idelalisib 150 mg twice-daily dosing increases the midazolam AUC 5.4-fold.  Clin., idelalisib is not an inhibitor of the transporters P-glycoprotein, breast cancer resistance protein, org. anion-transporting polypeptide (OATP) 1B1 or OAPT1B3.  In a population pharmacokinetic model, no meaningful impact on idelalisib pharmacokinetics was noted for any of the covariates tested.  Idelalisib exposure was ∼60 % higher with moderate/severe hepatic impairment; no relevant changes were obsd. with severe renal impairment.  This article reviews a comprehensive pharmacol. program, including drug-drug interaction studies and mechanistic and special population studies, which has allowed a thorough understanding of idelalisib clin. pharmacokinetics and their impact on clin. safety and efficacy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGprSL8hV_Gha7Vg90H21EOLACvtfcHk0lhZ85vZwb9c1w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtlSit7o%253D&md5=df1082fcbb0e1a9aa941769ade9fe962</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1007%2Fs40262-015-0304-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40262-015-0304-0%26sid%3Dliteratum%253Aachs%26aulast%3DRamanathan%26aufirst%3DS.%26aulast%3DJin%26aufirst%3DF.%26aulast%3DSharma%26aufirst%3DS.%26aulast%3DKearney%26aufirst%3DB.%2BP.%26atitle%3DClinical%2520pharmacokinetic%2520and%2520pharmacodynamic%2520profile%2520of%2520idelalisib%26jtitle%3DClin.%2520Pharmacokinet.%26date%3D2016%26volume%3D55%26spage%3D33%26epage%3D45%26doi%3D10.1007%2Fs40262-015-0304-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group">Jin, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robeson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moyer, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilbert, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murray, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ramanathan, S.</span><span> </span><span class="NLM_article-title">Clinical drug interaction profile of idelalisib in healthy subjects</span> <span class="citation_source-journal">J. Clin. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">909</span><span class="NLM_x">–</span> <span class="NLM_lpage">919</span><span class="refDoi"> DOI: 10.1002/jcph.495</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01821&amp;key=10.1002%2Fjcph.495" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01821&amp;key=25760671" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01821&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtFCru7%252FM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2015&pages=909-919&author=F.+Jinauthor=M.+Robesonauthor=H.+Zhouauthor=C.+Moyerauthor=S.+Wilbertauthor=B.+Murrayauthor=S.+Ramanathan&title=Clinical+drug+interaction+profile+of+idelalisib+in+healthy+subjects&doi=10.1002%2Fjcph.495"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Clinical drug interaction profile of idelalisib in healthy subjects</span></div><div class="casAuthors">Jin, Feng; Robeson, Michelle; Zhou, Huafeng; Moyer, Candra; Wilbert, Sibylle; Murray, Bernard; Ramanathan, Srini</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Pharmacology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">909-919</span>CODEN:
                <span class="NLM_cas:coden">JCPCBR</span>;
        ISSN:<span class="NLM_cas:issn">0091-2700</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Idelalisib, a potent phosphatidylinositol-3-kinase delta (PI3Kδ) inhibitor, is metabolized primarily by aldehyde oxidase to form GS-563117 and to a lesser extent by cytochrome P 450 (CYP) 3A and uridine 5'-diphospho-glucuronosyltransferase 1A4.  In vitro, idelalisib inhibits P-glycoprotein (P-gp) and org. anion transporting polypeptides 1B1 and 1B3, and GS-563117 is a time-dependent CYP3A inhibitor.  This study enrolled 24 healthy subjects and evaluated (1) the effect of idelalisib on the pharmacokinetics (PK) of digoxin, a P-gp probe substrate, rosuvastatin, a breast cancer resistance protein, and OATP1B1/OATP1B3 substrate, and midazolam, a CYP3A substrate; and (2) the effect of a strong inducer, rifampin, on idelalisib PK.  On treatment, the most common clin. adverse events (AEs) were headache and pyrexia.  Grade 3 transaminase increases were obsd. in 5 of 24 subjects and were reversible.  Two subjects had serious AEs after treatment completion (grade 3 pyrexia and/or drug-induced liver injury).  Idelalisib coadministration did not affect digoxin and rosuvastatin PK.  Coadministration with idelalisib increased plasma exposures of midazolam (138% and 437% for max. obsd. plasma concn. [Cmax] and area under the plasma concn.-time curve from time 0 extrapolated to infinity [AUCinf], resp.), consistent with the in vitro finding of CYP3A inhibition by GS-563117.  Rifampin caused a substantial decrease in idelalisib (58% and 75%, Cmax and AUCinf, resp.) and GS-563117 exposures, indicating an enhanced contribution of CYP3A to idelalisib metab. under a strongly induced state.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqnGy4bARtgkLVg90H21EOLACvtfcHk0lhSHtss5sG-Uw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtFCru7%252FM&md5=b4e8bb97a51561cecda3ecd0c7a16372</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1002%2Fjcph.495&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjcph.495%26sid%3Dliteratum%253Aachs%26aulast%3DJin%26aufirst%3DF.%26aulast%3DRobeson%26aufirst%3DM.%26aulast%3DZhou%26aufirst%3DH.%26aulast%3DMoyer%26aufirst%3DC.%26aulast%3DWilbert%26aufirst%3DS.%26aulast%3DMurray%26aufirst%3DB.%26aulast%3DRamanathan%26aufirst%3DS.%26atitle%3DClinical%2520drug%2520interaction%2520profile%2520of%2520idelalisib%2520in%2520healthy%2520subjects%26jtitle%3DJ.%2520Clin.%2520Pharmacol.%26date%3D2015%26volume%3D55%26spage%3D909%26epage%3D919%26doi%3D10.1002%2Fjcph.495" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group">Meanwell, N.</span><span> </span><span class="NLM_article-title">Synopsis of some recent tactical application of bioisosteres in drug design</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">2529</span><span class="NLM_x">–</span> <span class="NLM_lpage">2591</span><span class="refDoi"> DOI: 10.1021/jm1013693</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm1013693" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01821&amp;key=1%3ACAS%3A528%3ADC%252BC3MXjsVCnu7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=2529-2591&author=N.+Meanwell&title=Synopsis+of+some+recent+tactical+application+of+bioisosteres+in+drug+design&doi=10.1021%2Fjm1013693"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Synopsis of Some Recent Tactical Application of Bioisosteres in Drug Design</span></div><div class="casAuthors">Meanwell, Nicholas A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2529-2591</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The established utility of bioisosteres is broad in nature, extending to improving potency, enhancing selectivity, altering phys. properties, reducing or redirecting metab., eliminating or modifying toxicophores, and acquiring novel intellectual property.  In this Perspective, some contemporary themes exploring the role of isosteres in drug design are sampled, with an emphasis placed on tactical applications designed to solve the kinds of problems that impinge on compd. optimization and the long-term success of drug candidates.  Interesting concepts that may have been poorly effective in the context examd. are captured, since the ideas may have merit in alternative circumstances.  A comprehensive cataloging of bioisosteres is beyond the scope of what will be provided, although a synopsis of relevant isosteres of a particular functionality is summarized in a succinct fashion in several sections.  Isosterism has also found productive application in the design and optimization of organocatalysts, and there are several examples in which functional mimicry established initially in a medicinal chem. setting has been adopted by this community.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrZ9z_aPcU4ubVg90H21EOLACvtfcHk0lhSHtss5sG-Uw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXjsVCnu7o%253D&md5=0637ab60c379bef535f3f709b26f3582</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1021%2Fjm1013693&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm1013693%26sid%3Dliteratum%253Aachs%26aulast%3DMeanwell%26aufirst%3DN.%26atitle%3DSynopsis%2520of%2520some%2520recent%2520tactical%2520application%2520of%2520bioisosteres%2520in%2520drug%2520design%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D2529%26epage%3D2591%26doi%3D10.1021%2Fjm1013693" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group">Lin, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parikh, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lo, J.-L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, Y. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheng, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, R. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fisher, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wyvratt, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goulet, M. T.</span><span> </span><span class="NLM_article-title">Heterocyclic derivatives of 2-(3,5-dimethylphenyl)tryptamine as GnRH receptor antagonists</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">1077</span><span class="NLM_x">–</span> <span class="NLM_lpage">1080</span><span class="refDoi"> DOI: 10.1016/S0960-894X(01)00133-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01821&amp;key=10.1016%2FS0960-894X%2801%2900133-0" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2001&pages=1077-1080&author=P.+Linauthor=M.+Parikhauthor=J.-L.+Loauthor=Y.+T.+Yangauthor=K.+Chengauthor=R.+G.+Smithauthor=M.+H.+Fisherauthor=M.+J.+Wyvrattauthor=M.+T.+Goulet&title=Heterocyclic+derivatives+of+2-%283%2C5-dimethylphenyl%29tryptamine+as+GnRH+receptor+antagonists&doi=10.1016%2FS0960-894X%2801%2900133-0"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1016%2FS0960-894X%2801%2900133-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0960-894X%252801%252900133-0%26sid%3Dliteratum%253Aachs%26aulast%3DLin%26aufirst%3DP.%26aulast%3DParikh%26aufirst%3DM.%26aulast%3DLo%26aufirst%3DJ.-L.%26aulast%3DYang%26aufirst%3DY.%2BT.%26aulast%3DCheng%26aufirst%3DK.%26aulast%3DSmith%26aufirst%3DR.%2BG.%26aulast%3DFisher%26aufirst%3DM.%2BH.%26aulast%3DWyvratt%26aufirst%3DM.%2BJ.%26aulast%3DGoulet%26aufirst%3DM.%2BT.%26atitle%3DHeterocyclic%2520derivatives%2520of%25202-%25283%252C5-dimethylphenyl%2529tryptamine%2520as%2520GnRH%2520receptor%2520antagonists%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2001%26volume%3D11%26spage%3D1077%26epage%3D1080%26doi%3D10.1016%2FS0960-894X%2801%2900133-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group">Wright, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gregory, T. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kesten, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boxer, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Serpa, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meltzer, L. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wise, L. D.</span><span> </span><span class="NLM_article-title">Subtype-selective <i>N</i>-methyl-D-aspartate receptor antagonists: synthesis and biological evaluation of 1-(heteroarylalkynyl)-4-benzylpiperidines</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">43</span><span class="NLM_x">, </span> <span class="NLM_fpage">3408</span><span class="NLM_x">–</span> <span class="NLM_lpage">3419</span><span class="refDoi"> DOI: 10.1021/jm000023o</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm000023o" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01821&amp;key=1%3ACAS%3A528%3ADC%252BD3cXlslSrsr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2000&pages=3408-3419&author=J.+L.+Wrightauthor=T.+F.+Gregoryauthor=S.+R.+Kestenauthor=P.+A.+Boxerauthor=K.+A.+Serpaauthor=L.+T.+Meltzerauthor=L.+D.+Wise&title=Subtype-selective+N-methyl-D-aspartate+receptor+antagonists%3A+synthesis+and+biological+evaluation+of+1-%28heteroarylalkynyl%29-4-benzylpiperidines&doi=10.1021%2Fjm000023o"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Subtype-Selective N-Methyl-D-Aspartate Receptor Antagonists: Synthesis and Biological Evaluation of 1-(Heteroarylalkynyl)-4-benzylpiperidines</span></div><div class="casAuthors">Wright, Jon L.; Gregory, Tracy F.; Kesten, Suzanne R.; Boxer, Peter A.; Serpa, Kevin A.; Meltzer, Leonard T.; Wise, Lawrence D.; Espitia, Stephen A.; Konkoy, Christopher S.; Whittemore, Edward R.; Woodward, Richard M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">3408-3419</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">4-[4-(4-Benzylpiperidin-1-yl)but-1-ynyl]phenol and 4-[3-(4-benzylpiperidin-1-yl)prop-1-ynyl]phenol (I) are potent NR1A/2B receptor antagonists (IC50 values 0.17 and 0.10 μM, resp.).  Administered i.p., they both potentiated the activity of L-DOPA in the unilaterally 6-hydroxydopamine-lesioned (6-OHDA) rat, a model of Parkinson's disease.  However, I was not active orally, likely due to rapid first-pass metab. of the phenol moiety.  The phenol was replaced by several bicyclic heterocyclic systems contg. an NH group to function as a H-bond donor in the hope that these would be less likely to undergo rapid metab.  In general, indoles, indazoles, benzotriazoles, indolones, and isatins gave analogs with weaker NR1A/2B activity than the parent phenols, while benzimidazolones and benzimidazolinones gave equipotent or more potent analogs.  The preference for a para arrangement between the H-bond donor and the linking acetylene moiety was confirmed, and a propyne link was preferred over a butyne link.  Substitution on the benzyl group or a 4-hydroxyl group on the piperidine had little effect on NR1A/2B potency; however, 4-hydroxypiperidines demonstrated slightly improved selectivity for NR1A/2B receptors vs. α-1 adrenergic and dopamine D2 receptor affinity.  From this study, 5-[3-(4-benzylpiperidin-1-yl)prop-1-ynyl]-1,3-dihydrobenzimidazol-2-one (II) was identified as a very potent, selective NR1A/2B receptor antagonist (IC50 value 0.0053 μM).  After oral administration at 10 and 30 mg/kg, II potentiated the effects of L-DOPA in the 6-OHDA-lesioned rat and seemed to have improved oral bioavailability but lower brain penetration compared to I.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqcucGQrfk-zbVg90H21EOLACvtfcHk0linbEGTmNjTsw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXlslSrsr4%253D&md5=d088cf30e4a342b2248481aaaa3f9cad</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1021%2Fjm000023o&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm000023o%26sid%3Dliteratum%253Aachs%26aulast%3DWright%26aufirst%3DJ.%2BL.%26aulast%3DGregory%26aufirst%3DT.%2BF.%26aulast%3DKesten%26aufirst%3DS.%2BR.%26aulast%3DBoxer%26aufirst%3DP.%2BA.%26aulast%3DSerpa%26aufirst%3DK.%2BA.%26aulast%3DMeltzer%26aufirst%3DL.%2BT.%26aulast%3DWise%26aufirst%3DL.%2BD.%26atitle%3DSubtype-selective%2520N-methyl-D-aspartate%2520receptor%2520antagonists%253A%2520synthesis%2520and%2520biological%2520evaluation%2520of%25201-%2528heteroarylalkynyl%2529-4-benzylpiperidines%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2000%26volume%3D43%26spage%3D3408%26epage%3D3419%26doi%3D10.1021%2Fjm000023o" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group">Mewshaw, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nelson, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shah, U. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shi, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mazandarani, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coupet, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marquis, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brennan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Andree, T. H.</span><span> </span><span class="NLM_article-title">New generation dopaminergic agents. 7. Heterocyclic bioisosteres that exploit the 3-OH-phenoxyethylamine D<sub>2</sub> template</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">2593</span><span class="NLM_x">–</span> <span class="NLM_lpage">2598</span><span class="refDoi"> DOI: 10.1016/S0960-894X(99)00434-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01821&amp;key=10.1016%2FS0960-894X%2899%2900434-5" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=1999&pages=2593-2598&author=R.+E.+Mewshawauthor=J.+A.+Nelsonauthor=U.+S.+Shahauthor=X.+Shiauthor=H.+Mazandaraniauthor=J.+Coupetauthor=K.+Marquisauthor=J.+Brennanauthor=T.+H.+Andree&title=New+generation+dopaminergic+agents.+7.+Heterocyclic+bioisosteres+that+exploit+the+3-OH-phenoxyethylamine+D2+template&doi=10.1016%2FS0960-894X%2899%2900434-5"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1016%2FS0960-894X%2899%2900434-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0960-894X%252899%252900434-5%26sid%3Dliteratum%253Aachs%26aulast%3DMewshaw%26aufirst%3DR.%2BE.%26aulast%3DNelson%26aufirst%3DJ.%2BA.%26aulast%3DShah%26aufirst%3DU.%2BS.%26aulast%3DShi%26aufirst%3DX.%26aulast%3DMazandarani%26aufirst%3DH.%26aulast%3DCoupet%26aufirst%3DJ.%26aulast%3DMarquis%26aufirst%3DK.%26aulast%3DBrennan%26aufirst%3DJ.%26aulast%3DAndree%26aufirst%3DT.%2BH.%26atitle%3DNew%2520generation%2520dopaminergic%2520agents.%25207.%2520Heterocyclic%2520bioisosteres%2520that%2520exploit%2520the%25203-OH-phenoxyethylamine%2520D2%2520template%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D1999%26volume%3D9%26spage%3D2593%26epage%3D2598%26doi%3D10.1016%2FS0960-894X%2899%2900434-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group">Pryde, D. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dalvie, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Obach, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tran, T.-D.</span><span> </span><span class="NLM_article-title">Aldehyde oxidase: an enzyme of emerging importance in drug discovery</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">8441</span><span class="NLM_x">–</span> <span class="NLM_lpage">8460</span><span class="refDoi"> DOI: 10.1021/jm100888d</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm100888d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01821&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtFygt73N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=8441-8460&author=D.+C.+Prydeauthor=D.+Dalvieauthor=Q.+Huauthor=P.+Jonesauthor=R.+S.+Obachauthor=T.-D.+Tran&title=Aldehyde+oxidase%3A+an+enzyme+of+emerging+importance+in+drug+discovery&doi=10.1021%2Fjm100888d"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Aldehyde Oxidase: An Enzyme of Emerging Importance in Drug Discovery</span></div><div class="casAuthors">Pryde, David C.; Dalvie, Deepak; Hu, Qiyue; Jones, Peter; Obach, R. Scott; Tran, Thien-Duc</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">8441-8460</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Aldehyde oxidase has for many years been recognized as a metabolizing enzyme contained within the cytosolic compartment of many tissues and in many species.  The first literature ref. to AO dates from the 1930s, but literature citations to this enzyme have been steadily growing ever since, esp. in the past decade.  It has been increasingly recognized in this past decade that AO, through its unique structure, distribution, and substrate recognition, has an important role to play in the metab. of drugs.  In this timely Perspective, we present the current knowledge of the enzyme's expression, its structure, and its distribution across species.  We offer an anal. of substrates recognized by AO and highlight clin. examples where metab. by this enzyme has had significant clin. impact or led to the termination of a drug development program.  Finally, through anal. of the structure of known substrates, we present data to suggest the significant impact AO could play on future drug discovery programs along with strategies that could be employed to mitigate this.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqALwFS70G6tLVg90H21EOLACvtfcHk0linbEGTmNjTsw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtFygt73N&md5=972eb9862a7dc7bff024b530ab40de7f</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1021%2Fjm100888d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm100888d%26sid%3Dliteratum%253Aachs%26aulast%3DPryde%26aufirst%3DD.%2BC.%26aulast%3DDalvie%26aufirst%3DD.%26aulast%3DHu%26aufirst%3DQ.%26aulast%3DJones%26aufirst%3DP.%26aulast%3DObach%26aufirst%3DR.%2BS.%26aulast%3DTran%26aufirst%3DT.-D.%26atitle%3DAldehyde%2520oxidase%253A%2520an%2520enzyme%2520of%2520emerging%2520importance%2520in%2520drug%2520discovery%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D8441%26epage%3D8460%26doi%3D10.1021%2Fjm100888d" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="note"><p class="first last">Crystal structure of mouse p110b (residues114–1064) with a bound ligand has been published (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4BFR">4BFR</a>).<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> Since the chemotype discussed in this manuscript is significantly different, we preferred to use a homology model based on the crystal structure of (<i>S</i>)-2,4-diamino-6-((5-chloro-8-fluoro-4-oxo-3-(pyridin-3-yl)-3,4-dihydroquinazolin-2-yl)(cyclopropyl)methylamino)pyrimidine-5-carbonitrile (GS-9901) bound to PI3Kδ (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5T8I">5T8I</a>)<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> for evaluating the binding mode.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group">Rabilloud, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sillion, B.</span><span> </span><span class="NLM_article-title">Synthesis of 4<i>H</i>-3,1-benzoxazin-4-ones and 4-(3<i>H</i>)quinazolinones from anthranilic acids and their derivatives by the use of triphenyl phosphite and pyridine</span> <span class="citation_source-journal">J. Heterocycl. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1980</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">1065</span><span class="NLM_x">–</span> <span class="NLM_lpage">1068</span><span class="refDoi"> DOI: 10.1002/jhet.5570170542</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01821&amp;key=10.1002%2Fjhet.5570170542" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=1980&pages=1065-1068&author=R.+Rabilloudauthor=B.+Sillion&title=Synthesis+of+4H-3%2C1-benzoxazin-4-ones+and+4-%283H%29quinazolinones+from+anthranilic+acids+and+their+derivatives+by+the+use+of+triphenyl+phosphite+and+pyridine&doi=10.1002%2Fjhet.5570170542"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1002%2Fjhet.5570170542&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjhet.5570170542%26sid%3Dliteratum%253Aachs%26aulast%3DRabilloud%26aufirst%3DR.%26aulast%3DSillion%26aufirst%3DB.%26atitle%3DSynthesis%2520of%25204H-3%252C1-benzoxazin-4-ones%2520and%25204-%25283H%2529quinazolinones%2520from%2520anthranilic%2520acids%2520and%2520their%2520derivatives%2520by%2520the%2520use%2520of%2520triphenyl%2520phosphite%2520and%2520pyridine%26jtitle%3DJ.%2520Heterocycl.%2520Chem.%26date%3D1980%26volume%3D17%26spage%3D1065%26epage%3D1068%26doi%3D10.1002%2Fjhet.5570170542" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4XE0" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4XE0','PDB','4XE0'); return false;">PDB: 4XE0</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5T8I" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5T8I','PDB','5T8I'); return false;">PDB: 5T8I</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4BFR" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4BFR','PDB','4BFR'); return false;">PDB: 4BFR</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i52"><a href="/doi/suppl/10.1021/acs.jmedchem.6b01821">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_07607"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a class="ext-link" href="/">ACS Publications website</a> at DOI: <a class="ext-link" href="/doi/abs/10.1021/acs.jmedchem.6b01821">10.1021/acs.jmedchem.6b01821</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Details of all protocols for in vitro and in vivo experiments and kinase selectivity (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.6b01821/suppl_file/jm6b01821_si_001.pdf">PDF</a>)</p></li><li><p class="inline">Structure coordinates (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.6b01821/suppl_file/jm6b01821_si_002.pdb">PDB</a>)</p></li><li><p class="inline">Structure coordinates (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.6b01821/suppl_file/jm6b01821_si_003.pdb">PDB</a>)</p></li><li><p class="inline">Structure coordinates (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.6b01821/suppl_file/jm6b01821_si_004.pdb">PDB</a>)</p></li><li><p class="inline">Molecular formula strings and some data (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.6b01821/suppl_file/jm6b01821_si_005.csv">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.6b01821/suppl_file/jm6b01821_si_001.pdf">jm6b01821_si_001.pdf (206.92 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.6b01821/suppl_file/jm6b01821_si_002.pdb">jm6b01821_si_002.pdb (540.22 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.6b01821/suppl_file/jm6b01821_si_003.pdb">jm6b01821_si_003.pdb (3.27 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.6b01821/suppl_file/jm6b01821_si_004.pdb">jm6b01821_si_004.pdb (3.57 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.6b01821/suppl_file/jm6b01821_si_005.csv">jm6b01821_si_005.csv (3.08 kb)</a></li></ul></div></div><span class="author-information-subsection-header">Accession Codes</span><p class="last">The PI3Kβ homology model used was built from the crystal structure of (<i>S</i>)-2,4-diamino-6-((5-chloro-8-fluoro-4-oxo-3-(pyridin-3-yl)-3,4-dihydroquinazolin-2-yl)(cyclopropyl)methylamino)pyrimidine-5-carbonitrile (GS-9901) bound to PI3Kδ (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5T8I">5T8I</a>; coordinates available in <a href="/doi/suppl/10.1021/acs.jmedchem.6b01821/suppl_file/jm6b01821_si_001.pdf" class="ext-link">Supporting Information</a>).<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a></p><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.6b01821&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.6b01821%3Bwgroup%3Astring%3AACHS+website+Group%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2017.60.issue-4%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.6b01821" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                3MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"67998fc0bba8d1df","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
